assay_tissue,src_id,doc_id,variant_id,assay_test_type,src_assay_id,tid,assay_category,assay_subcellular_fraction,assay_cell_type,chembl_id,description,assay_organism,confidence_score,assay_tax_id,cell_id,curated_by,relationship_type,bao_format,tissue_id,assay_id,assay_type,assay_strain
,1,11087,,,,12052,,,,CHEMBL615117,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,8,,,Autocuration,H,BAO_0000019,,1,B,
,1,684,,,,22226,,,,CHEMBL615118,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,0,,,Autocuration,U,BAO_0000219,,2,F,
,1,15453,,,,22226,,,,CHEMBL615119,,,0,,,Autocuration,U,BAO_0000019,,3,B,
,1,17841,,,,104729,,,,CHEMBL615120,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Bos taurus,4,9913.0,,Autocuration,H,BAO_0000249,,4,B,
,1,17430,,,,80001,,,143B,CHEMBL615121,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,1,9606.0,163.0,Intermediate,N,BAO_0000219,,5,F,
,1,17430,,,,80001,,,143B,CHEMBL615122,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,1,9606.0,163.0,Intermediate,N,BAO_0000219,,6,F,
,1,13799,,,,80001,,,143B,CHEMBL615123,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Mus musculus,1,10090.0,163.0,Intermediate,N,BAO_0000219,,7,F,
,1,17774,,,,80001,,,143B,CHEMBL615124,In vitro cell cytotoxicity was determined against 143B cell line,Homo sapiens,1,9606.0,163.0,Expert,N,BAO_0000219,,8,F,
,1,3801,,,,80001,,,143B,CHEMBL615125,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Homo sapiens,1,9606.0,163.0,Intermediate,N,BAO_0000219,,9,F,
,1,17430,,,,80001,,,143B,CHEMBL615126,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,1,9606.0,163.0,Intermediate,N,BAO_0000219,,10,F,
,1,17430,,,,80001,,,143B,CHEMBL615127,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,1,9606.0,163.0,Intermediate,N,BAO_0000219,,11,F,
,1,17774,,,,80001,,,143B,CHEMBL615128,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Homo sapiens,1,9606.0,163.0,Expert,N,BAO_0000219,,12,F,
,1,11324,,,,50185,,,,CHEMBL857900,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1,1280.0,,Intermediate,N,BAO_0000218,,13,F,
,1,11324,,,,50185,,,,CHEMBL615129,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1,1280.0,,Intermediate,N,BAO_0000218,,14,F,
,1,11324,,,,50185,,,,CHEMBL615130,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1,1280.0,,Intermediate,N,BAO_0000218,,15,F,
,1,11324,,,,50185,,,,CHEMBL615131,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,1,1280.0,,Intermediate,N,BAO_0000218,,16,F,
,1,11347,,,,100122,,,,CHEMBL884521,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,17,A,
,1,16474,,,,12054,,,,CHEMBL615132,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,8,,,Autocuration,H,BAO_0000357,,18,B,
,1,10091,,,,12054,,,,CHEMBL615133,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,8,,,Autocuration,H,BAO_0000019,,19,B,
,1,16474,,,,12054,,,,CHEMBL615134,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,8,,,Autocuration,H,BAO_0000357,,20,B,
,1,16474,,,,12054,,,,CHEMBL615135,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,8,,,Autocuration,H,BAO_0000357,,21,B,
,1,16474,,,,12054,,,,CHEMBL615136,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,8,,,Autocuration,H,BAO_0000357,,22,B,
,1,16474,,,,12054,,,,CHEMBL615137,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,8,,,Autocuration,H,BAO_0000357,,23,B,
,1,16474,,,,12054,,,,CHEMBL615138,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,8,,,Autocuration,H,BAO_0000357,,24,B,
,1,14352,,,,22226,,,,CHEMBL836324,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,0,,,Autocuration,U,BAO_0000219,,25,B,
,1,5646,,,,12054,,,,CHEMBL615139,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000357,,26,B,
,1,5646,,,,12054,,,,CHEMBL615140,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000357,,27,B,
,1,10997,,,,12426,,,,CHEMBL615141,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,8,,,Autocuration,H,BAO_0000219,,28,B,
,1,6309,,,,12054,,,,CHEMBL615142,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,soya bean,8,3847.0,,Autocuration,H,BAO_0000357,,29,B,
,1,167,,,,12054,,,,CHEMBL615143,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,30,B,
,1,167,,,,12054,,,,CHEMBL615144,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,31,B,
,1,11087,,,,12054,,,,CHEMBL872867,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,32,B,
,1,11087,,,,12054,,,,CHEMBL615145,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,33,B,
,1,13622,,,,12054,,,,CHEMBL615146,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,34,B,
,1,13622,,,,12054,,,,CHEMBL615147,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,35,B,
,1,11347,,,,22226,,,,CHEMBL615148,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,36,A,
,1,5926,,,,22226,,,,CHEMBL615149,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Escherichia coli,0,562.0,,Autocuration,U,BAO_0000019,,37,B,
,1,4567,,,,22226,,,,CHEMBL615150,Dissociation constant with dimeric 16S rRNA RNA construct B,,0,,,Autocuration,U,BAO_0000019,,38,B,
,1,3782,,,,22222,,,,CHEMBL615151,Dissociation constant towards 16S rRNA construct A,,3,,,Intermediate,M,BAO_0000225,,39,B,
,1,3782,,,,22222,,,,CHEMBL615152,Dissociation constant towards 16S rRNA construct B,,3,,,Intermediate,M,BAO_0000225,,40,B,
,1,4466,,,,100263,,,,CHEMBL615153,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Escherichia coli,3,562.0,,Expert,M,BAO_0000225,,41,B,
,1,6592,,,,100263,,,,CHEMBL615154,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Escherichia coli,3,562.0,,Expert,M,BAO_0000225,,42,B,
,1,898,,,,13053,,,,CHEMBL615155,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,Autocuration,H,BAO_0000019,,43,B,
,1,898,,,,13053,,,,CHEMBL615156,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,Autocuration,H,BAO_0000019,,44,B,
,1,13163,,,,20001,,,,CHEMBL615157,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,8,9606.0,,Autocuration,H,BAO_0000019,,45,B,
,1,13163,,,,20001,,,,CHEMBL615158,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,8,9606.0,,Autocuration,H,BAO_0000019,,46,B,
,1,10691,,,,12971,,,,CHEMBL615159,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,47,B,
,1,10691,,,,12971,,,,CHEMBL615172,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,48,B,
,1,10691,,,,12971,,,,CHEMBL615173,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,49,B,
,1,10691,,,,12971,,,,CHEMBL615174,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,50,B,
,1,898,,,,13053,,,,CHEMBL884518,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,8,,,Autocuration,H,BAO_0000019,,51,B,
,1,912,,,,11512,,,,CHEMBL615175,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,8,,,Autocuration,H,BAO_0000357,,52,B,
,1,912,,,,11512,,,,CHEMBL615176,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,8,,,Autocuration,H,BAO_0000357,,53,B,
,1,912,,,,11512,,,,CHEMBL615177,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,8,,,Autocuration,H,BAO_0000357,,54,B,
,1,15103,,,,104740,,Membranes,,CHEMBL615178,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000249,,55,B,
,1,5116,,,,80002,,,1A9,CHEMBL615179,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,56,F,
,1,14578,,,,104835,,,Oocytes,CHEMBL615180,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000219,,57,F,
,1,14578,,,,104821,,,Oocytes,CHEMBL615181,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000219,,58,F,
,1,14578,,,,104848,,,Oocytes,CHEMBL615182,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000219,,59,F,
,1,4787,,,,80002,,,1A9,CHEMBL615183,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Homo sapiens,1,9606.0,506.0,Expert,N,BAO_0000219,,60,F,
,1,4787,,,,80002,,,1A9,CHEMBL615184,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,61,F,
,1,3547,,,,80002,,,1A9,CHEMBL615185,Cytotoxic activity against human ovarian cancer (1A9) cell line,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,62,F,
,1,3547,,,,80002,,,1A9,CHEMBL615186,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,63,F,
,1,6726,,,,80002,,,1A9,CHEMBL615187,Effective dose of compound against replication of 1A9 cell line was evaluated,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,64,F,
,1,3455,,,,80002,,,1A9,CHEMBL885343,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Homo sapiens,1,9606.0,506.0,Expert,N,BAO_0000219,,65,F,
,1,5726,,,,80002,,,1A9,CHEMBL615188,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,66,F,
,1,5726,,,,80002,,,1A9,CHEMBL615189,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,67,F,
,1,5726,,,,80002,,,1A9,CHEMBL615190,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,68,F,
,1,3395,,,,80002,,,1A9,CHEMBL615191,Inhibitory activity against Taxol resistant 1A9 cell lines,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,69,F,
,1,3415,,,,80002,,,1A9,CHEMBL615192,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Homo sapiens,1,9606.0,506.0,Expert,N,BAO_0000219,,70,F,
,1,3415,,,,80002,,,1A9,CHEMBL827083,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Homo sapiens,1,9606.0,506.0,Expert,N,BAO_0000219,,71,F,
,1,17099,,,,80002,,,1A9,CHEMBL615193,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Homo sapiens,1,9606.0,506.0,Expert,N,BAO_0000219,,72,F,
,1,17099,,,,80002,,,1A9,CHEMBL615194,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,73,F,
,1,17099,,,,80002,,,1A9,CHEMBL615195,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,74,F,
,1,17099,,,,80002,,,1A9,CHEMBL615196,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Homo sapiens,1,9606.0,506.0,Intermediate,N,BAO_0000219,,75,F,
,1,17721,,,,81072,,,Jurkat,CHEMBL615197,Inhibitory concentration against Jurkat cells,Homo sapiens,1,9606.0,503.0,Intermediate,N,BAO_0000219,,76,F,
,1,1229,,,,22226,,,,CHEMBL615198,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,77,F,
,1,11347,,,,100121,,,,CHEMBL615199,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,78,A,
,1,17117,,,,11231,,,,CHEMBL615200,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,8,,,Expert,H,BAO_0000357,,79,B,
,1,17117,,,,11231,,,,CHEMBL615201,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,8,,,Expert,H,BAO_0000357,,80,B,
,1,17117,,,,11231,,,,CHEMBL615202,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,8,,,Expert,H,BAO_0000357,,81,B,
,1,11375,,,,11231,,Microsomes,,CHEMBL615203,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Candida albicans,8,5476.0,,Autocuration,H,BAO_0000251,,82,B,
,1,11375,,,,11231,,Microsomes,,CHEMBL615204,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Candida albicans,8,5476.0,,Autocuration,H,BAO_0000251,,83,B,
,1,11375,,,,11231,,Microsomes,,CHEMBL615205,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,8,4932.0,,Autocuration,H,BAO_0000251,,84,B,
,1,11375,,,,11231,,Microsomes,,CHEMBL615206,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,8,4932.0,,Autocuration,H,BAO_0000251,,85,B,
Liver,1,11375,,,,12083,,Microsomes,,CHEMBL615207,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000251,2107.0,86,B,
,1,791,,,,11231,,,,CHEMBL827084,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Rattus norvegicus,8,10116.0,,Autocuration,H,BAO_0000019,,87,B,
,1,791,,,,11231,,,,CHEMBL615208,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Rattus norvegicus,8,10116.0,,Autocuration,H,BAO_0000019,,88,B,
,1,791,,,,11231,,,,CHEMBL615209,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Rattus norvegicus,8,10116.0,,Autocuration,H,BAO_0000019,,89,B,
Liver,1,11375,,,,12083,,Microsomes,,CHEMBL615210,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,90,B,
Liver,1,11375,,,,12083,,Microsomes,,CHEMBL615211,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,91,B,
Liver,1,153,,,,12083,,Microsomes,,CHEMBL615212,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,92,B,
,1,8269,,,,11377,,,,CHEMBL615213,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,8,,,Expert,H,BAO_0000357,,93,B,
,1,8269,,,,11377,,,,CHEMBL615273,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,8,,,Expert,H,BAO_0000357,,94,B,
,1,17653,,,,81020,,,HepG2,CHEMBL615274,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Homo sapiens,1,9606.0,726.0,Expert,N,BAO_0000219,,95,F,
,1,14277,,,,81020,,,HepG2,CHEMBL615275,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,96,F,
,1,1717,,,,81020,,,HepG2,CHEMBL615276,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,97,F,
,1,14091,,,,81020,,,HepG2,CHEMBL615277,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,98,F,
,1,14091,,,,81020,,,HepG2,CHEMBL615326,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,99,F,
,1,17653,,,,50606,,,,CHEMBL883130,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Hepatitis B virus,1,10407.0,,Expert,N,BAO_0000218,,100,F,
,1,13105,,,,81020,,,HepG2,CHEMBL884519,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,101,F,
,1,1717,,,,81020,,,HepG2,CHEMBL615327,Concentration required to inhibit 50% of 2.2.15 cell line,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,102,F,
,1,13105,,,,81020,,,HepG2,CHEMBL615328,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,103,A,
,1,13600,,,,50587,,,2.2.15,CHEMBL615329,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,104,F,
,1,13467,,,,50587,,,2.2.15,CHEMBL615330,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,105,F,
,1,17477,,,,50606,,,2.2.15,CHEMBL615331,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Hepatitis B virus,1,10407.0,,Expert,N,BAO_0000218,,106,F,
,1,1593,,,,50587,,,2.2.15,CHEMBL615332,In vitro anti-HBV activity in 2.2.15 cells,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,107,F,
,1,1593,,,,50587,,,2.2.15,CHEMBL615333,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,108,F,
,1,15089,,,,50587,,,2.2.15,CHEMBL615334,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,109,F,
,1,15089,,,,50587,,,2.2.15,CHEMBL615335,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,110,F,
,1,1593,,,,50587,,,2.2.15,CHEMBL615336,Cytotoxicity in 2.2.15 cells,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,111,F,
,1,1593,,,,50587,,,2.2.15,CHEMBL615337,Cytotoxicity in 2.2.15 cells; Not determined,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,112,F,
,1,13600,,,,50587,,,2.2.15,CHEMBL615338,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,113,F,
,1,13467,,,,50587,,,2.2.15,CHEMBL615339,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,114,F,
,1,13467,,,,50587,,,2.2.15,CHEMBL615340,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Homo sapiens,1,9606.0,,Intermediate,N,BAO_0000218,,115,F,
,1,14764,,,,81020,,,HepG2,CHEMBL615341,Antiviral activity against HBV was determined in 2.215 cell line,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,116,F,
,1,6531,,,,22226,,Microsomes,,CHEMBL615342,Inhibition of 20-HETE synthesis in human renal microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,117,B,
,1,17322,,,,22226,,,,CHEMBL615343,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,0,,,Autocuration,U,BAO_0000019,,118,B,
,1,17072,,,,80612,,,2008,CHEMBL615344,Inhibitory concentration against 2008 (ovarian) cells,Homo sapiens,1,9606.0,388.0,Intermediate,N,BAO_0000219,,119,F,
,1,16936,,,,80612,,,2008,CHEMBL615345,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Homo sapiens,1,9606.0,388.0,Intermediate,N,BAO_0000219,,120,F,
,1,16936,,,,80612,,,2008,CHEMBL615346,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Homo sapiens,1,9606.0,388.0,Intermediate,N,BAO_0000219,,121,F,
,1,17146,,,,80612,,,2008,CHEMBL615347,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Homo sapiens,1,9606.0,388.0,Intermediate,N,BAO_0000219,,122,F,
,1,17146,,,,80612,,,2008,CHEMBL615348,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Homo sapiens,1,9606.0,388.0,Intermediate,N,BAO_0000219,,123,F,
,1,10797,,,,80613,,,2008/R,CHEMBL827085,In vitro inhibition of 2008/R ovarian cancer cell line,Homo sapiens,1,9606.0,561.0,Intermediate,N,BAO_0000219,,124,F,
,1,10797,,,,80613,,,2008/R,CHEMBL615349,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Homo sapiens,1,9606.0,561.0,Intermediate,N,BAO_0000219,,125,F,
,1,10797,,,,80614,,,2008/S,CHEMBL615350,In vitro inhibition of 2008/S ovarian cancer cell line,Homo sapiens,1,9606.0,389.0,Intermediate,N,BAO_0000219,,126,F,
,1,10797,,,,80614,,,2008/S,CHEMBL615351,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Homo sapiens,1,9606.0,389.0,Intermediate,N,BAO_0000219,,127,F,
,1,4823,,,,100256,,,,CHEMBL615352,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Homo sapiens,2,9606.0,,Expert,S,BAO_0000220,,128,B,
,1,12912,,,,100256,,,,CHEMBL615353,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Homo sapiens,2,9606.0,,Intermediate,S,BAO_0000220,,129,B,
,1,2957,,,,100256,,,,CHEMBL615354,Inhibition of chymotrypsin-like activity of 20S proteasome,,2,,,Expert,S,BAO_0000220,,130,B,
,1,2957,,,,100256,,,,CHEMBL615355,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,2,,,Expert,S,BAO_0000220,,131,B,
,1,3260,,,,100256,,,,CHEMBL615356,Inhibitory activity against 20S proteosome,,2,,,Intermediate,S,BAO_0000220,,132,B,
,1,3451,,,,22226,,,,CHEMBL615357,Compound was tested for inhibitory activity against tryptase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,133,B,
,1,13885,,,,81020,,,HepG2,CHEMBL615358,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,134,F,
,1,13885,,,,81020,,,HepG2,CHEMBL827086,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,1,9606.0,726.0,Intermediate,N,BAO_0000219,,135,F,
,1,3676,,,,22226,,,,CHEMBL615359,Compound was tested for the inhibition of Alpha-glucosidase,,0,,,Autocuration,U,BAO_0000019,,136,B,
,1,6043,,,,235,,,,CHEMBL615360,Inhibitory concentration against human neutrophil elastase (HNE),,8,,,Autocuration,H,BAO_0000357,,137,B,
Heart,1,11140,,,,22226,,,,CHEMBL615361,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,948.0,138,F,
,1,10543,,,,19640,,,,CHEMBL615362,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,Autocuration,H,BAO_0000019,,139,F,
,1,10543,,,,19640,,,,CHEMBL615363,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,Expert,H,BAO_0000019,,140,F,
,1,10543,,,,19640,,,,CHEMBL615364,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,Autocuration,H,BAO_0000357,,141,B,
,1,10543,,,,19640,,,,CHEMBL615365,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,8,,,Expert,H,BAO_0000019,,142,F,
,1,11365,,,,80360,,,P338,CHEMBL615366,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Mus musculus,1,10090.0,524.0,Intermediate,N,BAO_0000219,,143,F,
,1,11365,,,,80360,,,P338,CHEMBL615367,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Mus musculus,1,10090.0,524.0,Intermediate,N,BAO_0000219,,144,F,
,1,11803,,,,80384,,,PBL,CHEMBL615368,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Homo sapiens,1,9606.0,554.0,Intermediate,N,BAO_0000219,,145,F,
,1,11803,,,,22226,,,,CHEMBL615369,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Ovis aries,0,9940.0,,Autocuration,U,BAO_0000019,,146,F,
,1,11803,,,,22226,,,,CHEMBL615370,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Ovis aries,0,9940.0,,Autocuration,U,BAO_0000019,,147,F,
,1,12278,,,,191,,,,CHEMBL615673,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,8,,,Autocuration,H,BAO_0000357,,148,B,
,1,8249,,,,22226,,,,CHEMBL615674,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,149,F,
,1,8249,,,,22226,,,,CHEMBL615675,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,150,F,
,1,8249,,,,22226,,,CCRF-CEM,CHEMBL615676,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Homo sapiens,0,9606.0,635.0,Autocuration,U,BAO_0000219,,151,F,
,1,8249,,,,22226,,,CCRF-CEM,CHEMBL615677,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Homo sapiens,0,9606.0,635.0,Autocuration,U,BAO_0000219,,152,F,
,1,8249,,,,22226,,,CCRF-CEM,CHEMBL615678,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Homo sapiens,0,9606.0,635.0,Autocuration,U,BAO_0000219,,153,F,
,1,8249,,,,22226,,,CCRF-CEM,CHEMBL615679,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Homo sapiens,0,9606.0,635.0,Autocuration,U,BAO_0000219,,154,F,
,1,8249,,,,22226,,,,CHEMBL615680,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,155,F,
,1,8249,,,,22226,,,,CHEMBL615681,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,156,F,
,1,16992,,,,104290,,,,CHEMBL857972,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,6,,,Autocuration,H,BAO_0000249,,157,B,
,1,10543,,,,50264,,,,CHEMBL857899,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Streptococcus pyogenes,1,1314.0,,Intermediate,N,BAO_0000218,,158,F,
,1,17833,,,,50527,,,,CHEMBL615371,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Human herpesvirus 3,1,10335.0,,Intermediate,N,BAO_0000218,,159,F,
,1,17290,,,,50527,,,HEL,CHEMBL615372,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,vericilla zoster virus,1,10335.0,468.0,Expert,N,BAO_0000218,,160,F,
,1,17290,,,,50527,,,,CHEMBL615373,Antiviral activity against 07/1 strain of VZV; ND: No data,vericilla zoster virus,1,10335.0,,Intermediate,N,BAO_0000218,,161,F,
,1,17290,,,,50527,,,,CHEMBL615374,Antiviral activity against 07/1 strain of VZV; ND=No data,vericilla zoster virus,1,10335.0,,Intermediate,N,BAO_0000218,,162,F,
,1,10932,,,,50145,,,,CHEMBL615375,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",escherichia cloac,1,561.0,,Intermediate,N,BAO_0000218,,163,F,
,1,9707,,,,22226,,,,CHEMBL615376,Ratio of Ki at A2 to Ki at A1 receptors,,0,,,Autocuration,U,BAO_0000019,,164,B,
,1,2346,,,,11143,,,,CHEMBL615377,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Candida albicans,8,5476.0,,Expert,H,BAO_0000249,,165,B,
,1,2205,,,,18077,,,,CHEMBL615378,"Inhibition of 1,3-beta-glucan synthase",Candida glabrata CBS 138,8,284593.0,,Expert,H,BAO_0000357,,166,B,
,1,11900,,,,80609,,,1-87 tumor cell line,CHEMBL615379,Inhibition of growth of 1-87 human tumor cell line,Homo sapiens,1,9606.0,832.0,Intermediate,N,BAO_0000219,,167,F,
,1,14864,,,,12166,,,,CHEMBL615380,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000219,,168,B,
,1,16474,,,,100171,,,,CHEMBL615381,Inhibitory activity against soybean 1-lipoxygenase (SLO),Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,169,B,
,1,16474,,,,100171,,,,CHEMBL615382,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,170,B,
,1,16474,,,,100171,,,,CHEMBL615383,% inhibition against soybean 1-lipoxygenase (SLO),Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,171,B,
,1,16474,,,,100171,,,,CHEMBL615384,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,172,B,
,1,3094,,,,100171,,,,CHEMBL615385,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,173,B,
,1,3094,,,,100171,,,,CHEMBL615386,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,174,B,
,1,3094,,,,100171,,,,CHEMBL615387,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,175,B,
,1,3094,,,,100171,,,,CHEMBL615388,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,176,B,
,1,3094,,,,100171,,,,CHEMBL615214,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,177,B,
,1,3094,,,,100171,,,,CHEMBL827087,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,178,B,
,1,3094,,,,100171,,,,CHEMBL615215,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,179,B,
,1,3094,,,,100171,,,,CHEMBL615216,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,180,B,
,1,3094,,,,100171,,,,CHEMBL615217,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,181,B,
,1,3094,,,,100171,,,,CHEMBL615218,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,182,B,
,1,3094,,,,100171,,,,CHEMBL615219,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Glycine max,9,3847.0,,Autocuration,D,BAO_0000357,,183,B,
,1,10413,,,,22226,,,,CHEMBL615220,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,184,B,
,1,16929,,,,80049,,,C3H 10T1/2,CHEMBL615221,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Mus musculus,1,10090.0,294.0,Intermediate,N,BAO_0000219,,185,F,
,1,1229,,,,22226,,,,CHEMBL615222,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,186,F,
,1,16587,,,,11489,,,,CHEMBL615223,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,8,,,Autocuration,H,BAO_0000357,,187,B,
,1,16587,,,,11862,,,,CHEMBL615224,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,8,,,Autocuration,H,BAO_0000357,,188,B,
,1,16587,,,,11862,,,,CHEMBL615225,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,8,,,Autocuration,H,BAO_0000357,,189,B,
,1,16587,,,,11489,,,,CHEMBL615226,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,8,,,Autocuration,H,BAO_0000357,,190,B,
,1,16587,,,,11862,,,,CHEMBL615227,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,8,,,Autocuration,H,BAO_0000357,,191,B,
,1,8058,,,,12347,,,,CHEMBL615228,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Bos taurus,9,9913.0,,Expert,D,BAO_0000019,,192,F,
,1,9065,,,,100120,,,,CHEMBL615229,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,193,B,
Adrenal gland,1,8865,,,,100120,,,,CHEMBL615230,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,2369.0,194,B,
,1,9066,,,,100120,,,,CHEMBL615231,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,195,B,
,1,8394,,,,100120,,,,CHEMBL884520,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,196,B,
,1,8394,,,,100120,,,,CHEMBL615232,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,197,B,
,1,6431,,,,10328,,,,CHEMBL615233,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,8,,,Autocuration,H,BAO_0000019,,198,B,
,1,6431,,,,11490,,,,CHEMBL827088,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,8,,,Autocuration,H,BAO_0000357,,199,B,
,1,6431,,,,11490,,,,CHEMBL615234,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,8,,,Autocuration,H,BAO_0000357,,200,B,
,1,9295,,,,11134,,,,CHEMBL615235,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,8,,,Autocuration,H,BAO_0000019,,201,F,
,1,10193,,,,12052,,,,CHEMBL615236,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,Autocuration,H,BAO_0000019,,202,B,
,1,13622,,,,11134,,,,CHEMBL615237,Compound was tested in vitro for inhibition of 12-LO human platelet,,8,,,Autocuration,H,BAO_0000019,,203,B,
,1,12079,,,,11134,,,,CHEMBL615238,Inhibitory concentration against human platelet 12-lipoxygenase,,8,,,Autocuration,H,BAO_0000019,,204,F,
,1,13622,,,,11134,,,,CHEMBL615239,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,8,,,Autocuration,H,BAO_0000019,,205,B,
,1,12079,,,,11134,,,,CHEMBL615240,Inhibitory concentration against human platelet 12-lipoxygenase,Homo sapiens,9,9606.0,,Autocuration,D,BAO_0000019,,206,F,
,1,13500,,,,11835,,,,CHEMBL615241,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,8,,,Expert,H,BAO_0000019,,207,B,
,1,13723,,,,11601,,,,CHEMBL615242,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,8,,,Expert,H,BAO_0000357,,208,B,
,1,16474,,,,11134,,,,CHEMBL615243,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,8,,,Autocuration,H,BAO_0000019,,209,B,
,1,1630,,,,11134,,,,CHEMBL615244,Inhibitory activity against human platelet 12-lipoxygenase,,8,,,Autocuration,H,BAO_0000019,,210,B,
,1,167,,,,11134,,,,CHEMBL615245,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,8,,,Autocuration,H,BAO_0000019,,211,B,
,1,16474,,,,11134,,,,CHEMBL615246,% inhibition against human platelet 12-lipoxygenase (12-HLO),,8,,,Autocuration,H,BAO_0000019,,212,B,
,1,167,,,,11134,,,,CHEMBL615247,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,8,,,Autocuration,H,BAO_0000019,,213,B,
,1,16474,,,,11134,,,,CHEMBL615248,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,8,,,Autocuration,H,BAO_0000019,,214,B,
,1,10091,,,,11601,,,,CHEMBL615249,Inhibitory activity towards porcine 12-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,215,B,
,1,11966,,,,11601,,,,CHEMBL615250,Tested for inhibition against porcine 12-LO,,8,,,Autocuration,H,BAO_0000357,,216,B,
,1,951,,,,12052,,,,CHEMBL615251,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,8,,,Autocuration,H,BAO_0000019,,217,B,
,1,10997,,,,12052,,,,CHEMBL615252,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,8,,,Autocuration,H,BAO_0000019,,218,B,
,1,10193,,,,12052,,,,CHEMBL828340,In vitro inhibition of rat platelet 12-lipoxygenase,,8,,,Expert,H,BAO_0000019,,219,B,
,1,10193,,,,12052,,,,CHEMBL615253,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,Autocuration,H,BAO_0000019,,220,B,
,1,10193,,,,12052,,,,CHEMBL615254,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,8,,,Autocuration,H,BAO_0000019,,221,B,
,1,10193,,,,12052,,,,CHEMBL615255,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,8,,,Autocuration,H,BAO_0000019,,222,B,
,1,10193,,,,12052,,,,CHEMBL615256,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,8,,,Autocuration,H,BAO_0000019,,223,B,
,1,10193,,,,12052,,,,CHEMBL615257,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,8,,,Autocuration,H,BAO_0000019,,224,B,
,1,11087,,,,12052,,,,CHEMBL615258,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,8,,,Autocuration,H,BAO_0000019,,225,B,
,1,15569,,,,80007,,,41M,CHEMBL615259,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Homo sapiens,1,9606.0,621.0,Intermediate,N,BAO_0000219,,226,F,
,1,12989,,,,80007,,,41M,CHEMBL615260,In vitro antitumor activity against 41M cell line.,Homo sapiens,1,9606.0,621.0,Expert,N,BAO_0000219,,227,F,
,1,16745,,,,80007,,,41M,CHEMBL615261,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Homo sapiens,1,9606.0,621.0,Intermediate,N,BAO_0000219,,228,F,
,1,15569,,,,80007,,,41M,CHEMBL615262,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Homo sapiens,1,9606.0,621.0,Intermediate,N,BAO_0000219,,229,F,
,1,12989,,,,80007,,,41M,CHEMBL615263,In vitro antitumor activity against 41McisR cell line.,Homo sapiens,1,9606.0,621.0,Expert,N,BAO_0000219,,230,F,
,1,12989,,,,80007,,,41M,CHEMBL838393,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Homo sapiens,1,9606.0,621.0,Expert,N,BAO_0000219,,231,F,
,1,16745,,,,80007,,,41M,CHEMBL615264,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Homo sapiens,1,9606.0,621.0,Intermediate,N,BAO_0000219,,232,F,
,1,6210,,,,84,,,,CHEMBL615265,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,233,B,
,1,6210,,,,68,,,,CHEMBL615266,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,234,B,
,1,6226,,,,68,,,,CHEMBL615267,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,8,,,Expert,H,BAO_0000357,,235,B,
,1,17855,,,,10201,,,,CHEMBL615268,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,8,,,Expert,H,BAO_0000357,,236,B,
,1,17855,,,,10201,,,,CHEMBL615269,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,8,,,Expert,H,BAO_0000357,,237,B,
,1,17855,,,,10201,,,,CHEMBL615270,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,8,,,Expert,H,BAO_0000357,,238,B,
,1,10413,,,,12220,,,,CHEMBL615271,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,8,,,Autocuration,H,BAO_0000357,,239,B,
,1,10413,,,,11303,,,,CHEMBL615272,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,240,B,
,1,10413,,,,11303,,,,CHEMBL615103,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,241,B,
,1,10413,,,,11303,,,,CHEMBL615104,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,242,B,
,1,10413,,,,12220,,,,CHEMBL615105,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,8,,,Autocuration,H,BAO_0000357,,243,B,
,1,10413,,,,12220,,,,CHEMBL872866,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,8,,,Autocuration,H,BAO_0000357,,244,B,
,1,7587,,,,11303,,,,CHEMBL615106,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,245,B,
,1,7587,,,,11303,,,,CHEMBL615107,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,246,B,
,1,7587,,,,11303,,,,CHEMBL615108,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,247,B,
,1,7587,,,,11303,,,,CHEMBL615109,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,248,B,
,1,7587,,,,11303,,,,CHEMBL615110,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,249,B,
,1,7587,,,,11303,,,,CHEMBL840105,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,250,B,
,1,7587,,,,11303,,,,CHEMBL615111,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,251,B,
,1,7587,,,,11303,,,,CHEMBL615112,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,252,B,
,1,7587,,,,11303,,,,CHEMBL615113,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,253,B,
,1,7587,,,,11303,,,,CHEMBL615114,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,254,B,
,1,7587,,,,11303,,,,CHEMBL615115,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,255,B,
,1,7587,,,,11303,,,,CHEMBL615116,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,256,B,
,1,7323,,,,11303,,,,CHEMBL615698,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,8,,,Autocuration,H,BAO_0000357,,257,B,
,1,7587,,,,22226,,,,CHEMBL615699,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,258,B,
,1,7587,,,,22226,,,,CHEMBL615700,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,259,B,
,1,13750,,,,100249,,,,CHEMBL615701,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Saccharomyces cerevisiae,8,4932.0,,Expert,H,BAO_0000357,,260,B,
,1,7662,,,,22226,,,,CHEMBL615702,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,261,B,
,1,7662,,,,22226,,,,CHEMBL615703,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,262,B,
,1,7662,,,,22226,,,,CHEMBL615704,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,263,B,
,1,12211,,,,104698,,,,CHEMBL615705,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,6,,,Autocuration,H,BAO_0000019,,264,F,
,1,12211,,,,104698,,,,CHEMBL615706,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,6,,,Autocuration,H,BAO_0000019,,265,F,
Ileum,1,12211,,,,20033,,,,CHEMBL615707,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,266,F,
,1,12211,,,,10623,,,,CHEMBL615708,Stimulatory activity of intragastric pressure was tested in the rat,,8,,,Expert,H,BAO_0000019,,267,F,
,1,15453,,,,121,,,,CHEMBL615709,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,8,,,Autocuration,H,BAO_0000357,,268,B,
,1,11884,,,,22226,,,,CHEMBL615710,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,269,F,
,1,7185,,,,12688,,,,CHEMBL615711,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,8,,,Autocuration,H,BAO_0000019,,270,F,
,1,6876,,,,121,,,,CHEMBL615712,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,271,B,
,1,6876,,,,121,,,,CHEMBL836325,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,272,B,
,1,11863,,,,12198,,,,CHEMBL615713,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,8,,,Autocuration,H,BAO_0000019,,273,F,
,1,11863,,,,12198,,,,CHEMBL615714,Inhibition constant of high-affinity 5-HT uptake,,8,,,Autocuration,H,BAO_0000357,,274,B,
,1,11863,,,,12198,,,,CHEMBL615715,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,8,,,Autocuration,H,BAO_0000019,,275,F,
,1,11863,,,,12198,,,,CHEMBL615716,Maximum rate was determined for high affinity transport of 5-HT,,8,,,Autocuration,H,BAO_0000019,,276,F,
,1,4639,,,,104714,,,,CHEMBL615717,Compound was tested for agonistic activity against 5-HT uptake,,4,,,Autocuration,H,BAO_0000019,,277,F,
,1,15796,,,,10577,,,,CHEMBL881818,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,8,,,Expert,H,BAO_0000019,,278,B,
,1,15796,,,,105,,,,CHEMBL884540,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Bos taurus,8,9913.0,,Expert,H,BAO_0000357,,279,B,
,1,12801,,,,104744,,,,CHEMBL615718,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,280,B,
,1,12801,,,,104744,,,,CHEMBL615719,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,4,,,Autocuration,H,BAO_0000224,,281,B,
,1,12120,,,,104744,,Membranes,,CHEMBL615720,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,4,,,Autocuration,H,BAO_0000249,,282,B,
,1,12120,,,,104744,,Membranes,,CHEMBL615721,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,4,,,Autocuration,H,BAO_0000249,,283,B,
,1,11963,,,,104744,,,,CHEMBL615722,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,284,B,
,1,11701,,,,51,,,,CHEMBL615723,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,8,,,Autocuration,H,BAO_0000019,,285,F,
Hippocampus,1,9995,,,,51,,,,CHEMBL615724,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,286,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615725,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,287,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615726,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,288,B,
,1,16394,,In vivo,,10576,,,,CHEMBL615727,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,8,,,Autocuration,H,BAO_0000218,,289,F,
,1,11574,,,,105570,,,,CHEMBL615728,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,290,F,
,1,15779,,,,279,,,CHO,CHEMBL857971,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,291,B,
,1,15363,,,,107,,,,CHEMBL615729,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,292,B,
,1,15363,,,,12687,,,,CHEMBL615730,Efficacy against 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,293,F,
,1,15329,,,,12687,,,,CHEMBL615731,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,8,,,Expert,H,BAO_0000019,,294,F,
,1,15329,,,,12687,,,,CHEMBL615732,Relative potency towards 5-HT2A receptor of rat tail artery,,8,,,Expert,H,BAO_0000019,,295,F,
,1,15329,,,,12687,,,,CHEMBL615733,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,8,,,Expert,H,BAO_0000019,,296,F,
,1,15329,,,,12687,,,,CHEMBL615734,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,8,,,Expert,H,BAO_0000019,,297,F,
,1,15329,,,,12687,,,,CHEMBL615735,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,8,,,Autocuration,H,BAO_0000019,,298,F,
,1,15329,,,,12687,,,,CHEMBL615736,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,8,,,Expert,H,BAO_0000019,,299,F,
Ileum,1,273,,,,20033,,,,CHEMBL615737,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,300,F,
Ileum,1,273,,,,20033,,,,CHEMBL615738,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,301,F,
Ileum,1,273,,,,20033,,,,CHEMBL615739,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,302,F,
,1,12092,,,,10623,,,,CHEMBL615278,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,8,,,Autocuration,H,BAO_0000357,,303,B,
,1,1317,,,,10623,,,,CHEMBL615279,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,304,F,
,1,12409,,,,168,,,,CHEMBL615280,Binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,Expert,H,BAO_0000357,,305,B,
,1,11126,,,,22226,,,,CHEMBL615281,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Gallus gallus,0,9031.0,,Autocuration,U,BAO_0000019,,306,B,
,1,11126,,,,22226,,,,CHEMBL615282,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,307,F,
,1,11126,,,,22226,,,,CHEMBL615283,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,308,F,
,1,11126,,,,80156,,,HL-60,CHEMBL615284,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Homo sapiens,1,9606.0,649.0,Autocuration,N,BAO_0000219,,309,B,
,1,11126,,,,22226,,,,CHEMBL615285,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,310,B,
,1,11126,,,,22226,,,,CHEMBL615286,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,311,B,
,1,17807,,,,104703,,,Oocytes,CHEMBL615287,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Homo sapiens,7,9606.0,,Autocuration,D,BAO_0000219,,312,B,
,1,16575,,,,100256,,,,CHEMBL615288,Chymotryptic inhibitory activity against 26S proteasome,,2,,,Intermediate,S,BAO_0000220,,313,F,
,1,15407,,,,100256,,,,CHEMBL615289,Inhibitory activity against 26S proteasome degradation of IkB,,2,,,Intermediate,S,BAO_0000220,,314,B,
,1,10797,,,,81034,,,A2780,CHEMBL615290,In vitro inhibition of 2780/DOX ovarian cancer cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,315,F,
,1,10797,,,,81034,,,A2780,CHEMBL884522,In vitro inhibition of 2780/S ovarian cancer cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,316,F,
,1,3469,,,,22226,,,,CHEMBL615291,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,317,F,
,1,16037,,,,22222,,,,CHEMBL615292,Association constant for binding to AATT 28-mer AATT hairpin,,3,,,Intermediate,M,BAO_0000225,,318,B,
,1,16037,,,,22222,,,,CHEMBL615293,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,3,,,Intermediate,M,BAO_0000225,,319,B,
,1,16037,,,,22222,,,,CHEMBL615294,Reaction Rate Parameter for 28-mer AATT hairpin,,3,,,Intermediate,M,BAO_0000225,,320,B,
,1,16037,,,,22222,,,,CHEMBL615295,Reaction Rate Parameter for 28-mer AATT hairpin,,3,,,Intermediate,M,BAO_0000225,,321,B,
,1,16524,,,,22226,,,,CHEMBL825021,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,322,F,
,1,16524,,,,22226,,,,CHEMBL615296,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,323,F,
,1,16524,,,,22226,,,,CHEMBL615297,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,324,F,
,1,16758,,,,22226,,,,CHEMBL615298,Cytotoxicity against cell line 2SC/20 determined by MTT test,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,325,F,
,1,16758,,,,22226,,,,CHEMBL615299,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,326,F,
,1,16758,,,,22226,,,,CHEMBL615300,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,327,F,
,1,14360,,,,241,,,,CHEMBL615301,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,8,,,Autocuration,H,BAO_0000357,,328,B,
,1,14360,,,,241,,,,CHEMBL615302,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,329,B,
,1,9964,,,,22226,,,,CHEMBL615303,Selectivity ratio of ID50 in liver and heart,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,330,B,
,1,9964,,,,12132,,,,CHEMBL615304,"Selectivity, ratio of relative ID50 in liver and heart",,8,,,Autocuration,H,BAO_0000019,,331,B,
,1,9964,,,,12132,,,,CHEMBL615305,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,8,,,Autocuration,H,BAO_0000019,,332,B,
,1,9964,,,,12132,,,,CHEMBL615306,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000218,,333,B,
,1,9964,,,,12132,,,,CHEMBL615307,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000218,,334,B,
,1,9964,,In vivo,,12132,,,,CHEMBL615308,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000218,,335,B,
,1,9964,,In vivo,,12132,,,,CHEMBL615309,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000218,,336,F,
,1,9964,,,,22226,,,,CHEMBL615310,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,0,,,Autocuration,U,BAO_0000019,,337,B,
,1,9964,,,,12132,,,,CHEMBL615311,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,8,,,Autocuration,H,BAO_0000019,,338,B,
,1,9964,,,,22226,,,,CHEMBL615312,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,339,B,
,1,9964,,,,12132,,,,CHEMBL615313,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,8,,,Autocuration,H,BAO_0000019,,340,B,
,1,9964,,,,12132,,,,CHEMBL615314,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,8,,,Autocuration,H,BAO_0000019,,341,F,
,1,9964,,,,12132,,,,CHEMBL615315,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000019,,342,B,
,1,9964,,,,22226,,,,CHEMBL615316,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,343,B,
,1,9964,,In vivo,,12132,,,,CHEMBL615317,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,8,,,Autocuration,H,BAO_0000218,,344,B,
,1,9964,,,,12132,,,,CHEMBL615318,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000218,,345,B,
,1,9964,,,,22226,,,,CHEMBL615319,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,346,B,
,1,9964,,,,12132,,,,CHEMBL615320,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000019,,347,B,
,1,9964,,,,12132,,,,CHEMBL615321,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,8,,,Autocuration,H,BAO_0000019,,348,F,
,1,3796,,,,22226,,,,CHEMBL615322,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,349,B,
,1,4251,,,,19690,,,,CHEMBL615323,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,350,B,
,1,4251,,,,19690,,,,CHEMBL615407,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,351,B,
,1,4251,,,,19690,,,,CHEMBL857267,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,352,B,
,1,4251,,,,19690,,,,CHEMBL615408,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,8,562.0,,Autocuration,H,BAO_0000357,,353,B,
,1,166,,,,19690,,,,CHEMBL615409,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,8,,,Autocuration,H,BAO_0000357,,354,B,
,1,17861,,,,19690,,,,CHEMBL615410,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,8,,,Autocuration,H,BAO_0000357,,355,B,
,1,166,,,,19690,,,,CHEMBL615411,Inhibition constant against 3-dehydroquinate synthase,,8,,,Autocuration,H,BAO_0000357,,356,B,
,1,166,,,,19690,,,,CHEMBL615412,Association rate constant against 3-dehydroquinate synthase,,8,,,Autocuration,H,BAO_0000357,,357,B,
,1,166,,,,19690,,,,CHEMBL615413,Rate constant against 3-dehydroquinate synthase,,8,,,Autocuration,H,BAO_0000357,,358,B,
,1,3548,,,,22226,,,,CHEMBL615414,Inhibitory activity against fuc-TVII,,0,,,Autocuration,U,BAO_0000019,,359,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615415,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,360,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615416,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,361,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615417,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,362,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615418,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,363,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615419,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,364,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615420,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,365,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615421,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,366,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615422,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,367,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615423,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,368,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL872868,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,369,B,
Liver,1,9877,,,,12236,,Microsomes,,CHEMBL615424,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000251,2107.0,370,B,
,1,3003,,,,104832,,,,CHEMBL825022,Inhibitory activity against 3-phosphoglycerate kinase.,,4,,,Autocuration,H,BAO_0000224,,371,B,
,1,3003,,,,104832,,,,CHEMBL615425,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,4,,,Autocuration,H,BAO_0000224,,372,B,
,1,3003,,,,104832,,,,CHEMBL615426,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,4,,,Autocuration,H,BAO_0000224,,373,B,
,1,17185,,,,10612,,,,CHEMBL615427,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,374,B,
,1,6072,,,,80616,,,3677 melanoma cell line,CHEMBL615428,Cytotoxicity on 3677 melanoma cells,Homo sapiens,1,9606.0,844.0,Intermediate,N,BAO_0000219,,375,F,
,1,6072,,,,80616,,,3677 melanoma cell line,CHEMBL615429,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Homo sapiens,1,9606.0,844.0,Intermediate,N,BAO_0000219,,376,F,
,1,5018,,,,80617,,,MC-38,CHEMBL615430,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Mus musculus,1,10090.0,700.0,Intermediate,N,BAO_0000219,,377,F,
,1,2852,,,,22226,,,,CHEMBL615431,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Homo sapiens,0,9606.0,,Intermediate,U,BAO_0000019,,378,F,
,1,8663,,,,22226,,,B16,CHEMBL615432,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,0,,798.0,Autocuration,U,BAO_0000218,,379,F,
,1,8663,,,,22226,,,B16,CHEMBL615433,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,0,,798.0,Autocuration,U,BAO_0000218,,380,F,
,1,3245,,,,12464,,,,CHEMBL615434,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Human rhinovirus 14,9,12131.0,,Expert,D,BAO_0000019,,381,F,
,1,3245,,,,50085,,,,CHEMBL615435,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Human rhinovirus sp.,1,169066.0,,Intermediate,N,BAO_0000218,,382,F,
,1,3877,,,,50679,,,,CHEMBL615436,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,human rhinovirus type 14,1,169066.0,,Intermediate,N,BAO_0000218,,383,F,
,1,3877,,,,50679,,,,CHEMBL615437,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,human rhinovirus type 14,1,169066.0,,Intermediate,N,BAO_0000218,,384,F,
,1,5861,,,,12464,,,,CHEMBL615438,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,9,12131.0,,Expert,D,BAO_0000019,,385,F,
,1,5861,,,,12464,,,,CHEMBL615439,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,9,12131.0,,Expert,D,BAO_0000019,,386,F,
,1,5861,,,,12464,,,,CHEMBL615440,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,9,12131.0,,Expert,D,BAO_0000019,,387,F,
,1,5861,,,,12464,,,,CHEMBL615441,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Human rhinovirus 14,9,12131.0,,Expert,D,BAO_0000019,,388,F,
,1,13748,,,,50665,,,,CHEMBL615641,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Enterovirus,1,12059.0,,Intermediate,N,BAO_0000218,,389,F,
,1,13748,,,,50665,,,,CHEMBL872065,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Enterovirus,1,12059.0,,Intermediate,N,BAO_0000218,,390,F,
,1,13748,,,,50665,,,,CHEMBL825023,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Enterovirus,1,12059.0,,Intermediate,N,BAO_0000218,,391,F,
,1,13748,,,,50665,,,,CHEMBL615642,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Enterovirus,1,12059.0,,Intermediate,N,BAO_0000218,,392,F,
,1,13748,,,,12464,,,,CHEMBL615643,Inhibition of human rhinovirus 3C protease,Human rhinovirus B,8,147712.0,,Expert,H,BAO_0000357,,393,B,
,1,17699,,,,22226,,,,CHEMBL615644,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,394,B,
,1,7145,,,,80619,,,3EM 37,CHEMBL615645,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,395,F,
,1,7145,,,,80619,,,3EM 37,CHEMBL615646,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,396,F,
,1,7145,,,,80619,,,3EM 37,CHEMBL615647,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,397,F,
,1,7145,,,,80619,,,3EM 37,CHEMBL615648,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,398,F,
,1,7145,,,,80619,,,3EM 37,CHEMBL615649,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,399,F,
,1,7145,,,,80619,,,3EM 37,CHEMBL615650,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Mus musculus,1,10090.0,833.0,Intermediate,N,BAO_0000218,,400,F,
,1,5325,,,,80620,,,3LL cell line,CHEMBL615651,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000218,,401,F,
,1,5325,,,,80620,,,3LL cell line,CHEMBL615652,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000218,,402,F,
,1,5325,,,,80620,,,3LL cell line,CHEMBL615653,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Mus musculus,1,10090.0,847.0,Expert,N,BAO_0000218,,403,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615654,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,404,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615655,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,405,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL825024,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,406,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615656,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,407,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615657,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,408,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615658,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,409,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615659,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,410,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615660,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,411,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615661,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,412,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615662,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,413,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615663,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,414,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615664,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,415,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615665,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,416,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615666,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,417,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615667,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,418,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615668,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,419,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615669,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,420,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615670,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,421,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL836739,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,422,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615671,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,423,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615672,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,424,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615791,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,425,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615792,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,426,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615793,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,427,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615794,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,428,F,
,1,16169,,,,80620,,,3LL cell line,CHEMBL615795,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,1,10090.0,847.0,Intermediate,N,BAO_0000219,,429,F,
,1,15547,,,,80621,,,3LLD122,CHEMBL615590,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Homo sapiens,1,9606.0,971.0,Intermediate,N,BAO_0000219,,430,F,
,1,8663,,,,22226,,,,CHEMBL615591,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,0,,,Autocuration,U,BAO_0000218,,431,F,
,1,8663,,,,22226,,,,CHEMBL615592,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,0,,,Autocuration,U,BAO_0000218,,432,F,
,1,8663,,,,22226,,,,CHEMBL615593,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,0,,,Autocuration,U,BAO_0000218,,433,F,
,1,8663,,,,22226,,,,CHEMBL615594,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,0,,,Autocuration,U,BAO_0000218,,434,F,
,1,4504,,,,80951,,,NIH3T3,CHEMBL615595,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,435,F,
,1,4504,,,,80951,,,NIH3T3,CHEMBL615596,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,436,F,
,1,12695,,,,11169,,,NIH3T3,CHEMBL615597,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,8,,723.0,Expert,H,BAO_0000219,,437,F,
,1,12695,,,,80951,,,NIH3T3,CHEMBL615598,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,438,F,
,1,12695,,,,80951,,,NIH3T3,CHEMBL615599,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,439,F,
,1,17642,,,,80951,,,NIH3T3,CHEMBL615600,Effective dose against murine 3T3 fibroblasts cells,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,440,F,
,1,17642,,,,80951,,,NIH3T3,CHEMBL615601,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,441,F,
,1,12340,,,,80951,,,NIH3T3,CHEMBL615602,Cytotoxic effect on 3T3 cells,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,442,F,
,1,12340,,,,80951,,,NIH3T3,CHEMBL615603,Cytotoxic effect on 3T3 cells,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,443,F,
,1,12716,,,,80951,,,NIH3T3,CHEMBL615604,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,444,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615605,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,445,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615606,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,446,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL884526,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,447,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615607,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,448,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615608,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,449,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615609,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,450,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615682,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,451,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615683,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,452,F,
,1,17780,,,,80951,,,NIH3T3,CHEMBL615684,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000218,,453,F,
,1,12751,,,,104860,,,,CHEMBL615685,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Mus musculus,7,10090.0,,Autocuration,D,BAO_0000219,,454,F,
,1,12380,,,,80951,,,NIH3T3,CHEMBL615686,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,455,F,
,1,14892,,,,80951,,,NIH3T3,CHEMBL615687,Inhibitory activity against 3T3 cell line,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,456,F,
,1,12695,,,,80951,,,NIH3T3,CHEMBL884523,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,457,F,
,1,12695,,,,11169,,,,CHEMBL615688,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,8,,,Expert,H,BAO_0000019,,458,F,
,1,12695,,,,80951,,,NIH3T3,CHEMBL615689,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,459,F,
,1,12695,,,,80951,,,NIH3T3,CHEMBL615690,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,460,F,
,1,12695,,,,11169,,,,CHEMBL615691,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,8,,,Expert,H,BAO_0000019,,461,F,
,1,12695,,,,11169,,,,CHEMBL615692,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,8,,,Expert,H,BAO_0000019,,462,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615693,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,463,F,
,1,6277,,,,80951,,,NIH3T3,CHEMBL615324,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,464,F,
,1,4959,,,,9,,,NIH3T3,CHEMBL615325,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Homo sapiens,9,9606.0,723.0,Expert,D,BAO_0000219,,465,F,
,1,4959,,,,9,,,NIH3T3,CHEMBL615490,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Homo sapiens,9,9606.0,723.0,Expert,D,BAO_0000219,,466,F,
,1,4959,,,,188,,,NIH3T3,CHEMBL615491,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Homo sapiens,9,9606.0,723.0,Expert,D,BAO_0000219,,467,F,
,1,4959,,,,188,,,NIH3T3,CHEMBL615492,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Homo sapiens,9,9606.0,723.0,Expert,D,BAO_0000219,,468,F,
,1,12082,,,,80951,,,NIH3T3,CHEMBL615493,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,469,F,
,1,12082,,,,80951,,,NIH3T3,CHEMBL615494,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,470,F,
,1,12082,,,,80951,,,NIH3T3,CHEMBL615495,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,471,F,
,1,12082,,,,80951,,,NIH3T3,CHEMBL615496,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,472,F,
,1,2643,,,,80951,,,NIH3T3,CHEMBL615497,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,473,F,
,1,11926,,,,80951,,,NIH3T3,CHEMBL615498,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,474,F,
,1,15204,,,,80951,,,NIH3T3,CHEMBL615499,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,475,A,
,1,15992,,,,80951,,,NIH3T3,CHEMBL835522,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,476,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615500,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,477,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615501,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,478,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615502,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,479,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615503,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,480,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615504,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,481,F,
,1,16279,,,,80951,,,NIH3T3,CHEMBL615505,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,482,F,
,1,12831,,,,80951,,,NIH3T3,CHEMBL615506,Inhibition of swiss 3T3 mouse fibroblast proliferation,Mus musculus,1,10090.0,723.0,Expert,N,BAO_0000219,,483,F,
,1,13497,,,,80951,,,NIH3T3,CHEMBL615507,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Mus musculus,1,10090.0,723.0,Intermediate,N,BAO_0000219,,484,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615508,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,485,F,
,1,13618,,,,80006,,,3T3-L1,CHEMBL615509,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,486,F,
,1,11902,,,,80006,,,3T3-L1,CHEMBL615510,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,487,F,
,1,11902,,,,80006,,,3T3-L1,CHEMBL615511,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,488,F,
,1,11902,,,,80006,,,3T3-L1,CHEMBL615512,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,489,F,
,1,14840,,,,80006,,,3T3-L1,CHEMBL615513,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000218,,490,F,
,1,14840,,,,80006,,,3T3-L1,CHEMBL615514,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000218,,491,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,1,,620.0,Intermediate,N,BAO_0000219,,492,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,493,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615517,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,494,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615518,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,495,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615519,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,496,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615520,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,497,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615521,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,498,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615522,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,499,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615523,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,500,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615524,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,1,,620.0,Expert,N,BAO_0000218,,501,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615525,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,,620.0,Expert,N,BAO_0000218,,502,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615526,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,503,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615527,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,504,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615528,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,505,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615529,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,,620.0,Expert,N,BAO_0000218,,506,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615530,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,,620.0,Expert,N,BAO_0000218,,507,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615531,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,1,,620.0,Expert,N,BAO_0000218,,508,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615532,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,509,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615533,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,510,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615534,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,1,,620.0,Intermediate,N,BAO_0000219,,511,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615535,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,512,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615536,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,513,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615537,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,514,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL615538,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,515,F,
,1,13715,,,,80006,,,3T3-L1,CHEMBL836166,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,1,,620.0,Intermediate,N,BAO_0000218,,516,F,
,1,6411,,,,11214,,,3T3-L1,CHEMBL615539,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,8,,620.0,Expert,H,BAO_0000219,,517,F,
,1,6411,,,,80006,,,3T3-L1,CHEMBL615540,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,518,F,
,1,6411,,,,11214,,,3T3-L1,CHEMBL615541,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,8,,620.0,Expert,H,BAO_0000219,,519,F,
,1,3966,,,,80006,,,3T3-L1,CHEMBL615542,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,520,F,
,1,3966,,,,80006,,,3T3-L1,CHEMBL615543,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Mus musculus,1,10090.0,620.0,Intermediate,N,BAO_0000219,,521,F,
,1,15556,,,,80006,,,3T3-L1,CHEMBL615544,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,522,F,
,1,5845,,,,80006,,,3T3-L1,CHEMBL615545,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,523,F,
,1,14422,,,,80006,,,3T3-L1,CHEMBL615546,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,524,F,
,1,5845,,,,80006,,,3T3-L1,CHEMBL615547,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,525,F,
,1,14508,,,,80006,,,3T3-L1,CHEMBL615548,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,526,F,
,1,14508,,,,80006,,,3T3-L1,CHEMBL615549,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,527,F,
,1,14508,,,,80006,,,3T3-L1,CHEMBL615550,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Mus musculus,1,10090.0,620.0,Expert,N,BAO_0000219,,528,F,
,1,6349,,,,80622,,,3Y1 cell line,CHEMBL615551,Inhibitory activity against rat fibroblast (3Y1) cell line,Rattus norvegicus,1,10116.0,1118.0,Intermediate,N,BAO_0000219,,529,F,
,1,15899,,,,80622,,,3Y1 cell line,CHEMBL615552,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Rattus norvegicus,1,10116.0,1118.0,Expert,N,BAO_0000219,,530,F,
,1,15899,,,,80622,,,3Y1 cell line,CHEMBL615553,Cytotoxicity in 3Y1 cells.,Rattus norvegicus,1,10116.0,1118.0,Expert,N,BAO_0000219,,531,F,
,1,15899,,,,80622,,,3Y1 cell line,CHEMBL615554,Cytostatic effect in 3Y1 cells.,Rattus norvegicus,1,10116.0,1118.0,Expert,N,BAO_0000219,,532,F,
,1,15899,,,,80622,,,3Y1 cell line,CHEMBL615555,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Rattus norvegicus,1,10116.0,1118.0,Intermediate,N,BAO_0000219,,533,F,
,1,17038,,,,80622,,,3Y1 cell line,CHEMBL615556,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Rattus norvegicus,1,10116.0,1118.0,Expert,N,BAO_0000219,,534,F,
,1,12421,,,,22226,,,,CHEMBL615557,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,0,,,Autocuration,U,BAO_0000019,,535,B,
,1,12947,,,,22226,,,,CHEMBL615558,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,0,,,Autocuration,U,BAO_0000019,,536,B,
,1,12947,,,,22226,,,,CHEMBL872066,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,0,,,Autocuration,U,BAO_0000019,,537,B,
,1,4896,,,,11607,,,,CHEMBL615559,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Sus scrofa,9,9823.0,,Expert,D,BAO_0000019,,538,B,
,1,6148,,,,11607,,,,CHEMBL615560,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,8,,,Autocuration,H,BAO_0000019,,539,B,
,1,16432,,,,11607,,,,CHEMBL615561,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,8,,,Autocuration,H,BAO_0000019,,540,B,
,1,4978,,,,11607,,,,CHEMBL857062,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,8,,,Expert,H,BAO_0000019,,541,B,
,1,4978,,,,11607,,,,CHEMBL615562,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,8,,,Expert,H,BAO_0000019,,542,B,
,1,3723,,,,11607,,,,CHEMBL615563,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,8,,,Autocuration,H,BAO_0000019,,543,B,
,1,3518,,,,11607,,,,CHEMBL615564,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,8,,,Autocuration,H,BAO_0000357,,544,B,
,1,4164,,,,11607,,,,CHEMBL615565,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,8,,,Autocuration,H,BAO_0000019,,545,B,
,1,3518,,,,11607,,,,CHEMBL615566,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,8,,,Autocuration,H,BAO_0000019,,546,B,
,1,4164,,,,11607,,,,CHEMBL615567,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Sus scrofa,9,9823.0,,Expert,D,BAO_0000019,,547,B,
,1,3518,,,,11607,,,,CHEMBL615568,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,8,,,Autocuration,H,BAO_0000019,,548,B,
,1,3518,,,,11607,,,,CHEMBL615569,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,8,,,Autocuration,H,BAO_0000357,,549,B,
,1,4978,,,,11607,,,,CHEMBL615570,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,8,,,Autocuration,H,BAO_0000019,,550,B,
,1,4978,,,,11607,,,,CHEMBL615571,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,8,,,Autocuration,H,BAO_0000019,,551,B,
,1,6455,,,,104733,,,,CHEMBL615572,Binding affinity against melatonin (MT1) receptor (pC1),,4,,,Autocuration,H,BAO_0000224,,552,B,
,1,2222,,,,22226,,,,CHEMBL615573,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,0,,,Autocuration,U,BAO_0000019,,553,B,
,1,13020,,,,22226,,,,CHEMBL615574,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,0,,,Autocuration,U,BAO_0000019,,554,B,
,1,13021,,,,22226,,,,CHEMBL615575,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,0,,,Autocuration,U,BAO_0000019,,555,B,
,1,14532,,,,10619,,,,CHEMBL615576,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,8,,,Autocuration,H,BAO_0000357,,556,B,
,1,14118,,,,10619,,,,CHEMBL615577,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,557,B,
Hippocampus,1,11884,,,,51,,,,CHEMBL615578,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000221,10000000.0,558,B,
,1,13969,,,,51,,,,CHEMBL615579,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,559,B,
,1,13392,,,,51,,,,CHEMBL615580,Binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,560,B,
,1,14430,,,,51,,,,CHEMBL615581,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,8,,,Expert,H,BAO_0000019,,561,B,
Hippocampus,1,12248,,,,51,,,,CHEMBL615582,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,562,B,
Hippocampus,1,12249,,,,51,,,,CHEMBL615583,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,563,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,564,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL833691,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,565,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615585,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,566,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615586,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,567,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL884524,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,568,B,
Hippocampus,1,12249,,,,51,,,,CHEMBL615587,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,569,B,
Hippocampus,1,11799,,,,51,,,,CHEMBL615588,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,8,,,Autocuration,H,BAO_0000221,10000000.0,570,B,
,1,14331,,,,10576,,Membranes,,CHEMBL615589,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,571,B,
Hippocampus,1,11884,,,,51,,,,CHEMBL615442,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Bos taurus,8,9913.0,,Expert,H,BAO_0000221,10000000.0,572,B,
Hippocampus,1,14331,,,,51,,,,CHEMBL615443,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,573,B,
Hippocampus,1,11701,,,,51,,,,CHEMBL615444,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,574,B,
Hippocampus,1,11701,,,,51,,,,CHEMBL615445,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,8,,,Expert,H,BAO_0000221,10000000.0,575,B,
Hippocampus,1,12248,,,,51,,,,CHEMBL615446,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,576,B,
,1,12248,,,,51,,,CHO,CHEMBL615447,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,577,B,
Hippocampus,1,12248,,,,51,,,,CHEMBL615448,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,578,B,
Hippocampus,1,12249,,,,51,,,,CHEMBL615449,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,579,B,
,1,12248,,,,51,,,CHO,CHEMBL615450,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,580,B,
Hippocampus,1,11799,,,,51,,,,CHEMBL615451,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,8,,,Expert,H,BAO_0000221,10000000.0,581,B,
,1,634,,,,51,,,,CHEMBL615452,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,8,,,Autocuration,H,BAO_0000357,,582,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615453,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,583,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615454,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,584,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615455,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,585,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615456,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,586,B,
Hippocampus,1,9995,,,,51,,,,CHEMBL615457,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,587,B,
Hippocampus,1,12210,,,,51,,,,CHEMBL615458,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,8,,,Expert,H,BAO_0000218,10000000.0,588,B,
Hippocampus,1,13311,,,,51,,,,CHEMBL615459,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,589,B,
,1,2331,,,,51,,,CHO,CHEMBL615460,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,590,B,
,1,1375,,,,51,,,,CHEMBL615461,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,591,F,
,1,1375,,,,51,,,,CHEMBL615462,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,592,F,
Hippocampus,1,11574,,,,51,,,,CHEMBL615463,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,10000000.0,593,F,
Ileum,1,12867,,,,51,,,,CHEMBL615464,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,594,B,
Ileum,1,12867,,,,51,,,,CHEMBL615465,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,595,B,
Ileum,1,12867,,,,51,,,,CHEMBL615466,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,596,B,
Ileum,1,12867,,,,51,,,,CHEMBL615467,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,597,B,
Ileum,1,12867,,,,51,,,,CHEMBL615468,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,598,B,
Ileum,1,12867,,,,51,,,,CHEMBL615469,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,2116.0,599,B,
,1,11574,,,,51,,,,CHEMBL615470,Binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,600,B,
,1,13114,,,,51,,,,CHEMBL615471,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,601,B,
,1,13181,,,,51,,,,CHEMBL615472,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,602,B,
Hippocampus,1,10639,,,,106,,,,CHEMBL883242,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,10000000.0,603,B,
Hippocampus,1,10639,,,,106,,,,CHEMBL615473,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000221,10000000.0,604,F,
,1,11883,,,,11863,,,CHO,CHEMBL615474,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Cricetulus griseus,8,10029.0,449.0,Autocuration,H,BAO_0000218,,605,B,
,1,17785,,,,51,,,,CHEMBL615475,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,606,B,
,1,1558,,,,51,,,HeLa,CHEMBL615476,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,8,,308.0,Autocuration,H,BAO_0000219,,607,F,
,1,1558,,,,51,,,HeLa,CHEMBL615477,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,8,,308.0,Autocuration,H,BAO_0000219,,608,F,
,1,15740,,,,51,,,,CHEMBL615478,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,609,F,
,1,17624,,,,51,,,CHO,CHEMBL615160,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,610,F,
,1,17624,,,,51,,,CHO,CHEMBL615161,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,8,,449.0,Expert,H,BAO_0000219,,611,F,
,1,17624,,,,51,,,CHO,CHEMBL615162,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,612,F,
,1,17624,,,,51,,,CHO,CHEMBL615163,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,8,,449.0,Autocuration,H,BAO_0000219,,613,F,
,1,17624,,,,51,,,CHO,CHEMBL615164,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,614,B,
,1,17624,,,,51,,,CHO,CHEMBL615165,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,615,B,
,1,17624,,,,51,,,CHO,CHEMBL615166,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,8,,449.0,Autocuration,H,BAO_0000219,,616,B,
,1,14256,,,,51,,,,CHEMBL615167,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,8,,,Autocuration,H,BAO_0000219,,617,F,
,1,3445,,,,51,,,HeLa,CHEMBL615168,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,618,B,
,1,3445,,,,51,,,HeLa,CHEMBL615169,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,619,B,
,1,17200,,,,51,,,CHO,CHEMBL615170,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,620,B,
,1,17200,,,,51,,,CHO,CHEMBL615171,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,621,B,
,1,15180,,,,51,,,,CHEMBL615694,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,622,F,
,1,15180,,,,51,,,,CHEMBL615695,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,623,F,
,1,16026,,,,51,,,,CHEMBL615696,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000019,,624,F,
,1,2759,,,,51,,,CHO,CHEMBL615697,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,625,F,
,1,2759,,,,51,,,CHO,CHEMBL859410,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,626,F,
,1,2759,,,,51,,,CHO,CHEMBL615841,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,8,,449.0,Autocuration,H,BAO_0000219,,627,F,
,1,2759,,,,51,,,CHO,CHEMBL615842,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,628,F,
,1,2759,,,,51,,,CHO,CHEMBL835003,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,629,F,
,1,2759,,,,51,,,CHO,CHEMBL615843,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,8,,449.0,Autocuration,H,BAO_0000219,,630,F,
,1,2759,,,,51,,,CHO,CHEMBL615979,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,631,F,
,1,2759,,,,51,,,CHO,CHEMBL615980,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,8,,449.0,Autocuration,H,BAO_0000219,,632,F,
,1,2759,,,,51,,,CHO,CHEMBL615981,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,633,F,
,1,3445,,,,51,,,,CHEMBL615982,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,634,F,
,1,5272,,,,51,,,,CHEMBL615983,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,635,F,
,1,5272,,,,51,,,,CHEMBL615984,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,636,F,
,1,5272,,,,51,,,,CHEMBL615985,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,637,F,
,1,17624,,,,51,,,CHO,CHEMBL615986,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,638,F,
,1,17624,,,,51,,,CHO,CHEMBL615987,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,639,F,
,1,17624,,,,51,,,CHO,CHEMBL615988,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,640,F,
,1,17624,,,,51,,,CHO,CHEMBL615989,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,641,F,
,1,17624,,,,51,,,CHO,CHEMBL615990,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,642,F,
,1,17624,,,,51,,,CHO,CHEMBL615991,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,8,,449.0,Autocuration,H,BAO_0000219,,643,F,
,1,17624,,,,51,,,CHO,CHEMBL615992,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,644,F,
,1,17624,,,,51,,,CHO,CHEMBL615993,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,645,F,
,1,17624,,,,51,,,CHO,CHEMBL615994,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,,449.0,Expert,H,BAO_0000219,,646,F,
,1,17624,,,,51,,,CHO,CHEMBL615995,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,8,,449.0,Autocuration,H,BAO_0000219,,647,F,
,1,17624,,,,51,,,CHO,CHEMBL615996,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,648,F,
,1,17624,,,,51,,,CHO,CHEMBL615997,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,649,F,
,1,6563,,,,51,,,,CHEMBL615998,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,Autocuration,H,BAO_0000019,,650,F,
,1,6563,,,,51,,,,CHEMBL615999,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,Autocuration,H,BAO_0000019,,651,F,
,1,6563,,,,51,,,,CHEMBL616000,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,8,,,Autocuration,H,BAO_0000019,,652,F,
,1,17296,,,,51,,,HEK293,CHEMBL616001,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,,722.0,Autocuration,H,BAO_0000219,,653,F,
,1,6876,,,,51,,,,CHEMBL616002,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,654,F,
,1,6876,,,,51,,,,CHEMBL616003,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,8,,,Expert,H,BAO_0000019,,655,F,
,1,5272,,,,51,,,,CHEMBL616004,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,656,F,
,1,5272,,,,51,,,,CHEMBL616005,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,657,F,
,1,5548,,,,51,,,,CHEMBL616006,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,Autocuration,H,BAO_0000019,,658,F,
,1,5548,,,,51,,,,CHEMBL616007,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,8,,,Expert,H,BAO_0000019,,659,F,
,1,5548,,,,51,,,,CHEMBL616008,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,Autocuration,H,BAO_0000019,,660,F,
,1,5548,,,,51,,,,CHEMBL616009,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,8,,,Autocuration,H,BAO_0000019,,661,F,
,1,5929,,,,51,,,,CHEMBL616010,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,8,,,Expert,H,BAO_0000019,,662,F,
,1,5929,,,,51,,,,CHEMBL616011,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,663,F,
,1,5929,,,,51,,,,CHEMBL615740,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,664,F,
,1,16245,,,,51,,,,CHEMBL615741,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000019,,665,F,
,1,5640,,,,51,,,,CHEMBL615742,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,8,,,Expert,H,BAO_0000019,,666,F,
,1,5640,,,,51,,,,CHEMBL615743,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,8,,,Autocuration,H,BAO_0000019,,667,F,
,1,14509,,,,51,,,CHO,CHEMBL615744,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,8,,449.0,Autocuration,H,BAO_0000219,,668,F,
,1,14509,,,,51,,,CHO,CHEMBL615745,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,8,,449.0,Expert,H,BAO_0000219,,669,F,
,1,15331,,,,51,,,,CHEMBL615746,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,670,B,
,1,15331,,,,51,,,,CHEMBL615747,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,671,B,
,1,6563,,,,51,,,,CHEMBL615748,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,Autocuration,H,BAO_0000019,,672,F,
,1,6563,,,,51,,,,CHEMBL615749,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,8,,,Autocuration,H,BAO_0000019,,673,F,
,1,6563,,,,51,,,,CHEMBL615750,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,8,,,Autocuration,H,BAO_0000019,,674,F,
,1,6563,,,,51,,,,CHEMBL616259,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,675,F,
,1,6563,,,,51,,,,CHEMBL616260,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,Autocuration,H,BAO_0000019,,676,F,
,1,5272,,,,51,,,,CHEMBL616261,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,677,F,
,1,5272,,,,51,,,,CHEMBL616262,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,678,F,
,1,5272,,,,51,,,,CHEMBL616263,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,679,F,
,1,5272,,,,51,,,,CHEMBL616264,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,680,F,
,1,5272,,,,51,,,,CHEMBL616265,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,681,F,
,1,5272,,,,51,,,,CHEMBL616266,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,682,F,
,1,5272,,,,51,,,,CHEMBL616267,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,683,F,
,1,5272,,,,51,,,,CHEMBL616268,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,684,F,
,1,16146,,,,51,,,,CHEMBL616269,Inhibition of human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,685,B,
,1,17624,,,,51,,,CHO,CHEMBL884528,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,686,B,
,1,13706,,,,105,,,HEK293,CHEMBL616270,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,9,,722.0,Expert,D,BAO_0000219,,687,B,
,1,15250,,,,51,,,CHO,CHEMBL616271,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,688,B,
,1,17624,,,,51,,,CHO,CHEMBL616272,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,689,F,
,1,6861,,,,51,,,,CHEMBL616273,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,8,,,Expert,H,BAO_0000357,,690,B,
,1,17200,,,,51,,,,CHEMBL616274,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,691,B,
,1,17624,,,,51,,,CHO,CHEMBL616275,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,692,B,
,1,17624,,,,51,,,CHO,CHEMBL616276,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,693,B,
,1,12058,,In vivo,,22226,,,,CHEMBL616277,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,694,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616278,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,695,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616279,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,696,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616280,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,697,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616281,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,698,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616282,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,699,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616283,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,700,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616284,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,701,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616285,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,702,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616286,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,703,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616287,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,704,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616288,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,705,F,
,1,12058,,In vivo,,22226,,,,CHEMBL616289,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,706,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615610,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,707,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615611,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,708,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615612,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,709,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615613,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,710,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615614,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,711,F,
,1,12058,,In vivo,,22226,,,,CHEMBL615615,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,712,F,
,1,11440,,,,105093,,,,CHEMBL615616,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,4,,,Autocuration,H,BAO_0000019,,713,B,
Hypothalamus,1,6238,,,,11923,,,,CHEMBL615617,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,8,,,Autocuration,H,BAO_0000249,1898.0,714,B,
,1,10046,,,,10577,,,,CHEMBL615618,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,8,,,Autocuration,H,BAO_0000019,,715,B,
,1,10046,,,,10577,,,,CHEMBL615619,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,8,,,Autocuration,H,BAO_0000019,,716,B,
,1,10046,,,,10577,,,,CHEMBL615620,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,8,,,Expert,H,BAO_0000019,,717,B,
,1,167,,,,55,,,,CHEMBL615621,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,8,,,Autocuration,H,BAO_0000357,,718,B,
,1,167,,,,55,,,,CHEMBL615622,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,8,,,Autocuration,H,BAO_0000357,,719,B,
,1,11520,,,,12166,,,,CHEMBL615623,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,8,,,Autocuration,H,BAO_0000019,,720,F,
,1,11520,,,,12166,,,,CHEMBL615624,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,Autocuration,H,BAO_0000019,,721,F,
,1,11520,,,,12166,,,,CHEMBL615625,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,Autocuration,H,BAO_0000019,,722,F,
,1,11520,,,,12166,,,,CHEMBL767045,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,8,,,Autocuration,H,BAO_0000019,,723,F,
,1,135,,,,55,,,,CHEMBL615626,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,724,F,
,1,135,,,,55,,,,CHEMBL615627,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,725,F,
,1,11311,,,,55,,,,CHEMBL615628,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,726,B,
,1,10193,,,,55,,,,CHEMBL615629,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,727,B,
,1,12281,,,,55,,,,CHEMBL615630,Inhibitory concentration against 5-lipoxygenase from human whole blood,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,728,B,
,1,11311,,,,55,,,,CHEMBL615631,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,729,B,
,1,12576,,,,17087,,,,CHEMBL615632,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,8,,,Autocuration,H,BAO_0000218,,730,F,
,1,12281,,,,17087,,,,CHEMBL615633,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,8,,,Autocuration,H,BAO_0000357,,731,B,
,1,12576,,,,17087,,,,CHEMBL615634,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,8,,,Autocuration,H,BAO_0000218,,732,F,
,1,11089,,,,55,,,,CHEMBL615635,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,733,B,
,1,11006,,,,12166,,,,CHEMBL615636,In vitro inhibition of rat 5-Lipoxygenase,,8,,,Expert,H,BAO_0000357,,734,B,
,1,11481,,,,12166,,,,CHEMBL615637,Inhibitory activity against 5-Lipoxygenase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,735,B,
,1,10864,,,,12166,,,RBL-1,CHEMBL615638,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,8,,702.0,Expert,H,BAO_0000219,,736,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL615639,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,,702.0,Autocuration,H,BAO_0000219,,737,B,
,1,11311,,,,12166,,,RBL-1,CHEMBL615640,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,8,,702.0,Autocuration,H,BAO_0000219,,738,B,
,1,11311,,,,12166,,,,CHEMBL615796,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,8,,,Autocuration,H,BAO_0000019,,739,B,
,1,11311,,,,12166,,,,CHEMBL615845,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,740,B,
,1,11006,,,,12166,,,,CHEMBL615846,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,8,,,Autocuration,H,BAO_0000357,,741,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL615847,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,742,B,
,1,11311,,,,12166,,,,CHEMBL615848,The compound was tested for inhibition of isolated 5-Lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,743,B,
,1,11481,,,,22226,,,,CHEMBL615849,Ratio of IC50 against 5-LO and COX,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,744,B,
,1,11006,,,,12166,,,,CHEMBL615850,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,8,,,Autocuration,H,BAO_0000357,,745,B,
,1,11006,,,,12166,,,,CHEMBL615851,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,8,,,Autocuration,H,BAO_0000357,,746,B,
,1,11311,,,,12166,,,,CHEMBL615852,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,8,,,Autocuration,H,BAO_0000219,,747,B,
,1,11006,,,,12166,,,,CHEMBL615853,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,8,,,Autocuration,H,BAO_0000019,,748,F,
Prostate gland,1,4288,,,,120,,,,CHEMBL884527,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,8,,,Autocuration,H,BAO_0000357,2367.0,749,B,
,1,7587,,,,22226,,,,CHEMBL872871,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Columba livia,0,8932.0,,Autocuration,U,BAO_0000019,,750,B,
,1,7587,,,,22226,,,,CHEMBL615854,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Columba livia,0,8932.0,,Autocuration,U,BAO_0000019,,751,B,
,1,7587,,,,22226,,,,CHEMBL767046,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Columba livia,0,8932.0,,Autocuration,U,BAO_0000019,,752,B,
,1,11249,,,,10732,,,,CHEMBL615855,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,8,,,Autocuration,H,BAO_0000357,,753,B,
,1,8003,,,,12198,,,,CHEMBL615856,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,754,F,
,1,8003,,,,12198,,,,CHEMBL615857,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,755,F,
,1,8003,,,,12198,,,,CHEMBL615858,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,756,F,
Hippocampus,1,12416,,,,10576,,,,CHEMBL615859,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,757,B,
,1,16293,,,,51,,,,CHEMBL615860,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,8,,,Autocuration,H,BAO_0000357,,758,B,
,1,13047,,,,22226,,,,CHEMBL615861,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,0,9986.0,,Autocuration,U,BAO_0000019,,759,B,
,1,13047,,,,22226,,,,CHEMBL615862,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,0,9986.0,,Autocuration,U,BAO_0000019,,760,B,
,1,13047,,,,22226,,,,CHEMBL615863,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,0,9986.0,,Autocuration,U,BAO_0000019,,761,B,
,1,13047,,,,22226,,,,CHEMBL615864,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,0,9986.0,,Autocuration,U,BAO_0000019,,762,B,
Hippocampus,1,10085,,,,104744,,,,CHEMBL615865,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,4,,,Autocuration,H,BAO_0000221,10000000.0,763,B,
Hippocampus,1,10085,,,,104744,,,,CHEMBL615866,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,4,,,Autocuration,H,BAO_0000221,10000000.0,764,B,
Hippocampus,1,10085,,,,104744,,,,CHEMBL615867,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,4,,,Autocuration,H,BAO_0000221,10000000.0,765,B,
,1,9841,,,,104744,,Membranes,,CHEMBL615868,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,4,,,Autocuration,H,BAO_0000249,,766,B,
,1,8822,,,,104744,,,,CHEMBL615869,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000249,,767,B,
,1,9806,,,,104744,,,,CHEMBL615870,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,768,B,
,1,9806,,,,104744,,,,CHEMBL615871,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,769,B,
,1,8868,,,,104744,,,,CHEMBL615872,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,4,,,Autocuration,H,BAO_0000224,,770,B,
Hippocampus,1,9036,,,,104744,,,,CHEMBL833492,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,4,,,Autocuration,H,BAO_0000221,10000000.0,771,B,
Hippocampus,1,11374,,,,104744,,,,CHEMBL615873,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,4,,,Autocuration,H,BAO_0000221,10000000.0,772,B,
,1,10881,,,,104744,,,,CHEMBL615479,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,4,,,Autocuration,H,BAO_0000224,,773,B,
,1,8822,,,,104744,,,,CHEMBL615480,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,4,,,Autocuration,H,BAO_0000019,,774,B,
,1,9806,,,,104744,,,,CHEMBL615481,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000249,,775,B,
,1,15463,,,,104744,,,,CHEMBL872869,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,776,B,
,1,15463,,,,104744,,,,CHEMBL615482,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,777,B,
Brain,1,14542,,,,104744,,,,CHEMBL615483,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,4,,,Autocuration,H,BAO_0000221,955.0,778,B,
Brain,1,14542,,,,104744,,,,CHEMBL615484,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,4,,,Autocuration,H,BAO_0000221,955.0,779,B,
,1,8569,,,,104744,,,,CHEMBL615485,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,4,,,Autocuration,H,BAO_0000019,,780,B,
,1,10062,,,,104744,,,,CHEMBL615486,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,781,B,
,1,4771,,,,104744,,,,CHEMBL615487,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,4,,,Autocuration,H,BAO_0000224,,782,B,
,1,10062,,,,104744,,,,CHEMBL615488,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,Autocuration,H,BAO_0000224,,783,B,
,1,10062,,,,104744,,,,CHEMBL615489,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,Autocuration,H,BAO_0000224,,784,B,
,1,10062,,,,104744,,,,CHEMBL615389,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,4,,,Autocuration,H,BAO_0000224,,785,B,
,1,15463,,,,104744,,,,CHEMBL615390,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,4,,,Autocuration,H,BAO_0000019,,786,B,
,1,15463,,,,104744,,,,CHEMBL615391,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,4,,,Autocuration,H,BAO_0000019,,787,B,
,1,9098,,,,104744,,,,CHEMBL615392,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,788,B,
,1,3070,,,,22226,,,,CHEMBL615393,Affinity for 5-hydroxytryptamine 1 receptor,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,789,B,
Brain,1,14542,,,,104744,,,,CHEMBL615394,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,4,,,Autocuration,H,BAO_0000221,955.0,790,B,
Brain,1,14542,,,,104744,,,,CHEMBL615395,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,4,,,Autocuration,H,BAO_0000221,955.0,791,B,
,1,6398,,,,104744,,,,CHEMBL615396,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,4,,,Autocuration,H,BAO_0000224,,792,B,
Brain,1,1344,,,,104744,,,,CHEMBL615397,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,4,,,Autocuration,H,BAO_0000221,955.0,793,B,
,1,11963,,,,104744,,,,CHEMBL615398,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,794,B,
,1,8908,,,,22226,,,,CHEMBL615399,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,795,B,
,1,9098,,,,104744,,,,CHEMBL615400,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,4,,,Autocuration,H,BAO_0000019,,796,B,
,1,8841,,,,104744,,,,CHEMBL615401,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,797,B,
,1,8814,,,,22226,,,,CHEMBL615402,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,798,B,
,1,11752,,,,104744,,,,CHEMBL615403,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,4,,,Autocuration,H,BAO_0000019,,799,B,
Brain,1,11642,,,,104744,,,,CHEMBL615404,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,4,,,Autocuration,H,BAO_0000221,955.0,800,B,
,1,11642,,,,104744,,,,CHEMBL615781,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,801,B,
Brain,1,9231,,,,104744,,,,CHEMBL615782,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,4,,,Autocuration,H,BAO_0000220,955.0,802,B,
Brain,1,11351,,,,104744,,,,CHEMBL615783,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,4,,,Autocuration,H,BAO_0000221,955.0,803,B,
,1,4639,,,,22226,,,,CHEMBL873481,Compound was tested for binding affinity against 5-HT1 receptor,,0,,,Autocuration,U,BAO_0000019,,804,B,
,1,1205,,,,22226,,,,CHEMBL615784,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,0,,,Autocuration,U,BAO_0000019,,805,B,
,1,10025,,,,10576,,,,CHEMBL615785,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,8,,,Expert,H,BAO_0000357,,806,B,
,1,13241,,,,10576,,,,CHEMBL615786,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000249,,807,F,
,1,16245,,In vivo,,10576,,,,CHEMBL615787,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,8,,,Autocuration,H,BAO_0000218,,808,F,
,1,16245,,In vivo,,10576,,,,CHEMBL615788,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,8,,,Autocuration,H,BAO_0000218,,809,F,
,1,12438,,,,10576,,,,CHEMBL767044,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,810,F,
,1,16245,,In vivo,,10576,,,,CHEMBL615789,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,8,,,Autocuration,H,BAO_0000218,,811,F,
,1,16245,,In vivo,,10576,,,,CHEMBL615790,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,8,,,Autocuration,H,BAO_0000218,,812,F,
,1,15740,,,,10576,,,,CHEMBL615813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,8,,,Autocuration,H,BAO_0000019,,813,F,
,1,15535,,,,10576,,,,CHEMBL615814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,8,,,Autocuration,H,BAO_0000219,,814,F,
,1,15535,,,,51,,,,CHEMBL615815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,8,,,Expert,H,BAO_0000219,,815,F,
,1,15535,,,,10576,,,,CHEMBL615816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,8,,,Autocuration,H,BAO_0000219,,816,F,
,1,9888,,,,10576,,,,CHEMBL615817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,8,,,Expert,H,BAO_0000249,,817,B,
Hippocampus,1,10085,,,,10576,,,,CHEMBL615818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000221,10000000.0,818,B,
Hippocampus,1,10085,,,,10576,,,,CHEMBL615819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000221,10000000.0,819,B,
,1,17331,,,,10576,,Membranes,,CHEMBL615820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,8,,,Expert,H,BAO_0000249,,820,B,
Hippocampus,1,10845,,,,10576,,,,CHEMBL615821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,821,B,
Hippocampus,1,10845,,,,10576,,,,CHEMBL615822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,822,B,
Hippocampus,1,10845,,,,10576,,,,CHEMBL615823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000221,10000000.0,823,B,
Hippocampus,1,10845,,,,10576,,,,CHEMBL615824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,824,B,
Hippocampus,1,10845,,,,10576,,,,CHEMBL615825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,825,B,
,1,13730,,,,10576,,,,CHEMBL615826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,826,B,
,1,13508,,,,10576,,,,CHEMBL615827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000249,,827,B,
Hippocampus,1,13508,,,,10576,,,,CHEMBL615828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000249,10000000.0,828,B,
Hippocampus,1,12073,,,,10576,,,,CHEMBL615829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,829,B,
Hippocampus,1,4671,,,,10576,,,,CHEMBL615830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,830,B,
Hippocampus,1,13631,,,,10576,,,,CHEMBL615831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,8,,,Expert,H,BAO_0000221,10000000.0,831,B,
,1,12438,,,,10576,,,,CHEMBL615832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,832,B,
,1,10483,,,,10576,,,,CHEMBL615833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,8,,,Autocuration,H,BAO_0000019,,833,B,
Hippocampus,1,10483,,,,10576,,,,CHEMBL615834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,834,B,
,1,12352,,,,10576,,,,CHEMBL615835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,8,,,Intermediate,H,BAO_0000249,,835,B,
Hippocampus,1,14732,,,,10576,,,,CHEMBL615836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,8,,,Autocuration,H,BAO_0000249,10000000.0,836,B,
,1,11049,,,,10576,,,,CHEMBL615837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,837,B,
,1,11049,,,,10576,,,,CHEMBL615838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,838,B,
,1,13657,,,,10576,,,,CHEMBL615839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,8,,,Expert,H,BAO_0000249,,839,B,
,1,11473,,,,10576,,,,CHEMBL884525,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000019,,840,B,
,1,2014,,,,10576,,,,CHEMBL615840,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,8,,,Autocuration,H,BAO_0000249,,841,B,
Hippocampus,1,3086,,,,10576,,,,CHEMBL615405,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,842,B,
,1,15854,,,,10576,,,,CHEMBL615406,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,Expert,H,BAO_0000019,,843,B,
Hippocampus,1,10922,,,,10576,,,,CHEMBL615900,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,8,,,Expert,H,BAO_0000221,10000000.0,844,B,
Hippocampus,1,13346,,,,10576,,,,CHEMBL615901,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,8,,,Expert,H,BAO_0000221,10000000.0,845,B,
,1,15311,,,,10576,,,,CHEMBL615902,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,8,,,Expert,H,BAO_0000357,,846,B,
Hippocampus,1,10922,,,,10576,,,,CHEMBL615903,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,8,,,Autocuration,H,BAO_0000221,10000000.0,847,B,
,1,10025,,,,10576,,,,CHEMBL615904,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,8,,,Autocuration,H,BAO_0000357,,848,B,
,1,10025,,,,10576,,,,CHEMBL615905,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,8,,,Expert,H,BAO_0000357,,849,B,
,1,9742,,,,10576,,,,CHEMBL615906,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,Autocuration,H,BAO_0000019,,850,B,
,1,9742,,,,10576,,,,CHEMBL615907,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,Autocuration,H,BAO_0000019,,851,F,
,1,12304,,,,10576,,,,CHEMBL615908,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,Expert,H,BAO_0000019,,852,B,
Hippocampus,1,15789,,,,10576,,,,CHEMBL615909,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,853,B,
,1,9912,,,,10576,,,,CHEMBL615910,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,8,,,Autocuration,H,BAO_0000019,,854,B,
,1,9912,,,,10576,,,,CHEMBL615911,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,8,,,Autocuration,H,BAO_0000019,,855,B,
,1,9912,,,,10576,,,,CHEMBL615912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,8,,,Autocuration,H,BAO_0000019,,856,B,
,1,16693,,,,10576,,,,CHEMBL615913,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000019,,857,B,
,1,13276,,,,10576,,,,CHEMBL615914,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000357,,858,B,
Hippocampus,1,12678,,,,10576,,,,CHEMBL615915,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,8,,,Autocuration,H,BAO_0000221,10000000.0,859,B,
,1,11825,,,,10576,,,,CHEMBL615916,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,8,,,Autocuration,H,BAO_0000357,,860,B,
,1,12443,,,,10576,,,,CHEMBL615917,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,8,,,Expert,H,BAO_0000357,,861,B,
,1,13830,,,,10576,,,,CHEMBL615918,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,862,B,
Hippocampus,1,14286,,,,10576,,,,CHEMBL615919,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,8,,,Expert,H,BAO_0000249,10000000.0,863,B,
Hippocampus,1,14356,,,,10576,,,,CHEMBL615920,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,864,B,
,1,15306,,,,10576,,,,CHEMBL615921,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,865,B,
,1,15306,,,,10576,,,,CHEMBL615922,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,8,,,Expert,H,BAO_0000357,,866,B,
,1,16616,,,,10576,,,,CHEMBL881290,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,867,F,
Hippocampus,1,3651,,,,10576,,,,CHEMBL615923,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,8,,,Autocuration,H,BAO_0000221,10000000.0,868,B,
Hippocampus,1,14331,,,,10576,,,,CHEMBL615924,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,869,F,
Hippocampus,1,14331,,,,10576,,,,CHEMBL615925,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,870,F,
,1,14178,,,,10576,,,,CHEMBL615926,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,871,B,
,1,10639,,,,10576,,,,CHEMBL615927,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,872,B,
Hippocampus,1,12306,,,,10576,,,,CHEMBL615928,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,873,B,
,1,1348,,,,10576,,,,CHEMBL615929,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,874,B,
Hippocampus,1,13605,,,,10576,,,,CHEMBL615930,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,875,B,
,1,17624,,,,51,,,CHO,CHEMBL615931,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,876,B,
,1,17624,,,,51,,,CHO,CHEMBL615932,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,877,F,
,1,17624,,,,51,,,CHO,CHEMBL615933,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,878,F,
,1,15267,,,,51,,,,CHEMBL615934,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,879,B,
,1,16532,,,,51,,,,CHEMBL615935,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,8,,,Autocuration,H,BAO_0000357,,880,B,
,1,6563,,,,51,,,,CHEMBL615936,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,8,,,Autocuration,H,BAO_0000019,,881,F,
,1,4751,,,,51,,,CHO,CHEMBL615937,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,8,,449.0,Autocuration,H,BAO_0000219,,882,B,
,1,15463,,,,51,,,,CHEMBL615938,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,883,B,
,1,3805,,,,51,,,,CHEMBL615797,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,884,B,
,1,5640,,,,51,,,,CHEMBL615798,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,885,B,
,1,6563,,,,51,,,,CHEMBL872870,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,8,,,Autocuration,H,BAO_0000357,,886,B,
,1,5548,,,,51,,,,CHEMBL615799,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,887,B,
,1,6347,,,,51,,,,CHEMBL615800,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,888,B,
,1,17296,,,,51,,,HEK293,CHEMBL615801,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,,722.0,Autocuration,H,BAO_0000219,,889,F,
,1,13047,,,,51,,,,CHEMBL615802,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,8,,,Autocuration,H,BAO_0000019,,890,B,
,1,15740,,,,51,,,,CHEMBL615803,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,8,,,Autocuration,H,BAO_0000357,,891,B,
,1,5640,,,,51,,,,CHEMBL835002,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,8,,,Expert,H,BAO_0000019,,892,F,
,1,5640,,,,51,,,,CHEMBL615804,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,8,,,Autocuration,H,BAO_0000019,,893,F,
,1,17211,,,,51,,,HeLa,CHEMBL615805,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,8,,308.0,Expert,H,BAO_0000219,,894,B,
,1,4751,,,,51,,,CHO,CHEMBL615806,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,895,B,
,1,6491,,,,51,,,,CHEMBL615807,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,896,B,
,1,4707,,,,51,,,,CHEMBL615808,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,8,,,Autocuration,H,BAO_0000357,,897,B,
,1,13910,,,,51,,,,CHEMBL615809,Binding affinity against 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,898,B,
,1,16190,,,,51,,,HeLa,CHEMBL615810,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,8,,308.0,Autocuration,H,BAO_0000219,,899,B,
,1,16633,,,,51,,,,CHEMBL615811,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,900,B,
,1,11898,,,,51,,,CHO,CHEMBL615812,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,901,B,
,1,11898,,,,51,,,CHO,CHEMBL615751,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,902,B,
,1,14331,,,,51,,,,CHEMBL615752,Binding affinity against human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,903,B,
,1,17624,,,,51,,,CHO,CHEMBL615753,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,8,,449.0,Expert,H,BAO_0000219,,904,B,
,1,17624,,,,51,,,CHO,CHEMBL615754,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,8,,449.0,Autocuration,H,BAO_0000219,,905,B,
,1,3307,,,,51,,,,CHEMBL615755,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,906,B,
,1,6563,,,,51,,,CHO,CHEMBL615756,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,907,B,
,1,14165,,,,51,,,,CHEMBL615757,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000019,,908,B,
,1,5732,,,,51,,,,CHEMBL615758,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,909,B,
,1,13366,,,,51,,,,CHEMBL615759,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,8,,,Expert,H,BAO_0000357,,910,B,
,1,17626,,,,51,,,,CHEMBL615760,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,911,B,
,1,6588,,,,51,,,HeLa,CHEMBL615761,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,8,,308.0,Expert,H,BAO_0000219,,912,B,
,1,16209,,,,51,,,,CHEMBL872104,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,913,B,
,1,15463,,,,51,,,,CHEMBL615762,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,914,B,
,1,15463,,,,51,,,,CHEMBL615763,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,915,B,
,1,14770,,,,51,,,,CHEMBL615764,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,916,B,
,1,16245,,,,51,,,Cell line,CHEMBL615765,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,8,,1167.0,Autocuration,H,BAO_0000219,,917,B,
,1,16245,,,,51,,,,CHEMBL615766,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,8,,,Autocuration,H,BAO_0000019,,918,B,
,1,5548,,,,51,,,,CHEMBL615767,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,919,B,
,1,5548,,,,51,,,,CHEMBL615768,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,920,B,
,1,5548,,,,51,,,,CHEMBL615769,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,921,B,
,1,6876,,,,51,,,,CHEMBL615770,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,8,,,Expert,H,BAO_0000357,,922,B,
,1,2598,,,,51,,,,CHEMBL615771,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,923,B,
,1,17785,,,,51,,,,CHEMBL615772,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,8,,,Expert,H,BAO_0000357,,924,B,
,1,6013,,,,51,,,,CHEMBL615773,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,925,B,
,1,5929,,,,51,,,,CHEMBL615774,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,926,B,
,1,16633,,,,51,,,,CHEMBL615775,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,927,B,
,1,1558,,,,51,,,,CHEMBL615776,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,928,B,
,1,16026,,,,51,,,,CHEMBL615777,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,929,B,
,1,12469,,,,51,,,,CHEMBL615778,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,8,,,Autocuration,H,BAO_0000219,,930,B,
,1,15874,,,,51,,,,CHEMBL615779,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,931,B,
,1,15874,,,,51,,,,CHEMBL615780,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,932,B,
,1,3935,,,,51,,,,CHEMBL616298,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,933,B,
,1,15818,,,,51,,,,CHEMBL616299,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,934,B,
,1,13706,,,,51,,,CHO-K1,CHEMBL616300,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,935,B,
,1,13729,,,,51,,,CHO-K1,CHEMBL616301,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,8,,485.0,Expert,H,BAO_0000219,,936,F,
,1,15413,,,,51,,,,CHEMBL616302,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,937,B,
,1,15413,,,,51,,,,CHEMBL616117,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,8,,,Autocuration,H,BAO_0000019,,938,B,
,1,15413,,,,51,,,,CHEMBL616118,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,8,,,Autocuration,H,BAO_0000019,,939,B,
,1,15413,,,,51,,,,CHEMBL616119,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,8,,,Autocuration,H,BAO_0000019,,940,B,
,1,3445,,,,51,,,HeLa,CHEMBL616120,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,941,B,
,1,15740,,,,51,,,,CHEMBL616121,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,942,B,
,1,15740,,,,51,,,,CHEMBL616122,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,8,,,Autocuration,H,BAO_0000357,,943,B,
,1,17626,,,,51,,,,CHEMBL616123,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,944,B,
,1,4234,,,,51,,,,CHEMBL616124,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,945,B,
,1,5640,,,,51,,,,CHEMBL616125,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,8,,,Expert,H,BAO_0000357,,946,B,
,1,5272,,,,51,,,,CHEMBL616126,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Rattus norvegicus,8,10116.0,,Expert,H,BAO_0000357,,947,B,
,1,4622,,,,51,,,CHO,CHEMBL616127,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,948,B,
,1,17085,,,,51,,,,CHEMBL616128,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000019,,949,B,
,1,3025,,,,51,,,,CHEMBL616129,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,8,,,Autocuration,H,BAO_0000357,,950,B,
,1,15315,,,,51,,,,CHEMBL616130,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,951,B,
,1,15267,,,,51,,,,CHEMBL616131,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,8,,,Autocuration,H,BAO_0000357,,952,B,
,1,17158,,,,51,,,HeLa,CHEMBL616132,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,8,,308.0,Autocuration,H,BAO_0000219,,953,B,
,1,14214,,,,51,,,HeLa,CHEMBL616133,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,954,B,
,1,17133,,,,51,,,,CHEMBL616134,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,955,B,
,1,16532,,,,51,,,,CHEMBL616135,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,8,,,Autocuration,H,BAO_0000357,,956,B,
,1,2391,,,,51,,,,CHEMBL616136,Affinity for 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,957,B,
,1,14447,,,,51,,,,CHEMBL616137,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,8,,,Autocuration,H,BAO_0000019,,958,B,
,1,14447,,,,51,,,,CHEMBL872105,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,8,,,Autocuration,H,BAO_0000019,,959,B,
,1,15086,,,,51,,,,CHEMBL616138,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,8,,,Autocuration,H,BAO_0000357,,960,B,
,1,13051,,,,51,,,,CHEMBL616139,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,961,B,
,1,16026,,,,51,,,,CHEMBL616140,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,8,,,Autocuration,H,BAO_0000019,,962,F,
,1,17085,,,,51,,,,CHEMBL616141,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,8,,,Expert,H,BAO_0000019,,963,B,
,1,17133,,,,51,,,,CHEMBL616142,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,964,B,
,1,17133,,,,51,,,,CHEMBL616143,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,8,,,Autocuration,H,BAO_0000357,,965,B,
,1,17211,,,,51,,,HeLa,CHEMBL616144,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,,308.0,Autocuration,H,BAO_0000219,,966,B,
,1,17211,,,,51,,,HeLa,CHEMBL616145,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,8,,308.0,Autocuration,H,BAO_0000219,,967,B,
,1,17211,,,,51,,,HeLa,CHEMBL616012,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,,308.0,Autocuration,H,BAO_0000219,,968,B,
,1,17211,,,,51,,,HeLa,CHEMBL616013,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,8,,308.0,Autocuration,H,BAO_0000219,,969,B,
,1,16394,,,,51,,,,CHEMBL616014,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,Autocuration,H,BAO_0000019,,970,F,
,1,16394,,,,51,,,,CHEMBL616015,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,Autocuration,H,BAO_0000019,,971,F,
,1,16394,,,,51,,,,CHEMBL616016,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,8,,,Autocuration,H,BAO_0000019,,972,F,
,1,16394,,In vivo,,51,,,,CHEMBL616017,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,8,,,Autocuration,H,BAO_0000218,,973,F,
,1,16394,,,,51,,,,CHEMBL616018,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,8,,,Autocuration,H,BAO_0000019,,974,B,
,1,15740,,,,51,,,,CHEMBL616019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,8,,,Autocuration,H,BAO_0000019,,975,F,
,1,15740,,,,51,,,,CHEMBL616020,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,8,,,Autocuration,H,BAO_0000019,,976,F,
,1,15740,,,,51,,,,CHEMBL858018,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,977,B,
,1,17296,,,,51,,,HEK293,CHEMBL616021,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,,722.0,Autocuration,H,BAO_0000219,,978,F,
,1,5640,,,,51,,,,CHEMBL616022,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,8,,,Expert,H,BAO_0000019,,979,F,
,1,5640,,,,51,,,,CHEMBL616023,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,8,,,Autocuration,H,BAO_0000019,,980,F,
,1,5640,,,,51,,,,CHEMBL616024,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,8,,,Autocuration,H,BAO_0000019,,981,F,
,1,5640,,,,51,,,,CHEMBL616025,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,8,,,Autocuration,H,BAO_0000019,,982,F,
,1,2759,,,,51,,,CHO,CHEMBL616026,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,8,,449.0,Autocuration,H,BAO_0000219,,983,F,
,1,16394,,,,51,,,,CHEMBL616027,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,8,,,Autocuration,H,BAO_0000019,,984,F,
,1,16394,,,,51,,,,CHEMBL616028,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,985,F,
,1,3445,,,,51,,,,CHEMBL616029,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,986,F,
,1,4316,,,,51,,,CHO,CHEMBL616030,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,8,,449.0,Expert,H,BAO_0000219,,987,B,
,1,4316,,,,51,,,,CHEMBL616031,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,8,,,Expert,H,BAO_0000019,,988,B,
,1,15180,,,,51,,,,CHEMBL616032,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,989,F,
,1,15180,,,,51,,,,CHEMBL616033,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,990,F,
,1,15042,,,,51,,,,CHEMBL616034,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,Autocuration,H,BAO_0000019,,991,F,
,1,15042,,,,51,,,,CHEMBL616035,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,Autocuration,H,BAO_0000019,,992,F,
,1,15042,,,,51,,,,CHEMBL616036,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,993,F,
,1,15042,,,,51,,,,CHEMBL616037,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,Autocuration,H,BAO_0000019,,994,F,
,1,15042,,,,51,,,,CHEMBL616038,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,Autocuration,H,BAO_0000019,,995,F,
,1,15042,,,,51,,,,CHEMBL616039,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,8,,,Autocuration,H,BAO_0000019,,996,F,
,1,15042,,,,51,,,,CHEMBL616040,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,997,F,
,1,15180,,,,51,,,HeLa,CHEMBL616041,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,998,F,
,1,15180,,,,51,,,HeLa,CHEMBL616042,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,999,F,
,1,15180,,,,51,,,HeLa,CHEMBL616043,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,1000,F,
,1,16245,,,,51,,,,CHEMBL616044,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000019,,1001,F,
,1,16026,,,,51,,,,CHEMBL616045,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000019,,1002,F,
,1,17296,,,,51,,,HEK293,CHEMBL616046,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,8,,722.0,Autocuration,H,BAO_0000219,,1003,F,
,1,2759,,,,51,,,CHO,CHEMBL616047,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,8,,449.0,Autocuration,H,BAO_0000219,,1004,F,
,1,2759,,,,51,,,CHO,CHEMBL616048,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1005,F,
,1,2759,,,,51,,,CHO,CHEMBL616049,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1006,F,
,1,2759,,,,51,,,CHO,CHEMBL616050,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,8,,449.0,Autocuration,H,BAO_0000219,,1007,F,
,1,15419,,,,51,,,,CHEMBL616051,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,8,,,Expert,H,BAO_0000219,,1008,F,
,1,15419,,,,51,,,,CHEMBL616212,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,8,,,Autocuration,H,BAO_0000219,,1009,F,
,1,16026,,,,51,,,,CHEMBL616213,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000019,,1010,F,
,1,1414,,In vitro,,51,,,,CHEMBL616214,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,8,,,Expert,H,BAO_0000219,,1011,B,
,1,1414,,In vitro,,51,,,,CHEMBL616215,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,8,,,Expert,H,BAO_0000219,,1012,B,
,1,12861,,,,51,,,,CHEMBL616216,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,1013,B,
,1,12861,,,,51,,,,CHEMBL616217,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,Autocuration,H,BAO_0000019,,1014,B,
,1,5104,,,,51,,,,CHEMBL616218,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1015,B,
,1,5105,,,,51,,,,CHEMBL616219,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1016,B,
,1,16312,,,,51,,,,CHEMBL616220,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1017,B,
,1,15180,,,,51,,,,CHEMBL833493,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1018,B,
,1,5033,,,,51,,,,CHEMBL616221,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1019,B,
,1,16909,,,,51,,,CHO,CHEMBL616222,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1020,B,
,1,2590,,,,51,,,,CHEMBL616223,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,1021,F,
,1,2590,,,,51,,,,CHEMBL616224,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,8,,,Autocuration,H,BAO_0000019,,1022,F,
,1,16394,,,,51,,,,CHEMBL616225,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,8,,,Expert,H,BAO_0000019,,1023,B,
,1,4540,,,,51,,,HEK293,CHEMBL616226,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,1024,B,
,1,17296,,,,51,,,HEK293,CHEMBL616227,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,8,,722.0,Autocuration,H,BAO_0000219,,1025,B,
,1,17296,,,,51,,,HEK293,CHEMBL616228,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1026,B,
,1,15779,,,,51,,,HEK293,CHEMBL616229,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,8,,722.0,Autocuration,H,BAO_0000219,,1027,B,
,1,15779,,,,51,,,HEK293,CHEMBL616230,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,8,,722.0,Autocuration,H,BAO_0000219,,1028,B,
,1,15779,,,,51,,,HEK293,CHEMBL616231,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,8,,722.0,Autocuration,H,BAO_0000219,,1029,B,
,1,6166,,,,51,,,,CHEMBL616232,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1030,B,
,1,15779,,,,51,,,HEK293,CHEMBL616233,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,8,,722.0,Autocuration,H,BAO_0000219,,1031,B,
,1,4199,,,,51,,,HEK293,CHEMBL857973,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1032,B,
,1,15316,,,,51,,,,CHEMBL616234,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,8,,,Autocuration,H,BAO_0000219,,1033,B,
,1,14875,,,,51,,,,CHEMBL616235,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1034,B,
,1,14727,,,,51,,,HeLa,CHEMBL616236,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,8,,308.0,Expert,H,BAO_0000219,,1035,B,
,1,14727,,,,51,,,,CHEMBL616237,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,8,,,Expert,H,BAO_0000019,,1036,B,
,1,15146,,,,51,,,HEK293,CHEMBL616238,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,8,,722.0,Autocuration,H,BAO_0000219,,1037,B,
,1,5213,,,,51,,,HEK293,CHEMBL616239,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1038,B,
,1,16429,,,,51,,,,CHEMBL616240,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,8,,,Autocuration,H,BAO_0000219,,1039,B,
,1,15042,,,,51,,,HeLa,CHEMBL616241,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,1040,B,
,1,14818,,,,51,,,HEK293,CHEMBL616242,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,8,,722.0,Autocuration,H,BAO_0000219,,1041,B,
,1,4829,,,,51,,,HEK293,CHEMBL616243,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,1042,B,
,1,17200,,,,51,,,,CHEMBL616244,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,9,,,Expert,D,BAO_0000357,,1043,B,
,1,13051,,,,51,,,,CHEMBL616245,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,9,9606.0,,Autocuration,D,BAO_0000357,,1044,B,
,1,5486,,,,106,,,,CHEMBL616246,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,8,,,Autocuration,H,BAO_0000357,,1045,B,
,1,5254,,,,105,,,,CHEMBL616247,Binding affinity against 5-HT1D receptor,,8,,,Autocuration,H,BAO_0000357,,1046,B,
,1,5254,,,,105,,,,CHEMBL616248,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1047,B,
,1,15331,,,,107,,,,CHEMBL616249,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,1048,B,
,1,13506,,,,10576,,,,CHEMBL616250,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Homo sapiens,8,9606.0,,Autocuration,H,BAO_0000357,,1049,B,
,1,15267,,,,51,,,,CHEMBL616251,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1050,B,
,1,16616,,In vivo,,11863,,,,CHEMBL616252,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,8,,,Autocuration,H,BAO_0000218,,1051,F,
,1,16616,,In vivo,,11863,,,,CHEMBL616253,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,8,,,Autocuration,H,BAO_0000218,,1052,F,
,1,16616,,In vivo,,11863,,,,CHEMBL616254,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,8,,,Autocuration,H,BAO_0000218,,1053,F,
,1,16616,,,,11863,,,,CHEMBL616255,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1054,F,
,1,16616,,,,11863,,,,CHEMBL832872,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1055,F,
,1,16616,,,,11863,,,,CHEMBL616256,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1056,F,
,1,16616,,,,11863,,,,CHEMBL616257,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1057,F,
,1,16616,,,,11863,,,,CHEMBL616258,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1058,F,
,1,16616,,,,11863,,,,CHEMBL616384,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Mus musculus,9,10090.0,,Expert,D,BAO_0000218,,1059,F,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616385,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1060,B,
,1,13704,,,,11863,,,,CHEMBL616386,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,8,,,Expert,H,BAO_0000357,,1061,B,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616387,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,9,10090.0,,Expert,D,BAO_0000221,10000000.0,1062,B,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616388,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1063,B,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616389,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,9,10090.0,,Expert,D,BAO_0000221,10000000.0,1064,B,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616390,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1065,B,
,1,217,,,,11863,,,,CHEMBL616391,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,8,,,Autocuration,H,BAO_0000357,,1066,B,
Hippocampus,1,10297,,,,11863,,,,CHEMBL616392,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Mus musculus,9,10090.0,,Expert,D,BAO_0000221,10000000.0,1067,B,
,1,4921,,,,51,,,,CHEMBL616393,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1068,B,
,1,4921,,,,51,,,,CHEMBL616394,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1069,B,
,1,4996,,,,51,,,,CHEMBL616395,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1070,B,
,1,12918,,,,51,,,,CHEMBL616396,Compound was evaluated for the binding affinity at 5- HT1A receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1071,B,
,1,5333,,,,51,,,,CHEMBL872907,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1072,B,
,1,4437,,,,51,,,,CHEMBL616397,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1073,B,
,1,1742,,,,51,,,,CHEMBL616398,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1074,B,
,1,16688,,,,51,,,,CHEMBL616399,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,8,9823.0,,Expert,H,BAO_0000357,,1075,B,
,1,12861,,,,51,,,,CHEMBL857065,Binding activity radioligand.,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1076,B,
,1,12861,,,,51,,,,CHEMBL616400,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,1077,B,
,1,12861,,,,51,,,,CHEMBL616401,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1078,B,
,1,12490,,,,10624,,,,CHEMBL616402,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,8,,,Expert,H,BAO_0000019,,1079,B,
,1,11828,,,,51,,,,CHEMBL616403,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,1080,B,
Hippocampus,1,11866,,,,51,,,,CHEMBL616404,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000221,10000000.0,1081,B,
,1,12827,,,,51,,,,CHEMBL616405,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000249,,1082,B,
,1,12918,,,,51,,,,CHEMBL616406,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,1083,B,
,1,12919,,,,51,,,,CHEMBL616407,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,1084,F,
,1,13047,,,,51,,,,CHEMBL616408,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1085,B,
,1,15796,,,,10576,,,,CHEMBL616409,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1086,B,
Hippocampus,1,3651,,,,10576,,,,CHEMBL616410,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1087,B,
,1,188,,,,10576,,,,CHEMBL616411,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,8,,,Autocuration,H,BAO_0000357,,1088,B,
,1,16616,,,,10576,,Membranes,,CHEMBL616412,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1089,F,
Hippocampus,1,16616,,,,10576,,Membranes,,CHEMBL616413,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,10000000.0,1090,F,
Hippocampus,1,12306,,,,10576,,,,CHEMBL616414,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,1091,B,
Hippocampus,1,17167,,,,10576,,,,CHEMBL616415,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1092,B,
,1,14776,,,,10576,,,,CHEMBL616416,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,8,,,Autocuration,H,BAO_0000019,,1093,B,
,1,12158,,,,10576,,,,CHEMBL616417,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000357,,1094,B,
,1,13481,,,,10576,,,,CHEMBL616418,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,1095,B,
,1,13427,,In vitro,,10576,,,,CHEMBL616419,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,8,,,Autocuration,H,BAO_0000219,,1096,B,
,1,10210,,,,10576,,,,CHEMBL616420,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1097,B,
,1,10205,,,,10576,,Membranes,,CHEMBL616421,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,8,,,Autocuration,H,BAO_0000249,,1098,B,
,1,10205,,,,10576,,Membranes,,CHEMBL616422,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,8,,,Autocuration,H,BAO_0000249,,1099,B,
,1,10205,,,,10576,,Membranes,,CHEMBL616423,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,8,,,Expert,H,BAO_0000249,,1100,B,
,1,12280,,,,10576,,,,CHEMBL616424,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1101,B,
,1,17386,,,,10576,,,,CHEMBL616425,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1102,B,
,1,13654,,,,10576,,,,CHEMBL616426,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,8,,,Expert,H,BAO_0000357,,1103,B,
Hippocampus,1,14423,,,,10576,,,,CHEMBL616427,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1104,B,
Hippocampus,1,15412,,,,10576,,,,CHEMBL616428,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1105,B,
Hippocampus,1,12073,,,,10576,,,,CHEMBL616290,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1106,B,
,1,4101,,,,10576,,,,CHEMBL616052,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1107,B,
,1,10062,,,,10576,,,,CHEMBL616053,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1108,B,
,1,6238,,,,10576,,,,CHEMBL616054,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000249,,1109,B,
,1,16273,,,,10576,,,,CHEMBL616055,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1110,B,
,1,11139,,,,10576,,,,CHEMBL616056,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,8,,,Autocuration,H,BAO_0000357,,1111,B,
,1,16796,,,,10576,,,,CHEMBL616057,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,8,,,Expert,H,BAO_0000019,,1112,B,
Brain,1,9548,,,,10576,,,,CHEMBL616058,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,955.0,1113,B,
Brain,1,10381,,,,10576,,,,CHEMBL616059,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,8,,,Autocuration,H,BAO_0000221,955.0,1114,B,
,1,13408,,,,10576,,,,CHEMBL616060,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000249,,1115,B,
Hippocampus,1,13825,,,,10576,,,,CHEMBL616061,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1116,B,
Hippocampus,1,11147,,,,10576,,,,CHEMBL616062,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,8,,,Expert,H,BAO_0000221,10000000.0,1117,B,
,1,10552,,,,10576,,,,CHEMBL616063,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000249,,1118,B,
Striatum,1,10552,,,,10576,,,,CHEMBL616064,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,8,,,Autocuration,H,BAO_0000249,2435.0,1119,B,
,1,17136,,,,10576,,Membranes,,CHEMBL616065,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1120,B,
,1,5778,,,,10576,,Membranes,,CHEMBL616066,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1121,B,
Hippocampus,1,13481,,,,10576,,,,CHEMBL616067,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1122,B,
Hippocampus,1,13481,,,,10576,,,,CHEMBL616068,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,8,,,Autocuration,H,BAO_0000221,10000000.0,1123,B,
Hippocampus,1,13630,,,,10576,,,,CHEMBL616069,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,8,,,Intermediate,H,BAO_0000221,10000000.0,1124,B,
,1,16245,,,,10576,,,,CHEMBL616070,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,Expert,H,BAO_0000249,,1125,B,
Hippocampus,1,14509,,,,10576,,,,CHEMBL616071,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1126,B,
Hippocampus,1,14509,,,,10576,,,,CHEMBL616072,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000221,10000000.0,1127,B,
Hippocampus,1,14509,,,,10576,,,,CHEMBL616073,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1128,B,
Hippocampus,1,14509,,,,10576,,,,CHEMBL616074,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1129,B,
,1,14256,,,,10576,,,,CHEMBL616075,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,8,,,Expert,H,BAO_0000019,,1130,B,
,1,11139,,,,10576,,,,CHEMBL616076,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1131,B,
,1,11047,,,,10576,,,,CHEMBL616077,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1132,B,
,1,11047,,,,10576,,,,CHEMBL616078,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1133,B,
,1,11047,,,,10576,,,,CHEMBL616079,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1134,B,
,1,2395,,,,10576,,,CHO-K1,CHEMBL616080,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,9,10116.0,485.0,Expert,D,BAO_0000219,,1135,B,
,1,9699,,,,10576,,,,CHEMBL616081,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1136,B,
Hippocampus,1,12028,,,,10576,,,,CHEMBL616082,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1137,B,
Hippocampus,1,12028,,,,10576,,,,CHEMBL616083,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,8,,,Autocuration,H,BAO_0000221,10000000.0,1138,B,
,1,5815,,,,10576,,,,CHEMBL616084,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,Autocuration,H,BAO_0000019,,1139,B,
,1,16616,,,,10576,,,,CHEMBL616085,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,8,,,Expert,H,BAO_0000019,,1140,B,
,1,5815,,,,10576,,,,CHEMBL616086,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,8,,,Autocuration,H,BAO_0000019,,1141,B,
Hippocampus,1,2761,,,,10576,,,,CHEMBL616087,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,8,,,Autocuration,H,BAO_0000221,10000000.0,1142,B,
,1,13133,,,,10576,,,,CHEMBL616088,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,8,,,Expert,H,BAO_0000357,,1143,B,
,1,10444,,,,10576,,,,CHEMBL616089,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,8,,,Autocuration,H,BAO_0000019,,1144,B,
,1,13278,,,,10576,,,,CHEMBL616090,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1145,B,
,1,15874,,,,10576,,,,CHEMBL616091,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1146,B,
Striatum,1,10552,,,,10576,,Membranes,,CHEMBL616092,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,8,,,Autocuration,H,BAO_0000249,2435.0,1147,B,
,1,11130,,,,10576,,,,CHEMBL616093,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,8,,,Autocuration,H,BAO_0000357,,1148,B,
,1,11130,,In vivo,,10576,,,,CHEMBL616094,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,8,,,Autocuration,H,BAO_0000218,,1149,B,
Brain,1,14542,,,,10576,,,,CHEMBL616095,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,8,,,Autocuration,H,BAO_0000221,955.0,1150,B,
,1,13670,,,,10576,,,,CHEMBL616096,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1151,B,
,1,9888,,,,10576,,,,CHEMBL616097,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,8,,,Expert,H,BAO_0000249,,1152,B,
,1,3678,,,,10576,,Membranes,,CHEMBL616098,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1153,B,
Hippocampus,1,11332,,,,10576,,,,CHEMBL616099,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1154,B,
Hippocampus,1,11332,,,,10576,,,,CHEMBL616100,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1155,B,
,1,1185,,,,10576,,,,CHEMBL616101,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1156,B,
,1,2014,,,,10576,,,,CHEMBL616102,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,8,,,Expert,H,BAO_0000249,,1157,B,
,1,1185,,,,10576,,,,CHEMBL616103,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1158,B,
,1,14429,,,,10576,,,,CHEMBL616104,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,8,,,Expert,H,BAO_0000019,,1159,B,
,1,16288,,,,10576,,,,CHEMBL616105,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,8,,,Expert,H,BAO_0000019,,1160,B,
,1,5432,,,,10576,,,,CHEMBL616106,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1161,B,
,1,14429,,,,10576,,,,CHEMBL616107,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,8,,,Autocuration,H,BAO_0000019,,1162,B,
,1,13672,,,,10576,,,,CHEMBL616108,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,8,,,Expert,H,BAO_0000357,,1163,B,
Hippocampus,1,11296,,,,10576,,,,CHEMBL616109,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,1164,B,
,1,11296,,,,10576,,,,CHEMBL616110,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,8,,,Autocuration,H,BAO_0000357,,1165,B,
,1,14749,,,,10576,,,CHO,CHEMBL616111,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,8,,449.0,Expert,H,BAO_0000219,,1166,B,
,1,15086,,,,10576,,,,CHEMBL616112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000019,,1167,B,
Hippocampus,1,13462,,,,10576,,,,CHEMBL616113,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1168,B,
,1,15363,,,,10576,,,,CHEMBL616114,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,1169,B,
,1,15363,,,,10576,,,,CHEMBL616115,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,1170,B,
,1,10796,,,,10576,,,,CHEMBL616116,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1171,B,
Brain,1,12816,,,,10576,,,,CHEMBL615844,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000221,955.0,1172,B,
Hippocampus,1,13542,,,,10576,,,,CHEMBL615939,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000221,10000000.0,1173,B,
,1,13308,,,,10576,,,,CHEMBL615940,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,8,,,Expert,H,BAO_0000019,,1174,B,
Hippocampus,1,13541,,,,10576,,,,CHEMBL615941,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,8,,,Expert,H,BAO_0000221,10000000.0,1175,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615942,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,8,,,Autocuration,H,BAO_0000221,10000000.0,1176,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615943,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1177,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615944,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,8,,,Autocuration,H,BAO_0000221,10000000.0,1178,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615945,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,8,,,Autocuration,H,BAO_0000221,10000000.0,1179,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615946,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1180,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615947,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1181,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615948,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,8,,,Autocuration,H,BAO_0000221,10000000.0,1182,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615949,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,8,,,Autocuration,H,BAO_0000221,10000000.0,1183,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615950,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,8,,,Autocuration,H,BAO_0000221,10000000.0,1184,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615951,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,8,,,Autocuration,H,BAO_0000221,10000000.0,1185,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615952,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,8,,,Autocuration,H,BAO_0000221,10000000.0,1186,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615953,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,8,,,Autocuration,H,BAO_0000221,10000000.0,1187,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615954,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,8,,,Autocuration,H,BAO_0000221,10000000.0,1188,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615955,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1189,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615956,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1190,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL615957,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,8,,,Autocuration,H,BAO_0000221,10000000.0,1191,B,
,1,12879,,,,10576,,,,CHEMBL615958,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,8,,,Expert,H,BAO_0000019,,1192,B,
,1,11964,,,,10576,,,,CHEMBL615959,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,8,,,Expert,H,BAO_0000019,,1193,B,
,1,11964,,,,10576,,,,CHEMBL615960,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,8,,,Autocuration,H,BAO_0000019,,1194,B,
,1,11964,,,,10576,,,,CHEMBL615961,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,8,,,Autocuration,H,BAO_0000019,,1195,B,
Brain,1,9548,,,,10576,,,,CHEMBL615962,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,8,,,Expert,H,BAO_0000221,955.0,1196,B,
,1,9098,,,,10576,,,,CHEMBL615963,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,8,,,Expert,H,BAO_0000019,,1197,B,
,1,9098,,,,10576,,,,CHEMBL615964,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,8,,,Autocuration,H,BAO_0000019,,1198,B,
,1,9098,,,,10576,,,,CHEMBL615965,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,8,,,Autocuration,H,BAO_0000019,,1199,B,
,1,13248,,,,10576,,,CHO,CHEMBL615966,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1200,B,
,1,3147,,,,10576,,,,CHEMBL615967,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,8,,,Expert,H,BAO_0000249,,1201,B,
,1,13949,,,,10576,,,,CHEMBL615968,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000019,,1202,B,
,1,11883,,,,10576,,,CHO,CHEMBL615969,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,8,,449.0,Autocuration,H,BAO_0000218,,1203,B,
,1,11883,,,,10576,,,,CHEMBL615970,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,8,,,Autocuration,H,BAO_0000218,,1204,B,
,1,11883,,,,10576,,,,CHEMBL615971,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1205,B,
,1,15535,,,,10576,,Membranes,,CHEMBL615972,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,Expert,H,BAO_0000249,,1206,B,
,1,15535,,,,10576,,,,CHEMBL615973,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,8,,,Autocuration,H,BAO_0000249,,1207,B,
,1,15535,,,,10576,,,,CHEMBL615974,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,8,,,Autocuration,H,BAO_0000249,,1208,B,
,1,16372,,,,51,,,CHO,CHEMBL615975,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1209,B,
,1,14608,,,,10576,,,,CHEMBL615976,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,8,,,Expert,H,BAO_0000249,,1210,B,
Hippocampus,1,4795,,,,10576,,,,CHEMBL872106,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1211,B,
,1,13863,,,,10576,,,,CHEMBL615977,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1212,B,
,1,13863,,,,10576,,,,CHEMBL615978,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,8,,,Autocuration,H,BAO_0000357,,1213,B,
,1,13863,,,,10576,,,,CHEMBL616166,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,8,,,Autocuration,H,BAO_0000357,,1214,B,
,1,13863,,,,10576,,,,CHEMBL616167,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,8,,,Autocuration,H,BAO_0000357,,1215,B,
,1,13863,,,,10576,,,,CHEMBL616168,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,8,,,Autocuration,H,BAO_0000357,,1216,B,
,1,13863,,,,10576,,,,CHEMBL616169,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,8,,,Autocuration,H,BAO_0000357,,1217,B,
,1,13863,,,,10576,,,,CHEMBL616170,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,8,,,Autocuration,H,BAO_0000357,,1218,B,
,1,13863,,,,10576,,,,CHEMBL616171,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,8,,,Autocuration,H,BAO_0000357,,1219,B,
,1,13863,,,,10576,,,,CHEMBL616172,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,8,,,Autocuration,H,BAO_0000357,,1220,B,
,1,13863,,,,10576,,,,CHEMBL616173,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,8,,,Autocuration,H,BAO_0000357,,1221,B,
,1,13863,,,,10576,,,,CHEMBL616174,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,8,,,Autocuration,H,BAO_0000357,,1222,B,
,1,13863,,,,10576,,,,CHEMBL616175,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,8,,,Autocuration,H,BAO_0000357,,1223,B,
,1,13863,,,,10576,,,,CHEMBL616176,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,8,,,Autocuration,H,BAO_0000357,,1224,B,
,1,13863,,,,10576,,,,CHEMBL616177,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,8,,,Autocuration,H,BAO_0000357,,1225,B,
,1,13863,,,,10576,,,,CHEMBL616178,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,8,,,Autocuration,H,BAO_0000357,,1226,B,
,1,9742,,,,10576,,,,CHEMBL616179,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,8,,,Autocuration,H,BAO_0000019,,1227,B,
,1,12073,,,,10576,,,,CHEMBL616180,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1228,B,
,1,4101,,,,10576,,,,CHEMBL616181,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1229,B,
,1,15360,,,,10576,,,,CHEMBL616182,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,8,,,Autocuration,H,BAO_0000019,,1230,B,
Hippocampus,1,11576,,,,10576,,,,CHEMBL616183,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000221,10000000.0,1231,B,
,1,5834,,,,10576,,,,CHEMBL615874,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,8,,,Expert,H,BAO_0000019,,1232,B,
,1,2395,,,,10576,,,CHO-K1,CHEMBL615875,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,9,10116.0,485.0,Expert,D,BAO_0000219,,1233,B,
,1,1375,,,,10576,,,,CHEMBL615876,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,8,,,Autocuration,H,BAO_0000019,,1234,B,
,1,1375,,,,10576,,,,CHEMBL615877,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,8,,,Autocuration,H,BAO_0000019,,1235,B,
,1,3967,,,,10576,,,,CHEMBL615878,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,8,,,Autocuration,H,BAO_0000357,,1236,B,
,1,12884,,,,10576,,,,CHEMBL615879,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,8,,,Expert,H,BAO_0000357,,1237,B,
,1,2343,,,,10576,,,,CHEMBL615880,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,8,,,Expert,H,BAO_0000357,,1238,B,
,1,11511,,,,10576,,,,CHEMBL615881,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,8,,,Autocuration,H,BAO_0000019,,1239,B,
,1,11511,,,,10576,,,,CHEMBL615882,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1240,B,
,1,16394,,In vivo,,10576,,,,CHEMBL615883,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,8,,,Autocuration,H,BAO_0000218,,1241,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615884,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,8,,,Autocuration,H,BAO_0000218,,1242,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615885,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,8,,,Autocuration,H,BAO_0000218,,1243,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615886,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,8,,,Autocuration,H,BAO_0000218,,1244,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615887,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,8,,,Autocuration,H,BAO_0000218,,1245,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615888,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,8,,,Autocuration,H,BAO_0000218,,1246,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615889,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,8,,,Autocuration,H,BAO_0000218,,1247,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615890,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,8,,,Autocuration,H,BAO_0000218,,1248,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615891,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,8,,,Autocuration,H,BAO_0000218,,1249,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615892,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,8,,,Autocuration,H,BAO_0000218,,1250,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615893,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,8,,,Autocuration,H,BAO_0000218,,1251,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615894,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,8,,,Autocuration,H,BAO_0000218,,1252,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615895,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,8,,,Autocuration,H,BAO_0000218,,1253,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615896,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,8,,,Autocuration,H,BAO_0000218,,1254,F,
,1,16394,,In vivo,,10576,,,,CHEMBL615897,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,8,,,Autocuration,H,BAO_0000218,,1255,F,
,1,16616,,,,10576,,Membranes,,CHEMBL615898,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1256,F,
,1,16796,,,,10576,,,,CHEMBL615899,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,8,,,Autocuration,H,BAO_0000019,,1257,B,
,1,16796,,,,10576,,,,CHEMBL616291,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,8,,,Autocuration,H,BAO_0000019,,1258,B,
,1,15629,,,,10576,,,,CHEMBL616292,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,8,,,Autocuration,H,BAO_0000357,,1259,B,
,1,13241,,,,10576,,,,CHEMBL616293,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,8,,,Autocuration,H,BAO_0000249,,1260,F,
Hippocampus,1,12073,,,,10576,,,,CHEMBL616294,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,1261,B,
Hippocampus,1,14286,,,,10576,,,,CHEMBL616295,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,8,,,Autocuration,H,BAO_0000249,10000000.0,1262,B,
Brain,1,14542,,,,10576,,,,CHEMBL616296,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,8,,,Autocuration,H,BAO_0000221,955.0,1263,B,
,1,13630,,,,10576,,,,CHEMBL616297,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1264,F,
,1,13630,,,,10576,,,,CHEMBL616605,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1265,F,
,1,13630,,,,10576,,,,CHEMBL616606,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1266,F,
,1,13630,,,,10576,,,,CHEMBL616607,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,8,,,Autocuration,H,BAO_0000019,,1267,F,
,1,13630,,,,10576,,,,CHEMBL616608,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,8,,,Expert,H,BAO_0000019,,1268,F,
,1,13630,,,,10576,,,,CHEMBL616609,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1269,F,
,1,13630,,,,10576,,,,CHEMBL616610,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1270,F,
,1,13630,,,,10576,,,,CHEMBL616611,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1271,F,
,1,13630,,,,10576,,,,CHEMBL616612,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,8,,,Expert,H,BAO_0000019,,1272,F,
,1,13630,,,,10576,,,,CHEMBL616613,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1273,F,
,1,13630,,,,10576,,,,CHEMBL616614,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,8,,,Expert,H,BAO_0000019,,1274,F,
,1,13630,,,,10576,,,,CHEMBL616615,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1275,F,
,1,13630,,,,10576,,,,CHEMBL616616,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,8,,,Expert,H,BAO_0000019,,1276,F,
,1,13630,,,,10576,,,,CHEMBL616617,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1277,F,
,1,13630,,,,10576,,,,CHEMBL616618,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1278,F,
,1,13630,,,,10576,,,,CHEMBL616619,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1279,F,
,1,13630,,,,10576,,,,CHEMBL616620,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,8,,,Expert,H,BAO_0000019,,1280,F,
,1,13630,,,,10576,,,,CHEMBL616621,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,8,,,Expert,H,BAO_0000019,,1281,F,
,1,13630,,,,10576,,,,CHEMBL616622,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,8,,,Autocuration,H,BAO_0000019,,1282,F,
,1,13630,,,,10576,,,,CHEMBL616146,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,8,,,Expert,H,BAO_0000019,,1283,F,
,1,13630,,,,10576,,,,CHEMBL832873,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1284,F,
,1,13630,,,,10576,,,,CHEMBL616147,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,8,,,Autocuration,H,BAO_0000019,,1285,F,
,1,13630,,,,10576,,,,CHEMBL872872,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1286,F,
,1,13630,,,,10576,,,,CHEMBL616148,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,8,,,Autocuration,H,BAO_0000019,,1287,F,
Hippocampus,1,9783,,,,10576,,,,CHEMBL616149,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,8,,,Autocuration,H,BAO_0000221,10000000.0,1288,B,
Hippocampus,1,9783,,,,10576,,,,CHEMBL616150,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,8,,,Expert,H,BAO_0000221,10000000.0,1289,B,
,1,14331,,,,10576,,Membranes,,CHEMBL616151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1290,B,
Hippocampus,1,15260,,,,10576,,,,CHEMBL872873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,8,,,Expert,H,BAO_0000221,10000000.0,1291,B,
Hippocampus,1,15260,,,,10576,,,,CHEMBL616670,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,8,,,Autocuration,H,BAO_0000221,10000000.0,1292,B,
Hippocampus,1,15260,,,,10576,,,,CHEMBL616671,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,8,,,Autocuration,H,BAO_0000221,10000000.0,1293,B,
,1,16616,,,,10576,,,,CHEMBL884861,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1294,F,
,1,15629,,,,10576,,,,CHEMBL616672,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1295,B,
,1,15086,,,,10576,,,,CHEMBL616673,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,8,,,Autocuration,H,BAO_0000019,,1296,B,
,1,5717,,,,10576,,,,CHEMBL616674,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000019,,1297,F,
,1,12652,,,,10576,,,,CHEMBL616675,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1298,B,
Hippocampus,1,14608,,,,10576,,,,CHEMBL616676,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,8,,,Autocuration,H,BAO_0000221,10000000.0,1299,B,
Hippocampus,1,12306,,,,10576,,,,CHEMBL616677,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,1300,B,
Hippocampus,1,12306,,,,10576,,,,CHEMBL616678,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,1301,B,
,1,15247,,,,10576,,,,CHEMBL616679,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1302,B,
Hippocampus,1,17529,,,,10576,,,,CHEMBL616680,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,8,,,Expert,H,BAO_0000221,10000000.0,1303,B,
Hippocampus,1,14826,,,,10576,,,,CHEMBL616681,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1304,B,
Hippocampus,1,14826,,,,10576,,,,CHEMBL616682,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1305,B,
Hippocampus,1,13241,,,,10576,,,,CHEMBL616683,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000221,10000000.0,1306,B,
Hippocampus,1,14093,,,,10576,,,,CHEMBL616684,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000221,10000000.0,1307,B,
Hippocampus,1,14093,,,,10576,,,,CHEMBL616685,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,8,,,Autocuration,H,BAO_0000221,10000000.0,1308,B,
Brain,1,14442,,,,10576,,,,CHEMBL616686,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,8,,,Autocuration,H,BAO_0000221,955.0,1309,B,
,1,9919,,,,10576,,,,CHEMBL616687,Affinity for 5-hydroxytryptamine 1A receptor site,,8,,,Autocuration,H,BAO_0000357,,1310,B,
,1,9919,,,,10576,,,,CHEMBL616688,Affinity for 5-hydroxytryptamine 1A receptor site,,8,,,Autocuration,H,BAO_0000357,,1311,B,
Hippocampus,1,11440,,,,10576,,,,CHEMBL616689,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1312,B,
,1,11257,,,,10576,,,,CHEMBL616690,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1313,B,
,1,10330,,,,10576,,,,CHEMBL616691,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,1314,B,
Hippocampus,1,17331,,,,10576,,,,CHEMBL616692,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1315,B,
,1,16567,,,,10576,,,,CHEMBL616693,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,8,,,Expert,H,BAO_0000249,,1316,B,
,1,12058,,,,10576,,,,CHEMBL616694,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1317,B,
Hippocampus,1,9699,,,,10576,,,,CHEMBL616695,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,8,,,Autocuration,H,BAO_0000221,10000000.0,1318,B,
,1,9547,,,,10576,,,,CHEMBL616696,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,8,,,Autocuration,H,BAO_0000357,,1319,B,
,1,10330,,,,10576,,,,CHEMBL616697,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,8,,,Autocuration,H,BAO_0000357,,1320,B,
,1,14331,,,,10576,,,,CHEMBL616698,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1321,B,
,1,14060,,,,10576,,,,CHEMBL616949,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1322,B,
Hippocampus,1,14744,,,,10576,,,,CHEMBL616950,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,1323,B,
,1,13506,,,,10576,,,,CHEMBL832875,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,8,,,Autocuration,H,BAO_0000357,,1324,B,
Brain,1,10862,,,,10576,,,,CHEMBL616951,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,8,,,Expert,H,BAO_0000221,955.0,1325,B,
Brain,1,10862,,,,10576,,,,CHEMBL616952,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,8,,,Expert,H,BAO_0000221,955.0,1326,B,
,1,10062,,,,10576,,,,CHEMBL616953,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,8,,,Expert,H,BAO_0000357,,1327,B,
,1,12073,,,,10576,,,,CHEMBL616954,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,8,,,Autocuration,H,BAO_0000357,,1328,B,
,1,14875,,,,106,,,,CHEMBL616955,GTPgammaS radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,1329,B,
,1,2391,,,,106,,,,CHEMBL616956,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,8,,,Autocuration,H,BAO_0000357,,1330,B,
,1,2391,,,,106,,,,CHEMBL616957,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,8,,,Autocuration,H,BAO_0000019,,1331,F,
,1,2391,,,,106,,,,CHEMBL616958,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,8,,,Autocuration,H,BAO_0000019,,1332,F,
,1,2391,,,,106,,,,CHEMBL616959,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1333,B,
,1,2391,,,,106,,,,CHEMBL616960,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,8,,,Autocuration,H,BAO_0000357,,1334,B,
,1,2391,,,,106,,,,CHEMBL616961,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,8,,,Autocuration,H,BAO_0000019,,1335,F,
,1,17211,,,,106,,,HeLa,CHEMBL616962,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,8,,308.0,Expert,H,BAO_0000219,,1336,B,
,1,17211,,,,106,,,HeLa,CHEMBL616963,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,8,,308.0,Autocuration,H,BAO_0000219,,1337,B,
,1,6491,,,,106,,,,CHEMBL616524,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1338,B,
,1,16190,,,,106,,,CHO,CHEMBL616525,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1339,B,
,1,14165,,,,106,,,,CHEMBL872908,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,8,,,Autocuration,H,BAO_0000019,,1340,B,
,1,14165,,,,106,,,,CHEMBL616526,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,8,,,Autocuration,H,BAO_0000019,,1341,B,
,1,4234,,,,106,,,,CHEMBL616527,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1342,B,
,1,6328,,,,106,,,,CHEMBL616528,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,8,,,Expert,H,BAO_0000219,,1343,B,
,1,14770,,,,106,,,,CHEMBL616529,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1344,B,
,1,2598,,,,106,,,,CHEMBL616530,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1345,B,
,1,6897,,,,106,,,,CHEMBL616531,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000357,,1346,B,
,1,6897,,,,106,,,,CHEMBL616532,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1347,B,
,1,6013,,,,106,,,,CHEMBL616533,Binding affinity towards 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1348,B,
,1,5843,,,,106,,,,CHEMBL616534,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000357,,1349,B,
,1,14454,,,,106,,,,CHEMBL616535,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,8,,,Expert,H,BAO_0000357,,1350,B,
,1,16209,,,,106,,,,CHEMBL616536,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,8,,,Autocuration,H,BAO_0000357,,1351,B,
,1,3935,,,,106,,,,CHEMBL616537,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1352,B,
,1,13729,,,,106,,,CHO-K1,CHEMBL616538,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,8,,485.0,Expert,H,BAO_0000219,,1353,F,
,1,14251,,,,106,,,,CHEMBL616539,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000019,,1354,F,
,1,17085,,,,106,,,,CHEMBL616540,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000019,,1355,B,
,1,3025,,,,106,,,,CHEMBL616429,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,8,,,Autocuration,H,BAO_0000357,,1356,B,
,1,15315,,,,106,,,,CHEMBL616430,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000357,,1357,B,
,1,14214,,,,106,,,,CHEMBL616431,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,,1358,B,
,1,3804,,,,106,,,,CHEMBL616432,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1359,B,
,1,2391,,,,106,,,,CHEMBL616433,Affinity for 5-hydroxytryptamine 1B receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1360,B,
,1,4175,,,,106,,,,CHEMBL616434,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1361,B,
,1,17296,,,,106,,,CHO,CHEMBL616435,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,1362,B,
,1,17085,,,,106,,,,CHEMBL616436,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,8,,,Expert,H,BAO_0000019,,1363,B,
,1,17211,,,,106,,,HeLa,CHEMBL616437,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,8,,308.0,Autocuration,H,BAO_0000219,,1364,B,
,1,17211,,,,106,,,HeLa,CHEMBL616438,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,8,,308.0,Autocuration,H,BAO_0000219,,1365,B,
,1,17211,,,,106,,,HeLa,CHEMBL616439,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,8,,308.0,Autocuration,H,BAO_0000219,,1366,B,
,1,15926,,,,106,,,,CHEMBL616440,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1367,B,
,1,16312,,,,106,,,CHO-K1,CHEMBL616441,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,8,,485.0,Autocuration,H,BAO_0000219,,1368,B,
,1,5843,,,,106,,,,CHEMBL616442,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,8,,,Expert,H,BAO_0000357,,1369,B,
,1,5843,,,,106,,,,CHEMBL616443,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1370,B,
,1,16312,,,,106,,,CHO-K1,CHEMBL616444,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,8,,485.0,Expert,H,BAO_0000219,,1371,B,
,1,15926,,,,106,,,,CHEMBL616445,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1372,B,
,1,15926,,,,106,,,,CHEMBL616446,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1373,B,
,1,4540,,,,106,,,CHO,CHEMBL616447,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1374,B,
,1,6166,,,,106,,,,CHEMBL616448,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1375,B,
,1,17296,,,,106,,,CHO,CHEMBL616449,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1376,B,
,1,17296,,,,106,,,CHO,CHEMBL616450,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1377,B,
,1,17296,,,,106,,,CHO,CHEMBL857974,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1378,B,
,1,15779,,,,106,,,CHO,CHEMBL616451,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1379,B,
,1,15779,,,,106,,,CHO,CHEMBL616452,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1380,B,
,1,15779,,,,106,,,CHO,CHEMBL616453,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,8,,449.0,Autocuration,H,BAO_0000219,,1381,B,
,1,4199,,,,106,,,CHO,CHEMBL616454,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1382,B,
,1,14875,,,,106,,,,CHEMBL616455,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1383,B,
,1,15146,,,,106,,,CHO,CHEMBL616456,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,1384,B,
,1,5213,,,,106,,,,CHEMBL616457,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000357,,1385,B,
,1,14818,,,,106,,,CHO,CHEMBL616458,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,1386,B,
,1,4829,,,,106,,,CHO,CHEMBL616459,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,1387,B,
,1,14454,,,,106,,,,CHEMBL616460,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,8,,,Expert,H,BAO_0000019,,1388,F,
,1,14454,,,,106,,,,CHEMBL616461,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,8,,,Expert,H,BAO_0000019,,1389,F,
,1,14875,,,,106,,,CHO,CHEMBL616462,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,8,,449.0,Autocuration,H,BAO_0000219,,1390,F,
,1,14875,,,,106,,,CHO,CHEMBL616463,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,8,,449.0,Autocuration,H,BAO_0000219,,1391,F,
,1,15250,,,,105,,,,CHEMBL616464,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,8,,,Autocuration,H,BAO_0000019,,1392,F,
,1,15250,,,,105,,,CHO,CHEMBL616465,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,8,,449.0,Autocuration,H,BAO_0000219,,1393,B,
,1,15086,,,,17105,,,,CHEMBL832874,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1394,B,
,1,3025,,,,106,,,,CHEMBL616184,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1395,F,
,1,14998,,,,106,,,,CHEMBL616185,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1396,B,
,1,14998,,,,106,,,,CHEMBL616186,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Oryctolagus cuniculus,8,9986.0,,Intermediate,H,BAO_0000019,,1397,B,
,1,14998,,,,106,,,,CHEMBL616187,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1398,B,
,1,13969,,,,10577,,,,CHEMBL616188,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,8,,,Expert,H,BAO_0000357,,1399,B,
,1,13392,,,,10577,,,,CHEMBL873475,Binding affinity for 5-hydroxytryptamine 1B receptor,,9,,,Intermediate,D,BAO_0000357,,1400,B,
Striatum,1,3651,,,,10577,,,,CHEMBL616189,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,2435.0,1401,B,
,1,10025,,,,10577,,,,CHEMBL616190,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,8,,,Expert,H,BAO_0000357,,1402,B,
,1,13863,,,,10576,,,,CHEMBL616191,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,8,,,Autocuration,H,BAO_0000357,,1403,B,
,1,13863,,,,10576,,,,CHEMBL616192,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,8,,,Autocuration,H,BAO_0000357,,1404,B,
,1,13863,,,,10576,,,,CHEMBL616193,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,8,,,Autocuration,H,BAO_0000357,,1405,B,
,1,13863,,,,10576,,,,CHEMBL616194,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,8,,,Autocuration,H,BAO_0000357,,1406,B,
,1,13863,,,,10576,,,,CHEMBL616195,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,8,,,Autocuration,H,BAO_0000357,,1407,B,
,1,13863,,,,10576,,,,CHEMBL616196,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,8,,,Autocuration,H,BAO_0000357,,1408,B,
Hippocampus,1,4622,,,,10576,,,,CHEMBL616197,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,8,,,Autocuration,H,BAO_0000249,10000000.0,1409,B,
,1,14911,,,,10576,,,,CHEMBL616198,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,8,,,Intermediate,H,BAO_0000019,,1410,B,
Hippocampus,1,12678,,,,10576,,,,CHEMBL616199,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,8,,,Autocuration,H,BAO_0000221,10000000.0,1411,B,
Hippocampus,1,12678,,,,10576,,,,CHEMBL616200,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,8,,,Expert,H,BAO_0000221,10000000.0,1412,B,
Hippocampus,1,14235,,,,10576,,,,CHEMBL616201,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000221,10000000.0,1413,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616202,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,8,,,Expert,H,BAO_0000221,10000000.0,1414,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616203,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,8,,,Expert,H,BAO_0000221,10000000.0,1415,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616204,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,8,,,Expert,H,BAO_0000221,10000000.0,1416,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616205,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,8,,,Expert,H,BAO_0000221,10000000.0,1417,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616206,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,8,,,Expert,H,BAO_0000221,10000000.0,1418,B,
,1,16118,,,,10576,,,,CHEMBL616207,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,8,,,Expert,H,BAO_0000249,,1419,B,
,1,3268,,,,10576,,,,CHEMBL616208,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,8,,,Autocuration,H,BAO_0000249,,1420,B,
,1,3268,,,,10576,,,,CHEMBL616209,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,8,,,Autocuration,H,BAO_0000249,,1421,B,
,1,16117,,,,10576,,,,CHEMBL616210,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,8,,,Expert,H,BAO_0000357,,1422,B,
Hippocampus,1,9783,,,,10576,,,,CHEMBL616211,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,8,,,Expert,H,BAO_0000221,10000000.0,1423,B,
Hippocampus,1,9783,,,,10576,,,,CHEMBL616504,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,8,,,Autocuration,H,BAO_0000221,10000000.0,1424,B,
Hippocampus,1,14356,,,,10576,,,,CHEMBL616505,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1425,B,
,1,15740,,,,10576,,,,CHEMBL616506,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000019,,1426,F,
Hippocampus,1,12306,,,,10576,,,,CHEMBL872107,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,8,,,Autocuration,H,BAO_0000221,10000000.0,1427,B,
Hippocampus,1,13348,,,,10576,,,,CHEMBL616507,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1428,B,
,1,10394,,,,10576,,,,CHEMBL616303,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,8,,,Autocuration,H,BAO_0000249,,1429,B,
Hippocampus,1,15260,,,,10576,,,,CHEMBL616304,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,8,,,Autocuration,H,BAO_0000221,10000000.0,1430,B,
Hippocampus,1,10046,,,,10576,,,,CHEMBL616305,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000221,10000000.0,1431,B,
Hippocampus,1,15260,,,,10576,,,,CHEMBL616306,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,8,,,Intermediate,H,BAO_0000221,10000000.0,1432,F,
,1,12851,,,,10576,,,,CHEMBL616307,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1433,B,
Hippocampus,1,2148,,,,10576,,,,CHEMBL881829,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1434,B,
,1,13134,,,,10576,,,,CHEMBL616308,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,8,,,Expert,H,BAO_0000357,,1435,B,
,1,12462,,,,10576,,,,CHEMBL616309,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,8,,,Autocuration,H,BAO_0000019,,1436,B,
,1,12462,,,,10576,,,,CHEMBL616310,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,8,,,Expert,H,BAO_0000019,,1437,B,
,1,12462,,,,10576,,,CHO,CHEMBL616311,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1438,B,
,1,11933,,,,10576,,,,CHEMBL616312,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,1439,B,
,1,11933,,,,10576,,,,CHEMBL616313,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,8,,,Autocuration,H,BAO_0000357,,1440,B,
Hippocampus,1,403,,,,10576,,,,CHEMBL616314,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1441,B,
Hippocampus,1,15538,,,,10576,,,,CHEMBL616315,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1442,B,
Hippocampus,1,15538,,,,10576,,,,CHEMBL616567,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,8,,,Autocuration,H,BAO_0000221,10000000.0,1443,B,
Hippocampus,1,15538,,,,10576,,,,CHEMBL616568,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1444,B,
,1,12464,,,,10576,,,,CHEMBL616569,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,8,,,Intermediate,H,BAO_0000019,,1445,B,
,1,1455,,,,10576,,,,CHEMBL616570,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,8,,,Expert,H,BAO_0000357,,1446,B,
,1,12652,,,,10576,,,,CHEMBL616571,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,8,,,Autocuration,H,BAO_0000357,,1447,B,
Hippocampus,1,12639,,,,10576,,,,CHEMBL616572,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,8,,,Autocuration,H,BAO_0000221,10000000.0,1448,B,
,1,13949,,,,10576,,,,CHEMBL616573,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,8,,,Expert,H,BAO_0000249,,1449,B,
,1,12463,,,,10576,,,,CHEMBL616574,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1450,B,
Hippocampus,1,14829,,,,10576,,,,CHEMBL616575,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,8,,,Expert,H,BAO_0000221,10000000.0,1451,B,
Hippocampus,1,14829,,,,10576,,,,CHEMBL872108,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,8,,,Autocuration,H,BAO_0000221,10000000.0,1452,B,
,1,12092,,,,10576,,,,CHEMBL616576,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1453,B,
,1,403,,,,10576,,,,CHEMBL616577,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,8,,,Autocuration,H,BAO_0000249,,1454,B,
,1,403,,,,10576,,,,CHEMBL616578,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,8,,,Autocuration,H,BAO_0000249,,1455,B,
,1,3967,,,,10576,,,,CHEMBL616579,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,8,,,Expert,H,BAO_0000357,,1456,B,
,1,12771,,,,10576,,,,CHEMBL616580,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1457,B,
,1,15086,,,,10576,,,,CHEMBL616581,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,8,,,Autocuration,H,BAO_0000019,,1458,B,
Hippocampus,1,14909,,,,10576,,,,CHEMBL616582,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1459,B,
Hippocampus,1,14949,,,,10576,,,,CHEMBL616583,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,1460,B,
Hippocampus,1,2309,,,,10576,,,,CHEMBL616584,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1461,B,
,1,4170,,,,10576,,,,CHEMBL616585,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1462,B,
Hippocampus,1,11642,,,,10576,,,,CHEMBL616586,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1463,B,
Hippocampus,1,11642,,,,10576,,,,CHEMBL616587,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1464,B,
Hippocampus,1,12953,,,,10576,,,,CHEMBL616588,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1465,B,
Hippocampus,1,12953,,,,10576,,,,CHEMBL616589,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1466,B,
Hippocampus,1,12953,,,,10576,,,,CHEMBL616590,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000221,10000000.0,1467,B,
,1,12903,,,,10576,,,CHO,CHEMBL616591,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,8,,449.0,Expert,H,BAO_0000219,,1468,B,
,1,12536,,,,10576,,,,CHEMBL616592,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1469,B,
,1,10058,,,,10576,,,,CHEMBL616593,The inhibition activity of 5-HT1A at 1 uM,,8,,,Autocuration,H,BAO_0000357,,1470,B,
,1,12902,,,,10576,,,CHO-K1,CHEMBL616594,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,8,,485.0,Expert,H,BAO_0000219,,1471,B,
,1,14057,,,,10576,,,,CHEMBL616595,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,8,,,Expert,H,BAO_0000249,,1472,B,
,1,11296,,,,10576,,,,CHEMBL616596,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,8,,,Autocuration,H,BAO_0000357,,1473,B,
Hippocampus,1,11296,,,,10576,,,,CHEMBL616597,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1474,B,
Hippocampus,1,11296,,,,10576,,,,CHEMBL616598,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,8,,,Expert,H,BAO_0000221,10000000.0,1475,B,
,1,16616,,,,10576,,Membranes,,CHEMBL616599,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1476,F,
Hippocampus,1,16616,,,,10576,,Membranes,,CHEMBL616600,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,10000000.0,1477,F,
,1,16567,,,,10576,,,,CHEMBL616601,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,8,,,Autocuration,H,BAO_0000019,,1478,B,
,1,16567,,,,10576,,,,CHEMBL616602,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,8,,,Autocuration,H,BAO_0000019,,1479,B,
,1,16567,,,,10576,,,,CHEMBL616603,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,8,,,Autocuration,H,BAO_0000019,,1480,B,
,1,16567,,,,10576,,,,CHEMBL616604,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,8,,,Autocuration,H,BAO_0000019,,1481,B,
,1,17136,,,,10576,,,,CHEMBL616316,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,8,,,Autocuration,H,BAO_0000249,,1482,B,
,1,17136,,,,10576,,,,CHEMBL616317,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,8,,,Autocuration,H,BAO_0000249,,1483,B,
,1,16616,,,,10576,,,,CHEMBL616318,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1484,B,
Hippocampus,1,17331,,,,10576,,,,CHEMBL616319,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,8,,,Autocuration,H,BAO_0000221,10000000.0,1485,B,
Hippocampus,1,17331,,,,10576,,,,CHEMBL616320,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,8,,,Autocuration,H,BAO_0000221,10000000.0,1486,B,
Hippocampus,1,17167,,,,10576,,,,CHEMBL616321,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1487,B,
,1,15740,,,,10576,,,,CHEMBL616322,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,8,,,Autocuration,H,BAO_0000019,,1488,F,
,1,15740,,,,10576,,,,CHEMBL616323,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,8,,,Autocuration,H,BAO_0000019,,1489,F,
,1,4671,,,,10576,,,,CHEMBL616324,Ratio of binding affinity to 5-HT 1A and D2 receptor,,8,,,Autocuration,H,BAO_0000357,,1490,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL616325,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,8,,,Autocuration,H,BAO_0000221,10000000.0,1491,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL616326,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,8,,,Autocuration,H,BAO_0000221,10000000.0,1492,B,
Hippocampus,1,10058,,,,10576,,,,CHEMBL616327,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,8,,,Autocuration,H,BAO_0000221,10000000.0,1493,B,
,1,12073,,,,10576,,,,CHEMBL616328,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1494,B,
,1,2759,,,,10576,,,,CHEMBL858110,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,8,,,Autocuration,H,BAO_0000249,,1495,B,
,1,2759,,,,10576,,,,CHEMBL616329,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,8,,,Autocuration,H,BAO_0000249,,1496,F,
,1,2759,,,,10576,,,,CHEMBL616330,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,8,,,Autocuration,H,BAO_0000249,,1497,B,
,1,2759,,,,10576,,,,CHEMBL616331,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,8,,,Autocuration,H,BAO_0000249,,1498,F,
,1,2759,,,,10576,,,,CHEMBL616332,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,8,,,Autocuration,H,BAO_0000249,,1499,F,
Brain,1,9737,,,,10576,,,,CHEMBL857063,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,8,,,Autocuration,H,BAO_0000249,955.0,1500,B,
,1,9737,,,,10576,,,,CHEMBL616333,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,8,,,Autocuration,H,BAO_0000019,,1501,B,
,1,5717,,,,10576,,,,CHEMBL616334,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000019,,1502,F,
Hippocampus,1,12253,,,,10576,,,,CHEMBL616335,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1503,B,
,1,14025,,,,10576,,,,CHEMBL616336,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,8,,,Autocuration,H,BAO_0000019,,1504,B,
,1,10425,,,,10576,,,,CHEMBL616337,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000249,,1505,B,
,1,14998,,,,10576,,,,CHEMBL616338,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,8,,,Autocuration,H,BAO_0000019,,1506,B,
Hippocampus,1,13694,,,,10576,,,,CHEMBL616339,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,8,,,Autocuration,H,BAO_0000221,10000000.0,1507,B,
Hippocampus,1,13694,,,,10576,,,,CHEMBL616340,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,8,,,Autocuration,H,BAO_0000221,10000000.0,1508,B,
,1,4342,,,,10576,,,,CHEMBL616341,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1509,B,
,1,12936,,,,10576,,,,CHEMBL616342,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1510,B,
,1,13144,,,,10576,,,,CHEMBL616343,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1511,B,
,1,13343,,,,10576,,,,CHEMBL616344,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,8,,,Expert,H,BAO_0000019,,1512,B,
,1,12132,,,,10576,,,,CHEMBL616345,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,Expert,H,BAO_0000357,,1513,B,
,1,15419,,,,10576,,,,CHEMBL616346,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,8,,,Expert,H,BAO_0000019,,1514,B,
Hippocampus,1,1479,,,,10576,,,,CHEMBL616347,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1515,B,
,1,14287,,,,10576,,,,CHEMBL616348,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,8,,,Expert,H,BAO_0000019,,1516,B,
,1,13116,,,,10576,,,,CHEMBL616349,Binding affinity at 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1517,B,
,1,2759,,,,10576,,Membranes,,CHEMBL616152,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1518,B,
,1,2759,,,,10576,,,,CHEMBL616153,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,8,,,Autocuration,H,BAO_0000249,,1519,B,
,1,14748,,,,10576,,,,CHEMBL616154,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,8,,,Expert,H,BAO_0000019,,1520,B,
,1,12304,,,,10576,,,,CHEMBL616155,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,8,,,Autocuration,H,BAO_0000019,,1521,B,
Hippocampus,1,12409,,,,10576,,,,CHEMBL616156,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1522,B,
Hippocampus,1,12409,,,,10576,,,,CHEMBL616157,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,1523,B,
Hippocampus,1,13267,,,,10576,,,,CHEMBL616158,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,1524,B,
,1,15194,,,,10576,,,,CHEMBL616159,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1525,B,
,1,14256,,,,10576,,,,CHEMBL616160,pKi value against rat 5-hydroxytryptamine 1A receptor.,,8,,,Expert,H,BAO_0000357,,1526,B,
,1,16567,,,,10576,,,,CHEMBL616161,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,8,,,Autocuration,H,BAO_0000019,,1527,B,
,1,15740,,,,10576,,,,CHEMBL616162,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,8,,,Autocuration,H,BAO_0000019,,1528,F,
,1,13278,,,,12687,,,,CHEMBL616163,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1529,B,
,1,1970,,,,10626,,Membranes,,CHEMBL616164,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,8,,,Expert,H,BAO_0000249,,1530,B,
Brain,1,10034,,,,10576,,,,CHEMBL616165,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,8,,,Autocuration,H,BAO_0000221,955.0,1531,B,
,1,13348,,,,51,,,,CHEMBL616355,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Rattus norvegicus,8,10116.0,,Autocuration,H,BAO_0000019,,1532,B,
,1,13630,,,,10576,,,,CHEMBL616356,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,8,,,Autocuration,H,BAO_0000019,,1533,F,
Brain,1,10862,,,,10576,,,,CHEMBL616357,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,8,,,Autocuration,H,BAO_0000221,955.0,1534,B,
,1,12058,,,,10576,,,,CHEMBL616358,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,8,,,Autocuration,H,BAO_0000019,,1535,B,
,1,4639,,,,51,,,,CHEMBL616359,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1536,B,
,1,15453,,,,51,,,,CHEMBL616360,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,8,,,Expert,H,BAO_0000357,,1537,B,
,1,4820,,,,51,,,,CHEMBL616361,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1538,B,
,1,1089,,,,51,,,,CHEMBL616362,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1539,B,
,1,386,,,,51,,Brain membranes,,CHEMBL616363,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,8,,,Autocuration,H,BAO_0000249,,1540,B,
,1,6011,,,,51,,,,CHEMBL616364,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,1541,B,
,1,5014,,,,51,,,,CHEMBL616365,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1542,B,
,1,4402,,,,51,,,,CHEMBL616366,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,8,,,Expert,H,BAO_0000357,,1543,B,
,1,17066,,,,51,,,,CHEMBL872906,Binding affinity towards 5-hydroxytryptamine 1A receptor,,8,,,Expert,H,BAO_0000357,,1544,B,
,1,17515,,,,51,,,,CHEMBL616367,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,1545,B,
,1,2474,,,,51,,,,CHEMBL616368,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1546,B,
,1,4775,,,,51,,,,CHEMBL616369,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1547,B,
,1,14294,,,,51,,,,CHEMBL616370,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1548,B,
,1,14294,,,,51,,,,CHEMBL616371,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1549,B,
,1,12249,,,,51,,,CHO,CHEMBL616372,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1550,B,
,1,11376,,,,51,,,,CHEMBL616373,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,8,,,Expert,H,BAO_0000219,,1551,B,
,1,2474,,In vivo,,51,,,,CHEMBL616374,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000218,,1552,B,
Hippocampus,1,13311,,,,51,,,,CHEMBL616375,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,1553,B,
,1,4373,,,,51,,,,CHEMBL616376,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1554,B,
,1,1633,,,,51,,,,CHEMBL857064,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,8,,,Expert,H,BAO_0000357,,1555,B,
,1,11866,,,,51,,,,CHEMBL616377,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1556,B,
,1,4373,,,,51,,,,CHEMBL616378,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1557,B,
,1,4687,,,,51,,,,CHEMBL616379,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1558,B,
,1,16946,,,,11863,,,,CHEMBL616380,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1559,B,
,1,13291,,,,11863,,,,CHEMBL616381,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,8,,,Autocuration,H,BAO_0000357,,1560,B,
,1,14159,,,,11863,,,,CHEMBL616382,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1561,B,
,1,10812,,,,11863,,,,CHEMBL616383,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1562,B,
,1,3032,,,,11863,,,CHO,CHEMBL616350,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Mus musculus,9,10090.0,449.0,Expert,D,BAO_0000219,,1563,B,
,1,16655,,,,11863,,,,CHEMBL616351,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1564,B,
,1,14532,,,,11863,,,,CHEMBL616352,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,8,,,Autocuration,H,BAO_0000357,,1565,B,
,1,13944,,,,11863,,,,CHEMBL616353,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1566,B,
,1,13033,,,,11863,,,,CHEMBL616354,Binding affinity against serotonergic 5-HT1a receptor,,8,,,Autocuration,H,BAO_0000357,,1567,B,
,1,10321,,,,11863,,,,CHEMBL616508,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1568,B,
,1,2968,,,,11863,,,,CHEMBL616559,Binding affinity for 5-hydroxytryptamine 1A receptor,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,1569,B,
,1,13964,,,,11863,,,,CHEMBL616560,Binding affinity at 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1570,B,
,1,15527,,,,11863,,,,CHEMBL616561,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,8,,,Autocuration,H,BAO_0000357,,1571,B,
,1,12248,,,,11863,,,CHO,CHEMBL616562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1572,B,
,1,12249,,,,11863,,,CHO,CHEMBL616563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,1573,B,
,1,15120,,,,11863,,,,CHEMBL616564,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1574,B,
,1,13313,,,,11863,,,,CHEMBL616565,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1575,B,
,1,2613,,,,11863,,,,CHEMBL616566,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000218,,1576,B,
,1,16700,,,,11863,,,,CHEMBL616989,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,1577,B,
,1,2201,,,,11863,,,,CHEMBL857975,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1578,B,
,1,1274,,,,11863,,,,CHEMBL616990,Binding affinity against 5-hydroxytryptamine 1A receptor,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,1579,B,
,1,1317,,,,11863,,,,CHEMBL616991,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,1580,B,
,1,12146,,,,11863,,,,CHEMBL616992,Tested against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1581,B,
,1,14059,,,,11863,,,,CHEMBL616993,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,1582,B,
,1,14025,,,,106,,,,CHEMBL616994,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000019,,1583,B,
,1,14025,,,,106,,,,CHEMBL616995,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1584,B,
,1,14447,,,,105571,,,HEK293,CHEMBL616996,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,9,9593.0,722.0,Intermediate,D,BAO_0000219,,1585,B,
,1,3025,,In vivo,,106,,,,CHEMBL616997,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000218,,1586,F,
,1,3025,,In vivo,,106,,,,CHEMBL616998,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000218,,1587,F,
,1,15329,,,,106,,,,CHEMBL616999,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,1588,F,
,1,15329,,,,106,,,,CHEMBL617000,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,1589,F,
,1,15847,,,,106,,,,CHEMBL617001,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,1590,F,
,1,15847,,,,106,,,,CHEMBL858111,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,1591,F,
,1,14165,,,,106,,,,CHEMBL617002,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,8,,,Autocuration,H,BAO_0000019,,1592,F,
,1,14214,,,,106,,,,CHEMBL617003,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,8,,,Autocuration,H,BAO_0000019,,1593,F,
,1,14214,,,,106,,,,CHEMBL617004,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,8,,,Autocuration,H,BAO_0000019,,1594,F,
,1,14214,,,,106,,,,CHEMBL617005,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,1595,F,
,1,13729,,,,106,,,CHO-K1,CHEMBL616623,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Homo sapiens,9,9606.0,485.0,Expert,D,BAO_0000219,,1596,F,
,1,3025,,,,106,,,CHO,CHEMBL616624,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,8,,449.0,Autocuration,H,BAO_0000219,,1597,F,
,1,2391,,,,106,,,,CHEMBL883243,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1598,B,
,1,2391,,,,106,,,,CHEMBL616625,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,8,,,Autocuration,H,BAO_0000019,,1599,F,
,1,14956,,,,106,,,CHO,CHEMBL616626,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,8,,449.0,Expert,H,BAO_0000219,,1600,F,
,1,2598,,,,106,,,CHO,CHEMBL616627,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,8,,449.0,Autocuration,H,BAO_0000219,,1601,F,
,1,2598,,,,106,,,CHO,CHEMBL616628,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,8,,449.0,Autocuration,H,BAO_0000219,,1602,F,
,1,2598,,,,106,,,CHO,CHEMBL616629,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,8,,449.0,Autocuration,H,BAO_0000219,,1603,F,
,1,2598,,,,106,,,CHO,CHEMBL616630,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,8,,449.0,Autocuration,H,BAO_0000219,,1604,F,
,1,14956,,,,106,,,,CHEMBL616631,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,8,,,Expert,H,BAO_0000019,,1605,F,
,1,14956,,,,106,,,,CHEMBL616632,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,8,,,Autocuration,H,BAO_0000019,,1606,F,
,1,14214,,,,106,,,,CHEMBL616633,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1607,B,
,1,3463,,,,106,,,CHO,CHEMBL616634,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,8,,449.0,Expert,H,BAO_0000219,,1608,B,
,1,15331,,,,106,,,,CHEMBL616635,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,1609,B,
,1,16146,,,,106,,,,CHEMBL885358,Binding affinity against 5-hydroxytryptamine 1B receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1610,B,
,1,14159,,,,106,,,CHO,CHEMBL616636,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1611,B,
,1,14158,,,,106,,,CHO,CHEMBL616637,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,8,,449.0,Expert,H,BAO_0000219,,1612,B,
,1,14159,,,,106,,,,CHEMBL616638,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1613,B,
,1,15250,,,,106,,,CHO,CHEMBL616639,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1614,B,
,1,15250,,,,106,,,CHO,CHEMBL616640,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,8,,449.0,Expert,H,BAO_0000219,,1615,B,
,1,15331,,,,106,,,CHO,CHEMBL616641,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1616,B,
,1,15332,,,,106,,,CHO,CHEMBL616642,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,8,,449.0,Expert,H,BAO_0000219,,1617,B,
,1,14956,,,,106,,,CHO,CHEMBL616643,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1618,B,
,1,3805,,,,106,,,,CHEMBL616644,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,1619,B,
,1,14875,,,,106,,,,CHEMBL616645,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,8,,,Autocuration,H,BAO_0000357,,1620,B,
,1,14454,,,,105,,,,CHEMBL616646,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1621,F,
,1,14454,,,,105,,,,CHEMBL616647,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000019,,1622,F,
,1,16288,,,,105,,,,CHEMBL616509,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,8,,,Autocuration,H,BAO_0000357,,1623,B,
,1,16288,,,,105,,,,CHEMBL616510,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,8,,,Autocuration,H,BAO_0000357,,1624,B,
,1,16312,,,,105,,,,CHEMBL616511,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1625,B,
,1,1348,,,,105,,,,CHEMBL616512,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Bos taurus,8,9913.0,,Expert,H,BAO_0000357,,1626,B,
,1,5834,,,,105,,,,CHEMBL616513,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1627,B,
Striatum,1,13366,,,,105,,,,CHEMBL616514,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000019,2435.0,1628,B,
,1,1414,,,,105,,,,CHEMBL616515,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Bos taurus,8,9913.0,,Expert,H,BAO_0000357,,1629,B,
,1,14998,,,,105,,,,CHEMBL616516,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000019,,1630,B,
,1,11473,,,,105,,,,CHEMBL616517,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1631,B,
,1,11473,,,,105,,,,CHEMBL616518,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1632,B,
,1,10639,,,,105,,,,CHEMBL616519,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1633,B,
,1,10639,,,,105,,,,CHEMBL616520,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1634,B,
,1,1375,,,,105,,,,CHEMBL616521,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1635,B,
,1,1375,,,,105,,,,CHEMBL616522,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1636,B,
,1,16532,,,,105,,,,CHEMBL884531,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1637,B,
,1,11147,,,,105,,,,CHEMBL616523,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1638,B,
Striatum,1,13366,,,,105,,,,CHEMBL616731,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000019,2435.0,1639,B,
,1,10444,,,,105,,,,CHEMBL616732,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000019,,1640,B,
,1,16532,,,,105,,,,CHEMBL616733,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1641,B,
,1,16532,,,,105,,,,CHEMBL616734,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1642,B,
,1,12827,,,,105,,,,CHEMBL616735,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000249,,1643,B,
,1,12827,,,,105,,,,CHEMBL616736,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000249,,1644,B,
,1,12919,,,,105,,,,CHEMBL616737,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,8,9913.0,,Expert,H,BAO_0000019,,1645,F,
,1,14025,,,,105,,,,CHEMBL616738,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000019,,1646,B,
,1,12919,,,,105,,,,CHEMBL616739,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,8,9913.0,,Expert,H,BAO_0000019,,1647,F,
,1,12919,,,,105,,,,CHEMBL616740,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,8,9913.0,,Expert,H,BAO_0000019,,1648,F,
,1,12919,,,,105,,,,CHEMBL616741,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,8,9913.0,,Expert,H,BAO_0000019,,1649,F,
,1,14447,,,,105,,,HEK293,CHEMBL616742,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,8,9593.0,722.0,Autocuration,H,BAO_0000219,,1650,B,
,1,1375,,,,105570,,,,CHEMBL616743,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1651,B,
,1,1375,,,,105570,,,,CHEMBL616744,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1652,B,
,1,12409,,,,105570,,,,CHEMBL616745,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1653,F,
,1,12409,,,,105570,,,,CHEMBL616746,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1654,F,
,1,12409,,,,105570,,,,CHEMBL616747,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1655,F,
,1,12409,,,,105570,,,,CHEMBL616748,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1656,F,
,1,12409,,,,105570,,,,CHEMBL616648,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1657,F,
,1,11574,,,,105570,,,,CHEMBL616649,Binding affinity against 5-hydroxytryptamine 1D receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,1658,B,
,1,1558,,,,105570,,,,CHEMBL616650,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,1659,B,
,1,12409,,,,105570,,,,CHEMBL616651,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000218,,1660,F,
,1,12409,,,,105570,,,,CHEMBL616652,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000218,,1661,F,
,1,12409,,,,105570,,,,CHEMBL616653,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000218,,1662,F,
,1,12409,,,,105570,,,,CHEMBL616654,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000218,,1663,F,
,1,12253,,,,105570,,,,CHEMBL616655,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,1664,B,
,1,12936,,,,105570,,,,CHEMBL616656,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,1665,B,
,1,13181,,,,105,,,,CHEMBL616657,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,1666,B,
Striatum,1,12409,,,,105570,,,,CHEMBL616658,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,1667,B,
,1,10639,,,,105570,,,,CHEMBL616659,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,1668,B,
,1,5254,,,,51,,,,CHEMBL616660,Binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1669,B,
,1,13051,,,,106,,,,CHEMBL616661,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,8,,,Autocuration,H,BAO_0000357,,1670,B,
,1,3463,,,,105,,,,CHEMBL616662,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,8,,,Expert,H,BAO_0000019,,1671,F,
,1,15315,,,,105,,,,CHEMBL616663,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1672,F,
,1,6011,,,,105,,,,CHEMBL616664,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1673,F,
,1,14159,,,,105,,,CHO,CHEMBL881820,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1674,F,
,1,14159,,,,105,,,CHO,CHEMBL616665,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,8,,449.0,Autocuration,H,BAO_0000219,,1675,F,
,1,15250,,,,105,,,CHO,CHEMBL616666,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,8,,449.0,Expert,H,BAO_0000219,,1676,B,
,1,15250,,,,105,,,CHO,CHEMBL616667,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,8,,449.0,Autocuration,H,BAO_0000219,,1677,B,
,1,15331,,,,105,,,CHO,CHEMBL616668,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,8,,449.0,Expert,H,BAO_0000219,,1678,F,
,1,15332,,,,105,,,CHO,CHEMBL616669,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1679,F,
,1,15332,,,,105,,,CHO,CHEMBL617040,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,8,,449.0,Expert,H,BAO_0000219,,1680,F,
,1,3294,,,,105,,,CHO,CHEMBL617041,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,8,,449.0,Autocuration,H,BAO_0000219,,1681,F,
,1,14158,,,,105,,,CHO,CHEMBL617042,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,8,,449.0,Expert,H,BAO_0000219,,1682,F,
,1,14956,,,,105,,,CHO,CHEMBL617043,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,8,,449.0,Expert,H,BAO_0000219,,1683,F,
,1,12469,,,,105,,,,CHEMBL617044,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1684,F,
,1,3463,,,,105,,,CHO,CHEMBL617045,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,8,,449.0,Expert,H,BAO_0000219,,1685,F,
,1,15250,,,,105,,,CHO,CHEMBL617046,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1686,F,
,1,15250,,,,105,,,CHO,CHEMBL617047,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1687,F,
,1,14956,,,,105,,,,CHEMBL617048,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,8,,,Expert,H,BAO_0000019,,1688,F,
,1,14159,,,,105,,,,CHEMBL616897,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,8,,,Autocuration,H,BAO_0000019,,1689,F,
,1,14159,,,,105,,,,CHEMBL616898,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,1690,F,
,1,14499,,,,105,,,CHO,CHEMBL858201,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1691,F,
,1,15315,,,,105,,,,CHEMBL616899,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1692,F,
,1,3294,,In vitro,,105,,,,CHEMBL616900,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,8,,,Autocuration,H,BAO_0000219,,1693,B,
,1,3463,,,,105,,,CHO,CHEMBL616901,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,8,,449.0,Expert,H,BAO_0000219,,1694,B,
,1,15331,,,,105,,,,CHEMBL616902,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,1695,B,
,1,14159,,,,105,,,CHO,CHEMBL616903,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1696,B,
,1,14158,,,,105,,,CHO,CHEMBL616904,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,8,,449.0,Expert,H,BAO_0000219,,1697,B,
,1,14159,,,,105,,,,CHEMBL616905,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1698,B,
,1,15250,,,,105,,,CHO,CHEMBL616906,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,8,,449.0,Expert,H,BAO_0000219,,1699,B,
,1,15250,,,,105,,,CHO,CHEMBL616907,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1700,B,
,1,15331,,,,105,,,CHO,CHEMBL616908,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1701,B,
,1,15332,,,,105,,,CHO,CHEMBL616909,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1702,B,
,1,14499,,,,105,,,CHO,CHEMBL616910,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1703,B,
,1,15332,,,,105,,,CHO,CHEMBL616911,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1704,B,
,1,14956,,,,105,,,CHO,CHEMBL616912,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,1705,B,
,1,3805,,,,105,,,,CHEMBL616913,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,1706,B,
,1,6011,,,,105,,,CHO,CHEMBL616914,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1707,B,
,1,16190,,,,105,,,CHO,CHEMBL616915,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1708,B,
,1,14165,,,,105,,,,CHEMBL616916,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,8,,,Autocuration,H,BAO_0000019,,1709,B,
,1,4234,,,,105,,,,CHEMBL616917,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1710,B,
,1,15527,,,,105,,,,CHEMBL616918,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,8,,,Autocuration,H,BAO_0000357,,1711,B,
,1,6328,,,,105,,,,CHEMBL616919,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,8,,,Expert,H,BAO_0000219,,1712,B,
,1,16209,,,,105,,,,CHEMBL616920,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1713,B,
,1,14770,,,,105,,,,CHEMBL872914,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1714,B,
,1,2598,,,,105,,,,CHEMBL616921,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1715,B,
,1,6897,,,,105,,,,CHEMBL616922,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,8,,,Expert,H,BAO_0000357,,1716,B,
,1,6013,,,,105,,,,CHEMBL616923,Binding affinity towards 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1717,B,
,1,5843,,,,105,,,,CHEMBL616924,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,8,,,Expert,H,BAO_0000357,,1718,B,
,1,14454,,,,105,,,,CHEMBL875909,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,8,,,Expert,H,BAO_0000357,,1719,B,
,1,14454,,,,105,,,,CHEMBL616925,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,8,,,Autocuration,H,BAO_0000357,,1720,B,
,1,14454,,,,105,,,,CHEMBL616926,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,8,,,Autocuration,H,BAO_0000357,,1721,B,
,1,15818,,,,105,,,,CHEMBL616927,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1722,B,
,1,13729,,,,105,,,CHO-K1,CHEMBL616928,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,8,,485.0,Expert,H,BAO_0000219,,1723,F,
,1,6011,,In vitro,,105,,,,CHEMBL616929,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,,1724,B,
,1,4234,,,,105,,,,CHEMBL616930,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1725,B,
,1,17085,,,,105,,,,CHEMBL616931,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,Expert,H,BAO_0000019,,1726,B,
,1,3025,,,,105,,,,CHEMBL616932,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,8,,,Autocuration,H,BAO_0000357,,1727,B,
,1,15315,,,,105,,,,CHEMBL616933,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,8,,,Expert,H,BAO_0000357,,1728,B,
,1,14214,,,,105,,,,CHEMBL616934,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,,1729,B,
,1,3804,,,,105,,,,CHEMBL616935,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1730,B,
,1,16700,,,,105,,,,CHEMBL616936,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,1731,B,
,1,2391,,,,105,,,,CHEMBL616937,Affinity for 5-hydroxytryptamine 1D receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1732,B,
,1,4175,,,,105,,,,CHEMBL616938,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1733,B,
,1,17085,,,,105,,,,CHEMBL616939,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1734,B,
,1,17085,,,,105,,,,CHEMBL616940,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,8,,,Expert,H,BAO_0000019,,1735,B,
,1,15926,,,,105,,,,CHEMBL616941,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1736,B,
,1,16312,,,,105,,,CHO-K1,CHEMBL616942,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,8,,485.0,Autocuration,H,BAO_0000219,,1737,B,
,1,16312,,,,105,,,CHO-K1,CHEMBL616943,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,8,,485.0,Autocuration,H,BAO_0000219,,1738,B,
,1,14956,,,,104802,,,CHO,CHEMBL616944,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,4,,449.0,Autocuration,H,BAO_0000219,,1739,B,
,1,3294,,,,105,,,,CHEMBL616945,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,8,,,Autocuration,H,BAO_0000019,,1740,F,
,1,12861,,,,105,,,,CHEMBL616946,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,1741,B,
,1,12861,,,,105,,,,CHEMBL616947,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,Autocuration,H,BAO_0000019,,1742,B,
,1,16312,,,,105,,,CHO-K1,CHEMBL616948,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,8,,485.0,Expert,H,BAO_0000219,,1743,B,
,1,5104,,,,105,,,,CHEMBL616851,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1744,B,
,1,5105,,,,105,,,,CHEMBL616852,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1745,B,
,1,14499,,,,105,,,,CHEMBL616853,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1746,B,
,1,15926,,,,105,,,,CHEMBL616854,Binding activity against human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1747,B,
,1,4540,,,,105,,,CHO,CHEMBL616855,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,1748,B,
,1,15779,,,,105,,,CHO,CHEMBL616856,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,1749,B,
,1,15779,,,,105,,,CHO,CHEMBL616857,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,1750,B,
,1,6166,,,,105,,,,CHEMBL616858,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1751,B,
,1,15779,,,,105,,,CHO,CHEMBL616859,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,1752,B,
,1,15779,,,,105,,,CHO,CHEMBL616860,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,8,,449.0,Autocuration,H,BAO_0000219,,1753,B,
,1,17451,,,,105,,,HEK293,CHEMBL616861,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1754,B,
,1,17451,,,,105,,,HEK293,CHEMBL616541,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1755,B,
,1,17451,,,,105,,,HEK293,CHEMBL616542,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,8,,722.0,Autocuration,H,BAO_0000219,,1756,B,
,1,4199,,,,105,,,CHO,CHEMBL616543,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,1757,B,
,1,14875,,,,105,,,,CHEMBL616544,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1758,B,
,1,15146,,,,105,,,CHO,CHEMBL616545,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,1759,B,
,1,5213,,,,105,,,,CHEMBL616546,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000357,,1760,B,
,1,14818,,,,105,,,CHO,CHEMBL616547,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,1761,B,
,1,4829,,,,105,,,CHO,CHEMBL616548,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,1762,B,
,1,14454,,,,105,,,,CHEMBL616549,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,8,,,Expert,H,BAO_0000019,,1763,F,
,1,14454,,,,105,,,,CHEMBL616550,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,8,,,Expert,H,BAO_0000019,,1764,F,
,1,5254,,,,108,,,,CHEMBL857066,Binding affinity against 5-HT2C receptor,,8,,,Autocuration,H,BAO_0000357,,1765,B,
,1,5254,,,,108,,,,CHEMBL616551,Binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1766,B,
,1,10639,,,,10577,,,,CHEMBL616552,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,8,,,Autocuration,H,BAO_0000357,,1767,B,
,1,10639,,,,10577,,,,CHEMBL832876,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,8,,,Autocuration,H,BAO_0000019,,1768,F,
,1,12352,,,,10577,,,,CHEMBL616553,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,8,,,Expert,H,BAO_0000019,,1769,B,
,1,9098,,,,10577,,,,CHEMBL616554,Binding affinity towards 5-HT1B was determined,,8,,,Autocuration,H,BAO_0000357,,1770,B,
,1,14430,,,,10577,,,,CHEMBL616555,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,8,,,Expert,H,BAO_0000019,,1771,B,
,1,13657,,,,10577,,,,CHEMBL616556,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,8,,,Expert,H,BAO_0000019,,1772,B,
,1,13657,,,,10577,,,,CHEMBL616557,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,8,,,Autocuration,H,BAO_0000019,,1773,B,
,1,15854,,,,10577,,,,CHEMBL616558,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,Expert,H,BAO_0000019,,1774,B,
,1,10639,,,,10577,,,,CHEMBL616749,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1775,B,
,1,10025,,,,10577,,,,CHEMBL616750,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,8,,,Autocuration,H,BAO_0000357,,1776,B,
,1,10025,,,,10577,,,,CHEMBL616751,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,8,,,Autocuration,H,BAO_0000357,,1777,B,
,1,14286,,,,10577,,,,CHEMBL616752,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,8,,,Autocuration,H,BAO_0000249,,1778,B,
Striatum,1,3651,,,,10577,,,,CHEMBL616753,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,8,,,Autocuration,H,BAO_0000019,2435.0,1779,B,
,1,14178,,,,10577,,,,CHEMBL616754,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1780,B,
,1,10639,,,,10577,,,,CHEMBL616755,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,1781,B,
Striatum,1,13605,,,,10577,,,,CHEMBL616756,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,8,,,Autocuration,H,BAO_0000019,2435.0,1782,B,
Striatum,1,5834,,,,10577,,,,CHEMBL616757,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,8,,,Autocuration,H,BAO_0000019,2435.0,1783,B,
Striatum,1,10922,,,,10577,,,,CHEMBL616758,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,8,,,Autocuration,H,BAO_0000357,2435.0,1784,B,
,1,14286,,,,10577,,,,CHEMBL616759,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,8,,,Autocuration,H,BAO_0000249,,1785,B,
,1,11825,,,,10577,,,,CHEMBL616760,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,8,,,Autocuration,H,BAO_0000357,,1786,B,
Striatum,1,14826,,,,10577,,,,CHEMBL616761,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,8,,,Autocuration,H,BAO_0000019,2435.0,1787,B,
Striatum,1,9699,,,,10577,,,,CHEMBL616762,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,8,,,Autocuration,H,BAO_0000019,2435.0,1788,B,
,1,14423,,,,10577,,,,CHEMBL616763,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,8,,,Autocuration,H,BAO_0000019,,1789,B,
,1,10062,,,,10577,,,,CHEMBL872909,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,8,,,Expert,H,BAO_0000357,,1790,B,
,1,10062,,,,10577,,,,CHEMBL616764,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1791,B,
,1,12280,,,,10577,,,,CHEMBL616765,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1792,B,
Striatum,1,15412,,,,10577,,,,CHEMBL616766,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,8,,,Autocuration,H,BAO_0000357,2435.0,1793,B,
Striatum,1,15412,,,,10577,,,,CHEMBL616767,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,8,,,Autocuration,H,BAO_0000357,2435.0,1794,B,
,1,10062,,,,10577,,,,CHEMBL616768,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1795,B,
,1,11147,,,,10577,,,,CHEMBL616769,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1796,B,
,1,9547,,,,10577,,,,CHEMBL616770,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,8,,,Autocuration,H,BAO_0000019,,1797,B,
,1,10444,,,,10577,,,,CHEMBL616771,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,8,,,Autocuration,H,BAO_0000019,,1798,B,
Striatum,1,12469,,,,10577,,,,CHEMBL616772,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,8,,,Autocuration,H,BAO_0000019,2435.0,1799,B,
,1,9098,,,,10577,,,,CHEMBL616773,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,8,,,Expert,H,BAO_0000019,,1800,B,
,1,9098,,,,10577,,,,CHEMBL616774,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,8,,,Autocuration,H,BAO_0000019,,1801,B,
,1,9699,,,,10577,,,,CHEMBL616775,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1802,B,
,1,10394,,,,10577,,,,CHEMBL616776,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000249,,1803,B,
,1,12092,,,,10577,,,,CHEMBL616777,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1804,B,
,1,16700,,,,10577,,,,CHEMBL616778,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,1805,B,
,1,403,,,,10577,,,,CHEMBL616779,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1806,B,
,1,12771,,,,10577,,,,CHEMBL616780,Binding affinity towards 5-hydroxytryptamine 1B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1807,B,
,1,11642,,,,10577,,,,CHEMBL616781,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,8,,,Autocuration,H,BAO_0000019,,1808,B,
,1,12953,,,,10577,,,,CHEMBL616782,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1809,B,
,1,12953,,,,10577,,,,CHEMBL616783,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1810,B,
Striatum,1,12953,,,,10577,,,,CHEMBL616784,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,8,,,Expert,H,BAO_0000019,2435.0,1811,B,
,1,12953,,,,10577,,,,CHEMBL616785,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,1812,B,
Brain,1,9737,,,,10577,,,,CHEMBL857067,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,8,,,Autocuration,H,BAO_0000249,955.0,1813,B,
,1,9737,,,,10577,,,,CHEMBL616786,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,8,,,Autocuration,H,BAO_0000019,,1814,B,
Brain,1,9737,,,,10577,,,,CHEMBL616787,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,8,,,Autocuration,H,BAO_0000249,955.0,1815,B,
,1,12827,,,,10577,,,,CHEMBL616788,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,8,,,Autocuration,H,BAO_0000357,,1816,B,
,1,5033,,,,10577,,,,CHEMBL616789,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1817,B,
,1,9786,,,,10577,,,,CHEMBL616790,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1818,B,
,1,13116,,,,10577,,,,CHEMBL616791,Binding affinity at 5-hydroxytryptamine 1B receptor,,8,,,Expert,H,BAO_0000357,,1819,B,
,1,16429,,,,10577,,,,CHEMBL616792,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,8,,,Autocuration,H,BAO_0000019,,1820,B,
,1,12409,,,,10577,,,,CHEMBL616793,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,1821,B,
,1,15194,,,,10577,,,,CHEMBL616794,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1822,B,
,1,15194,,,,10577,,,,CHEMBL616795,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1823,B,
,1,5486,,,,104686,,,,CHEMBL616796,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,1824,B,
,1,4639,,,,106,,,,CHEMBL616797,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1825,B,
,1,386,,,,106,,Brain membranes,,CHEMBL616798,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,8,,,Autocuration,H,BAO_0000249,,1826,B,
,1,2474,,,,106,,,,CHEMBL616799,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,8,,,Autocuration,H,BAO_0000357,,1827,B,
,1,6011,,,,106,,,,CHEMBL616800,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,1828,B,
,1,5014,,,,106,,,,CHEMBL616801,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1829,B,
,1,17515,,,,106,,,,CHEMBL616802,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,1830,B,
,1,4373,,,,106,,,,CHEMBL616803,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1831,B,
,1,1633,,,,106,,,,CHEMBL857068,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,8,,,Expert,H,BAO_0000357,,1832,B,
,1,1633,,,,106,,,,CHEMBL616804,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,8,,,Autocuration,H,BAO_0000357,,1833,B,
,1,4373,,,,106,,,,CHEMBL616805,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1834,B,
,1,4687,,,,106,,,,CHEMBL616806,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1835,B,
,1,11574,,,,106,,,,CHEMBL616807,Binding affinity against 5-hydroxytryptamine 1B receptor,,8,,,Autocuration,H,BAO_0000357,,1836,B,
,1,10321,,,,106,,,,CHEMBL616808,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1837,B,
,1,15527,,,,106,,,,CHEMBL616809,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1838,B,
,1,17200,,,,106,,,,CHEMBL616810,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,8,,,Autocuration,H,BAO_0000357,,1839,B,
,1,14423,,,,104802,,,,CHEMBL616811,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,4,,,Autocuration,H,BAO_0000224,,1840,B,
,1,5834,,,,108,,,,CHEMBL616812,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,1841,B,
,1,11473,,,,108,,,,CHEMBL616813,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1842,B,
,1,11473,,,,108,,,,CHEMBL616814,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1843,B,
,1,10639,,,,108,,,,CHEMBL616815,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1844,B,
,1,10639,,,,108,,,,CHEMBL616816,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1845,B,
,1,14331,,,,108,,,,CHEMBL616817,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1846,B,
,1,10796,,,,108,,,,CHEMBL616818,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1847,B,
,1,9098,,,,108,,,,CHEMBL616819,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Sus scrofa,8,9823.0,,Expert,H,BAO_0000357,,1848,B,
,1,14331,,,,108,,,,CHEMBL616820,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Sus scrofa,8,9823.0,,Expert,H,BAO_0000357,,1849,B,
,1,11828,,,,108,,,,CHEMBL616821,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,1850,B,
,1,11866,,,,108,,,,CHEMBL616822,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1851,B,
,1,13047,,,,108,,,,CHEMBL616823,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1852,B,
,1,188,,,,12689,,,,CHEMBL616824,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1853,B,
,1,11825,,,,12689,,,,CHEMBL616825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1854,B,
,1,11825,,,,12689,,,,CHEMBL616826,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1855,B,
,1,11624,,,,12689,,,,CHEMBL616827,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1856,B,
,1,11139,,,,12689,,,,CHEMBL616828,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1857,B,
,1,11147,,,,12689,,,,CHEMBL616829,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1858,B,
,1,10444,,,,12689,,,,CHEMBL616830,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,1859,B,
,1,11624,,,,12689,,,,CHEMBL616831,Binding affinity against 5-hydroxytryptamine 1C receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,1860,B,
,1,11662,,,,12689,,,,CHEMBL616832,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,1861,B,
,1,11662,,,,12689,,,,CHEMBL616833,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,1862,B,
,1,11662,,,,12689,,,,CHEMBL616834,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,1863,B,
,1,11662,,,,12689,,,,CHEMBL829595,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,1864,B,
,1,9098,,,,12689,,,,CHEMBL616835,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1865,B,
,1,10394,,,,12689,,,,CHEMBL872910,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000249,,1866,B,
,1,11933,,,,12689,,,,CHEMBL616836,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,8,,,Expert,H,BAO_0000357,,1867,B,
,1,12092,,,,12689,,,,CHEMBL616837,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000357,,1868,B,
,1,12253,,,,12689,,,,CHEMBL616466,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,1869,B,
,1,12253,,,,12689,,,HEK293,CHEMBL616467,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Rattus norvegicus,9,10116.0,722.0,Autocuration,D,BAO_0000219,,1870,B,
,1,1558,,,,108,,,,CHEMBL616468,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,8,,,Autocuration,H,BAO_0000357,,1871,B,
,1,2474,,,,108,,,,CHEMBL616469,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,1872,B,
,1,2474,,,,108,,,,CHEMBL616470,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,1873,B,
,1,11574,,,,12689,,,,CHEMBL616471,Binding affinity against 5-hydroxytryptamine 1C receptor,,8,,,Autocuration,H,BAO_0000357,,1874,B,
,1,1558,,,,12689,,,,CHEMBL616472,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,8,,,Autocuration,H,BAO_0000357,,1875,B,
,1,13944,,,,12689,,,,CHEMBL616473,Binding affinity against 5-hydroxytryptamine 1C receptor,,8,,,Autocuration,H,BAO_0000357,,1876,B,
,1,13033,,,,12689,,,,CHEMBL616474,Binding affinity against serotonergic 5-HT1c receptor,,8,,,Autocuration,H,BAO_0000357,,1877,B,
,1,10321,,,,12689,,,,CHEMBL616475,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,1878,B,
,1,11866,,,,12689,,,,CHEMBL616476,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1879,B,
,1,14454,,,,105,,,,CHEMBL616477,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1880,B,
,1,11574,,,,104686,,,,CHEMBL616478,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,4,,,Autocuration,H,BAO_0000224,,1881,B,
,1,11574,,,,104686,,,,CHEMBL616479,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,4,,,Autocuration,H,BAO_0000224,,1882,B,
,1,13631,,,,104686,,,,CHEMBL616480,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,4,,,Autocuration,H,BAO_0000019,,1883,B,
,1,9630,,,,104686,,,,CHEMBL616481,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,1884,B,
,1,8822,,,,104686,,,,CHEMBL616482,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000249,,1885,B,
Brain,1,9064,,,,104686,,,,CHEMBL884713,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000221,955.0,1886,B,
,1,8868,,,,104686,,,,CHEMBL616483,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,4,,,Autocuration,H,BAO_0000224,,1887,B,
,1,9064,,,,104686,,,,CHEMBL616484,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,4,,,Autocuration,H,BAO_0000224,,1888,B,
,1,9806,,,,104686,,,,CHEMBL616485,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,4,,,Autocuration,H,BAO_0000019,,1889,B,
,1,9098,,,,104686,,,,CHEMBL616486,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,1890,B,
,1,8868,,,,104686,,,,CHEMBL616487,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,4,,,Autocuration,H,BAO_0000224,,1891,B,
,1,12765,,,,104686,,,,CHEMBL616488,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,4,,,Autocuration,H,BAO_0000224,,1892,B,
,1,11049,,,,104686,,,,CHEMBL616489,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000019,,1893,B,
,1,11049,,,,104686,,,,CHEMBL616490,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000019,,1894,B,
,1,11049,,,,104686,,,,CHEMBL616491,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,4,,,Autocuration,H,BAO_0000019,,1895,B,
,1,11049,,,,104686,,,,CHEMBL616492,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,4,,,Autocuration,H,BAO_0000019,,1896,B,
,1,11049,,,,104686,,,,CHEMBL616493,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000019,,1897,B,
,1,11473,,,,104686,,,,CHEMBL616494,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,4,,,Autocuration,H,BAO_0000019,,1898,B,
,1,11473,,,,104686,,,,CHEMBL616495,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000019,,1899,B,
,1,3086,,,,104686,,,,CHEMBL616496,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,4,,,Autocuration,H,BAO_0000019,,1900,B,
,1,11049,,,,104686,,,,CHEMBL616497,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000019,,1901,B,
,1,11049,,,,104686,,,,CHEMBL616498,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000019,,1902,B,
,1,10639,,,,104686,,,,CHEMBL616499,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,4,,,Autocuration,H,BAO_0000019,,1903,B,
,1,10922,,,,104686,,,,CHEMBL616500,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,4,,,Autocuration,H,BAO_0000019,,1904,B,
Brain,1,9064,,,,104686,,,,CHEMBL616501,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000221,955.0,1905,B,
Brain,1,10748,,,,104686,,,,CHEMBL616502,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,4,,,Autocuration,H,BAO_0000221,955.0,1906,B,
,1,11614,,,,104686,,Membranes,,CHEMBL884529,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,4,,,Autocuration,H,BAO_0000249,,1907,B,
,1,11615,,,,104686,,Membranes,,CHEMBL616503,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,4,,,Autocuration,H,BAO_0000249,,1908,B,
,1,11615,,,,104686,,,,CHEMBL616964,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,1909,B,
,1,11614,,,,104686,,Membranes,,CHEMBL616965,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,4,,,Autocuration,H,BAO_0000249,,1910,B,
,1,11702,,,,104686,,,,CHEMBL616966,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,4,,,Autocuration,H,BAO_0000224,,1911,B,
,1,11702,,,,104686,,,,CHEMBL616967,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,Autocuration,H,BAO_0000224,,1912,B,
,1,11702,,,,104686,,,,CHEMBL616968,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,1913,B,
,1,11702,,,,104686,,,,CHEMBL616969,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,Autocuration,H,BAO_0000224,,1914,B,
,1,13346,,,,104686,,,,CHEMBL884530,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,4,,,Autocuration,H,BAO_0000019,,1915,B,
,1,10025,,,,104686,,,,CHEMBL616970,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,1916,B,
,1,10025,,,,104686,,,,CHEMBL616971,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,4,,,Autocuration,H,BAO_0000224,,1917,B,
,1,10025,,,,104686,,,,CHEMBL616972,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,4,,,Autocuration,H,BAO_0000224,,1918,B,
,1,9036,,,,104686,,,,CHEMBL616973,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,4,,,Autocuration,H,BAO_0000224,,1919,B,
,1,9036,,,,104686,,,,CHEMBL616974,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,4,,,Autocuration,H,BAO_0000224,,1920,B,
,1,9161,,,,104686,,,,CHEMBL616975,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,4,,,Autocuration,H,BAO_0000019,,1921,B,
,1,12304,,,,104686,,,,CHEMBL616976,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,1922,B,
,1,13276,,,,104686,,,,CHEMBL616977,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000224,,1923,B,
,1,11825,,,,104686,,,,CHEMBL616978,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,4,,,Autocuration,H,BAO_0000224,,1924,B,
,1,12443,,,,104686,,,,CHEMBL616979,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,4,,,Autocuration,H,BAO_0000224,,1925,B,
,1,13830,,,,104686,,,,CHEMBL616980,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,1926,B,
,1,9592,,,,104686,,Membranes,,CHEMBL616981,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,4,,,Autocuration,H,BAO_0000249,,1927,B,
,1,9592,,,,104686,,Membranes,,CHEMBL616982,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,4,,,Autocuration,H,BAO_0000249,,1928,B,
,1,10881,,,,104686,,,,CHEMBL616983,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,4,,,Autocuration,H,BAO_0000224,,1929,B,
,1,13605,,,,104686,,,,CHEMBL616984,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,4,,,Autocuration,H,BAO_0000019,,1930,B,
,1,11624,,,,104686,,,,CHEMBL616985,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,1931,B,
,1,4101,,,,104686,,,,CHEMBL616986,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4,,,Autocuration,H,BAO_0000224,,1932,B,
,1,4101,,,,104686,,,,CHEMBL616987,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4,,,Autocuration,H,BAO_0000224,,1933,B,
,1,15360,,,,104686,,,,CHEMBL616988,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,4,,,Autocuration,H,BAO_0000019,,1934,B,
,1,11576,,,,104686,,,,CHEMBL617243,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,Autocuration,H,BAO_0000019,,1935,B,
,1,5834,,,,104686,,,,CHEMBL617244,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,4,,,Autocuration,H,BAO_0000019,,1936,B,
,1,2395,,,,104686,,,CHO-K1,CHEMBL617245,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,5,10116.0,485.0,Autocuration,D,BAO_0000219,,1937,B,
,1,11965,,,,104686,,Membranes,,CHEMBL617246,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,4,,,Autocuration,H,BAO_0000249,,1938,B,
,1,3967,,,,104686,,,,CHEMBL617546,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,4,,,Autocuration,H,BAO_0000224,,1939,B,
,1,11130,,,,104686,,Brain membranes,,CHEMBL617547,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,4,,,Autocuration,H,BAO_0000249,,1940,B,
,1,13427,,In vitro,,104686,,,,CHEMBL617548,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,4,,,Autocuration,H,BAO_0000219,,1941,B,
,1,9443,,,,104686,,,,CHEMBL617549,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,1942,B,
,1,9443,,,,104686,,,,CHEMBL617550,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,4,,,Autocuration,H,BAO_0000224,,1943,B,
,1,11825,,,,104686,,,,CHEMBL617551,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,4,,,Autocuration,H,BAO_0000224,,1944,B,
,1,12120,,,,104686,,Membranes,,CHEMBL617552,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,4,,,Autocuration,H,BAO_0000249,,1945,B,
,1,12120,,,,104686,,Membranes,,CHEMBL617553,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,4,,,Autocuration,H,BAO_0000249,,1946,B,
Thoracic aorta,1,11963,,,,104686,,,,CHEMBL617554,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,4,,,Autocuration,H,BAO_0000019,1515.0,1947,F,
,1,9069,,,,104686,,,,CHEMBL617555,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000019,,1948,B,
,1,8868,,,,104686,,,,CHEMBL617556,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,4,,,Autocuration,H,BAO_0000224,,1949,B,
,1,17200,,,,10624,,,,CHEMBL617557,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,8,,,Autocuration,H,BAO_0000357,,1950,B,
,1,17200,,,,10624,,,,CHEMBL617558,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,8,,,Autocuration,H,BAO_0000357,,1951,B,
,1,13969,,,,17106,,,,CHEMBL617559,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,8,,,Expert,H,BAO_0000357,,1952,B,
,1,13392,,,,17106,,,,CHEMBL617560,Binding affinity for 5-hydroxytryptamine 1D receptor,,9,,,Expert,D,BAO_0000357,,1953,B,
,1,1742,,,,17106,,,,CHEMBL617561,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,Autocuration,H,BAO_0000249,,1954,B,
,1,1742,,,,17106,,,,CHEMBL617562,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,Autocuration,H,BAO_0000249,,1955,B,
Striatum,1,14331,,,,17106,,,,CHEMBL617563,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,8,,,Autocuration,H,BAO_0000357,2435.0,1956,B,
,1,12861,,,,17106,,,,CHEMBL617564,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1957,F,
,1,12861,,,,17106,,,,CHEMBL617565,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,8,,,Expert,H,BAO_0000019,,1958,B,
,1,12861,,,,17106,,,,CHEMBL856076,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,1959,B,
,1,12861,,,,17106,,,,CHEMBL617566,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,Autocuration,H,BAO_0000019,,1960,B,
,1,12861,,,,17106,,,,CHEMBL875911,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,Expert,H,BAO_0000019,,1961,B,
,1,12861,,,,17106,,,,CHEMBL617567,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,8,,,Autocuration,H,BAO_0000019,,1962,B,
,1,675,,,,17106,,,,CHEMBL617568,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,8,,,Autocuration,H,BAO_0000249,,1963,B,
,1,12490,,,,17106,,,,CHEMBL617569,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,8,,,Expert,H,BAO_0000019,,1964,B,
,1,11828,,,,17106,,,,CHEMBL617570,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,8,,,Expert,H,BAO_0000249,,1965,B,
,1,11866,,,,17106,,,,CHEMBL617571,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,8,,,Autocuration,H,BAO_0000357,,1966,B,
,1,773,,,,105,,,,CHEMBL617572,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,1967,B,
,1,13047,,,,105,,,,CHEMBL617573,The compound was tested for intrinsic activity against 5-HT1D receptor,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000357,,1968,B,
,1,13047,,,,105,,,,CHEMBL617574,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,1969,B,
,1,13047,,,,105,,,,CHEMBL617575,The compound was tested for binding affinity against 5-HT1D receptor,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000357,,1970,B,
,1,188,,,,10578,,,,CHEMBL617576,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,8,,,Autocuration,H,BAO_0000357,,1971,B,
,1,10639,,,,10578,,,,CHEMBL617577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,8,,,Autocuration,H,BAO_0000019,,1972,F,
,1,12438,,,,10578,,,,CHEMBL617578,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000019,,1973,F,
,1,12438,,,,10578,,,,CHEMBL617579,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1974,B,
,1,15854,,,,10578,,,,CHEMBL617580,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,8,,,Expert,H,BAO_0000019,,1975,B,
,1,10394,,,,10578,,,,CHEMBL617581,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000249,,1976,B,
,1,12092,,,,10578,,,,CHEMBL617582,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,8,,,Autocuration,H,BAO_0000357,,1977,B,
,1,3389,,,,10578,,,,CHEMBL617583,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,8,,,Expert,H,BAO_0000019,,1978,B,
,1,6011,,,,105,,,,CHEMBL617584,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,1979,B,
,1,4639,,,,105,,,,CHEMBL617585,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1980,B,
,1,2474,,,,105,,,,CHEMBL875912,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1981,B,
,1,5014,,,,105,,,,CHEMBL617586,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1982,B,
,1,17515,,,,105,,,,CHEMBL617587,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,1983,B,
,1,11866,,,,105,,,,CHEMBL617588,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,8,,,Autocuration,H,BAO_0000357,,1984,B,
,1,4687,,,,105,,,,CHEMBL857980,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1985,B,
,1,12146,,,,105,,,,CHEMBL617589,Tested against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,1986,B,
,1,10321,,,,105,,,,CHEMBL617590,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,1987,B,
,1,13267,,,,105,,,HEK293,CHEMBL617591,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,1988,B,
,1,1274,,,,105,,,,CHEMBL617592,Binding affinity against 5-Hydroxytryptamine 1D receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,1989,B,
,1,15250,,,,105,,,,CHEMBL617593,,,8,,,Autocuration,H,BAO_0000357,,1990,B,
,1,13706,,,,106,,,CHO-K1,CHEMBL617594,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,1991,B,
,1,13706,,,,105,,,CHO-K1,CHEMBL617595,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,1992,B,
,1,13706,,,,105,,,HEK293,CHEMBL617596,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,8,,722.0,Autocuration,H,BAO_0000219,,1993,B,
,1,13706,,,,105,,,HEK293,CHEMBL617597,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,8,,722.0,Autocuration,H,BAO_0000219,,1994,B,
,1,13047,,,,105,,,,CHEMBL617598,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,8,,,Autocuration,H,BAO_0000019,,1995,B,
,1,13366,,,,105,,,,CHEMBL872916,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,8,,,Autocuration,H,BAO_0000357,,1996,B,
,1,13366,,,,105,,,,CHEMBL617599,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,8,,,Expert,H,BAO_0000357,,1997,B,
,1,1558,,,,105,,,,CHEMBL617091,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,8,,,Autocuration,H,BAO_0000357,,1998,B,
,1,12902,,,,105,,,CHO-K1,CHEMBL617092,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,8,,485.0,Expert,H,BAO_0000219,,1999,B,
,1,13706,,,,105,,,CHO-K1,CHEMBL617093,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,2000,B,
,1,13706,,,,105,,,,CHEMBL617094,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,8,,,Autocuration,H,BAO_0000019,,2001,F,
,1,13706,,,,105,,,,CHEMBL617095,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,Autocuration,H,BAO_0000019,,2002,F,
,1,14251,,,,105,,,,CHEMBL617096,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,Autocuration,H,BAO_0000019,,2003,F,
,1,14251,,,,105,,,,CHEMBL617097,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,Autocuration,H,BAO_0000019,,2004,F,
,1,14251,,,,105,,,,CHEMBL617098,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,8,,,Autocuration,H,BAO_0000019,,2005,F,
,1,13313,,,,105,,,,CHEMBL617301,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2006,B,
,1,13313,,,,105,,,,CHEMBL617302,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2007,B,
,1,13366,,,,105,,,,CHEMBL617303,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,8,,,Autocuration,H,BAO_0000357,,2008,B,
,1,13051,,,,105,,,,CHEMBL617304,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,8,,,Expert,H,BAO_0000357,,2009,B,
,1,12903,,,,105,,,CHO,CHEMBL617305,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,8,,449.0,Expert,H,BAO_0000219,,2010,B,
,1,12469,,,,105,,,,CHEMBL617306,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Homo sapiens,9,9606.0,,Autocuration,D,BAO_0000219,,2011,B,
,1,5619,,,,17106,,,,CHEMBL617307,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,8,,,Autocuration,H,BAO_0000357,,2012,B,
,1,13047,,,,105,,,,CHEMBL617308,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,2013,B,
,1,16633,,,,105,,,,CHEMBL617309,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,8,,,Autocuration,H,BAO_0000357,,2014,B,
,1,16633,,,,105,,,,CHEMBL617310,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,8,,,Autocuration,H,BAO_0000357,,2015,B,
,1,16633,,,,105,,,,CHEMBL617311,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,8,,,Autocuration,H,BAO_0000357,,2016,B,
,1,16633,,,,105,,,,CHEMBL617312,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2017,B,
,1,3269,,,,105,,,,CHEMBL617313,Affinity against 5-hydroxytryptamine 1D receptor alpha,,8,,,Autocuration,H,BAO_0000357,,2018,B,
,1,12409,,,,105,,,,CHEMBL617314,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,8,,,Expert,H,BAO_0000357,,2019,B,
,1,13706,,,,106,,,,CHEMBL617315,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,Autocuration,H,BAO_0000019,,2020,F,
,1,13706,,,,106,,,HEK293,CHEMBL617316,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,8,,722.0,Autocuration,H,BAO_0000219,,2021,B,
,1,13706,,,,106,,,HEK293,CHEMBL617317,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,8,,722.0,Autocuration,H,BAO_0000219,,2022,B,
,1,12903,,,,106,,,CHO,CHEMBL617318,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,2023,B,
,1,13047,,,,106,,,,CHEMBL617319,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,8,,,Autocuration,H,BAO_0000019,,2024,B,
,1,13366,,,,106,,,,CHEMBL617320,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,Expert,D,BAO_0000357,,2025,B,
,1,13366,,,,106,,,,CHEMBL617321,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,Expert,D,BAO_0000357,,2026,B,
,1,13366,,,,106,,,,CHEMBL617322,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,9,,,Expert,D,BAO_0000357,,2027,B,
,1,13366,,,,106,,,,CHEMBL616862,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2028,B,
,1,13366,,,,106,,,,CHEMBL616863,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2029,B,
,1,12469,,,,106,,,CHO,CHEMBL616864,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,2030,B,
,1,13706,,,,106,,,CHO-K1,CHEMBL616865,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,2031,B,
,1,13706,,,,106,,,CHO-K1,CHEMBL616866,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,2032,B,
,1,13706,,,,106,,,,CHEMBL616867,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,8,,,Autocuration,H,BAO_0000019,,2033,F,
,1,12902,,,,106,,,CHO-K1,CHEMBL616868,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,8,,485.0,Expert,H,BAO_0000219,,2034,B,
,1,13051,,,,105,,,,CHEMBL616869,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,8,,,Expert,H,BAO_0000357,,2035,B,
,1,12903,,,,106,,,CHO,CHEMBL616870,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,8,,449.0,Expert,H,BAO_0000219,,2036,B,
,1,1558,,,,105,,,CHO-K1,CHEMBL616871,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,8,,485.0,Autocuration,H,BAO_0000219,,2037,F,
,1,1558,,,,105,,,CHO-K1,CHEMBL616872,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,8,,485.0,Autocuration,H,BAO_0000219,,2038,F,
,1,1558,,,,105,,,CHO-K1,CHEMBL616873,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,8,,485.0,Autocuration,H,BAO_0000219,,2039,F,
,1,1558,,,,105,,,CHO-K1,CHEMBL616838,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,8,,485.0,Autocuration,H,BAO_0000219,,2040,F,
,1,1558,,,,105,,,,CHEMBL616839,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,8,,,Autocuration,H,BAO_0000357,,2041,B,
,1,13047,,,,106,,,,CHEMBL616840,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,2042,B,
,1,13313,,,,105,,,,CHEMBL616841,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2043,B,
,1,13313,,,,105,,,,CHEMBL616842,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2044,B,
,1,12409,,,,105,,,,CHEMBL857976,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,8,,,Expert,H,BAO_0000357,,2045,B,
,1,15250,,,,10618,,,CHO,CHEMBL616843,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,2046,B,
,1,1348,,,,10618,,,,CHEMBL616844,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2047,B,
,1,1348,,,,10618,,,,CHEMBL616845,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,8,,,Autocuration,H,BAO_0000357,,2048,B,
,1,4234,,,,10618,,,,CHEMBL616846,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2049,B,
,1,16209,,,,10618,,,,CHEMBL616847,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2050,B,
,1,10444,,,,10618,,,,CHEMBL616848,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,8,,,Autocuration,H,BAO_0000019,,2051,B,
,1,3935,,,,10618,,,,CHEMBL616849,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000357,,2052,B,
,1,15818,,,,10618,,,,CHEMBL872911,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000357,,2053,B,
,1,17085,,,,10618,,,,CHEMBL616850,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000019,,2054,B,
,1,12936,,,,10618,,,CHO,CHEMBL616699,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2055,B,
,1,6166,,,,10618,,,,CHEMBL616700,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2056,B,
,1,15779,,,,10618,,,CHO,CHEMBL616701,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,2057,B,
,1,15779,,,,10618,,,CHO,CHEMBL616702,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,2058,B,
,1,15779,,,,10618,,,CHO,CHEMBL616703,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,8,,449.0,Autocuration,H,BAO_0000219,,2059,B,
,1,13181,,,,10618,,,,CHEMBL616704,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,8,,,Autocuration,H,BAO_0000357,,2060,B,
,1,4199,,,,10618,,,CHO,CHEMBL616705,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2061,B,
,1,14875,,,,10618,,,,CHEMBL616706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000357,,2062,B,
,1,15146,,,,10618,,,CHO,CHEMBL616707,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,2063,B,
,1,5213,,,,10618,,,,CHEMBL616708,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000357,,2064,B,
,1,12146,,,,10618,,,,CHEMBL616709,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2065,B,
,1,13267,,,,10618,,,CHO,CHEMBL616710,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2066,B,
,1,14818,,,,10618,,,CHO,CHEMBL616711,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,2067,B,
,1,4829,,,,10618,,,CHO,CHEMBL616712,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,2068,B,
,1,4373,,,,10618,,,,CHEMBL616713,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2069,B,
,1,4373,,,,10618,,,,CHEMBL616714,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2070,B,
,1,14159,,,,10618,,,,CHEMBL616715,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000357,,2071,B,
,1,16633,,,,10618,,,,CHEMBL616716,Binding affinity towards 5-hydroxytryptamine 1E receptor,,8,,,Autocuration,H,BAO_0000357,,2072,B,
,1,17085,,,,279,,,,CHEMBL616717,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,8,,,Autocuration,H,BAO_0000019,,2073,F,
,1,17085,,,,279,,,,CHEMBL616718,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,8,,,Expert,H,BAO_0000019,,2074,F,
,1,16209,,,,279,,,,CHEMBL875905,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000019,,2075,F,
,1,16209,,,,279,,,,CHEMBL616719,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000019,,2076,F,
,1,17085,,,,279,,,,CHEMBL616720,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,8,,,Expert,H,BAO_0000019,,2077,F,
,1,14159,,,,279,,,,CHEMBL616721,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2078,B,
,1,15250,,,,279,,,CHO,CHEMBL616722,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,2079,B,
,1,3805,,,,279,,,,CHEMBL616723,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,2080,B,
,1,16190,,,,279,,,CHO,CHEMBL616724,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2081,B,
,1,16190,,,,279,,,,CHEMBL616725,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,8,,,Autocuration,H,BAO_0000357,,2082,B,
,1,16209,,,,279,,,,CHEMBL616726,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2083,B,
,1,16209,,,,279,,,,CHEMBL616727,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2084,B,
,1,16209,,,,279,,,,CHEMBL616728,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,8,,,Autocuration,H,BAO_0000357,,2085,B,
,1,6866,,,,279,,,,CHEMBL616729,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2086,B,
,1,17085,,,,279,,,,CHEMBL616730,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,8,,,Expert,H,BAO_0000019,,2087,B,
,1,16312,,,,279,,,,CHEMBL617125,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2088,B,
,1,6166,,,,279,,,,CHEMBL857977,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2089,B,
,1,15779,,,,279,,,CHO,CHEMBL617126,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,8,,449.0,Autocuration,H,BAO_0000219,,2090,B,
,1,4199,,,,279,,,CHO,CHEMBL617127,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2091,B,
,1,14875,,,,279,,,,CHEMBL617128,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2092,B,
,1,15146,,,,279,,,CHO,CHEMBL617129,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,2093,B,
,1,5213,,,,279,,,,CHEMBL617130,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,8,,,Autocuration,H,BAO_0000357,,2094,B,
,1,14818,,,,279,,,CHO,CHEMBL617131,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,2095,B,
,1,4829,,,,279,,,CHO,CHEMBL617132,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,2096,B,
,1,4829,,,,279,,,CHO,CHEMBL617133,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,8,,449.0,Autocuration,H,BAO_0000219,,2097,B,
,1,4373,,,,279,,,,CHEMBL617134,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2098,B,
,1,4373,,,,279,,,,CHEMBL617135,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2099,B,
,1,5014,,,,279,,,,CHEMBL617136,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,8,,,Autocuration,H,BAO_0000357,,2100,B,
,1,11662,,,,104686,,,,CHEMBL617137,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,4,,,Autocuration,H,BAO_0000019,,2101,B,
,1,11662,,,,104686,,,,CHEMBL617138,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,4,,,Autocuration,H,BAO_0000019,,2102,B,
,1,11662,,,,104686,,,,CHEMBL617139,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,Autocuration,H,BAO_0000019,,2103,B,
,1,14093,,,,12687,,,,CHEMBL617140,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2104,B,
,1,11200,,In vivo,,104686,,,,CHEMBL617141,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,4,,,Autocuration,H,BAO_0000218,,2105,F,
,1,11200,,,,104686,,,,CHEMBL858112,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2106,F,
,1,12352,,,,17005,,,,CHEMBL617142,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,8,,,Intermediate,H,BAO_0000019,,2107,B,
,1,13657,,,,22226,,,,CHEMBL617143,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,2108,B,
,1,14331,,,,22226,,,,CHEMBL617144,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,2109,B,
,1,14331,,,,22226,,,,CHEMBL617145,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,2110,B,
,1,14331,,,,22226,,,,CHEMBL617146,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,0,,,Autocuration,U,BAO_0000019,,2111,B,
,1,12685,,,,104784,,,,CHEMBL617147,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,2112,B,
,1,14389,,,,104784,,,,CHEMBL617148,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,2113,B,
,1,14386,,,,104784,,,,CHEMBL617149,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,2114,B,
,1,5732,,,,104784,,,,CHEMBL617150,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,2115,B,
,1,16293,,,,104784,,,,CHEMBL617151,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,2116,B,
,1,2078,,,,104784,,,,CHEMBL617201,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2117,B,
,1,5486,,,,10209,,,,CHEMBL617202,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,8,,,Autocuration,H,BAO_0000357,,2118,B,
,1,11820,,In vivo,,104826,,,,CHEMBL617203,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,4,,,Autocuration,H,BAO_0000218,,2119,B,
,1,10297,,,,104826,,,,CHEMBL617204,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,2120,B,
,1,13704,,,,104826,,,,CHEMBL617205,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,4,,,Autocuration,H,BAO_0000224,,2121,B,
,1,10297,,,,104826,,,,CHEMBL617206,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Mus musculus,5,10090.0,,Autocuration,D,BAO_0000019,,2122,B,
,1,11820,,In vivo,,104826,,,,CHEMBL617207,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,4,,,Autocuration,H,BAO_0000218,,2123,B,
,1,10297,,,,104826,,,,CHEMBL617208,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Mus musculus,5,10090.0,,Autocuration,D,BAO_0000019,,2124,B,
,1,11555,,,,104826,,,,CHEMBL617209,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2125,B,
,1,11555,,,,104826,,,,CHEMBL617210,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,4,,,Autocuration,H,BAO_0000224,,2126,B,
,1,11555,,,,104826,,,,CHEMBL617211,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,4,,,Autocuration,H,BAO_0000224,,2127,B,
,1,10297,,,,104826,,,,CHEMBL617212,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Mus musculus,5,10090.0,,Autocuration,D,BAO_0000019,,2128,B,
,1,16688,,,,104784,,,,CHEMBL617213,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Sus scrofa,4,9823.0,,Autocuration,H,BAO_0000224,,2129,B,
,1,16688,,,,104784,,,,CHEMBL617214,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Sus scrofa,4,9823.0,,Autocuration,H,BAO_0000224,,2130,B,
,1,5333,,,,22226,,,,CHEMBL617215,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,0,,,Autocuration,U,BAO_0000221,,2131,B,
,1,4437,,,,22226,,,,CHEMBL617216,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,0,,,Autocuration,U,BAO_0000221,,2132,B,
,1,5033,,,,17005,,,,CHEMBL617217,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,2133,B,
,1,15267,,,,104686,,,,CHEMBL617218,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000019,,2134,B,
,1,15267,,,,104686,,,,CHEMBL872913,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000019,,2135,B,
,1,11820,,,,104826,,,,CHEMBL617219,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,4,,,Autocuration,H,BAO_0000019,,2136,B,
,1,9069,,,,104686,,,,CHEMBL873482,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2137,B,
,1,9162,,,,104686,,,,CHEMBL617220,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2138,B,
,1,9162,,,,104686,,,,CHEMBL617221,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,4,,,Autocuration,H,BAO_0000019,,2139,B,
,1,9162,,,,104686,,,,CHEMBL617222,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,4,,,Autocuration,H,BAO_0000019,,2140,B,
,1,10428,,,,104686,,,,CHEMBL875906,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,4,,,Autocuration,H,BAO_0000019,,2141,F,
,1,9628,,,,104686,,,,CHEMBL617223,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,4,,,Autocuration,H,BAO_0000019,,2142,B,
,1,12704,,,,104686,,,,CHEMBL617224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2143,B,
,1,15453,,,,104686,,,,CHEMBL617225,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2144,B,
,1,188,,,,104686,,,,CHEMBL617226,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,4,,,Autocuration,H,BAO_0000224,,2145,B,
,1,10349,,,,104686,,,,CHEMBL617227,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,4,,,Autocuration,H,BAO_0000224,,2146,B,
,1,10349,,,,104686,,,,CHEMBL617228,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,4,,,Autocuration,H,BAO_0000224,,2147,B,
,1,8868,,,,104686,,,,CHEMBL617229,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,4,,,Autocuration,H,BAO_0000224,,2148,B,
,1,10025,,,,104686,,,,CHEMBL617230,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,4,,,Autocuration,H,BAO_0000224,,2149,B,
,1,10025,,,,104686,,,,CHEMBL617231,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,4,,,Autocuration,H,BAO_0000224,,2150,B,
,1,11702,,,,104686,,,,CHEMBL617232,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,4,,,Autocuration,H,BAO_0000224,,2151,B,
,1,11702,,,,104686,,,,CHEMBL617233,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2152,B,
,1,11702,,,,104686,,,,CHEMBL617234,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,4,,,Autocuration,H,BAO_0000224,,2153,B,
,1,11702,,,,104686,,,,CHEMBL617235,Compound was tested for the inhibition of quipazine induced head twitches in rats,,4,,,Autocuration,H,BAO_0000019,,2154,F,
,1,11702,,,,104686,,,,CHEMBL617236,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,4,,,Autocuration,H,BAO_0000019,,2155,F,
Hippocampus,1,10085,,,,104686,,,,CHEMBL617237,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,4,,,Autocuration,H,BAO_0000221,10000000.0,2156,B,
Hippocampus,1,10085,,,,104686,,,,CHEMBL617238,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,4,,,Autocuration,H,BAO_0000221,10000000.0,2157,B,
Brain,1,9630,,,,104686,,,,CHEMBL617239,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000221,955.0,2158,B,
,1,11070,,,,104686,,,,CHEMBL617240,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,Autocuration,H,BAO_0000019,,2159,B,
,1,9841,,,,104686,,Membranes,,CHEMBL617241,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,4,,,Autocuration,H,BAO_0000249,,2160,B,
,1,9841,,,,104686,,Membranes,,CHEMBL875907,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,4,,,Autocuration,H,BAO_0000249,,2161,B,
,1,13291,,,,104686,,,,CHEMBL617242,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,4,,,Autocuration,H,BAO_0000019,,2162,B,
,1,10590,,,,104686,,,,CHEMBL617152,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,4,,,Autocuration,H,BAO_0000019,,2163,F,
Brain,1,9064,,,,104686,,,,CHEMBL617153,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000221,955.0,2164,B,
,1,12268,,,,104686,,Membranes,,CHEMBL617154,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000249,,2165,B,
Brain,1,13508,,,,104686,,,,CHEMBL617155,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000221,955.0,2166,B,
,1,11279,,,,104686,,,,CHEMBL617156,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,4,,,Autocuration,H,BAO_0000019,,2167,F,
,1,11200,,,,104686,,,,CHEMBL617157,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2168,F,
,1,11200,,,,104686,,,,CHEMBL617158,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2169,F,
,1,11200,,,,104686,,,,CHEMBL617159,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,4,,,Autocuration,H,BAO_0000019,,2170,F,
,1,11200,,,,104686,,,,CHEMBL617160,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,4,,,Autocuration,H,BAO_0000019,,2171,F,
,1,11200,,,,104686,,,,CHEMBL858113,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2172,F,
Brain,1,9231,,,,104686,,,,CHEMBL617247,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,4,,,Autocuration,H,BAO_0000220,955.0,2173,B,
,1,9737,,,,104686,,,,CHEMBL617248,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000019,,2174,B,
Brain,1,9737,,,,104686,,,,CHEMBL617249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,4,,,Autocuration,H,BAO_0000249,955.0,2175,B,
,1,9737,,,,104686,,,,CHEMBL617250,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2176,B,
,1,9737,,,,104686,,,,CHEMBL617251,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000019,,2177,B,
,1,11828,,,,104686,,,,CHEMBL617252,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2178,B,
,1,12253,,,,104686,,,,CHEMBL617006,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2179,B,
,1,12253,,,,104686,,,,CHEMBL617007,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2180,B,
,1,11279,,,,104686,,,,CHEMBL617008,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,4,,,Autocuration,H,BAO_0000019,,2181,F,
,1,11866,,,,104686,,,,CHEMBL617009,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,4,,,Autocuration,H,BAO_0000019,,2182,B,
,1,14424,,,,104686,,,,CHEMBL617010,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2183,B,
,1,15180,,,,104686,,,,CHEMBL857978,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2184,B,
,1,15180,,,,104686,,,,CHEMBL617011,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2185,B,
,1,9786,,,,104686,,,,CHEMBL617012,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2186,B,
,1,12132,,,,104686,,,,CHEMBL617013,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,4,,,Autocuration,H,BAO_0000224,,2187,B,
,1,5486,,,,104686,,,,CHEMBL617014,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,4,,,Autocuration,H,BAO_0000249,,2188,B,
,1,15316,,,,104686,,,,CHEMBL617015,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000019,,2189,B,
,1,16429,,,,104686,,,,CHEMBL617016,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,4,,,Autocuration,H,BAO_0000019,,2190,B,
,1,14617,,,,104686,,,,CHEMBL617017,pKi value for 5-hydroxytryptamine 2 receptor binding site,,4,,,Autocuration,H,BAO_0000224,,2191,B,
Brain,1,11351,,,,104686,,,,CHEMBL617018,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,4,,,Autocuration,H,BAO_0000221,955.0,2192,B,
,1,11279,,,,104686,,,,CHEMBL617019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,4,,,Autocuration,H,BAO_0000019,,2193,F,
,1,9523,,,,105075,,,,CHEMBL617020,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2194,B,
,1,9523,,,,105075,,,,CHEMBL617021,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2195,B,
,1,9523,,,,105075,,,,CHEMBL617022,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2196,B,
,1,9523,,,,105075,,,,CHEMBL617023,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2197,B,
,1,9523,,,,105075,,,,CHEMBL617024,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2198,B,
,1,9523,,,,105075,,,,CHEMBL617025,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2199,B,
,1,9523,,,,105075,,,,CHEMBL617026,Hill coefficient of compound was determined,,4,,,Autocuration,H,BAO_0000224,,2200,B,
,1,4771,,,,22226,,,,CHEMBL617027,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,0,,,Autocuration,U,BAO_0000019,,2201,B,
,1,5033,,,,104686,,,,CHEMBL617028,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2202,B,
,1,10845,,,,12687,,,,CHEMBL617029,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,8,,,Expert,H,BAO_0000019,,2203,B,
,1,10845,,,,12687,,,,CHEMBL875908,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,8,,,Expert,H,BAO_0000019,,2204,B,
,1,16288,,,,12687,,,,CHEMBL617030,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,8,,,Autocuration,H,BAO_0000357,,2205,B,
,1,16288,,,,12687,,,,CHEMBL617031,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,8,,,Autocuration,H,BAO_0000019,,2206,B,
,1,16190,,,,12687,,,,CHEMBL617032,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,8,,,Autocuration,H,BAO_0000019,,2207,B,
,1,12463,,,,104686,,,,CHEMBL617033,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2208,B,
,1,9699,,,,104686,,,,CHEMBL617034,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,4,,,Autocuration,H,BAO_0000224,,2209,B,
,1,9699,,,,104686,,,,CHEMBL617035,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000224,,2210,B,
,1,11662,,,,104686,,,,CHEMBL617036,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,Autocuration,H,BAO_0000019,,2211,B,
,1,1205,,,,104784,,,,CHEMBL617037,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2212,B,
,1,11376,,,,22226,,,,CHEMBL617038,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,0,,,Autocuration,U,BAO_0000219,,2213,B,
,1,11376,,,,104784,,,,CHEMBL617039,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,4,,,Autocuration,H,BAO_0000219,,2214,B,
,1,4639,,,,104784,,,,CHEMBL617161,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2215,B,
,1,2222,,,,104784,,,,CHEMBL617162,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2216,B,
,1,1558,,,,104784,,,,CHEMBL617163,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2217,B,
,1,1089,,,,104784,,,,CHEMBL617164,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2218,B,
,1,386,,,,104784,,Brain membranes,,CHEMBL617165,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,4,,,Autocuration,H,BAO_0000249,,2219,B,
,1,2474,,,,104784,,,,CHEMBL617166,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000224,,2220,B,
,1,17066,,,,104784,,,,CHEMBL617167,Binding affinity towards 5-HT2 receptor,,4,,,Autocuration,H,BAO_0000224,,2221,B,
,1,959,,,,104784,,,,CHEMBL872912,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2222,B,
,1,6398,,,,104784,,,,CHEMBL617168,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,4,,,Autocuration,H,BAO_0000224,,2223,B,
,1,11889,,,,104686,,,,CHEMBL617169,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,4,,,Autocuration,H,BAO_0000224,,2224,B,
,1,4221,,,,104784,,,,CHEMBL617170,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2225,B,
,1,11026,,,,104784,,,,CHEMBL617171,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000224,,2226,B,
,1,11866,,,,104784,,,,CHEMBL617172,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,2227,B,
,1,4221,,,,104784,,,,CHEMBL617173,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2228,B,
,1,13950,,,,22226,,,,CHEMBL617174,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,0,,,Autocuration,U,BAO_0000019,,2229,B,
,1,1263,,,,104784,,,,CHEMBL617175,5-hydroxytryptamine 2 receptor binding affinity,,4,,,Autocuration,H,BAO_0000224,,2230,B,
,1,13291,,,,17005,,,,CHEMBL617176,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,8,,,Autocuration,H,BAO_0000357,,2231,B,
,1,10812,,,,17005,,,,CHEMBL617177,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2232,B,
,1,13020,,,,104784,,,,CHEMBL617178,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,4,,,Autocuration,H,BAO_0000224,,2233,B,
,1,13021,,,,104784,,,,CHEMBL617179,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,4,,,Autocuration,H,BAO_0000224,,2234,B,
,1,13020,,,,104784,,,,CHEMBL617180,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,4,,,Autocuration,H,BAO_0000224,,2235,B,
,1,14532,,,,17005,,,,CHEMBL617181,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,8,,,Autocuration,H,BAO_0000357,,2236,B,
,1,13944,,,,17005,,,,CHEMBL617182,Binding affinity against 5-hydroxytryptamine 2 receptor,,8,,,Autocuration,H,BAO_0000357,,2237,B,
,1,14331,,,,17005,,,,CHEMBL617183,Binding affinity against 5-hydroxytryptamine 2 receptor,,8,,,Autocuration,H,BAO_0000357,,2238,B,
,1,14118,,,,17005,,,,CHEMBL617184,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2239,B,
,1,13033,,,,17005,,,,CHEMBL617185,Binding affinity against serotonergic 5-HT2 receptor,,8,,,Autocuration,H,BAO_0000357,,2240,B,
,1,10321,,,,17005,,,,CHEMBL617186,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2241,B,
,1,12918,,,,17005,,,,CHEMBL617187,Compound was evaluated for the binding affinity at 5- HT2 receptor,,8,,,Autocuration,H,BAO_0000357,,2242,B,
,1,15120,,,,17005,,,,CHEMBL617188,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,8,,,Autocuration,H,BAO_0000357,,2243,B,
,1,2613,,,,17005,,,,CHEMBL617189,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,8,,,Autocuration,H,BAO_0000218,,2244,B,
,1,13378,,,,104784,,,,CHEMBL617190,Inhibitory activity against cloned human 5-HT2 receptor,Homo sapiens,5,9606.0,,Autocuration,D,BAO_0000224,,2245,B,
,1,2331,,,,104784,,,CHO,CHEMBL617191,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Homo sapiens,5,9606.0,449.0,Autocuration,D,BAO_0000219,,2246,B,
,1,2331,,,,104784,,,CHO,CHEMBL617192,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Homo sapiens,5,9606.0,449.0,Autocuration,D,BAO_0000219,,2247,B,
,1,2331,,,,104784,,,CHO,CHEMBL617193,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Homo sapiens,5,9606.0,449.0,Autocuration,D,BAO_0000219,,2248,B,
,1,2331,,,,104784,,,CHO,CHEMBL617194,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Homo sapiens,5,9606.0,449.0,Autocuration,D,BAO_0000219,,2249,B,
,1,4170,,,,104784,,,,CHEMBL617195,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2250,B,
,1,15453,,,,104784,,,,CHEMBL881830,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,4,,,Autocuration,H,BAO_0000224,,2251,B,
,1,1479,,,,17005,,,,CHEMBL617196,Binding affinity towards 5-hydroxytryptamine 2 receptor,,8,,,Autocuration,H,BAO_0000357,,2252,B,
,1,11139,,,,104686,,,,CHEMBL617197,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,4,,,Autocuration,H,BAO_0000224,,2253,B,
,1,13969,,,,17005,,,,CHEMBL617198,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000357,,2254,B,
,1,13392,,,,17005,,,,CHEMBL873476,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2255,B,
,1,14430,,,,17005,,,,CHEMBL617199,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,8,,,Expert,H,BAO_0000019,,2256,B,
,1,13181,,,,107,,,,CHEMBL617200,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,2257,B,
,1,17200,,,,51,,,,CHEMBL617484,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,Autocuration,H,BAO_0000357,,2258,B,
,1,17200,,,,107,,,,CHEMBL617485,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,Autocuration,H,BAO_0000357,,2259,B,
,1,17200,,,,51,,,,CHEMBL617486,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,Autocuration,H,BAO_0000357,,2260,B,
,1,13463,,,,107,,,,CHEMBL858022,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2261,B,
,1,6347,,,,107,,,CHO,CHEMBL617049,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2262,B,
,1,6857,,,,107,,,CHO,CHEMBL617050,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2263,F,
,1,4176,,,,107,,,,CHEMBL617051,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,8,,,Autocuration,H,BAO_0000219,,2264,F,
,1,4176,,,,107,,,,CHEMBL617052,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,8,,,Autocuration,H,BAO_0000219,,2265,F,
,1,4176,,,,107,,,,CHEMBL617053,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,8,,,Autocuration,H,BAO_0000219,,2266,F,
,1,6347,,,,107,,,CHO,CHEMBL617054,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,8,,449.0,Autocuration,H,BAO_0000219,,2267,B,
,1,6347,,,,107,,,CHO,CHEMBL617055,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,8,,449.0,Autocuration,H,BAO_0000219,,2268,B,
,1,15331,,,,107,,,,CHEMBL882924,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,8,,,Autocuration,H,BAO_0000357,,2269,B,
,1,16146,,,,107,,,,CHEMBL617056,Inhibition of human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2270,B,
,1,15250,,,,107,,,CHO,CHEMBL617057,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,2271,B,
,1,13631,,,,107,,,,CHEMBL617058,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,8,,,Expert,H,BAO_0000219,,2272,B,
,1,3805,,,,107,,,,CHEMBL617059,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,2273,B,
,1,4011,,,,107,,,CHO,CHEMBL617060,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,8,,449.0,Autocuration,H,BAO_0000219,,2274,B,
,1,4012,,,,107,,,CHO,CHEMBL617061,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,8,,449.0,Expert,H,BAO_0000219,,2275,B,
,1,6366,,,,107,,,L929,CHEMBL617062,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,8,,307.0,Expert,H,BAO_0000219,,2276,B,
,1,15949,,,,107,,,CHO,CHEMBL617063,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2277,B,
,1,14093,,,,107,,,,CHEMBL617064,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,8,,,Autocuration,H,BAO_0000019,,2278,F,
,1,13481,,,,107,,,,CHEMBL617065,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000019,,2279,F,
,1,6347,,,,107,,,CHO,CHEMBL617066,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2280,B,
,1,6347,,,,107,,,CHO,CHEMBL617067,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,8,,449.0,Autocuration,H,BAO_0000219,,2281,B,
,1,14093,,,,107,,,,CHEMBL617068,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,8,,,Autocuration,H,BAO_0000019,,2282,F,
,1,14093,,,,107,,,,CHEMBL617069,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,8,,,Autocuration,H,BAO_0000019,,2283,F,
,1,13481,,,,107,,,,CHEMBL617070,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000019,,2284,F,
,1,14442,,,,107,,,,CHEMBL617071,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2285,B,
,1,14442,,,,107,,,,CHEMBL872915,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2286,B,
,1,14755,,,,107,,,,CHEMBL617072,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,8,,,Autocuration,H,BAO_0000357,,2287,B,
,1,16441,,,,107,,,,CHEMBL617073,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,8,,,Autocuration,H,BAO_0000357,,2288,B,
,1,14744,,,,107,,,,CHEMBL617074,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,8,,,Autocuration,H,BAO_0000357,,2289,B,
,1,16659,,,,107,,,CHO,CHEMBL617075,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2290,B,
,1,3307,,,,107,,,,CHEMBL617076,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2291,B,
,1,6857,,,,107,,,,CHEMBL617077,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,2292,B,
,1,5635,,,,107,,,,CHEMBL617078,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,8,,,Expert,H,BAO_0000357,,2293,B,
,1,4234,,,,107,,,,CHEMBL617079,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2294,B,
,1,15527,,,,107,,,,CHEMBL617080,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,2295,B,
,1,6588,,,,107,,,CHO,CHEMBL617081,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2296,B,
,1,13631,,,,107,,,,CHEMBL617082,Binding affinity towards human 5-HT2A receptor in BEK cells,,8,,,Expert,H,BAO_0000219,,2297,B,
,1,17723,,,,107,,,,CHEMBL617083,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2298,B,
,1,14770,,,,107,,,,CHEMBL617084,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,8,,,Autocuration,H,BAO_0000357,,2299,B,
,1,16293,,,,107,,,,CHEMBL617085,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2300,B,
,1,16209,,,,107,,,,CHEMBL617086,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2301,B,
,1,12469,,,,107,,,,CHEMBL617087,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,8,,,Autocuration,H,BAO_0000219,,2302,B,
,1,15363,,,,107,,,,CHEMBL617088,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2303,B,
,1,15363,,,,107,,,,CHEMBL617089,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2304,B,
,1,16441,,,,107,,,,CHEMBL617090,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,8,,,Expert,H,BAO_0000019,,2305,B,
,1,8,,,,107,,,,CHEMBL617513,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2306,B,
,1,4176,,,,107,,,HEK293,CHEMBL617514,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2307,B,
,1,17085,,,,107,,,,CHEMBL617515,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2308,B,
,1,17200,,,,107,,,,CHEMBL617516,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,8,,,Autocuration,H,BAO_0000357,,2309,B,
,1,17200,,,,107,,,,CHEMBL617517,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2310,B,
,1,4013,,,,107,,,CHO,CHEMBL617518,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2311,B,
,1,5088,,,,107,,,,CHEMBL617519,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2312,B,
,1,5088,,,,107,,,,CHEMBL617520,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2313,B,
,1,5088,,,,107,,,,CHEMBL617521,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,8,,,Autocuration,H,BAO_0000357,,2314,B,
,1,5088,,,,107,,,,CHEMBL617522,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2315,B,
,1,5088,,,,107,,,,CHEMBL617523,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2316,B,
,1,5088,,,,107,,,,CHEMBL617524,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,Autocuration,H,BAO_0000357,,2317,B,
,1,9786,,,,104686,,,,CHEMBL617525,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,4,,,Autocuration,H,BAO_0000019,,2318,B,
,1,9205,,,,104686,,,,CHEMBL617526,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2319,B,
,1,11257,,,,104686,,,,CHEMBL617527,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,4,,,Autocuration,H,BAO_0000224,,2320,B,
,1,9362,,,,104686,,,,CHEMBL617528,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,4,,,Autocuration,H,BAO_0000019,,2321,B,
,1,9362,,,,104686,,,,CHEMBL617529,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,4,,,Autocuration,H,BAO_0000019,,2322,B,
,1,10590,,,,104686,,,,CHEMBL617530,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,4,,,Autocuration,H,BAO_0000224,,2323,B,
,1,10468,,,,104686,,,,CHEMBL617531,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,4,,,Autocuration,H,BAO_0000019,,2324,B,
,1,13050,,,,104686,,,,CHEMBL617532,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,4,,,Autocuration,H,BAO_0000019,,2325,B,
,1,11624,,,,104686,,,,CHEMBL617533,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000019,,2326,B,
,1,10468,,,,104686,,,,CHEMBL617534,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,4,,,Autocuration,H,BAO_0000019,,2327,B,
,1,10330,,,,104686,,,,CHEMBL617535,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000224,,2328,B,
,1,10062,,,,104686,,,,CHEMBL617536,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,4,,,Autocuration,H,BAO_0000224,,2329,B,
,1,11642,,,,104686,,,,CHEMBL617537,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2330,B,
,1,10062,,,,104686,,,,CHEMBL617538,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2331,B,
,1,13427,,In vitro,,104686,,,,CHEMBL617539,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,4,,,Autocuration,H,BAO_0000219,,2332,B,
,1,12280,,,,104686,,,,CHEMBL617540,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2333,B,
,1,4101,,,,104686,,,,CHEMBL617541,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2334,B,
,1,10062,,,,104686,,,,CHEMBL617542,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2335,B,
,1,11147,,,,104686,,,,CHEMBL617543,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,4,,,Autocuration,H,BAO_0000224,,2336,B,
,1,2395,,,,104686,,,CHO-K1,CHEMBL617544,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,5,10116.0,485.0,Autocuration,D,BAO_0000219,,2337,B,
,1,2395,,,,104686,,,CHO-K1,CHEMBL617545,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,5,10116.0,485.0,Autocuration,D,BAO_0000219,,2338,B,
,1,9098,,,,104686,,,,CHEMBL617413,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2339,B,
,1,9098,,,,104686,,,,CHEMBL617414,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,4,,,Autocuration,H,BAO_0000019,,2340,B,
,1,9098,,,,104686,,,,CHEMBL617415,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2341,B,
,1,9443,,,,104686,,,,CHEMBL617416,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2342,B,
,1,9443,,,,104686,,,,CHEMBL617417,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,4,,,Autocuration,H,BAO_0000224,,2343,B,
,1,9699,,,,104686,,,,CHEMBL617418,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,4,,,Autocuration,H,BAO_0000019,,2344,B,
,1,9699,,,,104686,,,,CHEMBL617419,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,4,,,Autocuration,H,BAO_0000019,,2345,B,
,1,9098,,,,104686,,,,CHEMBL617420,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,4,,,Autocuration,H,BAO_0000224,,2346,B,
,1,3070,,,,104686,,,,CHEMBL617421,Affinity for 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2347,B,
,1,9547,,,,104686,,,,CHEMBL617422,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,4,,,Autocuration,H,BAO_0000224,,2348,B,
,1,10444,,,,104686,,,,CHEMBL617423,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,4,,,Autocuration,H,BAO_0000019,,2349,B,
,1,14617,,,,104686,,,,CHEMBL617424,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,4,,,Autocuration,H,BAO_0000019,,2350,B,
,1,14617,,,,104686,,,,CHEMBL617425,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,4,,,Autocuration,H,BAO_0000019,,2351,B,
,1,11130,,,,104686,,,,CHEMBL617426,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,4,,,Autocuration,H,BAO_0000224,,2352,B,
,1,11130,,In vivo,,104686,,,,CHEMBL617427,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,4,,,Autocuration,H,BAO_0000218,,2353,B,
Brain,1,14542,,,,104686,,,,CHEMBL617428,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,4,,,Autocuration,H,BAO_0000221,955.0,2354,B,
,1,2797,,,,104686,,,,CHEMBL617429,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,4,,,Autocuration,H,BAO_0000224,,2355,B,
,1,11332,,,,104686,,,,CHEMBL617430,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,4,,,Autocuration,H,BAO_0000019,,2356,B,
,1,11332,,,,104686,,,,CHEMBL617431,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,4,,,Autocuration,H,BAO_0000019,,2357,B,
Frontal cortex,1,10752,,,,104686,,,,CHEMBL617432,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,4,,,Autocuration,H,BAO_0000019,1870.0,2358,B,
,1,1185,,,,104686,,,,CHEMBL617433,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2359,B,
,1,1185,,,,104686,,,,CHEMBL617434,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2360,B,
,1,11624,,,,104686,,,,CHEMBL617435,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2361,B,
,1,1344,,,,104686,,,,CHEMBL617436,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,4,,,Autocuration,H,BAO_0000019,,2362,B,
Striatum,1,15453,,,,104686,,,,CHEMBL617437,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,2435.0,2363,B,
,1,11662,,,,104686,,,,CHEMBL617438,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,4,,,Autocuration,H,BAO_0000019,,2364,B,
,1,11662,,,,104686,,,,CHEMBL617439,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,4,,,Autocuration,H,BAO_0000019,,2365,B,
,1,10796,,,,104686,,,,CHEMBL617440,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2366,B,
,1,9069,,,,104686,,,,CHEMBL617441,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2367,B,
,1,8814,,,,104686,,,,CHEMBL872918,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2368,B,
,1,8908,,,,104686,,,,CHEMBL617442,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,2369,B,
,1,9098,,,,104686,,,,CHEMBL617443,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,4,,,Autocuration,H,BAO_0000019,,2370,B,
,1,9098,,,,104686,,,,CHEMBL617444,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,4,,,Autocuration,H,BAO_0000019,,2371,B,
,1,9098,,,,104686,,,,CHEMBL617445,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,4,,,Autocuration,H,BAO_0000019,,2372,B,
,1,9098,,,,104686,,,,CHEMBL617446,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,4,,,Autocuration,H,BAO_0000019,,2373,B,
,1,9098,,,,104686,,,,CHEMBL617447,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,4,,,Autocuration,H,BAO_0000249,,2374,B,
,1,9098,,,,104686,,,,CHEMBL617448,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,4,,,Autocuration,H,BAO_0000019,,2375,B,
,1,9098,,,,104686,,,,CHEMBL617449,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,4,,,Autocuration,H,BAO_0000019,,2376,B,
,1,9161,,,,104686,,,,CHEMBL617450,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,4,,,Autocuration,H,BAO_0000019,,2377,B,
,1,9161,,,,104686,,,,CHEMBL617451,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,4,,,Autocuration,H,BAO_0000019,,2378,B,
,1,9161,,,,104686,,,,CHEMBL617452,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,4,,,Autocuration,H,BAO_0000019,,2379,B,
,1,9161,,,,104686,,,,CHEMBL617453,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,4,,,Autocuration,H,BAO_0000019,,2380,B,
,1,9161,,,,104686,,,,CHEMBL617660,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,4,,,Autocuration,H,BAO_0000019,,2381,B,
,1,9161,,,,104686,,,,CHEMBL617661,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,4,,,Autocuration,H,BAO_0000019,,2382,B,
,1,9161,,,,104686,,,,CHEMBL617662,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,4,,,Autocuration,H,BAO_0000019,,2383,B,
,1,9161,,,,104686,,,,CHEMBL872919,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,4,,,Autocuration,H,BAO_0000019,,2384,B,
,1,9161,,,,104686,,,,CHEMBL617663,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,4,,,Autocuration,H,BAO_0000019,,2385,B,
,1,9161,,,,104686,,,,CHEMBL617664,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,4,,,Autocuration,H,BAO_0000019,,2386,B,
,1,9161,,,,104686,,,,CHEMBL617665,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,4,,,Autocuration,H,BAO_0000019,,2387,B,
,1,9161,,,,104686,,,,CHEMBL617666,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,4,,,Autocuration,H,BAO_0000019,,2388,B,
,1,12094,,,,104686,,,,CHEMBL617667,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,4,,,Autocuration,H,BAO_0000019,,2389,B,
,1,12018,,,,104686,,,,CHEMBL617668,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,4,,,Autocuration,H,BAO_0000249,,2390,B,
,1,10394,,,,104686,,,,CHEMBL617669,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,4,,,Autocuration,H,BAO_0000249,,2391,B,
,1,15260,,,,104686,,,,CHEMBL617670,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2392,B,
,1,11624,,,,104686,,,,CHEMBL617671,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2393,B,
,1,13654,,,,104686,,,,CHEMBL617672,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2394,B,
,1,9541,,,,104686,,,,CHEMBL617673,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,4,,,Autocuration,H,BAO_0000019,,2395,B,
,1,11933,,,,104686,,,,CHEMBL617674,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,4,,,Autocuration,H,BAO_0000224,,2396,B,
,1,15538,,,,104686,,,,CHEMBL617675,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,4,,,Autocuration,H,BAO_0000019,,2397,B,
,1,15538,,,,104686,,,,CHEMBL617676,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,4,,,Autocuration,H,BAO_0000019,,2398,B,
,1,15538,,,,104686,,,,CHEMBL617677,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,4,,,Autocuration,H,BAO_0000019,,2399,B,
,1,8841,,,,104686,,,,CHEMBL617678,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,5,,,Autocuration,D,BAO_0000019,,2400,B,
,1,1455,,,,104686,,,,CHEMBL617679,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,4,,,Autocuration,H,BAO_0000224,,2401,B,
,1,1455,,,,104686,,,,CHEMBL617680,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,4,,,Autocuration,H,BAO_0000224,,2402,B,
,1,11752,,,,104686,,,,CHEMBL617681,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,4,,,Autocuration,H,BAO_0000019,,2403,B,
Brain,1,11642,,,,104686,,,,CHEMBL617682,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,4,,,Autocuration,H,BAO_0000221,955.0,2404,B,
,1,12092,,,,104686,,,,CHEMBL617683,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,4,,,Autocuration,H,BAO_0000224,,2405,B,
,1,3967,,,,104686,,,,CHEMBL617684,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,4,,,Autocuration,H,BAO_0000224,,2406,B,
,1,12771,,,,104686,,,,CHEMBL617685,Binding affinity towards 5-hydroxytryptamine 2 receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,2407,B,
,1,11642,,,,104686,,,,CHEMBL617686,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,4,,,Autocuration,H,BAO_0000019,,2408,B,
,1,11628,,,,104686,,,,CHEMBL617687,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,4,,,Autocuration,H,BAO_0000224,,2409,B,
,1,13654,,,,104686,,,,CHEMBL617688,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,4,,,Autocuration,H,BAO_0000224,,2410,B,
,1,11200,,,,104686,,,,CHEMBL617689,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2411,F,
,1,11200,,,,104686,,,,CHEMBL617690,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,4,,,Autocuration,H,BAO_0000019,,2412,F,
,1,11200,,In vivo,,104686,,,,CHEMBL617691,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,4,,,Autocuration,H,BAO_0000218,,2413,F,
,1,11200,,In vivo,,104686,,,,CHEMBL617692,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,4,,,Autocuration,H,BAO_0000218,,2414,F,
,1,11200,,In vivo,,104686,,,,CHEMBL617693,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,4,,,Autocuration,H,BAO_0000218,,2415,F,
,1,11200,,In vivo,,104686,,,,CHEMBL617694,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,4,,,Autocuration,H,BAO_0000218,,2416,F,
Brain,1,15436,,,,12687,,,,CHEMBL857985,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,8,,,Expert,H,BAO_0000221,955.0,2417,B,
,1,15436,,,,12687,,,,CHEMBL617695,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2418,B,
,1,14025,,,,12687,,,,CHEMBL617696,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,8,,,Autocuration,H,BAO_0000019,,2419,B,
,1,4342,,,,12687,,,,CHEMBL617697,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2420,B,
,1,13735,,,,12687,,,,CHEMBL617257,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2421,B,
,1,5816,,,,12687,,,,CHEMBL617258,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2422,B,
,1,14287,,,,12687,,,,CHEMBL617259,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,8,,,Expert,H,BAO_0000019,,2423,B,
,1,15738,,,,12687,,,,CHEMBL617260,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,8,,,Autocuration,H,BAO_0000357,,2424,B,
,1,15738,,,,12687,,,,CHEMBL617261,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2425,B,
,1,15026,,,,12687,,,,CHEMBL617262,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000019,,2426,B,
,1,16647,,,,12687,,,,CHEMBL617263,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,8,,,Expert,H,BAO_0000019,,2427,B,
,1,16647,,,,12687,,,,CHEMBL617264,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,8,,,Autocuration,H,BAO_0000019,,2428,B,
,1,13345,,,,12687,,,,CHEMBL617265,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2429,B,
,1,1543,,,,12687,,Membranes,,CHEMBL617266,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000249,,2430,B,
,1,12444,,,,12687,,,,CHEMBL617267,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,8,,,Autocuration,H,BAO_0000019,,2431,B,
,1,16404,,,,12687,,,,CHEMBL617268,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,8,,,Expert,H,BAO_0000019,,2432,B,
,1,16404,,,,12687,,,CHO,CHEMBL617269,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,2433,B,
,1,15577,,,,12687,,,,CHEMBL617323,Kinetic inhibition constant evaluated by measuring serotonergic activity,,8,,,Expert,H,BAO_0000357,,2434,B,
,1,15577,,,,12687,,,,CHEMBL617324,Serotonergic activity of the compound.,,8,,,Autocuration,H,BAO_0000357,,2435,B,
,1,2495,,,,12687,,,,CHEMBL617325,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,8,,,Autocuration,H,BAO_0000249,,2436,B,
,1,15042,,,,12687,,,,CHEMBL617326,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2437,B,
,1,15026,,,,12687,,,,CHEMBL617327,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,8,,,Expert,H,BAO_0000249,,2438,B,
,1,12919,,,,12687,,,,CHEMBL617328,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2439,F,
,1,12919,,,,12687,,,,CHEMBL617329,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2440,F,
,1,12919,,,,12687,,,,CHEMBL617330,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2441,F,
,1,15194,,,,12687,,,,CHEMBL617331,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2442,B,
,1,15194,,,,12687,,,,CHEMBL617332,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,8,,,Autocuration,H,BAO_0000357,,2443,B,
,1,4820,,,,107,,,,CHEMBL617333,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2444,B,
,1,6736,,,,107,,,,CHEMBL617334,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,8,,,Autocuration,H,BAO_0000357,,2445,B,
,1,5163,,,,107,,,,CHEMBL617335,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,8,,,Autocuration,H,BAO_0000357,,2446,B,
,1,5163,,,,107,,,,CHEMBL617336,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,8,,,Autocuration,H,BAO_0000357,,2447,B,
,1,6011,,,,107,,,,CHEMBL617337,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,2448,B,
,1,14294,,,,107,,,,CHEMBL617338,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2449,B,
,1,5014,,,,107,,,,CHEMBL617339,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2450,B,
,1,17066,,,,107,,,,CHEMBL617340,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2451,B,
,1,17515,,,,107,,,,CHEMBL617341,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,2452,B,
,1,6736,,,,107,,,,CHEMBL617342,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2453,B,
,1,5163,,,,107,,,,CHEMBL617343,Affinity for 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2454,B,
,1,16911,,,,107,,,NIH3T3,CHEMBL617344,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,8,,723.0,Expert,H,BAO_0000219,,2455,B,
,1,6841,,,,107,,,,CHEMBL617345,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,8,,,Expert,H,BAO_0000357,,2456,B,
,1,6119,,,,107,,,,CHEMBL617346,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,8,,,Expert,H,BAO_0000357,,2457,B,
,1,3962,,,,107,,,,CHEMBL617347,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2458,B,
,1,4373,,,,107,,,,CHEMBL617348,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2459,B,
,1,4373,,,,107,,,,CHEMBL617349,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2460,B,
,1,3962,,,,107,,,,CHEMBL617350,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2461,F,
,1,1633,,,,107,,,,CHEMBL872339,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,8,,,Expert,H,BAO_0000357,,2462,B,
,1,4373,,,,107,,,,CHEMBL617351,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2463,B,
,1,6576,,,,107,,,,CHEMBL617352,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2464,B,
,1,4687,,,,107,,,,CHEMBL617353,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2465,B,
,1,16946,,,,107,,,,CHEMBL617354,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2466,B,
,1,14159,,,,107,,,,CHEMBL617355,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2467,B,
,1,3032,,,,107,,,CHO,CHEMBL617356,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Mus musculus,8,10090.0,449.0,Expert,H,BAO_0000219,,2468,B,
,1,16655,,,,107,,,,CHEMBL617357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2469,B,
,1,13964,,,,107,,,,CHEMBL617358,Binding affinity at 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2470,B,
,1,16989,,,,107,,,,CHEMBL617359,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2471,B,
,1,16117,,,,107,,,,CHEMBL617360,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2472,B,
,1,16700,,,,107,,,,CHEMBL875913,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,2473,B,
,1,3269,,,,107,,,,CHEMBL617361,Affinity against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2474,B,
,1,1274,,,,107,,,,CHEMBL617362,Binding affinity against 5-Hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2475,B,
,1,1317,,,,107,,,,CHEMBL617363,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,2476,B,
,1,12146,,,,107,,,,CHEMBL617364,Tested against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2477,B,
,1,12652,,,,105075,,,,CHEMBL617365,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,4,,,Autocuration,H,BAO_0000224,,2478,B,
,1,12652,,,,105075,,,,CHEMBL617366,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,4,,,Autocuration,H,BAO_0000224,,2479,B,
,1,12652,,,,105075,,,,CHEMBL617367,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,4,,,Autocuration,H,BAO_0000224,,2480,B,
,1,12652,,,,105075,,,,CHEMBL617368,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,4,,,Autocuration,H,BAO_0000224,,2481,B,
,1,16647,,,,107,,,,CHEMBL617369,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,8,,,Autocuration,H,BAO_0000357,,2482,B,
,1,15851,,,,227,,,HEK293,CHEMBL617370,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2483,B,
,1,6857,,,,227,,,CHO,CHEMBL617371,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2484,F,
,1,3805,,,,227,,,,CHEMBL617372,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,2485,B,
,1,6491,,,,227,,,,CHEMBL617373,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2486,B,
,1,14093,,,,227,,,,CHEMBL617374,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,8,,,Autocuration,H,BAO_0000019,,2487,F,
,1,13481,,,,227,,,,CHEMBL617375,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,8,,,Autocuration,H,BAO_0000019,,2488,F,
,1,14093,,,,227,,,,CHEMBL617376,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,8,,,Autocuration,H,BAO_0000019,,2489,F,
,1,14093,,,,227,,,,CHEMBL617377,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,8,,,Autocuration,H,BAO_0000019,,2490,F,
,1,14093,,,,227,,,,CHEMBL617378,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,8,,,Autocuration,H,BAO_0000019,,2491,F,
,1,13481,,,,227,,,,CHEMBL617379,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,8,,,Autocuration,H,BAO_0000019,,2492,F,
,1,14442,,,,227,,,,CHEMBL617380,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2493,B,
,1,14442,,,,227,,,,CHEMBL617381,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,8,,,Autocuration,H,BAO_0000357,,2494,B,
,1,14442,,,,227,,,,CHEMBL617382,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2495,B,
,1,12369,,,,107,,,,CHEMBL617383,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2496,B,
,1,12369,,,,107,,,,CHEMBL617384,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,8,,,Expert,H,BAO_0000357,,2497,B,
,1,12369,,,,107,,,,CHEMBL617385,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,8,,,Expert,H,BAO_0000357,,2498,B,
,1,14447,,,,107,,,,CHEMBL617386,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,8,,,Autocuration,H,BAO_0000019,,2499,B,
,1,14447,,,,107,,,,CHEMBL617387,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,8,,,Autocuration,H,BAO_0000019,,2500,B,
,1,17451,,,,107,,,NIH3T3,CHEMBL617388,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,,723.0,Autocuration,H,BAO_0000219,,2501,B,
,1,6857,,,,107,,,CHO,CHEMBL617389,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,2502,F,
,1,6857,,,,107,,,CHO,CHEMBL617390,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2503,F,
,1,5635,,,,104817,,,,CHEMBL617391,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,4,,,Autocuration,H,BAO_0000224,,2504,B,
,1,12861,,,,107,,,,CHEMBL617392,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,2505,B,
,1,12861,,,,107,,,,CHEMBL617393,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,Autocuration,H,BAO_0000019,,2506,B,
,1,5105,,,,107,,,L929,CHEMBL617394,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,8,,307.0,Autocuration,H,BAO_0000219,,2507,B,
,1,5104,,,,107,,,L929,CHEMBL617395,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,8,,307.0,Expert,H,BAO_0000219,,2508,B,
,1,5105,,,,107,,,L929,CHEMBL617396,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,8,,307.0,Expert,H,BAO_0000219,,2509,B,
,1,5105,,,,107,,,L929,CHEMBL617397,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,8,,307.0,Autocuration,H,BAO_0000219,,2510,B,
,1,5254,,,,107,,,,CHEMBL617398,Binding affinity against 5-HT2A receptor,,8,,,Autocuration,H,BAO_0000357,,2511,B,
,1,5254,,,,107,,,,CHEMBL617399,Binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2512,B,
,1,13267,,,,107,,,HEK293,CHEMBL617400,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2513,B,
,1,13267,,,,107,,,HEK293,CHEMBL617401,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2514,B,
,1,14157,,,,107,,,HEK293,CHEMBL617402,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2515,B,
,1,12936,,,,107,,,HEK293,CHEMBL617403,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2516,B,
,1,14068,,,,107,,,,CHEMBL617404,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,8,,,Expert,H,BAO_0000357,,2517,B,
,1,12936,,,,107,,,HEK293,CHEMBL857981,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2518,B,
,1,12936,,,,107,,,HEK293,CHEMBL617405,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2519,B,
,1,4540,,,,107,,,HEK293,CHEMBL617253,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2520,B,
,1,6166,,,,107,,,,CHEMBL617254,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,8,,,Expert,H,BAO_0000357,,2521,B,
,1,17296,,,,107,,,HEK293,CHEMBL617255,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2522,B,
,1,17296,,,,107,,,HEK293,CHEMBL617256,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2523,B,
,1,17296,,,,107,,,HEK293,CHEMBL616874,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2524,B,
,1,15779,,,,107,,,HEK293,CHEMBL616875,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2525,B,
,1,14391,,,,107,,,HEK293,CHEMBL616876,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,8,,722.0,Expert,H,BAO_0000219,,2526,B,
,1,15851,,,,107,,,HEK293,CHEMBL616877,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,8,,722.0,Expert,H,BAO_0000219,,2527,B,
,1,15851,,,,107,,,HEK293,CHEMBL616878,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2528,B,
,1,3832,,,,107,,,HEK293,CHEMBL616879,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,8,,722.0,Expert,H,BAO_0000219,,2529,B,
,1,3833,,,,107,,,HEK293,CHEMBL616880,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,8,,722.0,Expert,H,BAO_0000219,,2530,B,
,1,12936,,,,107,,,HEK293,CHEMBL616881,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2531,B,
,1,17451,,,,107,,,NIH3T3,CHEMBL616882,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,8,,723.0,Autocuration,H,BAO_0000219,,2532,B,
,1,17451,,,,107,,,NIH3T3,CHEMBL616883,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,,723.0,Autocuration,H,BAO_0000219,,2533,B,
,1,17451,,,,107,,,NIH3T3,CHEMBL616884,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,,723.0,Autocuration,H,BAO_0000219,,2534,B,
,1,4199,,,,107,,,HEK293,CHEMBL616885,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2535,B,
,1,1883,,,,107,,,CHO-K1,CHEMBL616886,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,8,,485.0,Autocuration,H,BAO_0000219,,2536,B,
,1,1883,,,,107,,,CHO-K1,CHEMBL616887,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,8,,485.0,Expert,H,BAO_0000219,,2537,B,
,1,14875,,,,107,,,,CHEMBL616888,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2538,B,
,1,15146,,,,107,,,HEK293,CHEMBL616889,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,8,,722.0,Autocuration,H,BAO_0000219,,2539,B,
,1,5213,,,,107,,,HEK293,CHEMBL616890,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2540,B,
,1,16404,,,,107,,,CHO,CHEMBL616891,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2541,B,
,1,14818,,,,107,,,HEK293,CHEMBL616892,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,8,,722.0,Autocuration,H,BAO_0000219,,2542,B,
,1,4829,,,,107,,,HEK293,CHEMBL616893,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2543,B,
,1,12652,,,,10620,,,NIH3T3,CHEMBL616894,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,8,,723.0,Autocuration,H,BAO_0000219,,2544,F,
,1,4682,,,,107,,,NIH3T3,CHEMBL616895,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,8,,723.0,Expert,H,BAO_0000219,,2545,B,
,1,12652,,,,10620,,,,CHEMBL616896,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2546,F,
,1,4921,,,,10621,,,,CHEMBL617099,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2547,B,
,1,4921,,,,10621,,,,CHEMBL617100,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,8,,,Autocuration,H,BAO_0000357,,2548,B,
,1,16312,,,,107,,,,CHEMBL884532,Binding affinity against rabbit aorta 5-HT2A receptor,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000357,,2549,B,
,1,14998,,,,107,,,,CHEMBL617101,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000357,,2550,B,
,1,14025,,,,107,,,,CHEMBL617102,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000357,,2551,B,
,1,13047,,,,107,,,,CHEMBL617103,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,2552,B,
,1,13047,,,,107,,,,CHEMBL617104,The compound was tested for binding affinity against 5-HT2A receptor,Oryctolagus cuniculus,8,9986.0,,Expert,H,BAO_0000357,,2553,B,
,1,1883,,,,10576,,,CHO-K1,CHEMBL857979,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,2554,B,
,1,13463,,,,12687,,,,CHEMBL857502,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,8,,,Autocuration,H,BAO_0000019,,2555,B,
,1,13463,,,,12687,,,,CHEMBL617105,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,8,,,Autocuration,H,BAO_0000019,,2556,B,
Stomach,1,13463,,,,12687,,,,CHEMBL858021,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,8,,,Autocuration,H,BAO_0000019,945.0,2557,B,
Stomach,1,13463,,,,12687,,,,CHEMBL875910,Binding affinity for 5-HT 2A in rat stomach fundus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,945.0,2558,B,
,1,13463,,,,12687,,,,CHEMBL617106,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,8,,,Autocuration,H,BAO_0000019,,2559,B,
,1,16326,,,,12687,,,NIH3T3,CHEMBL617107,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,8,,723.0,Expert,H,BAO_0000219,,2560,B,
,1,14093,,,,12687,,,,CHEMBL617108,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2561,F,
,1,14093,,,,12687,,,,CHEMBL617109,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2562,F,
,1,15740,,,,12687,,,,CHEMBL617110,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2563,B,
,1,16633,,,,12687,,,,CHEMBL617111,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,8,,,Autocuration,H,BAO_0000357,,2564,B,
,1,17200,,,,12687,,,,CHEMBL617112,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2565,F,
,1,17133,,,,12687,,,,CHEMBL617113,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2566,B,
,1,17133,,,,12687,,,,CHEMBL617114,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2567,B,
,1,17133,,,,12687,,,,CHEMBL617115,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2568,B,
,1,17200,,,,12687,,,,CHEMBL617116,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,8,,,Autocuration,H,BAO_0000219,,2569,F,
,1,15363,,,,12687,,,,CHEMBL617117,Efficacy at 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2570,F,
,1,17200,,,,12687,,,,CHEMBL617118,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,8,,,Autocuration,H,BAO_0000357,,2571,B,
,1,17200,,,,12687,,,,CHEMBL617119,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2572,B,
,1,17200,,,,12687,,,,CHEMBL617120,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2573,B,
,1,17200,,,,12687,,,,CHEMBL617121,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000219,,2574,F,
,1,17200,,,,12687,,,,CHEMBL617122,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,8,,,Autocuration,H,BAO_0000219,,2575,F,
,1,17211,,,,12687,,,,CHEMBL617123,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2576,B,
,1,17331,,,,12687,,,,CHEMBL617124,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,8,,,Expert,H,BAO_0000019,,2577,B,
,1,13565,,,,12687,,,,CHEMBL617600,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,8,,,Expert,H,BAO_0000249,,2578,B,
,1,13730,,,,12687,,,,CHEMBL617601,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,8,,,Expert,H,BAO_0000357,,2579,B,
,1,12416,,,,12687,,,,CHEMBL882923,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,8,,,Expert,H,BAO_0000019,,2580,B,
,1,15295,,,,12687,,,,CHEMBL617602,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2581,B,
,1,1742,,,,12687,,,,CHEMBL617603,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,8,,,Autocuration,H,BAO_0000019,,2582,B,
,1,15295,,,,12687,,,,CHEMBL617604,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2583,B,
,1,14970,,,,12687,,,,CHEMBL617605,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000019,,2584,B,
,1,16693,,,,12687,,,,CHEMBL617606,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000019,,2585,B,
,1,14776,,,,12687,,,,CHEMBL617607,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2586,B,
,1,14286,,,,12687,,,,CHEMBL617455,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2587,B,
,1,17200,,,,12687,,,,CHEMBL617456,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2588,B,
,1,15306,,,,12687,,,,CHEMBL617457,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,8,,,Expert,H,BAO_0000357,,2589,B,
,1,14178,,,,12687,,,,CHEMBL617458,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2590,B,
,1,14229,,,,12687,,,,CHEMBL617459,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2591,B,
,1,12884,,,,12687,,,,CHEMBL617460,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,8,,,Expert,H,BAO_0000357,,2592,B,
,1,13149,,,,12687,,,,CHEMBL617461,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,8,,,Expert,H,BAO_0000357,,2593,B,
,1,15295,,,,12687,,,,CHEMBL617462,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2594,B,
,1,15740,,,,12687,,,,CHEMBL617463,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,8,,,Autocuration,H,BAO_0000357,,2595,B,
,1,15185,,,,12687,,,,CHEMBL617464,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,8,,,Autocuration,H,BAO_0000019,,2596,B,
,1,15185,,,,12687,,,,CHEMBL617465,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,8,,,Autocuration,H,BAO_0000019,,2597,B,
,1,17529,,,,12687,,,,CHEMBL617466,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,8,,,Expert,H,BAO_0000019,,2598,B,
,1,14826,,,,12687,,,,CHEMBL617467,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,8,,,Autocuration,H,BAO_0000019,,2599,B,
,1,17211,,,,12687,,,,CHEMBL617468,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,8,,,Expert,H,BAO_0000019,,2600,B,
,1,14826,,,,12687,,,,CHEMBL617469,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,8,,,Autocuration,H,BAO_0000019,,2601,B,
,1,14093,,,,12687,,,,CHEMBL617470,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000019,,2602,B,
,1,14093,,,,12687,,,,CHEMBL617471,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,8,,,Autocuration,H,BAO_0000019,,2603,B,
,1,13246,,,,12687,,,NIH3T3,CHEMBL617472,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,8,,723.0,Expert,H,BAO_0000219,,2604,B,
,1,13246,,,,12687,,,,CHEMBL617473,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,8,,,Expert,H,BAO_0000357,,2605,B,
,1,15436,,,,12687,,,,CHEMBL617474,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2606,B,
,1,15436,,,,12687,,,,CHEMBL617475,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2607,B,
Brain,1,14442,,,,12687,,,,CHEMBL617476,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,8,,,Autocuration,H,BAO_0000221,955.0,2608,B,
,1,12457,,,,12687,,,,CHEMBL617477,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2609,B,
,1,12457,,,,12687,,,NIH3T3,CHEMBL617478,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,8,,723.0,Expert,H,BAO_0000219,,2610,B,
,1,14755,,,,12687,,,,CHEMBL617479,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,8,,,Autocuration,H,BAO_0000221,,2611,F,
,1,4707,,,,12687,,,,CHEMBL617480,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2612,B,
,1,13297,,,,12687,,,,CHEMBL617481,Binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,Expert,H,BAO_0000357,,2613,B,
,1,17331,,,,12687,,,,CHEMBL617482,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,8,,,Expert,H,BAO_0000019,,2614,B,
,1,4664,,,,12687,,,,CHEMBL617483,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000019,,2615,B,
,1,16633,,,,12687,,,,CHEMBL621528,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2616,B,
,1,4664,,,,12687,,,NIH3T3,CHEMBL621529,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Rattus norvegicus,9,10116.0,723.0,Expert,D,BAO_0000219,,2617,B,
,1,16133,,,,12687,,,,CHEMBL621530,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,Expert,H,BAO_0000357,,2618,B,
,1,16133,,,,12687,,,,CHEMBL621531,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000357,,2619,B,
,1,14060,,,,12687,,,,CHEMBL621532,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2620,B,
,1,16326,,,,12687,,,,CHEMBL621533,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,Expert,H,BAO_0000357,,2621,B,
,1,16659,,,,12687,,,CHO,CHEMBL621534,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2622,B,
,1,14776,,,,12687,,,,CHEMBL621535,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,8,,,Autocuration,H,BAO_0000019,,2623,B,
,1,13481,,,,12687,,,,CHEMBL621536,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,2624,B,
,1,17386,,,,12687,,,,CHEMBL621537,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2625,B,
,1,6611,,,,12687,,,,CHEMBL621538,Binding affinity for 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2626,B,
,1,14423,,,,12687,,,,CHEMBL621539,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,2627,B,
,1,15412,,,,12687,,,,CHEMBL621540,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,8,,,Autocuration,H,BAO_0000019,,2628,B,
,1,15412,,,,12687,,,,CHEMBL621541,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,8,,,Autocuration,H,BAO_0000019,,2629,B,
,1,6238,,,,12687,,,,CHEMBL621542,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000019,,2630,B,
,1,6648,,,,12687,,,,CHEMBL621543,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,8,,,Expert,H,BAO_0000357,,2631,B,
,1,5667,,,,12687,,,,CHEMBL621544,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000357,,2632,B,
,1,6611,,,,12687,,,,CHEMBL621545,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2633,B,
,1,13481,,,,12687,,,,CHEMBL621546,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2634,B,
,1,13481,,,,12687,,,,CHEMBL621547,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,8,,,Autocuration,H,BAO_0000357,,2635,B,
,1,15558,,,,12687,,,NIH3T3,CHEMBL618692,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,8,,723.0,Expert,H,BAO_0000219,,2636,B,
,1,6013,,,,12687,,,,CHEMBL618693,Binding affinity towards 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2637,B,
,1,16633,,,,12687,,,,CHEMBL872922,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2638,B,
,1,6013,,,,12687,,,,CHEMBL618694,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2639,B,
,1,6013,,,,12687,,,,CHEMBL618695,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2640,B,
,1,6013,,,,12687,,,,CHEMBL618696,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,8,,,Autocuration,H,BAO_0000357,,2641,B,
,1,6013,,,,12687,,,,CHEMBL618697,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,8,,,Expert,H,BAO_0000357,,2642,B,
,1,6013,,,,12687,,,,CHEMBL618892,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,8,,,Autocuration,H,BAO_0000357,,2643,B,
,1,6013,,,,12687,,,,CHEMBL618893,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2644,B,
,1,16293,,,,12687,,,,CHEMBL618894,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2645,B,
,1,17175,,,,12687,,,NIH3T3,CHEMBL618895,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,8,,723.0,Expert,H,BAO_0000219,,2646,B,
,1,13278,,,,12687,,,,CHEMBL618896,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2647,B,
Caudate-putamen,1,3682,,,,12687,,,,CHEMBL618897,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,8,,,Autocuration,H,BAO_0000019,5383.0,2648,B,
,1,2014,,,,12687,,,,CHEMBL618898,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,8,,,Autocuration,H,BAO_0000357,,2649,B,
,1,2014,,,,12687,,,,CHEMBL618899,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,8,,,Autocuration,H,BAO_0000357,,2650,B,
,1,4932,,,,12687,,,,CHEMBL618900,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,8,,,Autocuration,H,BAO_0000357,,2651,B,
,1,4932,,,,12687,,,,CHEMBL618901,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,8,,,Autocuration,H,BAO_0000019,,2652,B,
,1,3935,,,,12687,,,,CHEMBL618902,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2653,B,
Hippocampus,1,5432,,,,12687,,,,CHEMBL618903,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,10000000.0,2654,B,
,1,15818,,,,12687,,,,CHEMBL618904,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2655,B,
,1,13672,,,,12687,,,,CHEMBL618905,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,8,,,Autocuration,H,BAO_0000357,,2656,B,
,1,13672,,,,12687,,,,CHEMBL618906,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,8,,,Autocuration,H,BAO_0000357,,2657,B,
,1,14749,,,,12687,,,NIH3T3,CHEMBL618907,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,8,,723.0,Expert,H,BAO_0000219,,2658,B,
,1,13462,,,,12687,,,,CHEMBL618908,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,8,,,Autocuration,H,BAO_0000019,,2659,B,
,1,15740,,,,12687,,,,CHEMBL617909,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2660,B,
,1,16647,,,,12687,,,,CHEMBL617910,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,8,,,Expert,H,BAO_0000019,,2661,B,
Brain,1,13345,,,,12687,,,,CHEMBL617911,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,8,,,Autocuration,H,BAO_0000221,955.0,2662,B,
,1,16740,,,,12687,,,,CHEMBL872923,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2663,B,
,1,16740,,,,12687,,,,CHEMBL617912,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2664,B,
,1,15535,,,,12687,,,,CHEMBL617913,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2665,B,
,1,16740,,,,12687,,,,CHEMBL617914,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Expert,H,BAO_0000249,,2666,B,
,1,16740,,,,12687,,,,CHEMBL617915,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2667,B,
,1,16740,,,,12687,,,,CHEMBL617916,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2668,B,
,1,4795,,,,12687,,,,CHEMBL617917,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2669,B,
,1,8,,,,12687,,,,CHEMBL617918,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,8,,,Expert,H,BAO_0000019,,2670,B,
,1,8,,,,12687,,,,CHEMBL617919,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,8,,,Autocuration,H,BAO_0000019,,2671,B,
,1,17200,,,,12687,,,,CHEMBL617920,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2672,B,
,1,2148,,,,12687,,,,CHEMBL617921,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2673,B,
,1,13345,,,,105102,,,,CHEMBL617922,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Rattus norvegicus,5,10116.0,,Expert,D,BAO_0000224,,2674,B,
,1,5088,,,,12687,,,,CHEMBL617923,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,8,,,Autocuration,H,BAO_0000357,,2675,B,
,1,5088,,,,12687,,,,CHEMBL617924,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,8,,,Autocuration,H,BAO_0000357,,2676,B,
,1,17133,,,,12687,,,,CHEMBL617925,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2677,B,
,1,17133,,,,12687,,,,CHEMBL617926,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2678,B,
,1,16532,,,,12687,,,,CHEMBL617927,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,8,,,Autocuration,H,BAO_0000357,,2679,B,
,1,15086,,,,12687,,,,CHEMBL617928,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,8,,,Autocuration,H,BAO_0000357,,2680,B,
,1,2309,,,,12687,,,,CHEMBL617929,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2681,B,
,1,12953,,,,12687,,,,CHEMBL617930,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,8,,,Expert,H,BAO_0000019,,2682,B,
,1,12953,,,,12687,,,,CHEMBL617931,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,8,,,Autocuration,H,BAO_0000019,,2683,B,
,1,12953,,,,12687,,,,CHEMBL617932,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,8,,,Autocuration,H,BAO_0000019,,2684,B,
,1,16659,,,,12687,,,CHO,CHEMBL617933,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,8,,449.0,Autocuration,H,BAO_0000219,,2685,B,
,1,16740,,,,12687,,,,CHEMBL617934,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,8,,,Autocuration,H,BAO_0000019,,2686,B,
,1,16740,,,,12687,,,,CHEMBL617935,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,8,,,Autocuration,H,BAO_0000019,,2687,B,
,1,17133,,,,12687,,,,CHEMBL617936,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,8,,,Autocuration,H,BAO_0000357,,2688,B,
,1,17211,,,,12687,,,,CHEMBL617937,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,8,,,Autocuration,H,BAO_0000019,,2689,B,
,1,17331,,,,12687,,,,CHEMBL617938,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,8,,,Autocuration,H,BAO_0000019,,2690,B,
,1,16633,,,,12687,,,,CHEMBL617939,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,8,,,Autocuration,H,BAO_0000218,,2691,B,
,1,16633,,,,12687,,,,CHEMBL617940,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,8,,,Autocuration,H,BAO_0000218,,2692,B,
,1,16633,,,,12687,,,,CHEMBL617941,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,8,,,Autocuration,H,BAO_0000218,,2693,B,
,1,15026,,,,12687,,,,CHEMBL617942,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,8,,,Expert,H,BAO_0000357,,2694,B,
,1,15026,,,,12687,,,,CHEMBL617943,Ratio of pKi of 5-HT2A to that of D2 receptor,,8,,,Expert,H,BAO_0000357,,2695,B,
,1,16404,,,,105093,,,,CHEMBL617944,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,4,,,Expert,H,BAO_0000224,,2696,B,
,1,16404,,,,105093,,,,CHEMBL617945,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,4,,,Expert,H,BAO_0000224,,2697,B,
,1,16404,,,,105075,,,,CHEMBL617946,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,4,,,Expert,H,BAO_0000224,,2698,B,
,1,16404,,,,12687,,,,CHEMBL617947,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,8,,,Autocuration,H,BAO_0000357,,2699,B,
,1,16326,,,,12687,,,,CHEMBL617948,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,8,,,Expert,H,BAO_0000357,,2700,B,
,1,15847,,,,12687,,,,CHEMBL858116,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,8,,,Autocuration,H,BAO_0000019,,2701,F,
,1,15847,,,,12687,,,,CHEMBL617949,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,8,,,Autocuration,H,BAO_0000019,,2702,F,
,1,15329,,,,12687,,,,CHEMBL617950,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,8,,,Autocuration,H,BAO_0000019,,2703,F,
Thoracic aorta,1,16404,,,,12687,,,,CHEMBL617951,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,8,,,Expert,H,BAO_0000019,1515.0,2704,F,
Thoracic aorta,1,16404,,,,12687,,,,CHEMBL617952,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,8,,,Expert,H,BAO_0000019,1515.0,2705,F,
Thoracic aorta,1,16404,,,,12687,,,,CHEMBL617953,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,8,,,Autocuration,H,BAO_0000019,1515.0,2706,F,
,1,12861,,,,12687,,,,CHEMBL617954,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,2707,B,
,1,12861,,,,12687,,,,CHEMBL617955,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,Expert,H,BAO_0000019,,2708,B,
,1,12861,,,,12687,,,,CHEMBL857071,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,8,,,Autocuration,H,BAO_0000019,,2709,B,
,1,12490,,,,12687,,,,CHEMBL617270,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,8,,,Expert,H,BAO_0000019,,2710,B,
,1,12827,,,,12687,,,N1E-115,CHEMBL617271,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,8,,339.0,Autocuration,H,BAO_0000219,,2711,B,
,1,12827,,,,12687,,,N1E-115,CHEMBL617272,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,8,,339.0,Autocuration,H,BAO_0000219,,2712,B,
,1,12918,,,,12687,,,,CHEMBL617273,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,8,,,Autocuration,H,BAO_0000019,,2713,B,
,1,12919,,,,12687,,,,CHEMBL617274,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2714,F,
,1,17723,,,,108,,,,CHEMBL617275,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2715,B,
,1,6013,,,,108,,,,CHEMBL617276,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2716,B,
,1,16293,,,,108,,,,CHEMBL617277,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2717,B,
,1,3857,,,,108,,,,CHEMBL617278,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000019,,2718,B,
,1,3857,,,,108,,,,CHEMBL617279,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,8,,,Expert,H,BAO_0000019,,2719,B,
,1,3857,,,,108,,,,CHEMBL617280,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000019,,2720,B,
,1,15363,,,,108,,,,CHEMBL617281,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2721,B,
,1,15363,,,,108,,,,CHEMBL617282,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2722,B,
,1,16441,,,,108,,,,CHEMBL617283,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,8,,,Expert,H,BAO_0000019,,2723,B,
,1,16441,,,,108,,,,CHEMBL617284,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,8,,,Expert,H,BAO_0000019,,2724,B,
,1,4176,,,,108,,,HEK293,CHEMBL617285,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2725,B,
,1,17085,,,,108,,,,CHEMBL617286,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000019,,2726,B,
,1,17200,,,,108,,,,CHEMBL617287,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2727,B,
,1,5088,,,,108,,,,CHEMBL617288,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,8,,,Expert,H,BAO_0000357,,2728,B,
,1,5088,,,,108,,,,CHEMBL617289,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,8,,,Autocuration,H,BAO_0000357,,2729,B,
,1,5088,,,,108,,,,CHEMBL872917,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2730,B,
,1,5088,,,,108,,,,CHEMBL617290,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2731,B,
,1,16659,,,,108,,,CHO,CHEMBL617291,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,2732,B,
,1,16659,,,,108,,,CHO,CHEMBL617292,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,8,,449.0,Autocuration,H,BAO_0000219,,2733,B,
,1,17451,,,,108,,,NIH3T3,CHEMBL617293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,8,,723.0,Autocuration,H,BAO_0000219,,2734,B,
,1,6857,,,,108,,,CHO,CHEMBL617294,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2735,F,
,1,3857,,,,108,,,,CHEMBL617295,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,8,,,Expert,H,BAO_0000019,,2736,B,
,1,12861,,,,108,,,,CHEMBL617296,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,2737,B,
,1,12861,,,,108,,,,CHEMBL617297,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,8,,,Autocuration,H,BAO_0000019,,2738,B,
,1,5104,,,,108,,,CHO,CHEMBL617298,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,8,,449.0,Expert,H,BAO_0000219,,2739,B,
,1,5105,,,,108,,,CHO,CHEMBL617299,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,8,,449.0,Expert,H,BAO_0000219,,2740,B,
,1,5105,,,,108,,,CHO,CHEMBL617300,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,8,,449.0,Autocuration,H,BAO_0000219,,2741,B,
,1,5254,,,,108,,,,CHEMBL617454,Binding affinity against 5-HT2C receptor,,8,,,Autocuration,H,BAO_0000357,,2742,B,
,1,13267,,,,108,,,HEK293,CHEMBL617505,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2743,B,
,1,14157,,,,108,,,HEK293,CHEMBL617506,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2744,B,
,1,12936,,,,108,,,HEK293,CHEMBL617507,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2745,B,
,1,14068,,,,108,,,,CHEMBL617508,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,8,,,Expert,H,BAO_0000357,,2746,B,
,1,12936,,,,108,,,HEK293,CHEMBL857982,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2747,B,
,1,4540,,,,108,,,HEK293,CHEMBL617509,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2748,B,
,1,4540,,,,108,,,HEK293,CHEMBL617510,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2749,B,
,1,6166,,,,108,,,,CHEMBL617511,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2750,B,
,1,17296,,,,108,,,HEK293,CHEMBL617512,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2751,B,
,1,17296,,,,108,,,HEK293,CHEMBL617749,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2752,B,
,1,15779,,,,108,,,HEK293,CHEMBL617750,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,2753,B,
,1,15779,,,,108,,,HEK293,CHEMBL617751,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,2754,B,
,1,14391,,,,108,,,HEK293,CHEMBL617752,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,8,,722.0,Expert,H,BAO_0000219,,2755,B,
,1,15779,,,,108,,,HEK293,CHEMBL617753,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2756,B,
,1,15851,,,,108,,,HEK293,CHEMBL617754,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,8,,722.0,Expert,H,BAO_0000219,,2757,B,
,1,15851,,,,108,,,HEK293,CHEMBL617755,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2758,B,
,1,15779,,,,108,,,HEK293,CHEMBL617756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,8,,722.0,Autocuration,H,BAO_0000219,,2759,B,
,1,3832,,,,108,,,HEK293,CHEMBL617757,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,8,,722.0,Expert,H,BAO_0000219,,2760,B,
,1,3833,,,,108,,,HEK293,CHEMBL617758,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,8,,722.0,Expert,H,BAO_0000219,,2761,B,
,1,17451,,,,108,,,NIH3T3,CHEMBL617759,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,8,,723.0,Autocuration,H,BAO_0000219,,2762,B,
,1,4199,,,,108,,,HEK293,CHEMBL617760,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2763,B,
,1,1883,,,,108,,,CHO-K1,CHEMBL617761,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,8,,485.0,Expert,H,BAO_0000219,,2764,B,
,1,4321,,,,108,,,,CHEMBL617762,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2765,B,
,1,14875,,,,108,,,,CHEMBL617763,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2766,B,
,1,15146,,,,108,,,HEK293,CHEMBL857983,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,8,,722.0,Autocuration,H,BAO_0000219,,2767,B,
,1,5213,,,,108,,,HEK293,CHEMBL617764,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2768,B,
,1,16404,,,,108,,,HeLa,CHEMBL617765,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,8,,308.0,Autocuration,H,BAO_0000219,,2769,B,
,1,13267,,,,108,,,,CHEMBL617766,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000019,,2770,F,
Hippocampus,1,13267,,,,108,,,,CHEMBL617767,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,8,,,Autocuration,H,BAO_0000221,10000000.0,2771,F,
,1,14818,,,,108,,,HEK293,CHEMBL617768,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,8,,722.0,Autocuration,H,BAO_0000219,,2772,B,
,1,4829,,,,108,,,HEK293,CHEMBL617769,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2773,B,
,1,13463,,,,11864,,,,CHEMBL858023,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2774,B,
Stomach,1,13463,,,,11864,,,,CHEMBL617770,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,8,,,Autocuration,H,BAO_0000019,945.0,2775,B,
Stomach,1,13463,,,,11864,,,,CHEMBL617771,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,8,,,Autocuration,H,BAO_0000019,945.0,2776,B,
,1,12652,,,,11864,,,A9,CHEMBL617772,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,8,,625.0,Autocuration,H,BAO_0000219,,2777,F,
,1,4682,,,,11864,,,NIH3T3,CHEMBL617773,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,8,,723.0,Autocuration,H,BAO_0000219,,2778,B,
,1,4682,,,,11864,,,NIH3T3,CHEMBL617850,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,8,,723.0,Autocuration,H,BAO_0000219,,2779,B,
,1,4682,,,,11864,,,NIH3T3,CHEMBL617851,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,8,,723.0,Autocuration,H,BAO_0000219,,2780,B,
,1,12652,,,,11864,,,,CHEMBL617852,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000019,,2781,F,
Stomach,1,13463,,,,12689,,,,CHEMBL858024,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Mus musculus,8,10090.0,,Autocuration,H,BAO_0000019,945.0,2782,B,
Stomach,1,13463,,,,12689,,,,CHEMBL617853,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,945.0,2783,B,
,1,13969,,,,108,,,,CHEMBL617854,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,8,,,Expert,H,BAO_0000357,,2784,B,
,1,13392,,,,108,,,,CHEMBL873477,Binding affinity for 5-hydroxytryptamine 2C receptor,Sus scrofa,8,9823.0,,Expert,H,BAO_0000357,,2785,B,
,1,13392,,,,108,,,,CHEMBL617855,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,2786,B,
,1,14430,,,,108,,,,CHEMBL617856,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,8,,,Expert,H,BAO_0000019,,2787,B,
,1,1742,,,,108,,,,CHEMBL617857,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,8,,,Autocuration,H,BAO_0000019,,2788,B,
,1,14286,,,,108,,,,CHEMBL617858,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,8,,,Autocuration,H,BAO_0000249,,2789,B,
,1,5619,,,,108,,,,CHEMBL617859,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2790,B,
,1,15086,,,,108,,,,CHEMBL617860,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2791,B,
,1,12861,,,,108,,,,CHEMBL617861,Binding activity radioligand.,,8,,,Autocuration,H,BAO_0000357,,2792,B,
,1,12861,,,,108,,,,CHEMBL617862,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,Expert,H,BAO_0000019,,2793,B,
,1,12861,,,,108,,,,CHEMBL617863,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,8,,,Autocuration,H,BAO_0000019,,2794,B,
,1,12827,,,,108,,,,CHEMBL617864,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,8,,,Autocuration,H,BAO_0000249,,2795,B,
,1,12827,,,,108,,,,CHEMBL617649,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,8,,,Autocuration,H,BAO_0000249,,2796,B,
,1,12919,,,,108,,,,CHEMBL617650,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,2797,F,
,1,12919,,,,108,,,,CHEMBL617651,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,8,9823.0,,Expert,H,BAO_0000019,,2798,F,
,1,16429,,,,108,,,,CHEMBL617652,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,2799,B,
,1,773,,,,108,,,,CHEMBL857072,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,2800,B,
,1,5033,,,,108,,,,CHEMBL617653,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,2801,B,
,1,12861,,,,12687,,,,CHEMBL617654,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,8,,,Autocuration,H,BAO_0000019,,2802,B,
,1,14093,,,,12689,,,,CHEMBL617655,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000019,,2803,F,
,1,14970,,,,12689,,,,CHEMBL617656,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,8,,,Expert,H,BAO_0000357,,2804,B,
,1,14970,,,,12689,,,,CHEMBL617657,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2805,B,
,1,14970,,,,12689,,,,CHEMBL617658,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,8,,,Autocuration,H,BAO_0000357,,2806,B,
,1,14178,,,,12689,,,,CHEMBL617659,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2807,B,
,1,14178,,,,12689,,,,CHEMBL617838,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2808,B,
,1,14229,,,,12689,,Brain membranes,,CHEMBL617839,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,2809,B,
,1,16532,,,,12689,,,,CHEMBL617840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,8,,,Autocuration,H,BAO_0000357,,2810,B,
,1,14826,,,,12689,,,,CHEMBL617841,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,8,,,Autocuration,H,BAO_0000019,,2811,B,
,1,17211,,,,12689,,,,CHEMBL875915,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,8,,,Autocuration,H,BAO_0000019,,2812,B,
,1,17211,,In vitro,,12689,,,,CHEMBL617842,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,8,,,Expert,H,BAO_0000219,,2813,B,
,1,13246,,,,12689,,,NIH3T3,CHEMBL617843,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,8,,723.0,Expert,H,BAO_0000219,,2814,B,
,1,13246,,,,12689,,,,CHEMBL617844,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,8,,,Expert,H,BAO_0000357,,2815,B,
,1,12457,,,,12689,,,,CHEMBL617845,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,2816,B,
,1,12457,,,,12689,,,NIH3T3,CHEMBL617846,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,8,,723.0,Expert,H,BAO_0000219,,2817,B,
,1,4707,,,,12689,,,,CHEMBL617847,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2818,B,
,1,13297,,,,12689,,,,CHEMBL617848,Binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,2819,B,
,1,16633,,,,12689,,,,CHEMBL617849,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2820,B,
,1,16133,,,,12689,,,,CHEMBL621507,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,Expert,H,BAO_0000357,,2821,B,
,1,16326,,,,12689,,,,CHEMBL621508,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,8,,,Expert,H,BAO_0000357,,2822,B,
,1,14423,,,,12689,,,,CHEMBL621509,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,2823,B,
,1,15412,,,,12689,,,,CHEMBL621510,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,8,,,Autocuration,H,BAO_0000019,,2824,B,
,1,15412,,,,12689,,,,CHEMBL621511,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,8,,,Autocuration,H,BAO_0000019,,2825,B,
,1,15558,,,,12689,,,A9,CHEMBL621512,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,8,,625.0,Expert,H,BAO_0000219,,2826,B,
,1,16633,,,,12689,,,,CHEMBL621513,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2827,B,
,1,6013,,,,12689,,,,CHEMBL621514,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,8,,,Expert,H,BAO_0000357,,2828,B,
,1,17175,,In vitro,,12689,,,,CHEMBL621515,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,8,,,Expert,H,BAO_0000219,,2829,B,
,1,12469,,,,12689,,,,CHEMBL621516,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,8,,,Autocuration,H,BAO_0000219,,2830,B,
Caudate-putamen,1,3682,,,,12689,,,,CHEMBL621517,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,8,,,Autocuration,H,BAO_0000019,5383.0,2831,B,
,1,4932,,,,12689,,,,CHEMBL621518,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,8,,,Autocuration,H,BAO_0000357,,2832,B,
,1,4932,,,,12689,,,,CHEMBL621519,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,8,,,Autocuration,H,BAO_0000019,,2833,B,
,1,3935,,,,12689,,,,CHEMBL621520,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2834,B,
,1,15818,,,,12689,,,,CHEMBL621521,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2835,B,
,1,15818,,,,12689,,,,CHEMBL621522,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2836,B,
,1,14749,,,,12689,,,,CHEMBL621523,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,8,,,Expert,H,BAO_0000219,,2837,B,
,1,15740,,,,12689,,,,CHEMBL621524,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2838,B,
,1,17133,,,,12689,,,,CHEMBL621525,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,2839,B,
,1,16532,,,,12689,,,,CHEMBL872921,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,8,,,Autocuration,H,BAO_0000357,,2840,B,
,1,12369,,,,12689,,,,CHEMBL621526,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2841,B,
,1,12369,,,,12689,,,,CHEMBL621527,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,8,,,Expert,H,BAO_0000219,,2842,B,
,1,2309,,,,12689,,,,CHEMBL617865,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2843,B,
,1,12953,,,,12689,,,,CHEMBL617866,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2844,B,
,1,12953,,,,12689,,,,CHEMBL617867,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,8,,,Autocuration,H,BAO_0000019,,2845,B,
,1,12953,,,,12689,,,,CHEMBL617487,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,2846,B,
,1,12953,,,,12689,,,,CHEMBL617488,Binding affinity for 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,2847,B,
,1,17133,,,,12689,,,,CHEMBL617489,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,8,,,Autocuration,H,BAO_0000357,,2848,B,
,1,17211,,,,12689,,,,CHEMBL617490,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,8,,,Autocuration,H,BAO_0000019,,2849,B,
,1,17211,,,,12689,,,,CHEMBL617491,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,8,,,Autocuration,H,BAO_0000019,,2850,B,
,1,14025,,,,12689,,,,CHEMBL617492,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,8,,,Autocuration,H,BAO_0000019,,2851,B,
,1,14998,,,,12689,,,,CHEMBL617493,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,8,,,Autocuration,H,BAO_0000019,,2852,B,
,1,4342,,,,12689,,,,CHEMBL617494,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2853,B,
,1,13735,,,,12689,,,,CHEMBL617495,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2854,B,
,1,13181,,,,12689,,,,CHEMBL617496,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2855,B,
,1,1883,,,,12689,,,CHO-K1,CHEMBL617497,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,8,,485.0,Autocuration,H,BAO_0000219,,2856,B,
,1,15194,,,,12689,,,,CHEMBL617498,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2857,B,
,1,15194,,,,12689,,,,CHEMBL617499,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,8,,,Autocuration,H,BAO_0000357,,2858,B,
,1,14579,,,,12689,,,,CHEMBL617500,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000019,,2859,F,
,1,4639,,,,108,,,,CHEMBL617501,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2860,B,
,1,4820,,,,108,,,,CHEMBL617502,Binding affinity towards 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,2861,B,
,1,14442,,,,227,,,,CHEMBL617503,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,8,,,Autocuration,H,BAO_0000357,,2862,B,
,1,14755,,,,227,,,,CHEMBL617504,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,8,,,Autocuration,H,BAO_0000357,,2863,B,
,1,14744,,,,227,,,,CHEMBL617406,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,8,,,Autocuration,H,BAO_0000357,,2864,B,
,1,6857,,,,227,,,,CHEMBL617407,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,2865,B,
,1,16209,,,,227,,,,CHEMBL617408,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,2866,B,
,1,15363,,,,227,,,,CHEMBL617409,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2867,B,
,1,15363,,,,227,,,,CHEMBL617410,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2868,B,
,1,15363,,,,227,,,,CHEMBL617411,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2869,B,
,1,17085,,,,227,,,,CHEMBL617412,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000019,,2870,B,
,1,17200,,,,227,,,,CHEMBL617774,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2871,B,
,1,15851,,,,227,,,HEK293,CHEMBL617775,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2872,B,
,1,15851,,,,227,,,HEK293,CHEMBL617776,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2873,B,
,1,6857,,,,227,,,CHO,CHEMBL617777,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2874,F,
,1,6857,,,,227,,,CHO,CHEMBL617778,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2875,F,
,1,15779,,,,227,,,HEK293,CHEMBL617779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2876,B,
,1,15851,,,,227,,,HEK293,CHEMBL617780,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,8,,722.0,Expert,H,BAO_0000219,,2877,B,
,1,15779,,,,227,,,HEK293,CHEMBL617781,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,8,,722.0,Autocuration,H,BAO_0000219,,2878,B,
,1,14157,,,,227,,,HEK293,CHEMBL617782,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2879,B,
,1,4540,,,,227,,,HEK293,CHEMBL617783,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2880,B,
,1,6166,,,,227,,,,CHEMBL617784,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2881,B,
,1,15779,,,,227,,,HEK293,CHEMBL617785,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,2882,B,
,1,14391,,,,227,,,HEK293,CHEMBL857984,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,8,,722.0,Expert,H,BAO_0000219,,2883,B,
,1,3832,,,,227,,,HEK293,CHEMBL617786,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,8,,722.0,Expert,H,BAO_0000219,,2884,B,
,1,3833,,,,227,,,HEK293,CHEMBL617787,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,8,,722.0,Expert,H,BAO_0000219,,2885,B,
,1,15851,,,,227,,,HEK293,CHEMBL617788,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2886,B,
,1,15851,,,,227,,,HEK293,CHEMBL617789,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,2887,B,
,1,4199,,,,227,,,HEK293,CHEMBL617790,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2888,B,
,1,1883,,,,227,,,CHO-K1,CHEMBL617791,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,8,,485.0,Expert,H,BAO_0000219,,2889,B,
,1,4321,,,,227,,,,CHEMBL617608,Binding affinity against 5-hydroxytryptamine 2B receptor,,8,,,Expert,H,BAO_0000357,,2890,B,
,1,15146,,,,227,,,HEK293,CHEMBL617609,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,8,,722.0,Autocuration,H,BAO_0000219,,2891,B,
,1,5213,,,,227,,,HEK293,CHEMBL617610,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,2892,B,
,1,14818,,,,227,,,HEK293,CHEMBL617611,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,8,,722.0,Autocuration,H,BAO_0000219,,2893,B,
,1,4829,,,,227,,,HEK293,CHEMBL617612,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2894,B,
,1,4829,,,,227,,,HEK293,CHEMBL617613,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,2895,B,
,1,14025,,,,227,,,,CHEMBL617614,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,2896,B,
Stomach,1,13463,,,,12688,,,,CHEMBL617615,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,8,,,Expert,H,BAO_0000019,945.0,2897,B,
Stomach,1,7259,,,,12688,,,,CHEMBL858114,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,8,,,Expert,H,BAO_0000357,945.0,2898,B,
Stomach,1,7259,,,,12688,,,,CHEMBL617616,Affinity against serotonergic receptor in the isolated rat stomach fundus,,8,,,Autocuration,H,BAO_0000357,945.0,2899,B,
Stomach,1,7185,,,,12688,,,,CHEMBL617617,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,945.0,2900,F,
,1,7185,,,,12688,,,,CHEMBL875914,Antagonistic against 5-hydroxytryptamine 2B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,2901,F,
Stomach,1,13267,,,,12688,,,,CHEMBL617618,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,8,,,Autocuration,H,BAO_0000019,945.0,2902,F,
Stomach,1,13735,,,,12688,,,,CHEMBL617619,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,945.0,2903,B,
,1,15738,,,,12688,,,,CHEMBL617620,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,8,,,Autocuration,H,BAO_0000019,,2904,F,
,1,15738,,,,12688,,,,CHEMBL617621,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,8,,,Autocuration,H,BAO_0000019,,2905,F,
,1,15738,,,,12688,,,,CHEMBL617622,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,8,,,Autocuration,H,BAO_0000019,,2906,F,
Stomach,1,12936,,,,12688,,,,CHEMBL617623,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,945.0,2907,B,
Stomach,1,12936,,,,12688,,,,CHEMBL617624,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,945.0,2908,B,
Stomach,1,12936,,,,12688,,,,CHEMBL617625,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,945.0,2909,B,
Stomach,1,12936,,,,12688,,,,CHEMBL617626,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,945.0,2910,B,
Stomach,1,16404,,,,12688,,,,CHEMBL617627,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,8,,,Autocuration,H,BAO_0000019,945.0,2911,F,
Stomach,1,16404,,,,12688,,,,CHEMBL617628,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,8,,,Expert,H,BAO_0000019,945.0,2912,F,
Stomach,1,16404,,,,12688,,,,CHEMBL617629,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,8,,,Autocuration,H,BAO_0000019,945.0,2913,F,
Stomach,1,16404,,,,12688,,,,CHEMBL858115,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,8,,,Autocuration,H,BAO_0000019,945.0,2914,F,
Stomach,1,16404,,,,12688,,,,CHEMBL617630,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,945.0,2915,F,
Thoracic aorta,1,16404,,,,12688,,,,CHEMBL617631,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,8,,,Autocuration,H,BAO_0000019,1515.0,2916,F,
,1,7483,,,,12688,,,,CHEMBL617632,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,Autocuration,H,BAO_0000357,,2917,B,
,1,7483,,,,12688,,,,CHEMBL617633,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,8,,,Expert,H,BAO_0000357,,2918,B,
,1,7483,,,,12688,,,,CHEMBL617634,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,Autocuration,H,BAO_0000357,,2919,B,
,1,7483,,,,12688,,,,CHEMBL617635,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,8,,,Autocuration,H,BAO_0000357,,2920,B,
Stomach,1,16404,,,,12688,,,,CHEMBL617637,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,945.0,2922,F,
,1,6347,,,,227,,,,CHEMBL617638,Binding affinity against 5-hydroxytryptamine 1A receptor,,8,,,Autocuration,H,BAO_0000357,,2923,B,
,1,4373,,,,227,,,,CHEMBL617639,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2924,B,
,1,4373,,,,227,,,,CHEMBL617640,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,8,,,Autocuration,H,BAO_0000357,,2925,B,
,1,4687,,,,227,,,,CHEMBL617641,Evaluated for the binding affinity to 5-HT 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2926,B,
,1,16946,,,,227,,,,CHEMBL617642,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2927,B,
,1,16633,,,,227,,,,CHEMBL617643,Binding affinities against 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2928,B,
,1,16633,,,,227,,,,CHEMBL617644,Binding affinities towards 5-hydroxytryptamine 2B receptor,,8,,,Autocuration,H,BAO_0000357,,2929,B,
,1,16633,,,,227,,,,CHEMBL617645,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2930,B,
,1,15026,,,,108,,,,CHEMBL617646,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,8,,,Expert,H,BAO_0000357,,2931,B,
,1,15738,,,,108,,,,CHEMBL617647,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,2932,B,
,1,15738,,,,108,,,,CHEMBL617648,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,2933,B,
,1,15738,,,,108,,,,CHEMBL617875,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,2934,B,
,1,15738,,,,108,,,,CHEMBL617876,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,2935,B,
,1,16404,,,,108,,,,CHEMBL617877,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Bos taurus,8,9913.0,,Expert,H,BAO_0000357,,2936,B,
,1,15026,,,,108,,,,CHEMBL617878,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Bos taurus,8,9913.0,,Expert,H,BAO_0000357,,2937,B,
,1,15738,,,,108,,,,CHEMBL617879,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,2938,B,
,1,16312,,,,108,,,,CHEMBL617880,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,2939,B,
Striatum,1,5486,,,,20033,,,,CHEMBL617881,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,2940,B,
,1,5254,,,,51,,,,CHEMBL857073,Binding affinity against 5-HT1A receptor,,8,,,Autocuration,H,BAO_0000357,,2941,B,
,1,3857,,,,108,,,CHO,CHEMBL617882,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,8,,449.0,Expert,H,BAO_0000219,,2942,F,
,1,6857,,,,108,,,CHO,CHEMBL617883,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,2943,F,
,1,4176,,,,108,,,,CHEMBL617884,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,8,,,Autocuration,H,BAO_0000219,,2944,F,
,1,6347,,,,108,,,CHO,CHEMBL617885,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,2945,B,
,1,6347,,,,108,,,CHO,CHEMBL617886,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,8,,449.0,Autocuration,H,BAO_0000219,,2946,B,
,1,16146,,,,108,,,,CHEMBL617887,Inhibition of human 5-hydroxytryptamine 2C receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2947,B,
,1,3805,,,,108,,,,CHEMBL617888,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,2948,B,
,1,3857,,,,108,,,,CHEMBL617889,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,8,,,Autocuration,H,BAO_0000019,,2949,B,
,1,5635,,,,108,,,,CHEMBL617890,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,2950,B,
,1,5635,,,,108,,,,CHEMBL617891,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,8,,,Autocuration,H,BAO_0000357,,2951,B,
,1,5635,,,,108,,,,CHEMBL617892,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,8,,,Autocuration,H,BAO_0000357,,2952,B,
,1,4012,,,,108,,,CHO,CHEMBL617893,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,8,,449.0,Expert,H,BAO_0000219,,2953,B,
,1,6366,,,,108,,,CHO,CHEMBL617894,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2954,B,
,1,15949,,,,108,,,CHO,CHEMBL617895,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2955,B,
,1,17211,,,,108,,,CHO,CHEMBL617896,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,8,,449.0,Autocuration,H,BAO_0000219,,2956,B,
,1,6491,,,,108,,,,CHEMBL617897,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2957,B,
,1,14093,,,,108,,,,CHEMBL617898,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,8,,,Autocuration,H,BAO_0000019,,2958,F,
,1,13481,,,,108,,,,CHEMBL617899,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000019,,2959,F,
,1,6347,,,,108,,,CHO,CHEMBL617900,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Rattus norvegicus,8,10116.0,449.0,Expert,H,BAO_0000219,,2960,B,
,1,14093,,,,108,,,,CHEMBL617901,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,8,,,Autocuration,H,BAO_0000019,,2961,F,
,1,14093,,,,108,,,,CHEMBL617902,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,8,,,Autocuration,H,BAO_0000019,,2962,F,
,1,13481,,,,108,,,,CHEMBL617903,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000019,,2963,F,
,1,14442,,,,108,,,,CHEMBL617904,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2964,B,
,1,14442,,,,108,,,,CHEMBL617905,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,2965,B,
,1,14442,,,,108,,,,CHEMBL617906,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,8,,,Autocuration,H,BAO_0000357,,2966,B,
,1,14755,,,,108,,,,CHEMBL617907,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,8,,,Autocuration,H,BAO_0000357,,2967,B,
,1,14744,,,,108,,,,CHEMBL617908,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,8,,,Autocuration,H,BAO_0000357,,2968,B,
,1,16659,,,,108,,,CHO,CHEMBL620617,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,2969,B,
,1,6857,,,,108,,,,CHEMBL620618,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,2970,B,
,1,5635,,,,108,,,,CHEMBL620619,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,8,,,Expert,H,BAO_0000357,,2971,B,
,1,4234,,,,108,,,,CHEMBL620620,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,2972,B,
,1,16209,,,,108,,,,CHEMBL620621,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,8,,,Autocuration,H,BAO_0000357,,2973,B,
,1,5778,,,,104698,,Membranes,,CHEMBL872920,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000249,,2974,B,
,1,5094,,,,104698,,,,CHEMBL620622,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,6,,,Autocuration,H,BAO_0000223,,2975,B,
,1,809,,,,104698,,,,CHEMBL620623,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,2976,B,
,1,1578,,,,104698,,,,CHEMBL620624,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,6,,,Autocuration,H,BAO_0000019,,2977,B,
,1,809,,,,104698,,,,CHEMBL620625,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,6,,,Autocuration,H,BAO_0000019,,2978,B,
,1,12469,,,,104698,,,,CHEMBL620626,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,6,,,Autocuration,H,BAO_0000219,,2979,B,
,1,14290,,,,104698,,,,CHEMBL621307,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,6,,,Autocuration,H,BAO_0000019,,2980,B,
,1,14290,,,,104698,,,,CHEMBL621308,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,6,,,Autocuration,H,BAO_0000019,,2981,B,
,1,10609,,,,104698,,,,CHEMBL621309,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,6,,,Autocuration,H,BAO_0000223,,2982,B,
,1,10609,,,,104698,,,,CHEMBL621310,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,6,,,Autocuration,H,BAO_0000223,,2983,B,
,1,10609,,,,104698,,,,CHEMBL621311,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,6,,,Autocuration,H,BAO_0000223,,2984,B,
,1,15253,,,,104698,,,,CHEMBL621502,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,6,,,Autocuration,H,BAO_0000249,,2985,B,
,1,15253,,,,104698,,,,CHEMBL621503,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,6,,,Autocuration,H,BAO_0000249,,2986,B,
,1,11683,,,,104698,,Membranes,,CHEMBL621504,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,6,,,Autocuration,H,BAO_0000249,,2987,B,
,1,12092,,,,104698,,,,CHEMBL621505,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000223,,2988,B,
,1,1946,,,,104698,,,,CHEMBL621506,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,6,,,Autocuration,H,BAO_0000019,,2989,B,
,1,11623,,,,104698,,,,CHEMBL619781,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,6,,,Autocuration,H,BAO_0000223,,2990,B,
,1,11623,,,,104698,,,,CHEMBL619782,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,6,,,Autocuration,H,BAO_0000223,,2991,B,
,1,14788,,,,104698,,,,CHEMBL619783,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,6,,,Autocuration,H,BAO_0000019,,2992,B,
,1,5432,,,,104698,,,,CHEMBL619784,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,2993,B,
,1,14826,,,,104698,,,,CHEMBL619785,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,Autocuration,H,BAO_0000249,,2994,B,
,1,2222,,,,104698,,,,CHEMBL619786,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000223,,2995,B,
,1,11963,,,,104698,,,,CHEMBL619787,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,6,,,Autocuration,H,BAO_0000019,,2996,B,
,1,14145,,,,104698,,,,CHEMBL872925,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,6,,,Autocuration,H,BAO_0000019,,2997,B,
,1,17819,,,,104698,,,,CHEMBL619788,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,6,,,Autocuration,H,BAO_0000019,,2998,B,
,1,10394,,,,104698,,,,CHEMBL619789,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,6,,,Autocuration,H,BAO_0000249,,2999,B,
,1,10394,,,,104698,,,,CHEMBL619790,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,6,,,Autocuration,H,BAO_0000249,,3000,B,
,1,15034,,,,104698,,,,CHEMBL619791,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,6,,,Autocuration,H,BAO_0000019,,3001,B,
,1,691,,,,104698,,,,CHEMBL619792,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,6,,,Autocuration,H,BAO_0000019,,3002,B,
,1,12092,,,,104698,,Membranes,,CHEMBL619793,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,6,,,Autocuration,H,BAO_0000249,,3003,B,
,1,11752,,,,104698,,,,CHEMBL619794,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3004,B,
Brain,1,11752,,,,104698,,,,CHEMBL619795,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,6,,,Autocuration,H,BAO_0000221,955.0,3005,B,
,1,301,,,,104698,,,,CHEMBL619796,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,6,,,Autocuration,H,BAO_0000019,,3006,B,
,1,16532,,,,104698,,,,CHEMBL620448,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,6,,,Autocuration,H,BAO_0000223,,3007,B,
,1,16532,,,,104698,,,,CHEMBL620449,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,6,,,Autocuration,H,BAO_0000223,,3008,B,
,1,12092,,,,104698,,,,CHEMBL620450,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,6,,,Autocuration,H,BAO_0000223,,3009,B,
,1,11684,,,,104698,,,,CHEMBL620451,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,6,,,Autocuration,H,BAO_0000223,,3010,B,
,1,11684,,,,104698,,,,CHEMBL620631,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,6,,,Autocuration,H,BAO_0000223,,3011,B,
,1,12953,,,,104698,,,,CHEMBL620632,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,6,,,Autocuration,H,BAO_0000019,,3012,B,
,1,12953,,,,104698,,,,CHEMBL620633,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,6,,,Autocuration,H,BAO_0000019,,3013,B,
,1,12953,,,,104698,,,,CHEMBL620634,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,6,,,Autocuration,H,BAO_0000223,,3014,B,
,1,12861,,,,104698,,,,CHEMBL620635,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,6,,,Autocuration,H,BAO_0000019,,3015,B,
,1,11454,,In vivo,,104698,,,,CHEMBL620636,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3016,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620637,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3017,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620638,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3018,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620639,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3019,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620640,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3020,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620641,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3021,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620642,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3022,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620643,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3023,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620644,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3024,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620645,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3025,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620646,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3026,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620647,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3027,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620648,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3028,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620649,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3029,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620650,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3030,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620651,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3031,F,
,1,11454,,In vivo,,104698,,,,CHEMBL872875,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3032,F,
,1,11454,,In vivo,,104698,,,,CHEMBL620652,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3033,F,
,1,10609,,,,104698,,,,CHEMBL620653,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,6,,,Autocuration,H,BAO_0000019,,3034,F,
,1,12861,,,,104698,,,,CHEMBL857076,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,6,,,Autocuration,H,BAO_0000019,,3035,B,
,1,12861,,,,104698,,,,CHEMBL620654,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3036,B,
,1,12861,,,,104698,,,,CHEMBL620655,Binding activity radioligand.,,6,,,Autocuration,H,BAO_0000223,,3037,B,
,1,10728,,,,104698,,Brain membranes,,CHEMBL620656,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,6,,,Autocuration,H,BAO_0000249,,3038,B,
,1,10728,,,,104698,,Brain membranes,,CHEMBL620657,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,6,,,Autocuration,H,BAO_0000249,,3039,B,
,1,5163,,,,108,,,,CHEMBL620658,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,8,,,Autocuration,H,BAO_0000357,,3040,B,
,1,5163,,,,108,,,,CHEMBL620659,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,8,,,Autocuration,H,BAO_0000357,,3041,B,
,1,6011,,,,108,,,,CHEMBL620660,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,3042,B,
,1,5014,,,,108,,,,CHEMBL620661,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3043,B,
,1,5635,,,,108,,,,CHEMBL620662,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3044,B,
,1,5163,,,,108,,,,CHEMBL620663,Affinity for 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,3045,B,
,1,6841,,,,108,,,,CHEMBL620664,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,8,,,Autocuration,H,BAO_0000357,,3046,B,
,1,6119,,,,108,,,,CHEMBL620665,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,8,,,Expert,H,BAO_0000357,,3047,B,
,1,4373,,,,108,,,,CHEMBL620666,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3048,B,
,1,1633,,,,108,,,,CHEMBL620667,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,8,,,Autocuration,H,BAO_0000357,,3049,B,
,1,1633,,,,108,,,,CHEMBL620668,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,8,,,Expert,H,BAO_0000357,,3050,B,
,1,4373,,,,108,,,,CHEMBL620669,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3051,B,
,1,6576,,,,108,,,,CHEMBL620670,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,3052,B,
,1,4687,,,,108,,,,CHEMBL620671,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3053,B,
,1,12146,,,,108,,,,CHEMBL620672,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,8,,,Autocuration,H,BAO_0000357,,3054,B,
,1,12146,,,,108,,,,CHEMBL620673,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,8,,,Autocuration,H,BAO_0000357,,3055,B,
,1,16946,,,,108,,,,CHEMBL620674,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3056,B,
,1,14159,,,,108,,,,CHEMBL620675,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3057,B,
,1,16700,,,,108,,,,CHEMBL620676,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,3058,B,
,1,3269,,,,108,,,,CHEMBL621382,Affinity against 5-hydroxytryptamine 2C receptor,,8,,,Autocuration,H,BAO_0000357,,3059,B,
,1,1274,,,,108,,,,CHEMBL621383,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3060,B,
,1,1317,,,,108,,,,CHEMBL621384,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,8,,,Autocuration,H,BAO_0000357,,3061,B,
,1,5834,,,,144,,,,CHEMBL621385,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,3062,B,
,1,11147,,,,144,,,,CHEMBL617989,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Bos taurus,8,9913.0,,Autocuration,H,BAO_0000357,,3063,B,
,1,14145,,,,104714,,,,CHEMBL617990,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Cavia porcellus,4,10141.0,,Expert,H,BAO_0000019,,3064,F,
Ileum,1,10561,,,,104714,,,,CHEMBL875085,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3065,B,
,1,15847,,,,104714,,,,CHEMBL617991,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3066,F,
,1,15847,,,,104714,,,,CHEMBL617992,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3067,F,
Ileum,1,10561,,,,104714,,,,CHEMBL617993,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3068,B,
Ileum,1,11454,,,,104714,,,,CHEMBL617994,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3069,B,
,1,4639,,,,104714,,,,CHEMBL617995,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3070,F,
,1,4639,,,,104714,,,,CHEMBL617996,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3071,F,
,1,4639,,,,104714,,,,CHEMBL617997,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3072,F,
,1,4639,,,,104714,,,,CHEMBL617998,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3073,F,
,1,4639,,,,104714,,,,CHEMBL617999,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3074,F,
,1,4639,,,,104714,,,,CHEMBL618000,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3075,F,
Ileum,1,15253,,,,104714,,,,CHEMBL617815,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3076,F,
Ileum,1,15253,,,,104714,,,,CHEMBL617816,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3077,F,
Ileum,1,11963,,,,104714,,,,CHEMBL617817,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3078,F,
Ileum,1,1946,,,,104714,,,,CHEMBL617818,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3079,B,
Ileum,1,1946,,,,104714,,,,CHEMBL617819,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3080,B,
,1,12045,,,,104714,,,,CHEMBL617820,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000223,,3081,B,
Ileum,1,1559,,,,104714,,,,CHEMBL617821,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3082,B,
Ileum,1,273,,,,104714,,,,CHEMBL617822,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3083,F,
Ileum,1,273,,,,104714,,,,CHEMBL617823,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3084,F,
Ileum,1,188,,,,104714,,,,CHEMBL617824,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3085,F,
Ileum,1,12919,,,,104714,,,,CHEMBL617825,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3086,F,
Ileum,1,12918,,,,104714,,,,CHEMBL617826,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3087,F,
Ileum,1,1559,,,,104714,,,,CHEMBL617827,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3088,B,
Ileum,1,273,,,,104714,,,,CHEMBL617828,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3089,F,
Ileum,1,1559,,,,104714,,,,CHEMBL617829,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3090,B,
Ileum,1,1559,,,,104714,,,,CHEMBL617830,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3091,B,
Ileum,1,1559,,,,104714,,,,CHEMBL617831,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3092,B,
Ileum,1,14424,,,,104714,,,,CHEMBL617832,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3093,B,
,1,13181,,,,22226,,,,CHEMBL617833,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,3094,B,
,1,5486,,,,51,,,,CHEMBL617834,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,8,,,Autocuration,H,BAO_0000357,,3095,B,
,1,6491,,,,104714,,,,CHEMBL617835,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Homo sapiens,5,9606.0,,Expert,D,BAO_0000223,,3096,B,
,1,6013,,,,104714,,,,CHEMBL617836,Binding affinity towards 5-HT3 receptor,,4,,,Autocuration,H,BAO_0000223,,3097,B,
,1,12861,,,,104714,,,,CHEMBL617837,Binding activity radioligand.,,4,,,Autocuration,H,BAO_0000223,,3098,B,
,1,12861,,,,104714,,,,CHEMBL620392,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,4,,,Autocuration,H,BAO_0000019,,3099,B,
,1,5104,,,,104714,,,,CHEMBL620393,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3100,B,
,1,5105,,,,104714,,,,CHEMBL620394,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3101,B,
,1,5104,,,,104714,,,,CHEMBL620395,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,4,,,Autocuration,H,BAO_0000223,,3102,B,
,1,3935,,,,22226,,,,CHEMBL620396,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,0,,,Autocuration,U,BAO_0000019,,3103,B,
,1,13657,,,,105030,,,NG108-15,CHEMBL620582,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,4,,433.0,Expert,H,BAO_0000219,,3104,B,
,1,10369,,In vivo,,105030,,,,CHEMBL620583,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,4,,,Autocuration,H,BAO_0000218,,3105,B,
,1,10369,,,,105030,,,,CHEMBL620584,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,4,,,Autocuration,H,BAO_0000019,,3106,B,
,1,12918,,,,105030,,,,CHEMBL620585,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,4,,,Autocuration,H,BAO_0000224,,3107,B,
,1,12918,,,,105030,,,,CHEMBL620586,Compound was evaluated for the binding affinity at 5- HT3 receptor,,4,,,Autocuration,H,BAO_0000224,,3108,B,
,1,10369,,,,105030,,,,CHEMBL620587,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,4,,,Autocuration,H,BAO_0000019,,3109,B,
,1,773,,,,105030,,,,CHEMBL620588,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,4,,,Autocuration,H,BAO_0000019,,3110,B,
,1,12918,,,,105030,,,,CHEMBL620589,5-hydroxytryptamine 3 receptor agonism in mouse,,4,,,Autocuration,H,BAO_0000218,,3111,F,
,1,10561,,,,105030,,,,CHEMBL620590,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,4,,,Autocuration,H,BAO_0000219,,3112,B,
,1,12827,,,,105030,,,,CHEMBL617956,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,4,,,Autocuration,H,BAO_0000019,,3113,B,
,1,12827,,,,105030,,,,CHEMBL617957,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,4,,,Autocuration,H,BAO_0000019,,3114,B,
,1,12918,,,,105030,,,,CHEMBL617958,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,4,,,Autocuration,H,BAO_0000224,,3115,B,
,1,273,,,,105030,,,,CHEMBL617959,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,4,,,Autocuration,H,BAO_0000219,,3116,B,
,1,273,,,,105030,,,,CHEMBL617960,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,4,,,Autocuration,H,BAO_0000219,,3117,B,
,1,10561,,,,105030,,,,CHEMBL617961,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,4,,,Autocuration,H,BAO_0000224,,3118,B,
,1,5033,,In vitro,,105030,,,,CHEMBL617962,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,4,,,Autocuration,H,BAO_0000219,,3119,B,
,1,16429,,,,105030,,,N1E-115,CHEMBL617963,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,4,,339.0,Autocuration,H,BAO_0000219,,3120,B,
,1,10322,,,,11765,,,,CHEMBL617964,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,8,,,Autocuration,H,BAO_0000019,,3121,B,
,1,14331,,,,11765,,,,CHEMBL617965,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,8,,,Autocuration,H,BAO_0000219,,3122,B,
,1,13462,,,,10630,,,,CHEMBL617966,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Mus musculus,9,10090.0,,Autocuration,D,BAO_0000357,,3123,B,
,1,12861,,,,17106,,,,CHEMBL857074,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,8,,,Autocuration,H,BAO_0000019,,3124,B,
,1,15086,,,,144,,,,CHEMBL617967,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,3125,B,
,1,12861,,,,144,,,,CHEMBL617968,Binding activity radioligand.,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000357,,3126,B,
,1,10561,,,,104714,,,,CHEMBL617969,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000223,,3127,B,
,1,10561,,,,104714,,,,CHEMBL617970,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000223,,3128,B,
,1,10561,,,,104714,,,,CHEMBL617971,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000223,,3129,B,
,1,10561,,,,104714,,,,CHEMBL617972,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3130,B,
,1,273,,,,104714,,,,CHEMBL617973,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3131,F,
,1,273,,,,104714,,,,CHEMBL617974,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3132,F,
Ileum,1,273,,,,104714,,,,CHEMBL617975,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000221,2116.0,3133,F,
,1,273,,,,104714,,,,CHEMBL617976,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3134,F,
,1,273,,,,104714,,,,CHEMBL617977,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3135,F,
,1,273,,,,104714,,,,CHEMBL617978,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3136,F,
,1,273,,,,104714,,,,CHEMBL617979,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,4,9986.0,,Autocuration,H,BAO_0000019,,3137,F,
,1,13047,,,,104714,,,CHO,CHEMBL617980,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Oryctolagus cuniculus,4,9986.0,449.0,Autocuration,H,BAO_0000219,,3138,B,
,1,1650,,,,104698,,,,CHEMBL617981,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3139,B,
,1,16288,,,,12020,,,,CHEMBL617982,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,8,,,Autocuration,H,BAO_0000019,,3140,B,
,1,16288,,,,12020,,,,CHEMBL617983,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,8,,,Autocuration,H,BAO_0000357,,3141,B,
,1,10254,,,,104698,,,,CHEMBL617984,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3142,B,
,1,14532,,,,104698,,,,CHEMBL617985,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,6,,,Autocuration,H,BAO_0000019,,3143,B,
Heart,1,13392,,In vivo,,104698,,,,CHEMBL617986,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,6,,,Autocuration,H,BAO_0000218,948.0,3144,F,
Heart,1,13392,,,,104698,,,,CHEMBL617987,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,6,,,Autocuration,H,BAO_0000019,948.0,3145,F,
Heart,1,13392,,,,104698,,,,CHEMBL617988,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,6,,,Autocuration,H,BAO_0000019,948.0,3146,F,
Heart,1,13392,,,,104698,,,,CHEMBL617792,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,6,,,Autocuration,H,BAO_0000019,948.0,3147,F,
Heart,1,13392,,,,104698,,,,CHEMBL617793,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,6,,,Autocuration,H,BAO_0000019,948.0,3148,F,
,1,13392,,,,104698,,,,CHEMBL617794,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,6,,,Autocuration,H,BAO_0000019,,3149,F,
,1,13392,,,,104698,,,,CHEMBL617795,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,6,,,Autocuration,H,BAO_0000019,,3150,F,
,1,13392,,,,104698,,,,CHEMBL617796,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,6,,,Autocuration,H,BAO_0000019,,3151,F,
,1,13392,,,,104698,,,,CHEMBL617797,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,6,,,Autocuration,H,BAO_0000019,,3152,F,
,1,1089,,In vivo,,104698,,,,CHEMBL617798,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000218,,3153,F,
,1,1089,,In vivo,,104698,,,,CHEMBL617799,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,6,,,Autocuration,H,BAO_0000218,,3154,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617800,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000218,,3155,F,
,1,11454,,,,104698,,,,CHEMBL617801,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3156,F,
,1,12205,,In vivo,,104698,,,,CHEMBL617802,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000218,,3157,F,
,1,1089,,,,104698,,,,CHEMBL617803,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3158,F,
,1,5094,,,,104698,,,,CHEMBL617804,Binding affinity towards 5-HT3 receptor in rat was evaluated,,6,,,Autocuration,H,BAO_0000019,,3159,B,
,1,2622,,,,104698,,,,CHEMBL617805,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3160,B,
,1,245,,,,104698,,,,CHEMBL617806,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000223,,3161,B,
,1,14788,,,,104698,,,,CHEMBL617807,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,6,,,Autocuration,H,BAO_0000019,,3162,B,
,1,14788,,,,104698,,,,CHEMBL617808,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,6,,,Autocuration,H,BAO_0000019,,3163,B,
,1,3020,,,,104698,,,,CHEMBL617809,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,6,,,Autocuration,H,BAO_0000249,,3164,B,
,1,1742,,,,104698,,,,CHEMBL617810,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,6,,,Autocuration,H,BAO_0000019,,3165,B,
Brain,1,17394,,,,104698,,,,CHEMBL617811,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,6,,,Autocuration,H,BAO_0000249,955.0,3166,B,
Brain,1,17394,,,,104698,,,,CHEMBL617812,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,6,,,Autocuration,H,BAO_0000221,955.0,3167,B,
,1,17394,,,,104698,,,,CHEMBL617813,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,Autocuration,H,BAO_0000249,,3168,B,
,1,14286,,,,104698,,,,CHEMBL617814,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,6,,,Autocuration,H,BAO_0000249,,3169,B,
,1,14178,,,,104698,,,,CHEMBL617698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,6,,,Autocuration,H,BAO_0000019,,3170,B,
,1,14178,,,,104698,,,,CHEMBL617699,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3171,B,
,1,14178,,,,104698,,,,CHEMBL617700,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3172,B,
,1,14178,,,,104698,,,,CHEMBL617701,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3173,B,
,1,15034,,,,104698,,,,CHEMBL617702,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,6,,,Autocuration,H,BAO_0000019,,3174,B,
,1,1089,,,,104698,,Membranes,,CHEMBL617703,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,6,,,Autocuration,H,BAO_0000249,,3175,B,
,1,1089,,,,104698,,,,CHEMBL617704,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3176,B,
,1,16532,,,,104698,,,,CHEMBL617705,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,6,,,Autocuration,H,BAO_0000223,,3177,B,
,1,12801,,,,104698,,,,CHEMBL617706,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3178,B,
,1,15194,,,,104698,,,NG108-15,CHEMBL617707,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,6,,433.0,Autocuration,H,BAO_0000219,,3179,B,
,1,15194,,,,104698,,,NG108-15,CHEMBL617708,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,6,,433.0,Autocuration,H,BAO_0000219,,3180,B,
,1,15194,,,,104698,,,,CHEMBL617709,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,6,,,Autocuration,H,BAO_0000019,,3181,B,
,1,15194,,,,104698,,,,CHEMBL617710,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,6,,,Autocuration,H,BAO_0000019,,3182,B,
,1,15194,,,,104698,,,,CHEMBL882925,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,6,,,Autocuration,H,BAO_0000019,,3183,B,
,1,15194,,,,104698,,,,CHEMBL617711,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,6,,,Autocuration,H,BAO_0000019,,3184,B,
,1,10610,,,,104698,,,,CHEMBL617712,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,6,,,Autocuration,H,BAO_0000019,,3185,F,
,1,10355,,,,104698,,,,CHEMBL617713,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3186,F,
,1,691,,,,104698,,,,CHEMBL617714,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,6,,,Autocuration,H,BAO_0000019,,3187,F,
,1,10611,,,,104698,,,,CHEMBL617715,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,6,,,Autocuration,H,BAO_0000218,,3188,F,
,1,12801,,In vivo,,104698,,,,CHEMBL617716,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,6,,,Autocuration,H,BAO_0000218,,3189,F,
,1,10609,,,,104698,,,,CHEMBL617717,Inhibition of 5-HT evoked reflex bradycardia in rat.,,6,,,Autocuration,H,BAO_0000218,,3190,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617718,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3191,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617719,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3192,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617720,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,6,,,Autocuration,H,BAO_0000218,,3193,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617721,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000218,,3194,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617722,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3195,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617723,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,6,,,Autocuration,H,BAO_0000218,,3196,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617724,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3197,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617725,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3198,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617726,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3199,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617727,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3200,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617728,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3201,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617729,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3202,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617730,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3203,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617731,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3204,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617732,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3205,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617733,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3206,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617734,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3207,F,
,1,11454,,In vivo,,104698,,,,CHEMBL872874,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,6,,,Autocuration,H,BAO_0000218,,3208,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617735,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,6,,,Autocuration,H,BAO_0000218,,3209,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617736,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,6,,,Autocuration,H,BAO_0000218,,3210,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617737,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,6,,,Autocuration,H,BAO_0000218,,3211,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617738,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,6,,,Autocuration,H,BAO_0000218,,3212,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617739,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3213,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617740,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3214,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617741,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3215,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617742,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3216,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617743,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3217,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617744,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3218,F,
,1,11454,,In vivo,,104698,,,,CHEMBL617745,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,6,,,Autocuration,H,BAO_0000218,,3219,F,
,1,670,,,,104698,,,,CHEMBL617746,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,6,,,Autocuration,H,BAO_0000218,,3220,F,
,1,670,,,,104698,,,,CHEMBL617747,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,6,,,Autocuration,H,BAO_0000218,,3221,F,
,1,10321,,In vivo,,104698,,,,CHEMBL617748,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,6,,,Autocuration,H,BAO_0000218,,3222,F,
,1,10321,,In vivo,,104698,,,,CHEMBL618909,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,6,,,Autocuration,H,BAO_0000218,,3223,F,
,1,10321,,In vivo,,104698,,,,CHEMBL618910,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,6,,,Autocuration,H,BAO_0000218,,3224,F,
,1,10321,,In vivo,,104698,,,,CHEMBL618911,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,6,,,Autocuration,H,BAO_0000218,,3225,F,
,1,10321,,In vivo,,104698,,,,CHEMBL618912,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,6,,,Autocuration,H,BAO_0000218,,3226,F,
,1,10322,,In vivo,,104698,,,,CHEMBL618913,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,6,,,Autocuration,H,BAO_0000218,,3227,F,
,1,15412,,,,104698,,,,CHEMBL618914,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,6,,,Autocuration,H,BAO_0000019,,3228,F,
,1,15412,,,,104698,,,,CHEMBL618915,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,6,,,Autocuration,H,BAO_0000019,,3229,F,
,1,15412,,,,104698,,,,CHEMBL618916,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3230,B,
,1,15412,,,,104698,,,,CHEMBL618917,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,6,,,Autocuration,H,BAO_0000019,,3231,F,
Hippocampus,1,15412,,,,104698,,,,CHEMBL618918,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,7,,,Intermediate,D,BAO_0000221,10000000.0,3232,B,
,1,15412,,,,104698,,,,CHEMBL618919,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3233,B,
,1,17394,,,,104698,,,,CHEMBL618920,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3234,B,
,1,12457,,,,104698,,,,CHEMBL618921,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000223,,3235,B,
,1,12457,,,,104698,,,,CHEMBL618922,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000019,,3236,B,
,1,12205,,,,104698,,,,CHEMBL618923,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,6,,,Autocuration,H,BAO_0000019,,3237,B,
,1,14532,,,,104698,,,,CHEMBL618924,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,6,,,Autocuration,H,BAO_0000019,,3238,B,
,1,1122,,,,104698,,,,CHEMBL618925,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,6,,,Autocuration,H,BAO_0000019,,3239,B,
,1,5094,,,,104698,,,,CHEMBL618926,Binding affinity towards 5-HT3 receptor in rat was evaluated,,6,,,Autocuration,H,BAO_0000019,,3240,B,
Ileum,1,809,,,,20033,,,,CHEMBL618927,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3241,F,
Ileum,1,809,,,,20033,,,,CHEMBL618928,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3242,F,
Ileum,1,14290,,,,20033,,,,CHEMBL618929,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3243,F,
Ileum,1,14290,,,,20033,,,,CHEMBL618930,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3244,F,
Ileum,1,14290,,,,20033,,,,CHEMBL618931,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3245,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619594,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3246,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619595,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3247,F,
Ileum,1,13961,,,,20033,,,,CHEMBL619596,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3248,F,
Ileum,1,13961,,,,20033,,,,CHEMBL619755,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3249,F,
Ileum,1,809,,,,20033,,,,CHEMBL619756,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3250,F,
Ileum,1,809,,,,20033,,,,CHEMBL619757,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3251,F,
Ileum,1,809,,,,20033,,,,CHEMBL619758,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3252,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619759,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3253,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619760,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3254,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619761,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3255,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619762,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3256,F,
Ileum,1,14290,,,,20033,,,,CHEMBL619763,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3257,F,
Ileum,1,14290,,,,20033,,,,CHEMBL617868,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3258,F,
,1,15034,,,,20033,,,,CHEMBL617869,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3259,B,
Striatum,1,5094,,,,20033,,,,CHEMBL882926,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000249,2435.0,3260,B,
Striatum,1,5094,,,,20033,,,,CHEMBL617870,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000249,2435.0,3261,B,
Striatum,1,5399,,,,20033,,,,CHEMBL617871,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3262,B,
Striatum,1,17394,,,,20033,,,,CHEMBL617872,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3263,B,
Striatum,1,17394,,,,20033,,,,CHEMBL617873,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3264,B,
Striatum,1,17394,,,,20033,,,,CHEMBL617874,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3265,B,
Ileum,1,13961,,,,20033,,,,CHEMBL619067,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3266,F,
Ileum,1,13961,,,,20033,,,,CHEMBL619068,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3267,F,
Ileum,1,13961,,,,20033,,,,CHEMBL619069,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3268,F,
,1,16946,,,,20033,,,,CHEMBL619070,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3269,B,
,1,16946,,,,20033,,,,CHEMBL619071,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3270,B,
,1,15034,,,,20033,,,,CHEMBL619072,Agonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3271,F,
,1,15034,,,,20033,,,,CHEMBL619073,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3272,F,
,1,12918,,,,20033,,,,CHEMBL619074,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3273,F,
,1,16946,,,,20033,,,,CHEMBL619075,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3274,B,
Striatum,1,17394,,,,20033,,,,CHEMBL619076,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3275,B,
Striatum,1,15034,,,,20033,,,,CHEMBL619077,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3276,B,
Striatum,1,5094,,,,20033,,,,CHEMBL619078,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000249,2435.0,3277,B,
Striatum,1,5094,,,,20033,,,,CHEMBL619079,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000249,2435.0,3278,B,
Ileum,1,17358,,,,20033,,,,CHEMBL619080,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3279,B,
,1,12953,,,,20033,,,,CHEMBL619081,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Cavia porcellus,9,10141.0,,Expert,D,BAO_0000357,,3280,B,
,1,12953,,,,20033,,,,CHEMBL619082,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3281,B,
,1,12953,,,,20033,,,,CHEMBL619083,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3282,B,
,1,12953,,,,20033,,,,CHEMBL619084,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3283,B,
Ileum,1,273,,,,20033,,,,CHEMBL859397,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3284,F,
Ileum,1,12918,,,,20033,,,,CHEMBL619085,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3285,F,
Ileum,1,12919,,,,20033,,,,CHEMBL619086,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3286,F,
Ileum,1,273,,,,20033,,,,CHEMBL619087,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3287,F,
Ileum,1,273,,,,20033,,,,CHEMBL619088,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3288,F,
,1,13181,,,,20033,,,,CHEMBL619089,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3289,B,
,1,13181,,,,168,,,,CHEMBL619090,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,3290,B,
,1,15034,,,,20033,,,,CHEMBL619091,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3291,F,
,1,5033,,,,20033,,,,CHEMBL619092,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3292,B,
,1,1980,,,,20033,,,,CHEMBL619093,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3293,B,
,1,13181,,,,168,,,HEK293,CHEMBL619094,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Cavia porcellus,8,10141.0,722.0,Autocuration,H,BAO_0000219,,3294,B,
,1,14287,,,,20033,,,,CHEMBL619095,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3295,B,
,1,1317,,,,20033,,,,CHEMBL857988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3296,B,
,1,15316,,,,20033,,,,CHEMBL619096,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3297,B,
Striatum,1,16429,,,,20033,,,,CHEMBL619097,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,2435.0,3298,B,
Hippocampus,1,14818,,,,20033,,,,CHEMBL619098,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,10000000.0,3299,B,
,1,15194,,,,20033,,,,CHEMBL619751,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3300,B,
,1,15194,,,,20033,,,,CHEMBL619752,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3301,B,
Ileum,1,13961,,,,20033,,,,CHEMBL875096,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3302,F,
,1,5486,,,,108,,,,CHEMBL619004,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,8,,,Autocuration,H,BAO_0000357,,3303,B,
,1,16209,,,,168,,,,CHEMBL619005,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,3304,B,
,1,17085,,,,168,,,,CHEMBL619006,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000019,,3305,B,
,1,4199,,,,168,,,HeLa,CHEMBL619007,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,8,,308.0,Autocuration,H,BAO_0000219,,3306,B,
,1,15146,,,,168,,,,CHEMBL619008,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3307,B,
,1,5213,,,,168,,,,CHEMBL619009,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3308,B,
,1,4829,,,,168,,,HeLa,CHEMBL619010,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,8,,308.0,Autocuration,H,BAO_0000219,,3309,B,
,1,17358,,,,10622,,,,CHEMBL619011,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,8,,,Autocuration,H,BAO_0000357,,3310,B,
,1,17358,,,,10622,,,,CHEMBL619012,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,8,,,Autocuration,H,BAO_0000357,,3311,B,
,1,16946,,,,10622,,,,CHEMBL619013,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,8,,,Autocuration,H,BAO_0000219,,3312,B,
,1,17358,,,,10622,,,,CHEMBL619014,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,8,,,Autocuration,H,BAO_0000357,,3313,B,
Cardiac atrium,1,268,,,,11249,,,,CHEMBL857503,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,8,,,Autocuration,H,BAO_0000019,2081.0,3314,F,
Cardiac atrium,1,268,,,,11249,,,,CHEMBL619015,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,8,,,Autocuration,H,BAO_0000019,2081.0,3315,F,
,1,15086,,,,11249,,,,CHEMBL619016,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3316,B,
Hippocampus,1,14875,,,,11249,,,,CHEMBL619017,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000221,10000000.0,3317,B,
Hippocampus,1,13267,,,,168,,,,CHEMBL619018,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000221,10000000.0,3318,B,
,1,13047,,,,168,,,,CHEMBL619019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,3319,B,
,1,1650,,,,10623,,,,CHEMBL619020,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3320,B,
,1,567,,,,10623,,,,CHEMBL619021,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,8,,,Autocuration,H,BAO_0000019,,3321,F,
,1,17358,,,,10623,,,,CHEMBL619022,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,8,,,Autocuration,H,BAO_0000357,,3322,B,
,1,188,,,,10623,,,,CHEMBL619023,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,8,,,Autocuration,H,BAO_0000357,,3323,B,
,1,670,,,,10623,,,,CHEMBL619024,lntrinsic activity relative to 5-HT receptor,,8,,,Autocuration,H,BAO_0000019,,3324,F,
,1,204,,,,10623,,,,CHEMBL619025,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,8,,,Autocuration,H,BAO_0000019,,3325,F,
,1,1946,,,,10623,,,,CHEMBL619026,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,8,,,Expert,H,BAO_0000019,,3326,F,
,1,6398,,,,10623,,,,CHEMBL619027,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,8,,,Autocuration,H,BAO_0000019,,3327,F,
,1,6398,,,,10623,,,,CHEMBL619028,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,8,,,Autocuration,H,BAO_0000019,,3328,F,
,1,17358,,,,10623,,,,CHEMBL619029,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,8,,,Autocuration,H,BAO_0000019,,3329,F,
,1,6398,,,,10623,,,,CHEMBL619030,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,8,,,Autocuration,H,BAO_0000019,,3330,F,
,1,11752,,,,10623,,,,CHEMBL619031,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,8,,,Expert,H,BAO_0000357,,3331,B,
,1,809,,,,10623,,,,CHEMBL619032,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,8,,,Autocuration,H,BAO_0000019,,3332,F,
,1,14178,,,,10623,,,,CHEMBL619033,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3333,B,
,1,567,,,,10623,,,,CHEMBL619034,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,8,,,Autocuration,H,BAO_0000357,,3334,B,
,1,1946,,,,10623,,,,CHEMBL619035,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,8,,,Autocuration,H,BAO_0000357,,3335,B,
,1,1946,,,,10623,,,,CHEMBL619036,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,8,,,Autocuration,H,BAO_0000357,,3336,B,
,1,13961,,,,10623,,,,CHEMBL619037,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,3337,B,
Striatum,1,6238,,,,10623,,,,CHEMBL619038,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,8,,,Autocuration,H,BAO_0000249,2435.0,3338,B,
,1,14290,,,,10623,,,,CHEMBL619039,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,8,,,Autocuration,H,BAO_0000249,,3339,B,
,1,14290,,,,10623,,,,CHEMBL619040,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,8,,,Expert,H,BAO_0000249,,3340,B,
Striatum,1,809,,,,10623,,,,CHEMBL619041,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,2435.0,3341,B,
Striatum,1,1578,,,,10623,,,,CHEMBL619042,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,8,,,Autocuration,H,BAO_0000019,2435.0,3342,B,
Striatum,1,16709,,,,10623,,,,CHEMBL619043,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,8,,,Expert,H,BAO_0000249,2435.0,3343,B,
Striatum,1,1946,,,,10623,,,,CHEMBL619044,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,8,,,Expert,H,BAO_0000019,2435.0,3344,B,
Striatum,1,15253,,,,10623,,,,CHEMBL619045,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,8,,,Expert,H,BAO_0000249,2435.0,3345,B,
Striatum,1,4535,,,,10623,,,,CHEMBL619046,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,8,,,Expert,H,BAO_0000249,2435.0,3346,B,
,1,13961,,,,10623,,,,CHEMBL619047,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,8,,,Expert,H,BAO_0000249,,3347,B,
Brain,1,17358,,,,10623,,,,CHEMBL619048,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,8,,,Autocuration,H,BAO_0000221,955.0,3348,F,
,1,15847,,,,10623,,,,CHEMBL859398,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,8,,,Autocuration,H,BAO_0000019,,3349,F,
,1,15847,,,,10623,,,,CHEMBL619049,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,8,,,Autocuration,H,BAO_0000019,,3350,F,
,1,670,,,,10623,,,,CHEMBL857886,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,8,,,Autocuration,H,BAO_0000019,,3351,F,
,1,670,,,,10623,,,,CHEMBL619050,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,8,,,Autocuration,H,BAO_0000019,,3352,F,
,1,1317,,,,10623,,,,CHEMBL620591,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,8,,,Autocuration,H,BAO_0000019,,3353,F,
,1,12936,,,,10623,,,,CHEMBL620592,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3354,B,
Striatum,1,4535,,,,10623,,,,CHEMBL620593,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,8,,,Expert,H,BAO_0000249,2435.0,3355,B,
,1,14424,,,,10623,,,,CHEMBL620594,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,3356,F,
,1,14424,,,,10623,,,,CHEMBL875079,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,8,,,Expert,H,BAO_0000019,,3357,F,
,1,14424,,,,10623,,,,CHEMBL620595,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,8,,,Expert,H,BAO_0000019,,3358,F,
,1,14424,,,,10623,,,,CHEMBL620596,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,3359,F,
,1,14424,,,,10623,,,,CHEMBL620597,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,8,,,Autocuration,H,BAO_0000019,,3360,F,
,1,14424,,,,10623,,,,CHEMBL620598,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,8,,,Expert,H,BAO_0000019,,3361,F,
,1,14424,,,,10623,,,,CHEMBL620599,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,8,,,Expert,H,BAO_0000218,,3362,F,
,1,14424,,,,10623,,,,CHEMBL620600,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,8,,,Autocuration,H,BAO_0000019,,3363,F,
,1,1980,,,,168,,,,CHEMBL620601,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Rattus norvegicus,8,10116.0,,Autocuration,H,BAO_0000019,,3364,F,
,1,4639,,,,168,,,,CHEMBL620602,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,8,,,Autocuration,H,BAO_0000019,,3365,F,
,1,17358,,,,168,,,,CHEMBL620603,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3366,B,
,1,17358,,,,168,,,,CHEMBL620604,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,8,,,Autocuration,H,BAO_0000357,,3367,B,
,1,17358,,,,168,,,,CHEMBL620605,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,8,,,Autocuration,H,BAO_0000357,,3368,B,
,1,1558,,,,168,,,,CHEMBL620606,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3369,B,
,1,17358,,,,168,,,,CHEMBL620607,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,Autocuration,H,BAO_0000019,,3370,F,
,1,16117,,,,168,,,,CHEMBL620608,In vitro binding affinity towards 5-HT4 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3371,B,
,1,17358,,,,168,,,,CHEMBL620609,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,Autocuration,H,BAO_0000019,,3372,F,
,1,17358,,,,168,,,,CHEMBL620610,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000019,,3373,F,
,1,17358,,,,168,,,,CHEMBL620611,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3374,B,
,1,17358,,,,168,,,,CHEMBL620612,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,8,,,Autocuration,H,BAO_0000357,,3375,B,
,1,17358,,,,168,,,,CHEMBL620613,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,8,,,Autocuration,H,BAO_0000357,,3376,B,
,1,17358,,,,168,,,,CHEMBL620614,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,8,,,Autocuration,H,BAO_0000357,,3377,B,
,1,1274,,,,168,,,,CHEMBL620615,Binding affinity against 5-Hydroxytryptamine 4 receptor,,8,,,Expert,H,BAO_0000357,,3378,B,
,1,10728,,,,104698,,Brain membranes,,CHEMBL857075,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,6,,,Autocuration,H,BAO_0000249,,3379,B,
,1,11695,,,,104698,,Brain membranes,,CHEMBL620616,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,6,,,Autocuration,H,BAO_0000249,,3380,B,
,1,11695,,,,104698,,Brain membranes,,CHEMBL619411,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,6,,,Autocuration,H,BAO_0000249,,3381,B,
,1,12490,,,,104698,,,,CHEMBL619412,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,6,,,Autocuration,H,BAO_0000019,,3382,B,
,1,11828,,,,104698,,,,CHEMBL619413,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3383,B,
Hippocampus,1,12253,,,,104698,,,,CHEMBL619414,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,6,,,Autocuration,H,BAO_0000221,10000000.0,3384,B,
,1,10561,,,,104698,,,,CHEMBL619415,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,6,,,Autocuration,H,BAO_0000019,,3385,B,
,1,10561,,,,104698,,,,CHEMBL619416,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,6,,,Autocuration,H,BAO_0000019,,3386,B,
,1,14432,,,,104698,,,,CHEMBL619417,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,6,,,Autocuration,H,BAO_0000019,,3387,F,
,1,12936,,,,104698,,,,CHEMBL619418,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3388,B,
,1,1274,,,,104698,,,,CHEMBL619419,Binding affinity against 5-Hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3389,B,
,1,1980,,,,104698,,,,CHEMBL619420,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,6,,,Autocuration,H,BAO_0000019,,3390,B,
,1,670,,,,104698,,,,CHEMBL619421,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,6,,,Autocuration,H,BAO_0000249,,3391,B,
,1,968,,,,104698,,,,CHEMBL619422,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000019,,3392,B,
,1,14287,,,,104698,,,,CHEMBL619423,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,6,,,Autocuration,H,BAO_0000019,,3393,B,
,1,567,,,,104698,,,,CHEMBL875080,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,6,,,Autocuration,H,BAO_0000019,,3394,B,
,1,13267,,,,104698,,,,CHEMBL619424,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,6,,,Autocuration,H,BAO_0000019,,3395,B,
,1,14826,,,,104698,,,,CHEMBL619425,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,6,,,Autocuration,H,BAO_0000249,,3396,B,
,1,15194,,,,104698,,,,CHEMBL619426,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,6,,,Autocuration,H,BAO_0000223,,3397,B,
,1,15194,,,,104698,,,,CHEMBL619427,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,6,,,Autocuration,H,BAO_0000223,,3398,B,
,1,10394,,,,104698,,,,CHEMBL619645,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,7,10116.0,,Autocuration,D,BAO_0000223,,3399,B,
,1,13657,,,,10576,,,,CHEMBL619646,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,9,,,Expert,D,BAO_0000249,,3400,B,
Brain,1,1879,,,,12020,,,,CHEMBL619647,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,8,,,Autocuration,H,BAO_0000221,955.0,3401,F,
,1,1879,,,,12020,,,,CHEMBL619648,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000019,,3402,F,
,1,1879,,,,12020,,,,CHEMBL619165,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,8,,,Autocuration,H,BAO_0000019,,3403,F,
,1,204,,In vivo,,12020,,,,CHEMBL620719,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000218,,3404,F,
,1,1879,,,,12020,,,,CHEMBL872924,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3405,B,
,1,1879,,,,12020,,,,CHEMBL620720,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3406,B,
,1,1879,,,,12020,,,,CHEMBL620721,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3407,B,
,1,1879,,,,12020,,,,CHEMBL620722,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3408,B,
,1,10641,,,,104698,,,,CHEMBL620723,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,6,,,Autocuration,H,BAO_0000019,,3409,B,
,1,773,,,,12020,,,,CHEMBL620724,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,8,,,Autocuration,H,BAO_0000019,,3410,B,
,1,11952,,,,104698,,,,CHEMBL620725,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,6,,,Autocuration,H,BAO_0000249,,3411,B,
,1,14145,,,,12020,,,,CHEMBL620726,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,3412,F,
,1,17066,,,,144,,,,CHEMBL620727,Binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,Expert,H,BAO_0000357,,3413,B,
,1,6398,,,,104714,,,,CHEMBL620728,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,4,,,Autocuration,H,BAO_0000223,,3414,B,
,1,10321,,,,22226,,,,CHEMBL620729,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,0,,,Autocuration,U,BAO_0000019,,3415,B,
,1,511,,,,104714,,,,CHEMBL858288,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,4,,,Autocuration,H,BAO_0000019,,3416,F,
,1,4639,,,,104714,,,,CHEMBL620730,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3417,B,
,1,4639,,,,104714,,,,CHEMBL620731,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3418,B,
,1,4639,,,,104714,,,,CHEMBL620732,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3419,F,
,1,4639,,,,104714,,,,CHEMBL618042,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3420,F,
,1,4639,,,,104714,,,,CHEMBL618043,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3421,F,
,1,1558,,,,104714,,,,CHEMBL618044,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3422,B,
,1,268,,,,104714,,,,CHEMBL618045,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,4,,,Autocuration,H,BAO_0000019,,3423,F,
,1,2474,,,,104714,,,,CHEMBL618046,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,4,,,Autocuration,H,BAO_0000223,,3424,B,
,1,5067,,,,104714,,,,CHEMBL618047,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,4,,,Autocuration,H,BAO_0000019,,3425,F,
,1,5067,,,,104714,,,,CHEMBL875084,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,4,,,Autocuration,H,BAO_0000019,,3426,F,
,1,5067,,,,104714,,,,CHEMBL618048,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,4,,,Autocuration,H,BAO_0000019,,3427,F,
,1,5067,,,,104714,,,,CHEMBL618049,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,4,,,Autocuration,H,BAO_0000223,,3428,B,
,1,5067,,,,104714,,,,CHEMBL619764,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,4,,,Autocuration,H,BAO_0000019,,3429,F,
,1,5067,,,,104714,,,,CHEMBL619765,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,4,,,Autocuration,H,BAO_0000019,,3430,F,
,1,5067,,,,104714,,,,CHEMBL619766,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,4,,,Autocuration,H,BAO_0000019,,3431,F,
,1,5067,,,,104714,,,,CHEMBL619767,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,4,,,Autocuration,H,BAO_0000223,,3432,B,
,1,5067,,,,104714,,,,CHEMBL619768,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,4,,,Autocuration,H,BAO_0000223,,3433,B,
,1,5067,,,,104714,,,,CHEMBL619769,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,4,,,Autocuration,H,BAO_0000019,,3434,F,
,1,5067,,,,104714,,,,CHEMBL619770,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,4,,,Autocuration,H,BAO_0000223,,3435,B,
,1,5067,,,,104714,,,,CHEMBL619771,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3436,B,
,1,14331,,,,104714,,,,CHEMBL619772,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,4,,,Autocuration,H,BAO_0000219,,3437,B,
,1,5067,,,,104714,,,,CHEMBL619773,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,4,,,Autocuration,H,BAO_0000223,,3438,B,
,1,6179,,,,104714,,,NG108-15,CHEMBL619774,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,4,,433.0,Autocuration,H,BAO_0000219,,3439,B,
,1,4265,,,,104714,,,,CHEMBL875083,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,4,,,Autocuration,H,BAO_0000019,,3440,B,
,1,4265,,,,104714,,,NG108-15,CHEMBL620718,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,4,,433.0,Autocuration,H,BAO_0000219,,3441,B,
,1,17358,,,,104714,,,,CHEMBL618127,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,4,,,Autocuration,H,BAO_0000223,,3442,B,
,1,17358,,,,104714,,,,CHEMBL618128,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,4,,,Autocuration,H,BAO_0000223,,3443,B,
,1,13628,,In vitro,,104714,,,,CHEMBL618129,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,4,,,Autocuration,H,BAO_0000219,,3444,B,
,1,4612,,,,104714,,,,CHEMBL618130,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,4,,,Autocuration,H,BAO_0000223,,3445,B,
,1,17358,,,,104714,,,,CHEMBL618131,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,4,,,Autocuration,H,BAO_0000019,,3446,F,
,1,4639,,,,104714,,,,CHEMBL618132,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3447,F,
,1,4639,,,,104714,,,,CHEMBL618133,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3448,F,
,1,4639,,,,104714,,,,CHEMBL618134,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3449,F,
,1,4639,,,,104714,,,,CHEMBL618135,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3450,F,
,1,511,,,,104714,,,,CHEMBL618136,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,4,,,Autocuration,H,BAO_0000223,,3451,B,
,1,1479,,,,104714,,,,CHEMBL618137,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3452,B,
,1,1317,,,,104714,,,,CHEMBL618138,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,4,,,Autocuration,H,BAO_0000223,,3453,B,
,1,12146,,,,104714,,,,CHEMBL618139,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,4,,,Autocuration,H,BAO_0000223,,3454,B,
,1,12146,,,,104714,,,,CHEMBL618140,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,4,,,Autocuration,H,BAO_0000223,,3455,B,
,1,13969,,,,104714,,,,CHEMBL618141,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,4,,,Autocuration,H,BAO_0000223,,3456,B,
,1,13392,,,,108,,,,CHEMBL873478,Binding affinity for 5-hydroxytryptamine 2C receptor,,8,,,Expert,H,BAO_0000357,,3457,B,
,1,13392,,,,104698,,,,CHEMBL618142,Binding affinity towards 5-hydroxytryptamine 3 receptor,,6,,,Autocuration,H,BAO_0000223,,3458,B,
,1,14159,,,,144,,,,CHEMBL618143,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3459,B,
,1,1558,,,,144,,,,CHEMBL618144,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3460,B,
,1,16655,,,,144,,,,CHEMBL618145,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3461,B,
,1,13020,,,,104714,,,,CHEMBL618146,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,4,,,Autocuration,H,BAO_0000223,,3462,B,
,1,13021,,,,104714,,,,CHEMBL618147,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,4,,,Autocuration,H,BAO_0000223,,3463,B,
,1,13020,,,,104714,,,,CHEMBL618148,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,4,,,Autocuration,H,BAO_0000223,,3464,B,
,1,10321,,,,144,,,,CHEMBL618149,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,8,,,Autocuration,H,BAO_0000019,,3465,B,
,1,15818,,,,144,,,,CHEMBL872927,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3466,B,
,1,15818,,,,144,,,,CHEMBL618150,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3467,B,
,1,17358,,,,144,,,,CHEMBL618151,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,8,,,Autocuration,H,BAO_0000357,,3468,B,
,1,2222,,,,144,,,,CHEMBL875094,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,8,,,Autocuration,H,BAO_0000357,,3469,B,
,1,10322,,,,144,,,,CHEMBL618152,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,8,,,Autocuration,H,BAO_0000019,,3470,B,
,1,16117,,,,144,,,,CHEMBL618153,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3471,B,
,1,17200,,,,144,,,,CHEMBL618888,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,8,,,Autocuration,H,BAO_0000357,,3472,B,
,1,17358,,,,144,,,,CHEMBL618889,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,8,,,Autocuration,H,BAO_0000019,,3473,F,
,1,16700,,,,144,,,,CHEMBL618890,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,3474,B,
,1,1980,,,,144,,,,CHEMBL618891,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,8,,,Autocuration,H,BAO_0000019,,3475,B,
,1,1980,,,,144,,,,CHEMBL619054,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,8,,,Autocuration,H,BAO_0000019,,3476,B,
,1,12409,,,,104714,,,,CHEMBL619055,Binding affinity against the 5-hydroxytryptamine 3 receptor,,4,,,Autocuration,H,BAO_0000223,,3477,B,
,1,4365,,,,144,,,,CHEMBL619056,Binding affinity against human 5-hydroxytryptamine 3A receptor,,8,,,Autocuration,H,BAO_0000357,,3478,B,
,1,4365,,,,144,,,,CHEMBL619057,Percent efficacy against 5-hydroxytryptamine 3A receptor,,8,,,Autocuration,H,BAO_0000019,,3479,F,
,1,4365,,,,144,,,,CHEMBL619058,Binding affinity against human 5-hydroxytryptamine 3A receptor,,8,,,Autocuration,H,BAO_0000357,,3480,B,
,1,6769,,,,12020,,,Oocytes,CHEMBL619059,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000219,,3481,F,
,1,6769,,,,12020,,,Oocytes,CHEMBL619060,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000219,,3482,F,
,1,6769,,,,12020,,,Oocytes,CHEMBL875095,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000219,,3483,F,
Ileum,1,809,,,,20033,,,,CHEMBL619061,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3484,F,
Ileum,1,809,,,,20033,,,,CHEMBL619062,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3485,F,
,1,14290,,,,20033,,,,CHEMBL619063,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000019,,3486,F,
Ileum,1,17358,,,,20033,,,,CHEMBL619064,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3487,B,
,1,17358,,,,20033,,,,CHEMBL619065,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,3488,B,
Ileum,1,17358,,,,20033,,,,CHEMBL619066,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000221,2116.0,3489,B,
Ileum,1,17386,,,,10209,,,,CHEMBL619775,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,8,,,Autocuration,H,BAO_0000221,2116.0,3490,B,
,1,3269,,,,10209,,,,CHEMBL619776,Affinity against 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3491,B,
,1,7721,,,,104841,,,,CHEMBL619777,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000224,,3492,B,
,1,7721,,,,104841,,,,CHEMBL619778,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000224,,3493,B,
Ileum,1,9117,,,,104841,,,,CHEMBL619779,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000221,2116.0,3494,B,
,1,7721,,,,104841,,,,CHEMBL619780,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000224,,3495,B,
,1,7721,,,,104841,,,,CHEMBL619166,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000224,,3496,B,
,1,15796,,,,104841,,,,CHEMBL619167,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3497,F,
,1,15796,,,,104841,,,,CHEMBL619168,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3498,F,
Cardiac atrium,1,15650,,,,168,,,,CHEMBL619169,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,2081.0,3499,B,
Cardiac atrium,1,15650,,,,168,,,,CHEMBL619170,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,2081.0,3500,B,
,1,6866,,,,104841,,,,CHEMBL619171,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Homo sapiens,5,9606.0,,Autocuration,D,BAO_0000019,,3501,F,
Cardiac atrium,1,15650,,,,168,,,,CHEMBL619172,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,2081.0,3502,F,
,1,10063,,,,22226,,,,CHEMBL619173,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,3503,B,
,1,12665,,,,22226,,,,CHEMBL619174,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,3504,B,
,1,7504,,,,104705,,,,CHEMBL619175,5-hydroxytryptamine receptor binding affinity was determined in rats,,4,,,Autocuration,H,BAO_0000019,,3505,B,
,1,7504,,,,104705,,,,CHEMBL619176,Binding affinity at rat 5-hydroxytryptamine receptor.,,4,,,Autocuration,H,BAO_0000224,,3506,B,
,1,7038,,,,104705,,,,CHEMBL619177,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,4,,,Autocuration,H,BAO_0000019,,3507,B,
,1,7626,,,,104705,,,,CHEMBL619178,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,4,,,Autocuration,H,BAO_0000224,,3508,B,
,1,7626,,,,104705,,,,CHEMBL619179,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,4,,,Autocuration,H,BAO_0000224,,3509,B,
Stomach,1,7185,,,,104705,,,,CHEMBL619180,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,4,,,Autocuration,H,BAO_0000019,945.0,3510,F,
Stomach,1,7185,,,,104705,,,,CHEMBL619181,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,4,,,Autocuration,H,BAO_0000019,945.0,3511,F,
,1,7185,,,,104705,,,,CHEMBL619182,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,4,,,Autocuration,H,BAO_0000019,,3512,F,
,1,6960,,,,104705,,,,CHEMBL619183,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,4,,,Autocuration,H,BAO_0000224,,3513,B,
,1,6960,,,,104705,,,,CHEMBL619184,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,4,,,Autocuration,H,BAO_0000224,,3514,B,
Hippocampus,1,12416,,,,10576,,,,CHEMBL619185,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,8,,,Autocuration,H,BAO_0000221,10000000.0,3515,B,
,1,15753,,,,12198,,,,CHEMBL619186,Binding affinity for rat 5-hydroxytryptamine transporter.,,8,,,Expert,H,BAO_0000357,,3516,B,
,1,8062,,,,104705,,,,CHEMBL619187,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,4,,,Autocuration,H,BAO_0000019,,3517,B,
,1,9036,,,,104705,,,,CHEMBL619188,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,3518,B,
,1,15067,,,,104705,,,,CHEMBL619189,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,3519,B,
Brain,1,15753,,,,12198,,,,CHEMBL619190,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,955.0,3520,F,
Cerebellum,1,15753,,,,12198,,,,CHEMBL619191,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000221,2037.0,3521,F,
,1,15295,,,,104705,,,,CHEMBL619192,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,,3522,B,
,1,6347,,,,104705,,,,CHEMBL619193,Percent binding affinity against 5-hydroxytryptamine receptor,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,3523,B,
,1,6763,,,,22226,,,,CHEMBL619194,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,0,,,Autocuration,U,BAO_0000019,,3524,B,
,1,12092,,,,104705,,,,CHEMBL619195,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,3525,B,
,1,1579,,,,104705,,,,CHEMBL619196,Affinity against 5-hydroxytryptamine receptor was determined,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,3526,B,
Stomach,1,1579,,,,104705,,,,CHEMBL619197,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000019,945.0,3527,B,
,1,5963,,In vitro,,121,,,,CHEMBL619198,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,,3528,B,
,1,5963,,In vitro,,121,,,,CHEMBL875081,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,9,9606.0,,Expert,D,BAO_0000219,,3529,B,
,1,5030,,,,18065,,,,CHEMBL884712,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,8,,,Autocuration,H,BAO_0000357,,3530,B,
,1,15796,,,,121,,,,CHEMBL884710,Inhibition of 5-hydroxytryptamine reuptake,,8,,,Expert,H,BAO_0000357,,3531,B,
,1,15413,,,,18065,,,,CHEMBL619199,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,8,,,Autocuration,H,BAO_0000019,,3532,F,
,1,15413,,,,18065,,,,CHEMBL619200,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,8,,,Autocuration,H,BAO_0000019,,3533,F,
,1,15413,,,,18065,,,,CHEMBL619201,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,8,,,Autocuration,H,BAO_0000019,,3534,F,
,1,12409,,,,18065,,,,CHEMBL619202,Tested for 5-hydroxytryptamine receptor uptake,,8,,,Autocuration,H,BAO_0000019,,3535,F,
,1,16909,,,,51,,,CHO,CHEMBL619203,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,3536,B,
,1,16909,,,,51,,,,CHEMBL619204,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,3537,F,
,1,15629,,,,10576,,,,CHEMBL619205,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Homo sapiens,8,9606.0,,Autocuration,H,BAO_0000249,,3538,B,
,1,15629,,,,10576,,,,CHEMBL619206,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,8,,,Autocuration,H,BAO_0000357,,3539,B,
,1,15629,,,,10576,,,,CHEMBL619207,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,8,,,Expert,H,BAO_0000249,,3540,B,
Striatum,1,10034,,,,10825,,,,CHEMBL619208,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3541,F,
Striatum,1,10034,,,,10825,,,,CHEMBL619209,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3542,F,
Striatum,1,10034,,,,10825,,,,CHEMBL619210,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3543,F,
Striatum,1,10034,,,,10825,,,,CHEMBL619211,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3544,F,
Striatum,1,10034,,,,10825,,,,CHEMBL619212,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3545,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620681,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3546,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620682,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3547,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620683,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3548,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620684,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3549,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620685,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3550,F,
Striatum,1,10034,,,,10825,,,,CHEMBL620686,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,8,,,Autocuration,H,BAO_0000019,2435.0,3551,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620687,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3552,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620688,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3553,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620689,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3554,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620690,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3555,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620691,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3556,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620692,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3557,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL620693,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3558,F,
,1,1274,,,,168,,,,CHEMBL620694,Binding affinity against 5-hydroxytryptamine 4 receptor,,8,,,Expert,H,BAO_0000357,,3559,B,
,1,17358,,,,168,,,,CHEMBL857986,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,8,,,Autocuration,H,BAO_0000019,,3560,F,
,1,14532,,,,168,,,,CHEMBL620695,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,8,,,Autocuration,H,BAO_0000357,,3561,B,
,1,16989,,,,168,,,,CHEMBL620696,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,8,,,Expert,H,BAO_0000357,,3562,B,
,1,17200,,,,168,,,,CHEMBL620697,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,8,,,Autocuration,H,BAO_0000357,,3563,B,
,1,15779,,,,168,,,,CHEMBL620698,Binding affinity towards 5-hydroxytryptamine 4 receptor,,8,,,Autocuration,H,BAO_0000357,,3564,B,
,1,15779,,,,168,,,,CHEMBL620699,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,8,,,Autocuration,H,BAO_0000357,,3565,B,
,1,15779,,,,168,,,,CHEMBL620700,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,8,,,Autocuration,H,BAO_0000357,,3566,B,
,1,15650,,,,168,,,COS-7,CHEMBL620701,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,8,,643.0,Autocuration,H,BAO_0000219,,3567,B,
,1,15650,,,,168,,,COS-7,CHEMBL875082,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,8,,643.0,Autocuration,H,BAO_0000219,,3568,B,
,1,15650,,,,168,,,COS-7,CHEMBL620702,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,8,,643.0,Autocuration,H,BAO_0000219,,3569,B,
,1,15650,,,,168,,,COS-7,CHEMBL620703,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,8,,643.0,Autocuration,H,BAO_0000219,,3570,B,
,1,17046,,,,168,,,C6,CHEMBL620704,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,8,,673.0,Autocuration,H,BAO_0000219,,3571,B,
,1,17046,,,,168,,,C6,CHEMBL620705,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,8,,673.0,Expert,H,BAO_0000219,,3572,B,
,1,15650,,,,168,,,C6,CHEMBL620706,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,8,,673.0,Expert,H,BAO_0000219,,3573,B,
,1,17046,,,,168,,,C6,CHEMBL620707,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,8,,673.0,Expert,H,BAO_0000219,,3574,B,
,1,17066,,,,10624,,,,CHEMBL620708,Binding affinity towards 5-hydroxytryptamine 5 receptor,,8,,,Expert,H,BAO_0000357,,3575,B,
,1,17200,,,,105,,,,CHEMBL620709,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,8,,,Autocuration,H,BAO_0000357,,3576,B,
,1,16146,,,,10624,,,,CHEMBL620710,Binding affinity against 5-hydroxytryptamine 5A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3577,B,
,1,15250,,,,10624,,,CHO,CHEMBL620711,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,3578,B,
,1,6491,,,,10624,,,,CHEMBL620712,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3579,B,
,1,17066,,,,10624,,,,CHEMBL620713,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3580,B,
,1,17066,,,,10624,,,,CHEMBL620714,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3581,B,
,1,4234,,,,10624,,,,CHEMBL620715,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3582,B,
,1,6013,,,,10624,,,,CHEMBL620716,Binding affinity towards 5-HT5A receptor,,8,,,Autocuration,H,BAO_0000357,,3583,B,
,1,17175,,,,10624,,,,CHEMBL620717,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,8,,,Expert,H,BAO_0000357,,3584,B,
,1,15818,,,,10624,,,,CHEMBL618072,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,8,,,Autocuration,H,BAO_0000357,,3585,B,
,1,6166,,,,10624,,,,CHEMBL857987,Binding affinity towards cloned human 5-HT5A receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3586,B,
,1,15779,,,,10624,,,HEK293,CHEMBL618073,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3587,B,
,1,15779,,,,10624,,,HEK293,CHEMBL618074,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,8,,722.0,Autocuration,H,BAO_0000219,,3588,B,
,1,5213,,,,10624,,,HEK293,CHEMBL618075,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,8,,722.0,Autocuration,H,BAO_0000219,,3589,B,
,1,17066,,,,10625,,,,CHEMBL618076,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3590,B,
,1,17066,,,,10625,,,,CHEMBL618077,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3591,B,
,1,17066,,,,10625,,,,CHEMBL618078,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3592,B,
,1,17066,,,,10625,,,,CHEMBL881821,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3593,B,
,1,17066,,,,10625,,,,CHEMBL618079,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3594,B,
,1,17175,,,,10625,,,,CHEMBL618080,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,8,,,Expert,H,BAO_0000357,,3595,B,
,1,16190,,,,10576,,,HEK293,CHEMBL618081,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,3596,B,
,1,16190,,,,10626,,,HEK293,CHEMBL618082,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,8,,722.0,Autocuration,H,BAO_0000219,,3597,B,
,1,4820,,,,10624,,,,CHEMBL618083,Binding affinity towards 5-HT5a receptor,,8,,,Expert,H,BAO_0000357,,3598,B,
,1,17066,,,,10624,,,,CHEMBL618084,Binding affinity towards 5-hydroxytryptamine 5A receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3599,B,
,1,17066,,,,10624,,,,CHEMBL618085,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,8,,,Expert,H,BAO_0000357,,3600,B,
,1,17175,,,,10624,,,,CHEMBL618086,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,8,,,Expert,H,BAO_0000357,,3601,B,
,1,16633,,,,10624,,,,CHEMBL875092,Binding affinities against 5-hydroxytryptamine 5A receptor,,8,,,Autocuration,H,BAO_0000357,,3602,B,
,1,16633,,,,10624,,,,CHEMBL618087,Binding affinities towards 5-hydroxytryptamine 5A receptor,,8,,,Autocuration,H,BAO_0000357,,3603,B,
,1,16700,,,,10624,,,,CHEMBL872926,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,3604,B,
,1,4639,,,,104714,,,,CHEMBL618088,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,4,10141.0,,Autocuration,H,BAO_0000019,,3605,F,
,1,5486,,,,104714,,,,CHEMBL618089,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,4,,,Autocuration,H,BAO_0000223,,3606,B,
,1,16146,,,,10627,,,,CHEMBL618090,Inhibition of human 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3607,B,
,1,17273,,,,10627,,,,CHEMBL618091,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3608,B,
,1,17687,,,,10627,,,,CHEMBL618092,Inhibition against human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3609,B,
,1,6491,,,,10627,,,,CHEMBL618093,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3610,B,
,1,16190,,,,10627,,,HeLa,CHEMBL618094,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,8,,308.0,Expert,H,BAO_0000219,,3611,B,
,1,17066,,,,10627,,,,CHEMBL618095,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3612,B,
,1,17066,,,,10627,,,,CHEMBL875093,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3613,B,
,1,17066,,,,10627,,,,CHEMBL618096,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3614,B,
,1,17066,,,,10627,,,,CHEMBL618118,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3615,B,
,1,3555,,,,10627,,,,CHEMBL618119,Binding affinity against 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3616,B,
,1,5808,,,,10627,,,,CHEMBL618120,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000357,,3617,B,
,1,6013,,,,10627,,,,CHEMBL618121,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3618,B,
,1,15818,,,,10627,,,HEK293,CHEMBL618122,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,8,,722.0,Expert,H,BAO_0000219,,3619,B,
,1,16209,,,,10627,,,,CHEMBL618123,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,8,,,Autocuration,H,BAO_0000357,,3620,B,
,1,3935,,,,10627,,,HEK293,CHEMBL618124,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,8,,722.0,Expert,H,BAO_0000219,,3621,B,
,1,15818,,,,10627,,,,CHEMBL618125,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3622,B,
,1,3805,,,,10627,,,HEK293,CHEMBL618126,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,3623,B,
,1,16441,,,,10627,,,,CHEMBL618236,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,8,,,Expert,H,BAO_0000019,,3624,B,
,1,16441,,,,10627,,,,CHEMBL618237,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,8,,,Expert,H,BAO_0000019,,3625,B,
,1,6786,,,,10627,,,COS-7,CHEMBL618238,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,8,,643.0,Expert,H,BAO_0000219,,3626,B,
,1,4234,,,,10627,,,,CHEMBL618239,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3627,B,
,1,17085,,,,10627,,,,CHEMBL618240,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000019,,3628,B,
,1,17200,,,,10627,,,,CHEMBL618241,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,8,,,Autocuration,H,BAO_0000357,,3629,B,
,1,17451,,,,10627,,,HEK293,CHEMBL859399,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,8,,722.0,Autocuration,H,BAO_0000219,,3630,B,
,1,3935,,,,10627,,,,CHEMBL618242,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,8,,,Autocuration,H,BAO_0000019,,3631,F,
,1,5033,,,,10627,,,,CHEMBL857991,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3632,B,
,1,4540,,,,10627,,,,CHEMBL619951,Binding affinity against human 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000357,,3633,B,
,1,4540,,,,10627,,,HeLa,CHEMBL619952,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,3634,B,
,1,4540,,,,10627,,,HeLa,CHEMBL619953,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,9,9606.0,308.0,Expert,D,BAO_0000219,,3635,B,
,1,17296,,,,10627,,,HeLa,CHEMBL619954,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,8,,308.0,Autocuration,H,BAO_0000219,,3636,B,
,1,17296,,,,10627,,,HeLa,CHEMBL619955,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,8,,308.0,Autocuration,H,BAO_0000219,,3637,B,
,1,17296,,,,10627,,,HeLa,CHEMBL619956,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,8,,308.0,Autocuration,H,BAO_0000219,,3638,B,
,1,15779,,,,10627,,,CHO,CHEMBL619957,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,3639,B,
,1,15779,,,,10627,,,HEK293,CHEMBL619958,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3640,B,
,1,15779,,,,10627,,,HEK293,CHEMBL620627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,8,,722.0,Autocuration,H,BAO_0000219,,3641,B,
,1,15779,,,,10627,,,HEK293,CHEMBL620628,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,8,,722.0,Autocuration,H,BAO_0000219,,3642,B,
,1,15779,,,,10627,,,HeLa,CHEMBL620629,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,8,,308.0,Autocuration,H,BAO_0000219,,3643,B,
,1,6166,,,,10627,,,,CHEMBL620630,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3644,B,
,1,17451,,,,10627,,,HeLa,CHEMBL620782,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,8,,308.0,Autocuration,H,BAO_0000219,,3645,B,
,1,15316,,,,10627,,,,CHEMBL620783,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3646,B,
,1,4199,,,,10627,,,,CHEMBL620784,Binding affinity against human 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000357,,3647,B,
,1,15146,,,,10627,,,HeLa,CHEMBL620785,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,8,,308.0,Expert,H,BAO_0000219,,3648,B,
,1,5213,,,,10627,,,,CHEMBL857992,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,8,,,Autocuration,H,BAO_0000357,,3649,B,
,1,16429,,,,10627,,,,CHEMBL620786,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,8,,,Autocuration,H,BAO_0000219,,3650,B,
,1,14818,,,,10627,,,HeLa,CHEMBL620787,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,8,,308.0,Autocuration,H,BAO_0000219,,3651,B,
,1,4829,,,,10627,,,HeLa,CHEMBL620788,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,8,,308.0,Autocuration,H,BAO_0000219,,3652,B,
,1,4829,,,,10627,,,HeLa,CHEMBL620789,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,8,,308.0,Autocuration,H,BAO_0000219,,3653,B,
,1,4829,,,,10627,,,HeLa,CHEMBL620790,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,8,,308.0,Autocuration,H,BAO_0000219,,3654,B,
,1,15250,,,,10628,,,CHO,CHEMBL620791,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,3655,B,
,1,14423,,,,10628,,,,CHEMBL620792,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3656,B,
,1,15086,,,,10628,,,,CHEMBL620793,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3657,B,
,1,4342,,,,10628,,,,CHEMBL620794,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3658,B,
,1,16190,,,,10627,,,HeLa,CHEMBL620795,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Homo sapiens,9,9606.0,308.0,Autocuration,D,BAO_0000219,,3659,B,
,1,4820,,,,10627,,,,CHEMBL620796,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000357,,3660,B,
,1,4639,,,,10627,,,,CHEMBL620797,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,8,,,Autocuration,H,BAO_0000357,,3661,B,
,1,17066,,,,10627,,,,CHEMBL620798,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,3662,F,
,1,6011,,,,10627,,,,CHEMBL620799,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,3663,B,
,1,17066,,,,10627,,,,CHEMBL620800,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000357,,3664,B,
,1,17515,,,,10627,,,,CHEMBL620801,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,3665,B,
,1,5014,,,,10627,,,,CHEMBL875100,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3666,B,
,1,4373,,,,10627,,,,CHEMBL620802,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3667,B,
,1,17066,,,,10627,,,,CHEMBL620803,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,8,,,Expert,H,BAO_0000019,,3668,F,
,1,17066,,,,10627,,,,CHEMBL620804,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,8,,,Expert,H,BAO_0000019,,3669,F,
,1,4373,,,,10627,,,,CHEMBL620805,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3670,B,
,1,4687,,,,10627,,,,CHEMBL620806,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3671,B,
,1,16946,,,,10627,,,,CHEMBL620807,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,8,,,Autocuration,H,BAO_0000357,,3672,B,
,1,16946,,,,10627,,,,CHEMBL620808,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,8,,,Autocuration,H,BAO_0000357,,3673,B,
,1,16633,,,,10627,,,,CHEMBL620809,Binding affinities against 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3674,B,
,1,16633,,,,10627,,,,CHEMBL620810,Binding affinities towards 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3675,B,
,1,17066,,,,10627,,,,CHEMBL620811,Binding affinity towards 5-hydroxytryptamine 6 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3676,B,
,1,16700,,,,10627,,,,CHEMBL620812,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,3677,B,
,1,3269,,,,10627,,,,CHEMBL620813,Affinity against 5-hydroxytryptamine 6 receptor,,8,,,Autocuration,H,BAO_0000357,,3678,B,
,1,5486,,,,10627,,,,CHEMBL620814,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,8,,,Autocuration,H,BAO_0000357,,3679,B,
,1,16146,,,,10209,,,,CHEMBL620815,Inhibition of human 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3680,B,
,1,5014,,,,10209,,,HEK293,CHEMBL620816,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,8,,722.0,Autocuration,H,BAO_0000219,,3681,B,
,1,15463,,,,10209,,,,CHEMBL620817,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3682,B,
,1,3805,,,,10209,,,,CHEMBL620818,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,8,,,Autocuration,H,BAO_0000357,,3683,B,
,1,5014,,,,10209,,,HEK293,CHEMBL620819,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,8,,722.0,Expert,H,BAO_0000219,,3684,B,
,1,6491,,,,10209,,,,CHEMBL620820,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3685,B,
,1,16190,,,,10209,,,CHO,CHEMBL620821,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,3686,B,
,1,17066,,,,10209,,,,CHEMBL620822,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3687,B,
,1,17066,,,,10209,,,,CHEMBL620823,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3688,B,
,1,3555,,,,10209,,,,CHEMBL620824,Binding affinity against 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3689,B,
,1,6588,,,,10209,,,CHO,CHEMBL620825,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,8,,449.0,Expert,H,BAO_0000219,,3690,B,
,1,15463,,,,10209,,,,CHEMBL872930,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,8,,,Autocuration,H,BAO_0000357,,3691,B,
,1,6013,,,,10209,,,,CHEMBL620826,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3692,B,
,1,16209,,,,10209,,,,CHEMBL620827,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,3693,B,
,1,3935,,,,10209,,,,CHEMBL620828,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3694,B,
,1,15818,,,,10209,,,,CHEMBL620829,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3695,B,
,1,5014,,,,10209,,,HEK293,CHEMBL620830,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,8,,722.0,Expert,H,BAO_0000219,,3696,B,
,1,16441,,,,10209,,,,CHEMBL620831,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,8,,,Expert,H,BAO_0000019,,3697,B,
,1,16441,,,,10209,,,,CHEMBL620832,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,8,,,Expert,H,BAO_0000019,,3698,B,
,1,4234,,,,10209,,,,CHEMBL621548,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3699,B,
,1,17085,,,,10209,,,,CHEMBL621549,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000019,,3700,B,
,1,17200,,,,10209,,,,CHEMBL621550,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,8,,,Autocuration,H,BAO_0000357,,3701,B,
,1,17451,,,,10209,,,CHO,CHEMBL621551,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,8,,449.0,Autocuration,H,BAO_0000219,,3702,B,
,1,17085,,,,10209,,,,CHEMBL621552,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,8,,,Autocuration,H,BAO_0000019,,3703,B,
,1,5104,,,,10209,,,,CHEMBL857077,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3704,B,
,1,5104,,,,10209,,,,CHEMBL618158,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,8,,,Autocuration,H,BAO_0000357,,3705,B,
,1,5033,,,,10209,,,COS-7,CHEMBL618159,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Homo sapiens,9,9606.0,643.0,Expert,D,BAO_0000219,,3706,B,
,1,5486,,,,10209,,,COS-7,CHEMBL875101,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,8,,643.0,Autocuration,H,BAO_0000219,,3707,B,
,1,4540,,,,10209,,,HEK293,CHEMBL618160,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,3708,B,
,1,6166,,,,10209,,,,CHEMBL618161,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,8,,,Expert,H,BAO_0000357,,3709,B,
,1,17342,,,,10209,,,HEK293,CHEMBL618162,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,8,,722.0,Expert,H,BAO_0000219,,3710,B,
,1,17342,,,,10209,,,,CHEMBL618163,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,8,,,Expert,H,BAO_0000357,,3711,B,
,1,17296,,,,10209,,,,CHEMBL618164,Binding affinity against 5-hydroxytryptamine 7 human receptors,,8,,,Autocuration,H,BAO_0000357,,3712,B,
,1,16429,,,,10209,,,,CHEMBL618165,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,8,,,Expert,H,BAO_0000219,,3713,B,
,1,15779,,,,10209,,,HEK293,CHEMBL618166,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3714,B,
,1,15779,,,,10209,,,HEK293,CHEMBL857989,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3715,B,
,1,15779,,,,10209,,,HEK293,CHEMBL619888,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3716,B,
,1,15779,,,,10209,,,HEK293,CHEMBL619889,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3717,B,
,1,15779,,,,10209,,,HEK293,CHEMBL619890,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,8,,722.0,Autocuration,H,BAO_0000219,,3718,B,
,1,17451,,,,10209,,,CHO,CHEMBL619891,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,8,,449.0,Autocuration,H,BAO_0000219,,3719,B,
,1,4199,,,,10209,,,HEK293,CHEMBL619892,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,8,,722.0,Autocuration,H,BAO_0000219,,3720,B,
,1,4199,,,,10209,,,HEK293,CHEMBL619893,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,9,,722.0,Expert,D,BAO_0000219,,3721,B,
,1,4199,,,,10209,,,HEK293,CHEMBL619894,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,8,,722.0,Autocuration,H,BAO_0000219,,3722,B,
,1,3680,,,,10209,,,HEK293,CHEMBL619895,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,9,,722.0,Intermediate,D,BAO_0000219,,3723,B,
,1,3680,,,,10209,,,,CHEMBL619896,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,9,,,Intermediate,D,BAO_0000357,,3724,B,
,1,15316,,,,10209,,,COS-7,CHEMBL619897,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,8,,643.0,Autocuration,H,BAO_0000219,,3725,B,
,1,15146,,,,10209,,,HEK293,CHEMBL619898,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,8,,722.0,Autocuration,H,BAO_0000219,,3726,B,
,1,5213,,,,10209,,,HEK293,CHEMBL619899,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,8,,722.0,Expert,H,BAO_0000219,,3727,B,
,1,5213,,,,10209,,,HEK293,CHEMBL619900,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,8,,722.0,Autocuration,H,BAO_0000219,,3728,B,
,1,14818,,,,10209,,,HEK293,CHEMBL619901,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,3729,B,
,1,14818,,,,10209,,,HEK293,CHEMBL620580,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,8,,722.0,Autocuration,H,BAO_0000219,,3730,B,
,1,14818,,,,10209,,,HEK293,CHEMBL620581,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,8,,722.0,Autocuration,H,BAO_0000219,,3731,B,
,1,4829,,,,10209,,,HEK293,CHEMBL620733,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,8,,722.0,Autocuration,H,BAO_0000219,,3732,B,
,1,17200,,,,10209,,,,CHEMBL620734,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Homo sapiens,9,9606.0,,Autocuration,D,BAO_0000357,,3733,B,
,1,17066,,,,10022,,,,CHEMBL620735,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3734,B,
,1,14025,,,,10209,,,,CHEMBL620736,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,3735,B,
,1,15250,,,,11923,,,CHO,CHEMBL620737,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,8,,449.0,Autocuration,H,BAO_0000219,,3736,B,
,1,16372,,,,11923,,,CHO,CHEMBL620738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3737,B,
,1,16372,,,,11923,,,CHO,CHEMBL620739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3738,B,
,1,16372,,,,11923,,,CHO,CHEMBL620740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3739,B,
,1,16372,,,,11923,,,CHO,CHEMBL620741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,3740,B,
,1,16372,,,,11923,,,CHO,CHEMBL620742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,3741,B,
,1,16372,,,,11923,,,CHO,CHEMBL620743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,8,,449.0,Autocuration,H,BAO_0000219,,3742,B,
,1,16372,,,,11923,,,CHO,CHEMBL620744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3743,B,
,1,16372,,,,11923,,,CHO,CHEMBL620745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3744,B,
,1,16372,,,,11923,,,CHO,CHEMBL620746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,8,,449.0,Autocuration,H,BAO_0000219,,3745,B,
,1,16372,,,,11923,,,CHO,CHEMBL620747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,3746,B,
,1,16372,,,,11923,,,CHO,CHEMBL620748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,3747,B,
,1,16372,,,,11923,,,CHO,CHEMBL620749,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,8,,449.0,Autocuration,H,BAO_0000219,,3748,B,
,1,17066,,,,11923,,,,CHEMBL620750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3749,B,
,1,17066,,,,11923,,,,CHEMBL620751,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3750,B,
,1,17386,,,,11923,,,,CHEMBL620752,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3751,B,
,1,14423,,,,11923,,,,CHEMBL872929,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3752,B,
,1,15874,,,,11923,,,,CHEMBL620753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3753,B,
,1,15874,,,,11923,,,,CHEMBL620754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3754,B,
,1,16372,,,,11923,,,CHO,CHEMBL620755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Rattus norvegicus,9,10116.0,449.0,Expert,D,BAO_0000219,,3755,B,
,1,4622,,,,11923,,,,CHEMBL620756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,3756,B,
,1,15086,,,,11923,,,,CHEMBL620757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3757,B,
,1,16372,,,,11923,,,CHO,CHEMBL620758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,8,,449.0,Autocuration,H,BAO_0000219,,3758,B,
,1,16372,,,,11923,,,CHO,CHEMBL620759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,8,,449.0,Autocuration,H,BAO_0000219,,3759,B,
,1,16372,,,,11923,,,CHO,CHEMBL620760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,8,,449.0,Autocuration,H,BAO_0000219,,3760,B,
,1,16372,,,,11923,,,CHO,CHEMBL620761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,8,,449.0,Autocuration,H,BAO_0000219,,3761,B,
Ileum,1,17386,,,,11923,,,,CHEMBL620762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,8,,,Autocuration,H,BAO_0000221,2116.0,3762,F,
Ileum,1,17386,,,,11923,,,,CHEMBL620763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,8,,,Autocuration,H,BAO_0000221,2116.0,3763,F,
Ileum,1,17386,,,,11923,,,,CHEMBL620764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,8,,,Autocuration,H,BAO_0000221,2116.0,3764,F,
,1,5831,,,,11923,,Membranes,,CHEMBL857990,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,3765,B,
,1,4342,,,,11923,,,,CHEMBL620765,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3766,B,
,1,17319,,,,11923,,,,CHEMBL620766,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,8,,,Expert,H,BAO_0000357,,3767,B,
Hypothalamus,1,17342,,,,11923,,,,CHEMBL620767,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,8,,,Expert,H,BAO_0000019,1898.0,3768,B,
,1,17342,,,,11923,,,,CHEMBL620768,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,8,,,Autocuration,H,BAO_0000357,,3769,B,
Hypothalamus,1,3680,,,,11923,,,,CHEMBL619051,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,8,,,Expert,H,BAO_0000249,1898.0,3770,B,
,1,3680,,,,11923,,,,CHEMBL619052,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3771,B,
,1,17319,,,,11923,,,HEK293,CHEMBL619053,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Rattus norvegicus,9,10116.0,722.0,Expert,D,BAO_0000219,,3772,F,
,1,17319,,,,11923,,,HEK293,CHEMBL619703,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Rattus norvegicus,9,10116.0,722.0,Expert,D,BAO_0000219,,3773,F,
,1,17319,,,,11923,,,HEK293,CHEMBL619704,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Rattus norvegicus,9,10116.0,722.0,Autocuration,D,BAO_0000219,,3774,F,
,1,4820,,,,10209,,,,CHEMBL619851,Binding affinity towards 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3775,B,
,1,4639,,,,10209,,,,CHEMBL619852,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,8,,,Autocuration,H,BAO_0000357,,3776,B,
,1,6011,,,,10209,,,,CHEMBL619853,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,8,,,Autocuration,H,BAO_0000357,,3777,B,
,1,17066,,,,10209,,,,CHEMBL619854,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3778,B,
,1,17066,,,,10209,,,,CHEMBL619855,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3779,B,
,1,17515,,,,10209,,,,CHEMBL619856,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,8,,,Autocuration,H,BAO_0000357,,3780,B,
,1,4373,,,,10209,,,,CHEMBL619857,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3781,B,
,1,17066,,,,10209,,,,CHEMBL619858,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,8,,,Expert,H,BAO_0000019,,3782,F,
,1,4373,,,,10209,,,,CHEMBL619859,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3783,B,
,1,4373,,,,10209,,,,CHEMBL619860,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,8,,,Autocuration,H,BAO_0000357,,3784,B,
,1,4687,,,,10209,,,,CHEMBL619861,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3785,B,
,1,17342,,,,10209,,,,CHEMBL619862,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3786,B,
,1,16946,,,,10209,,,,CHEMBL619863,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,8,,,Autocuration,H,BAO_0000357,,3787,B,
,1,16946,,,,10209,,,,CHEMBL619864,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,8,,,Autocuration,H,BAO_0000357,,3788,B,
,1,16633,,,,10209,,,,CHEMBL872928,Binding affinities against 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3789,B,
,1,16633,,,,10209,,,,CHEMBL619865,Binding affinities towards 5-hydroxytryptamine 7 receptor,,8,,,Autocuration,H,BAO_0000357,,3790,B,
,1,17066,,,,10209,,,,CHEMBL619866,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,8,,,Expert,H,BAO_0000357,,3791,B,
,1,16700,,,,10209,,,,CHEMBL619867,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,8,,,Autocuration,H,BAO_0000357,,3792,B,
Ileum,1,17386,,,,10209,,,,CHEMBL619868,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,8,,,Autocuration,H,BAO_0000221,2116.0,3793,B,
,1,14080,,,,55,,,,CHEMBL619869,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,8,,,Autocuration,H,BAO_0000019,,3794,F,
,1,14080,,,,55,,,,CHEMBL619870,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,3795,F,
,1,409,,,,55,,,,CHEMBL619871,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,8,,,Autocuration,H,BAO_0000357,,3796,B,
,1,409,,,,55,,,,CHEMBL619872,In vitro inhibition of human recombinant lipoxygenase enzyme,,8,,,Autocuration,H,BAO_0000357,,3797,B,
,1,409,,,,55,,,,CHEMBL619873,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,8,,,Autocuration,H,BAO_0000357,,3798,B,
Blood,1,11090,,,,55,,,,CHEMBL619874,Inhibition of 5-lipoxygenase in human whole blood.,,8,,,Expert,H,BAO_0000357,178.0,3799,B,
Blood,1,11090,,,,55,,,,CHEMBL619875,Inhibition of 5-lipoxygenase in human whole blood.,,8,,,Expert,H,BAO_0000357,178.0,3800,B,
,1,948,,,,55,,,,CHEMBL619876,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,8,,,Autocuration,H,BAO_0000357,,3801,B,
,1,948,,,,55,,,,CHEMBL619877,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,8,,,Autocuration,H,BAO_0000357,,3802,B,
,1,13622,,,,55,,,,CHEMBL619878,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,8,,,Expert,H,BAO_0000219,,3803,F,
Blood,1,13622,,,,55,,,,CHEMBL619879,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,8,,,Autocuration,H,BAO_0000019,178.0,3804,F,
,1,9637,,,,55,,,,CHEMBL619880,In vitro inhibition of 5-lipoxygenase from human polymorphs,,8,,,Autocuration,H,BAO_0000357,,3805,B,
,1,11320,,,,55,,,,CHEMBL619881,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,8,,,Autocuration,H,BAO_0000357,,3806,B,
,1,11320,,,,55,,,,CHEMBL619882,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3807,B,
,1,6838,,,,55,,,,CHEMBL619883,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,8,,,Autocuration,H,BAO_0000357,,3808,B,
Blood,1,17667,,,,55,,,,CHEMBL619884,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,178.0,3809,B,
,1,12703,,,,55,,,,CHEMBL619885,In vitro potency against human 5-Lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,3810,B,
,1,14312,,,,55,,,,CHEMBL619886,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,3811,F,
Blood,1,14312,,,,55,,,,CHEMBL619887,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,8,,,Autocuration,H,BAO_0000019,178.0,3812,F,
,1,5364,,,,55,,,,CHEMBL875097,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,8,,,Autocuration,H,BAO_0000019,,3813,F,
,1,951,,,,55,,,,CHEMBL618001,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,8,,,Autocuration,H,BAO_0000219,,3814,B,
,1,951,,,,55,,,,CHEMBL618002,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,8,,,Autocuration,H,BAO_0000219,,3815,B,
,1,951,,,,55,,,,CHEMBL618003,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,8,,,Autocuration,H,BAO_0000219,,3816,B,
,1,951,,,,55,,,,CHEMBL618004,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,8,,,Autocuration,H,BAO_0000219,,3817,B,
,1,12365,,,,55,,,,CHEMBL618005,Inhibition of human 5-lipoxygenase in human cells,,8,,,Autocuration,H,BAO_0000219,,3818,B,
,1,10603,,,,55,,,,CHEMBL618006,Inhibition of human neutrophil 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3819,B,
,1,10501,,,,55,,,,CHEMBL875086,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,8,,,Autocuration,H,BAO_0000019,,3820,B,
Blood,1,12281,,,,55,,,,CHEMBL618007,Inhibition of 5-lipoxygenase from human whole blood,,8,,,Expert,H,BAO_0000357,178.0,3821,B,
,1,2567,,,,55,,,,CHEMBL618008,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,8,,,Autocuration,H,BAO_0000357,,3822,B,
,1,2567,,,,55,,,,CHEMBL618009,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,8,,,Autocuration,H,BAO_0000219,,3823,B,
,1,10193,,,,55,,,,CHEMBL618010,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3824,B,
,1,10193,,,,55,,,,CHEMBL618011,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,Autocuration,H,BAO_0000357,,3825,B,
,1,13623,,,,55,,,,CHEMBL618012,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3826,B,
,1,12780,,,,55,,,,CHEMBL882927,Tested against 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,3827,B,
,1,12780,,,,55,,,,CHEMBL618013,Tested for activity against 5-Lipoxygenase (5-LO),,8,,,Autocuration,H,BAO_0000357,,3828,B,
,1,12780,,,,55,,,,CHEMBL618014,Tested for activity against 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,3829,B,
,1,11966,,,,55,,,,CHEMBL618015,Tested for inhibition of 5-HPETE production by human 5-LO,,8,,,Autocuration,H,BAO_0000357,,3830,B,
,1,5364,,,,55,,,,CHEMBL618016,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,8,,,Autocuration,H,BAO_0000019,,3831,F,
,1,13165,,,,55,,,,CHEMBL618017,Inhibition of Human 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3832,B,
,1,5364,,,,55,,,,CHEMBL618018,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,8,,,Autocuration,H,BAO_0000019,,3833,B,
,1,11311,,,,55,,,,CHEMBL875087,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,3834,B,
,1,11311,,,,55,,,,CHEMBL618019,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,3835,B,
,1,14863,,,,55,,,,CHEMBL618020,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,8,,,Autocuration,H,BAO_0000019,,3836,B,
,1,14863,,,,55,,,,CHEMBL618021,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,8,,,Autocuration,H,BAO_0000019,,3837,B,
Blood,1,11087,,,,55,,,,CHEMBL618022,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,8,,,Autocuration,H,BAO_0000357,178.0,3838,B,
,1,455,,,,55,,,,CHEMBL618023,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,8,,,Autocuration,H,BAO_0000357,,3839,B,
,1,13183,,,,55,,,,CHEMBL618024,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,Autocuration,H,BAO_0000357,,3840,B,
,1,10319,,,,55,,,,CHEMBL873950,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,8,,,Expert,H,BAO_0000019,,3841,B,
,1,10193,,,,55,,,,CHEMBL618025,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,Autocuration,H,BAO_0000357,,3842,B,
,1,951,,,,55,,,,CHEMBL618026,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,8,,,Autocuration,H,BAO_0000219,,3843,B,
,1,951,,,,55,,,,CHEMBL618027,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,8,,,Autocuration,H,BAO_0000219,,3844,B,
,1,951,,,,55,,,,CHEMBL618028,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,8,,,Autocuration,H,BAO_0000219,,3845,B,
,1,951,,,,55,,,,CHEMBL618029,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,8,,,Autocuration,H,BAO_0000219,,3846,B,
,1,9859,,,,55,,,,CHEMBL618030,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,8,,,Expert,H,BAO_0000357,,3847,B,
,1,9859,,,,55,,,,CHEMBL618031,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,8,,,Expert,H,BAO_0000357,,3848,B,
,1,9859,,,,55,,,,CHEMBL618032,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,8,,,Autocuration,H,BAO_0000357,,3849,B,
,1,2567,,,,55,,,,CHEMBL618033,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,8,,,Autocuration,H,BAO_0000357,,3850,B,
,1,10193,,,,55,,,,CHEMBL618034,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,8,,,Autocuration,H,BAO_0000357,,3851,B,
,1,10193,,,,55,,,,CHEMBL875088,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,8,,,Autocuration,H,BAO_0000357,,3852,B,
,1,949,,,,55,,,,CHEMBL618035,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,8,,,Autocuration,H,BAO_0000019,,3853,B,
,1,949,,,,55,,,,CHEMBL618036,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,8,,,Autocuration,H,BAO_0000019,,3854,B,
,1,10603,,,,55,,,,CHEMBL618037,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,8,,,Expert,H,BAO_0000357,,3855,B,
,1,10603,,,,55,,,,CHEMBL618038,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,8,,,Expert,H,BAO_0000357,,3856,B,
,1,10603,,,,55,,,,CHEMBL618761,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,8,,,Autocuration,H,BAO_0000019,,3857,F,
,1,10603,,,,55,,,,CHEMBL618762,Inhibition of lipoxygenase at the concentration of 0.1 uM,,8,,,Expert,H,BAO_0000357,,3858,B,
,1,10603,,,,55,,,,CHEMBL618763,Inhibition of lipoxygenase at the concentration of 1 uM,,8,,,Expert,H,BAO_0000357,,3859,B,
,1,10193,,,,55,,,,CHEMBL618764,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,8,,,Autocuration,H,BAO_0000357,,3860,B,
,1,14580,,,,55,,,,CHEMBL618765,Inhibition of 5-Lipoxygenase (5-LOX),Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,3861,B,
,1,11090,,,,17087,,,,CHEMBL618766,Inhibition of 5-lipoxygenase in mouse macrophages.,,8,,,Expert,H,BAO_0000357,,3862,B,
,1,11090,,,,17087,,,,CHEMBL618767,Inhibition of 5-lipoxygenase in mouse macrophages.,,8,,,Expert,H,BAO_0000357,,3863,B,
,1,6339,,,,17087,,,,CHEMBL619380,Inhibitory activity against lipoxygenase-2 in mice,,8,,,Autocuration,H,BAO_0000357,,3864,B,
,1,6339,,,,17087,,,,CHEMBL619381,Inhibitory activity against murine lipoxygenase-2.,,8,,,Expert,H,BAO_0000357,,3865,B,
,1,12281,,,,17087,,,,CHEMBL619382,Inhibition of 5-lipoxygenase from mouse macrophage,Mus musculus,9,10090.0,,Expert,D,BAO_0000357,,3866,B,
,1,11311,,,,17087,,,,CHEMBL619383,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,8,,,Autocuration,H,BAO_0000357,,3867,B,
,1,11089,,,,55,,,,CHEMBL619384,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,3868,B,
,1,10091,,,,55,,,,CHEMBL619385,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Sus scrofa,8,9823.0,,Autocuration,H,BAO_0000019,,3869,B,
,1,14352,,,,55,,,,CHEMBL882928,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Oryctolagus cuniculus,8,9986.0,,Autocuration,H,BAO_0000019,,3870,B,
,1,13329,,,,12166,,,,CHEMBL619386,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,3871,B,
,1,13329,,,,12166,,,,CHEMBL619387,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,8,,,Autocuration,H,BAO_0000019,,3872,B,
,1,13329,,,,12166,,,,CHEMBL619388,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,8,,,Autocuration,H,BAO_0000019,,3873,B,
,1,13329,,,,12166,,,,CHEMBL619389,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,8,,,Autocuration,H,BAO_0000019,,3874,B,
,1,13329,,,,12166,,,,CHEMBL619390,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,8,,,Expert,H,BAO_0000019,,3875,B,
,1,13329,,,,12166,,,,CHEMBL619391,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,8,,,Expert,H,BAO_0000019,,3876,B,
,1,13329,,,,12166,,,,CHEMBL619392,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,8,,,Autocuration,H,BAO_0000019,,3877,B,
,1,11311,,,,12166,,,,CHEMBL619393,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,8,,,Autocuration,H,BAO_0000019,,3878,B,
,1,11311,,,,12166,,,,CHEMBL619394,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,8,,,Autocuration,H,BAO_0000019,,3879,B,
,1,105,,,,12166,,,RBL-1,CHEMBL619395,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,8,,702.0,Autocuration,H,BAO_0000219,,3880,B,
,1,105,,,,12166,,,RBL-1,CHEMBL619396,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,8,,702.0,Autocuration,H,BAO_0000219,,3881,B,
,1,9138,,,,12166,,,,CHEMBL619397,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,8,,,Autocuration,H,BAO_0000357,,3882,B,
,1,9138,,,,12166,,,,CHEMBL619398,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,8,,,Autocuration,H,BAO_0000357,,3883,B,
,1,9138,,,,12166,,,,CHEMBL619399,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,8,,,Autocuration,H,BAO_0000357,,3884,B,
,1,14427,,,,12166,,,,CHEMBL619400,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,8,,,Autocuration,H,BAO_0000357,,3885,B,
,1,13329,,,,12166,,,,CHEMBL619401,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,8,,,Autocuration,H,BAO_0000019,,3886,B,
,1,13329,,,,12166,,,,CHEMBL619402,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,8,,,Autocuration,H,BAO_0000019,,3887,B,
,1,14427,,,,12166,,,RBL-2H3,CHEMBL619403,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Rattus norvegicus,9,10116.0,663.0,Expert,D,BAO_0000219,,3888,B,
,1,14427,,,,12166,,,,CHEMBL619404,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,8,,,Autocuration,H,BAO_0000357,,3889,B,
,1,14427,,,,12166,,,,CHEMBL619405,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,8,,,Autocuration,H,BAO_0000357,,3890,B,
,1,10293,,,,12166,,,RBL-1,CHEMBL619406,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,8,,702.0,Expert,H,BAO_0000219,,3891,B,
,1,338,,,,12166,,,RBL-1,CHEMBL619407,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3892,B,
,1,303,,,,12166,,,,CHEMBL619408,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,8,,,Autocuration,H,BAO_0000357,,3893,B,
,1,303,,,,12166,,,RBL-1,CHEMBL619409,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,8,,702.0,Autocuration,H,BAO_0000219,,3894,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL619410,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,8,,702.0,Expert,H,BAO_0000219,,3895,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL619753,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,8,,702.0,Autocuration,H,BAO_0000219,,3896,B,
,1,137,,,,12166,,,RBL-1,CHEMBL619754,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,8,,702.0,Autocuration,H,BAO_0000219,,3897,B,
,1,11481,,,,12166,,,,CHEMBL619903,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3898,B,
,1,11481,,,,12166,,,,CHEMBL619904,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,8,,,Expert,H,BAO_0000357,,3899,B,
,1,9029,,,,12166,,,,CHEMBL619905,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,8,,,Expert,H,BAO_0000357,,3900,B,
,1,1701,,,,12166,,,,CHEMBL619906,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,8,,,Autocuration,H,BAO_0000019,,3901,B,
,1,1701,,,,12166,,,,CHEMBL619907,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,8,,,Autocuration,H,BAO_0000019,,3902,B,
,1,1701,,,,12166,,,,CHEMBL619908,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,8,,,Autocuration,H,BAO_0000019,,3903,B,
,1,1701,,,,12166,,,,CHEMBL619909,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,8,,,Autocuration,H,BAO_0000019,,3904,B,
,1,13358,,,,12166,,,RBL-1,CHEMBL619910,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,8,,702.0,Expert,H,BAO_0000219,,3905,F,
,1,1175,,,,12166,,,RBL-1,CHEMBL882929,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,8,,702.0,Expert,H,BAO_0000219,,3906,B,
,1,8797,,,,12166,,,RBL-1,CHEMBL619911,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,8,,702.0,Expert,H,BAO_0000219,,3907,B,
,1,8797,,,,12166,,,,CHEMBL619912,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,8,,,Autocuration,H,BAO_0000019,,3908,B,
,1,577,,,,12166,,,,CHEMBL619913,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,3909,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL619914,In vitro inhibitory activity against RBL-1 5-LO,,8,,702.0,Expert,H,BAO_0000219,,3910,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL619915,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,8,,702.0,Autocuration,H,BAO_0000219,,3911,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL619916,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,8,,702.0,Autocuration,H,BAO_0000219,,3912,B,
,1,9295,,,,12166,,,,CHEMBL619917,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,8,,,Autocuration,H,BAO_0000218,,3913,B,
,1,9295,,,,12166,,,,CHEMBL619918,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,8,,,Autocuration,H,BAO_0000357,,3914,B,
,1,216,,,,12166,,,,CHEMBL619919,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,8,,,Autocuration,H,BAO_0000218,,3915,B,
,1,11090,,,,12166,,,RBL-1,CHEMBL883710,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,8,,702.0,Autocuration,H,BAO_0000219,,3916,B,
Blood,1,11090,,,,12166,,,,CHEMBL619920,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,8,,,Autocuration,H,BAO_0000019,178.0,3917,B,
,1,10091,,,,12166,,,,CHEMBL619921,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,3918,B,
,1,10274,,,,12166,,,,CHEMBL619922,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,8,,,Autocuration,H,BAO_0000019,,3919,F,
,1,13622,,,,12166,,,,CHEMBL619923,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,8,,,Autocuration,H,BAO_0000219,,3920,F,
,1,12118,,,,12166,,,RBL-1,CHEMBL619924,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,8,,702.0,Expert,H,BAO_0000219,,3921,B,
,1,12576,,,,12166,,,,CHEMBL619925,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,8,,,Expert,H,BAO_0000357,,3922,B,
,1,9546,,,,12166,,,RBL-1,CHEMBL619926,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,8,,702.0,Expert,H,BAO_0000219,,3923,B,
,1,9521,,,,12166,,,RBL-1,CHEMBL619927,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,8,,702.0,Autocuration,H,BAO_0000219,,3924,B,
,1,10626,,,,12166,,,RBL-1,CHEMBL619928,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,8,,702.0,Expert,H,BAO_0000219,,3925,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619929,In vitro inhibition of RBL-1 5-lipoxygenase,,8,,702.0,Autocuration,H,BAO_0000219,,3926,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL875089,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,8,,702.0,Autocuration,H,BAO_0000219,,3927,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,8,,702.0,Autocuration,H,BAO_0000219,,3928,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,8,,702.0,Autocuration,H,BAO_0000219,,3929,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,8,,702.0,Autocuration,H,BAO_0000219,,3930,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,8,,702.0,Autocuration,H,BAO_0000219,,3931,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,8,,702.0,Autocuration,H,BAO_0000219,,3932,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,8,,702.0,Autocuration,H,BAO_0000219,,3933,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,8,,702.0,Autocuration,H,BAO_0000219,,3934,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,8,,702.0,Autocuration,H,BAO_0000219,,3935,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,8,,702.0,Autocuration,H,BAO_0000219,,3936,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,8,,702.0,Autocuration,H,BAO_0000219,,3937,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,8,,702.0,Autocuration,H,BAO_0000219,,3938,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL875090,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,8,,702.0,Autocuration,H,BAO_0000219,,3939,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,8,,702.0,Autocuration,H,BAO_0000219,,3940,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,8,,702.0,Autocuration,H,BAO_0000219,,3941,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL883711,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,8,,702.0,Autocuration,H,BAO_0000219,,3942,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,8,,702.0,Autocuration,H,BAO_0000219,,3943,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,8,,702.0,Autocuration,H,BAO_0000219,,3944,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,8,,702.0,Autocuration,H,BAO_0000219,,3945,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,8,,702.0,Autocuration,H,BAO_0000219,,3946,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,8,,702.0,Autocuration,H,BAO_0000219,,3947,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,8,,702.0,Autocuration,H,BAO_0000219,,3948,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL619949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,8,,702.0,Autocuration,H,BAO_0000219,,3949,B,
,1,9401,,,,12166,,,,CHEMBL619950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,8,,,Expert,H,BAO_0000019,,3950,B,
,1,10325,,,,12166,,,,CHEMBL618050,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,8,,,Autocuration,H,BAO_0000019,,3951,B,
,1,1556,,,,12166,,,RBL-2H3,CHEMBL875091,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,8,,663.0,Expert,H,BAO_0000219,,3952,F,
,1,1556,,,,12166,,,RBL-2H3,CHEMBL618051,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,8,,663.0,Expert,H,BAO_0000219,,3953,F,
,1,961,,,,12166,,,RBL-1,CHEMBL618052,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3954,B,
,1,6838,,,,12166,,,,CHEMBL618053,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,8,,,Autocuration,H,BAO_0000019,,3955,B,
,1,10325,,,,12166,,,,CHEMBL618054,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,8,,,Expert,H,BAO_0000019,,3956,B,
,1,9209,,,,12166,,,RBL-1,CHEMBL618055,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3957,B,
,1,11520,,,,12166,,,RBL-1,CHEMBL618056,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,8,,702.0,Expert,H,BAO_0000219,,3958,B,
,1,137,,,,12166,,,,CHEMBL618057,In vitro inhibitory activity against 5-lipoxygenase was determined,,8,,,Autocuration,H,BAO_0000357,,3959,B,
,1,4717,,,,12166,,,RBL-1,CHEMBL618058,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,8,,702.0,Autocuration,H,BAO_0000219,,3960,B,
,1,10636,,,,12166,,,RBL-1,CHEMBL618059,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,8,,702.0,Expert,H,BAO_0000219,,3961,B,
,1,14312,,,,12166,,,,CHEMBL618060,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,3962,F,
,1,1203,,,,12166,,,RBL-1,CHEMBL618061,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,8,,702.0,Autocuration,H,BAO_0000219,,3963,B,
,1,1203,,,,12166,,,,CHEMBL618062,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,8,,,Autocuration,H,BAO_0000019,,3964,B,
,1,13622,,,,12166,,,RBL-1,CHEMBL618063,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,8,,702.0,Expert,H,BAO_0000219,,3965,B,
,1,9793,,,,12166,,,,CHEMBL618064,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,8,,,Autocuration,H,BAO_0000357,,3966,B,
,1,1143,,,,12166,,,RBL-1,CHEMBL618065,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3967,B,
,1,11854,,,,12166,,,RBL-1,CHEMBL618066,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3968,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL618067,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,,702.0,Autocuration,H,BAO_0000219,,3969,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL618068,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,8,,702.0,Autocuration,H,BAO_0000219,,3970,B,
,1,10501,,,,12166,,,RBL-1,CHEMBL618069,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,3971,B,
,1,12526,,,,12166,,,RBL-1,CHEMBL618070,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,,702.0,Expert,H,BAO_0000219,,3972,B,
Limbic system,1,10034,,,,10825,,,,CHEMBL618071,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3973,F,
Limbic system,1,10034,,,,10825,,,,CHEMBL619247,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,8,,,Autocuration,H,BAO_0000019,349.0,3974,F,
,1,10034,,,,10825,,,,CHEMBL619248,Approximate dose levels for a half maximal reduction of 5-HTP levels,,8,,,Autocuration,H,BAO_0000019,,3975,F,
Hippocampus,1,10046,,,,10576,,,,CHEMBL619249,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,8,,,Autocuration,H,BAO_0000221,10000000.0,3976,B,
Hippocampus,1,10046,,,,10576,,,,CHEMBL619250,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,8,,,Autocuration,H,BAO_0000221,10000000.0,3977,B,
,1,10046,,,,10577,,,,CHEMBL619251,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,8,,,Autocuration,H,BAO_0000019,,3978,B,
Blood,1,12079,,,,55,,,,CHEMBL619252,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000019,178.0,3979,F,
Blood,1,12079,,,,55,,,,CHEMBL619253,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,8,,,Autocuration,H,BAO_0000019,178.0,3980,F,
,1,11311,,,,12166,,,,CHEMBL619254,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,3981,B,
,1,12338,,,,17140,,,,CHEMBL619255,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,8,,,Expert,H,BAO_0000219,,3982,B,
,1,12143,,,,17140,,,,CHEMBL619256,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,8,,,Expert,H,BAO_0000219,,3983,B,
,1,12143,,,,17140,,,,CHEMBL875418,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,8,,,Autocuration,H,BAO_0000219,,3984,B,
,1,12143,,,,17140,,,,CHEMBL619257,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,8,,,Expert,H,BAO_0000219,,3985,B,
,1,12143,,,,17140,,,,CHEMBL619258,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,8,,,Autocuration,H,BAO_0000219,,3986,B,
,1,12365,,,,17140,,,,CHEMBL619259,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,8,,,Expert,H,BAO_0000357,,3987,B,
,1,13500,,,,17140,,,,CHEMBL619260,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,8,,,Expert,H,BAO_0000357,,3988,B,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619261,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3989,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619263,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3990,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619264,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3991,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619265,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3992,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619266,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3993,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619902,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3994,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620058,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3995,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620059,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3996,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620060,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3997,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620061,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3998,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620062,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,3999,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620063,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4000,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620064,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4001,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620065,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4002,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620066,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4003,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620067,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4004,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620068,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4005,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620069,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4006,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620070,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4007,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620071,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4008,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620072,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4009,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620036,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4010,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL857702,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4011,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620037,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4012,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620038,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4013,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620039,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4014,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620040,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4015,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620041,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4016,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620042,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4017,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620043,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4018,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620044,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4019,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620045,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4020,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4021,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620047,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4022,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620048,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4023,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL857703,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4024,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620049,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4025,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620050,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4026,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL620051,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4027,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619213,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4028,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619214,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4029,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619804,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4030,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619805,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4031,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619806,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4032,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619807,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4033,F,
Blood,1,12832,,In vivo,,55,,,,CHEMBL619808,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,178.0,4034,F,
,1,3595,,,,55,,,,CHEMBL619809,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4035,B,
,1,3595,,,,55,,,,CHEMBL619810,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4036,B,
,1,3595,,,,55,,,,CHEMBL619811,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4037,B,
,1,3595,,,,55,,,,CHEMBL620769,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4038,B,
,1,3595,,,,55,,,,CHEMBL620770,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4039,B,
,1,3595,,,,55,,,,CHEMBL620771,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4040,B,
,1,3595,,,,55,,,,CHEMBL620772,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4041,B,
,1,3595,,,,55,,,,CHEMBL620773,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Canis lupus familiaris,8,9615.0,,Autocuration,H,BAO_0000218,,4042,B,
,1,9203,,,,55,,,,CHEMBL620774,Ability to inhibit 5-lipoxygenase in guinea pig,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4043,B,
,1,82,,,,55,,,,CHEMBL620775,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Cavia porcellus,8,10141.0,,Expert,H,BAO_0000357,,4044,B,
,1,11090,,,,55,,,,CHEMBL620776,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4045,B,
Blood,1,12832,,,,55,,,,CHEMBL620777,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000218,178.0,4046,B,
,1,1065,,,,55,,,,CHEMBL620778,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4047,B,
,1,1065,,,,55,,,,CHEMBL620779,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4048,B,
,1,12832,,,,55,,,,CHEMBL621500,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,8,10141.0,,Expert,H,BAO_0000019,,4049,B,
,1,12832,,,,55,,,,CHEMBL621501,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,8,10141.0,,Expert,H,BAO_0000019,,4050,B,
,1,12832,,,,55,,,,CHEMBL618098,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,4051,B,
,1,10504,,,,55,,,,CHEMBL618099,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,4052,B,
,1,7788,,,,55,,,,CHEMBL618100,Inhibitory activity against 5-lipoxygenase,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4053,B,
,1,10001,,,,55,,,,CHEMBL618101,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4054,B,
,1,10193,,,,55,,,,CHEMBL618102,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4055,B,
,1,13243,,,,55,,,,CHEMBL618103,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4056,B,
,1,13243,,,,55,,,,CHEMBL618104,Inhibitory activity uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4057,B,
,1,969,,,,55,,,,CHEMBL883712,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000219,,4058,B,
,1,10001,,,,55,,,,CHEMBL618105,Inhibitory activity against 5-lipoxygenase at 10 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4059,B,
,1,7788,,,,55,,,,CHEMBL618106,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4060,B,
,1,10001,,,,55,,,,CHEMBL618107,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4061,B,
,1,10193,,,,55,,,,CHEMBL618108,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4062,B,
,1,13243,,,,55,,,,CHEMBL618109,Inhibitory activity uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4063,B,
,1,13243,,,,55,,,,CHEMBL618110,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4064,B,
,1,13243,,,,55,,,,CHEMBL618111,Inhibitory activity uM,Cavia porcellus,8,10141.0,,Expert,H,BAO_0000357,,4065,B,
,1,13243,,,,55,,,,CHEMBL618112,Inhibitory activity uM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,4066,F,
,1,10504,,,,55,,,,CHEMBL618113,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000019,,4067,B,
,1,7788,,,,55,,,,CHEMBL618114,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Cavia porcellus,8,10141.0,,Autocuration,H,BAO_0000357,,4068,B,
Ileum,1,10546,,,,55,,,,CHEMBL620871,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Cavia porcellus,8,10141.0,,Expert,H,BAO_0000221,2116.0,4069,F,
,1,13183,,,,55,,,,CHEMBL620872,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,Autocuration,H,BAO_0000357,,4070,B,
,1,13183,,,,55,,,,CHEMBL620873,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,8,,,Autocuration,H,BAO_0000357,,4071,B,
,1,2578,,,,55,,,,CHEMBL620874,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,8,,,Autocuration,H,BAO_0000357,,4072,B,
,1,12780,,,,55,,,,CHEMBL620875,In vitro inhibition of human 5-Lipoxygenase.,,8,,,Expert,H,BAO_0000357,,4073,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620876,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4074,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620877,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4075,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL857854,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4076,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620878,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4077,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620879,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4078,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620880,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4079,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620881,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4080,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620882,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4081,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620883,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4082,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620884,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4083,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620885,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4084,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620886,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4085,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620887,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4086,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618039,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4087,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618040,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4088,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618041,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4089,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618216,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4090,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618217,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4091,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618218,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4092,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618219,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4093,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618220,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4094,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618221,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4095,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618222,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4096,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618223,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4097,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618224,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4098,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618225,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4099,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4100,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618227,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4101,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618228,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4102,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618229,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4103,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618230,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4104,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618231,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4105,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618232,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4106,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618233,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4107,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618234,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4108,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618235,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4109,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4110,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4111,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL618117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4112,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619968,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4113,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619969,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4114,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619970,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4115,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619971,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4116,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619972,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4117,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619973,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4118,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619974,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4119,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619975,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4120,B,
,1,7411,,,,22226,,Microsomes,,CHEMBL619976,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,,4121,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619977,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4122,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619978,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4123,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619979,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4124,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619980,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4125,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619981,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4126,B,
,1,10797,,,,80433,,,RPMI-8226,CHEMBL619982,In vitro inhibition of 7226/S myeloma cancer cell line,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,4127,F,
,1,6881,,,,80698,,,BEL-7404 tumor cell line,CHEMBL619983,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Homo sapiens,1,9606.0,993.0,Intermediate,N,BAO_0000219,,4128,F,
,1,3838,,,,80640,,,786-0,CHEMBL620031,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4129,F,
,1,3838,,,,80640,,,786-0,CHEMBL620032,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4130,F,
,1,12981,,,,81264,,,V79,CHEMBL620033,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Cricetulus griseus,1,10029.0,505.0,Expert,N,BAO_0000219,,4131,F,
,1,12981,,,,81264,,,V79,CHEMBL620034,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Cricetulus griseus,1,10029.0,505.0,Expert,N,BAO_0000219,,4132,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL620035,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4133,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL618318,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4134,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL618319,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4135,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL618320,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4136,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL618321,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4137,F,
,1,7653,,,,80635,,,7800C1 cell line,CHEMBL883118,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Rattus norvegicus,1,10116.0,1119.0,Intermediate,N,BAO_0000219,,4138,F,
,1,17229,,,,80640,,,786-0,CHEMBL883795,In vitro antitumor activity against renal 786-0 tumor cell lines,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4139,F,
,1,12858,,,,80640,,,786-0,CHEMBL618322,Cytotoxic activity against 786-0 Renal cancer cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4140,F,
,1,16325,,,,80640,,,786-0,CHEMBL618323,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4141,F,
,1,16325,,,,80640,,,786-0,CHEMBL618324,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4142,F,
,1,5858,,,,80640,,,786-0,CHEMBL618325,In vitro antitumor activity against human renal 786-0 cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4143,F,
,1,16325,,,,80640,,,786-0,CHEMBL875416,Inhibition of Renal cancer in 786-0 cancer cell lines,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4144,F,
,1,14696,,,,80640,,,786-0,CHEMBL618326,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4145,F,
,1,3786,,,,80640,,,786-0,CHEMBL618327,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4146,F,
,1,14696,,,,80640,,,786-0,CHEMBL619215,inhibition of the growth of renal cancer(786-0) cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4147,F,
,1,14769,,,,80640,,,786-0,CHEMBL619216,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4148,F,
,1,15354,,,,80640,,,786-0,CHEMBL619217,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4149,F,
,1,14255,,,,80640,,,786-0,CHEMBL619218,The IC50 value was measured on 786-0 cell line in ovarian tumor,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4150,F,
,1,14255,,,,80640,,,786-0,CHEMBL619219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4151,F,
,1,14255,,,,80640,,,786-0,CHEMBL619220,The IC50 value was measured on 786-0 cell line in renal tumor type.,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4152,F,
,1,14696,,,,80640,,,786-0,CHEMBL619221,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4153,F,
,1,12016,,,,80640,,,786-0,CHEMBL619222,Tested for cytotoxic activity against renal cancer 786-0 cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4154,F,
,1,2597,,,,80640,,,786-0,CHEMBL857454,Compound was tested for growth inhibitory activity against 786-0 cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,4155,F,
,1,12526,,,,12166,,,RBL-1,CHEMBL619223,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4156,B,
,1,12526,,,,12166,,,RBL-1,CHEMBL619224,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,8,,702.0,Autocuration,H,BAO_0000219,,4157,B,
,1,14799,,,,12166,,,,CHEMBL619225,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,8,,,Autocuration,H,BAO_0000019,,4158,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL619226,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,8,,702.0,Expert,H,BAO_0000219,,4159,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL619227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,8,,702.0,Expert,H,BAO_0000219,,4160,B,
,1,12767,,,,12166,,,,CHEMBL619228,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4161,B,
,1,10997,,,,12166,,,,CHEMBL619229,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,8,,,Autocuration,H,BAO_0000219,,4162,B,
,1,11388,,,,12166,,,RBL-1,CHEMBL619230,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,8,,702.0,Autocuration,H,BAO_0000219,,4163,B,
,1,167,,,,12166,,,,CHEMBL619231,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,8,,,Autocuration,H,BAO_0000357,,4164,B,
,1,167,,,,12166,,,,CHEMBL619232,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,8,,,Autocuration,H,BAO_0000357,,4165,B,
,1,13744,,,,12166,,,,CHEMBL619233,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,8,,,Expert,H,BAO_0000357,,4166,B,
,1,1630,,,,12166,,,,CHEMBL619234,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4167,B,
,1,1630,,,,12166,,,,CHEMBL619235,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,8,,,Autocuration,H,BAO_0000357,,4168,B,
,1,969,,,,12166,,,,CHEMBL619236,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,4169,B,
,1,13621,,,,12166,,,RBL-1,CHEMBL619237,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,8,,702.0,Autocuration,H,BAO_0000219,,4170,B,
,1,10089,,,,12166,,,,CHEMBL619238,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,8,,,Autocuration,H,BAO_0000357,,4171,B,
,1,10193,,,,12166,,,,CHEMBL619239,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,8,,,Expert,H,BAO_0000357,,4172,B,
,1,11966,,,,12166,,,,CHEMBL619240,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,8,,,Autocuration,H,BAO_0000357,,4173,B,
,1,12251,,,,12166,,,,CHEMBL875417,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,8,,,Autocuration,H,BAO_0000019,,4174,B,
,1,211,,,,12166,,,RBL-1,CHEMBL619241,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,8,,702.0,Autocuration,H,BAO_0000219,,4175,B,
,1,12251,,,,12166,,,,CHEMBL619242,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,8,,,Expert,H,BAO_0000019,,4176,F,
,1,12495,,,,12166,,,RBL-1,CHEMBL883796,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,8,,702.0,Autocuration,H,BAO_0000219,,4177,B,
,1,414,,,,12166,,,,CHEMBL619243,Tested for its inhibitory activity against 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4178,B,
,1,414,,,,12166,,,,CHEMBL619244,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,8,,,Autocuration,H,BAO_0000357,,4179,B,
,1,10325,,,,12166,,,,CHEMBL619245,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,8,,,Expert,H,BAO_0000019,,4180,B,
,1,11966,,,,12166,,,,CHEMBL619246,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,8,,,Expert,H,BAO_0000019,,4181,B,
,1,165,,,,12166,,,RBL-1,CHEMBL619984,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,,702.0,Expert,H,BAO_0000219,,4182,B,
,1,165,,,,12166,,,RBL-1,CHEMBL619985,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4183,B,
,1,165,,,,12166,,,RBL-1,CHEMBL619986,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,,702.0,Autocuration,H,BAO_0000219,,4184,B,
,1,165,,,,12166,,,RBL-1,CHEMBL619987,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,8,,702.0,Expert,H,BAO_0000219,,4185,B,
,1,11311,,,,12166,,,,CHEMBL619988,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,8,,,Autocuration,H,BAO_0000218,,4186,B,
,1,11311,,,,12166,,,RBL-1,CHEMBL619989,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,8,,702.0,Autocuration,H,BAO_0000219,,4187,B,
,1,11311,,,,12166,,,RBL-1,CHEMBL619990,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,8,,702.0,Autocuration,H,BAO_0000219,,4188,B,
,1,11311,,,,12166,,,,CHEMBL619991,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000219,,4189,B,
,1,11311,,,,12166,,,,CHEMBL619992,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,8,,,Autocuration,H,BAO_0000219,,4190,B,
,1,11311,,In vivo,,12166,,,,CHEMBL619993,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,8,,,Autocuration,H,BAO_0000218,,4191,B,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL619994,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4192,F,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL619995,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4193,F,
,1,11311,,,,12166,,,,CHEMBL619996,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,8,,,Autocuration,H,BAO_0000019,,4194,B,
,1,11732,,,,12166,,,,CHEMBL619997,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000019,,4195,B,
,1,11732,,,,12166,,,,CHEMBL619998,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,8,,,Expert,H,BAO_0000019,,4196,B,
,1,11087,,,,12166,,,,CHEMBL619999,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,8,,,Expert,H,BAO_0000019,,4197,B,
,1,11087,,,,12166,,,,CHEMBL620000,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,8,,,Autocuration,H,BAO_0000019,,4198,B,
,1,11087,,,,12166,,,RBL-1,CHEMBL620001,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,8,,702.0,Autocuration,H,BAO_0000219,,4199,B,
,1,11087,,,,12166,,,,CHEMBL620002,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,4200,B,
,1,496,,,,12166,,,RBL-1,CHEMBL620003,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,8,,702.0,Autocuration,H,BAO_0000219,,4201,B,
,1,13986,,,,12166,,,RBL-1,CHEMBL620004,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,8,,702.0,Expert,H,BAO_0000219,,4202,F,
,1,11520,,,,12166,,,,CHEMBL874063,Compound was evaluated for the inhibition of 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4203,B,
,1,10293,,,,12166,,,RBL-1,CHEMBL620005,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4204,B,
,1,303,,,,12166,,,RBL-1,CHEMBL620006,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,8,,702.0,Autocuration,H,BAO_0000219,,4205,B,
,1,303,,,,12166,,,RBL-1,CHEMBL620007,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,8,,702.0,Autocuration,H,BAO_0000219,,4206,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620008,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4207,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620009,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,4208,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620010,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,8,,702.0,Autocuration,H,BAO_0000219,,4209,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620011,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4210,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620677,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4211,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620678,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4212,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620679,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4213,B,
,1,9247,,,,12166,,,RBL-1,CHEMBL620680,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4214,B,
,1,11481,,,,12166,,,,CHEMBL620838,Inhibitory activity against 5-lipoxygenase at 10 uM,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000357,,4215,B,
,1,105,,,,12166,,,,CHEMBL620839,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,8,,,Autocuration,H,BAO_0000357,,4216,B,
,1,9029,,,,12166,,,,CHEMBL620840,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,8,,,Expert,H,BAO_0000357,,4217,B,
,1,1175,,,,12166,,,RBL-1,CHEMBL620841,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,8,,702.0,Expert,H,BAO_0000219,,4218,B,
,1,12118,,,,12166,,,RBL-1,CHEMBL620842,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4219,B,
,1,12118,,,,12166,,,RBL-1,CHEMBL620843,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,8,,702.0,Autocuration,H,BAO_0000219,,4220,B,
,1,12118,,,,12166,,,RBL-1,CHEMBL620844,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4221,B,
,1,9225,,,,12166,,,RBL-1,CHEMBL620845,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4222,B,
,1,9401,,,,12166,,,,CHEMBL620846,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,8,,,Autocuration,H,BAO_0000019,,4223,B,
,1,137,,,,12166,,,,CHEMBL873951,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,8,,,Autocuration,H,BAO_0000357,,4224,B,
,1,137,,,,12166,,,,CHEMBL620847,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,8,,,Autocuration,H,BAO_0000357,,4225,B,
,1,4717,,,,12166,,,RBL-1,CHEMBL620848,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,8,,702.0,Autocuration,H,BAO_0000219,,4226,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL620849,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4227,B,
,1,10501,,,,12166,,,RBL-1,CHEMBL620850,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,8,,702.0,Autocuration,H,BAO_0000219,,4228,B,
,1,10501,,,,12166,,,RBL-1,CHEMBL620851,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4229,B,
,1,10501,,,,12166,,,RBL-1,CHEMBL620852,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,8,,702.0,Autocuration,H,BAO_0000219,,4230,B,
,1,12526,,,,12166,,,RBL-1,CHEMBL875098,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,,702.0,Autocuration,H,BAO_0000219,,4231,B,
,1,14799,,,,12166,,,RBL-1,CHEMBL620853,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,4232,B,
,1,14799,,,,12166,,,,CHEMBL620854,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,8,,,Autocuration,H,BAO_0000019,,4233,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL620855,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4234,B,
,1,3595,,,,12166,,,RBL-1,CHEMBL839884,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,8,,702.0,Expert,H,BAO_0000219,,4235,B,
,1,12526,,,,12166,,,RBL-1,CHEMBL620856,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,,702.0,Autocuration,H,BAO_0000219,,4236,B,
,1,12526,,,,12166,,,RBL-1,CHEMBL620857,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,8,,702.0,Autocuration,H,BAO_0000219,,4237,B,
,1,10193,,,,12166,,,,CHEMBL620858,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,8,,,Autocuration,H,BAO_0000019,,4238,B,
,1,10193,,,,12166,,,,CHEMBL620859,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,8,,,Autocuration,H,BAO_0000019,,4239,B,
,1,10193,,,,12166,,,,CHEMBL620860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,8,,,Autocuration,H,BAO_0000019,,4240,B,
,1,10193,,,,12166,,,,CHEMBL620861,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,8,,,Autocuration,H,BAO_0000019,,4241,B,
,1,9138,,,,12166,,,,CHEMBL620862,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,8,,,Expert,H,BAO_0000357,,4242,B,
,1,9138,,,,12166,,,,CHEMBL620863,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,8,,,Autocuration,H,BAO_0000357,,4243,B,
,1,11966,,,,12166,,,,CHEMBL620864,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,8,,,Autocuration,H,BAO_0000019,,4244,B,
,1,165,,,,12166,,,RBL-1,CHEMBL620865,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4245,B,
,1,165,,,,12166,,,RBL-1,CHEMBL620866,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4246,B,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL620867,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4247,B,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL620868,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4248,B,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL620869,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4249,F,
,1,11311,,,,12166,,,,CHEMBL873952,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000019,,4250,F,
,1,11311,,,,12166,,,,CHEMBL875099,The compound was tested for inhibition of isolated 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4251,B,
,1,11311,,,,12166,,,RBL-2H3,CHEMBL620870,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,8,,663.0,Autocuration,H,BAO_0000219,,4252,F,
,1,11087,,,,12166,,,,CHEMBL618261,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,8,,,Autocuration,H,BAO_0000019,,4253,B,
,1,11087,,,,12166,,,,CHEMBL618262,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,8,,,Autocuration,H,BAO_0000019,,4254,B,
,1,11087,,,,12166,,,,CHEMBL619428,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,8,,,Autocuration,H,BAO_0000019,,4255,B,
,1,11087,,,,12166,,,,CHEMBL619429,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,8,,,Autocuration,H,BAO_0000019,,4256,B,
,1,11087,,,,12166,,,,CHEMBL619430,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,8,,,Autocuration,H,BAO_0000019,,4257,B,
,1,496,,,,12166,,,RBL-1,CHEMBL620017,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4258,B,
,1,496,,,,12166,,,RBL-1,CHEMBL620018,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4259,B,
,1,13986,,,,12166,,,RBL-1,CHEMBL620019,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4260,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620020,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4261,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620021,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,8,,702.0,Autocuration,H,BAO_0000219,,4262,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620022,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4263,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620023,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,8,,702.0,Autocuration,H,BAO_0000219,,4264,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620024,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4265,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620025,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4266,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620026,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4267,F,
,1,13986,,,,12166,,,RBL-1,CHEMBL620027,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4268,F,
,1,13986,,,,12166,,,,CHEMBL620028,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,4269,F,
,1,10193,,,,12166,,,,CHEMBL620029,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4270,B,
,1,9295,,,,12166,,,,CHEMBL620030,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,8,,,Autocuration,H,BAO_0000357,,4271,B,
,1,4717,,,,12166,,,RBL-1,CHEMBL875415,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,8,,702.0,Autocuration,H,BAO_0000219,,4272,B,
,1,4717,,,,12166,,,RBL-1,CHEMBL618256,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,8,,702.0,Autocuration,H,BAO_0000219,,4273,B,
,1,11854,,,,12166,,,RBL-1,CHEMBL618257,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,8,,702.0,Autocuration,H,BAO_0000219,,4274,B,
,1,11854,,,,12166,,,RBL-1,CHEMBL618258,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4275,B,
,1,11854,,,,12166,,,RBL-1,CHEMBL618259,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4276,B,
,1,10193,,,,12166,,,,CHEMBL618260,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,8,,,Autocuration,H,BAO_0000019,,4277,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL618215,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4278,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL618390,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4279,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL618391,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4280,B,
,1,9295,,,,12166,,,RBL-1,CHEMBL618392,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4281,B,
,1,165,,,,12166,,,RBL-1,CHEMBL618393,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,8,,702.0,Autocuration,H,BAO_0000219,,4282,B,
,1,11311,,,,12166,,,,CHEMBL618394,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,8,,,Autocuration,H,BAO_0000219,,4283,B,
,1,10489,,,,12166,,,RBL-1,CHEMBL618395,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Homo sapiens,8,9606.0,702.0,Expert,H,BAO_0000219,,4284,B,
,1,10489,,,,12166,,,RBL-1,CHEMBL618396,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,4285,B,
,1,10489,,,,12166,,,RBL-1,CHEMBL858253,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Rattus norvegicus,9,10116.0,702.0,Expert,D,BAO_0000219,,4286,B,
,1,14799,,,,12166,,,,CHEMBL618397,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Rattus norvegicus,9,10116.0,,Autocuration,D,BAO_0000019,,4287,B,
,1,9295,,,,12054,,,,CHEMBL618398,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Glycine max,8,3847.0,,Autocuration,H,BAO_0000357,,4288,B,
,1,16811,,,,22226,,,,CHEMBL618399,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,0,,,Autocuration,U,BAO_0000019,,4289,B,
,1,168,,,,55,,,,CHEMBL618400,In vitro inhibition of 5-Lipoxygenase; Inactive.,,8,,,Expert,H,BAO_0000357,,4290,B,
,1,6309,,,,55,,,,CHEMBL618401,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,8,,,Autocuration,H,BAO_0000357,,4291,B,
,1,6309,,,,55,,,,CHEMBL618402,Inhibitory concentration against 5-lipoxygenase; No inhibition,,8,,,Autocuration,H,BAO_0000357,,4292,B,
,1,3092,,,,55,,,RBL-1,CHEMBL876400,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,8,,702.0,Autocuration,H,BAO_0000219,,4293,B,
,1,168,,,,55,,,,CHEMBL618403,Inhibitory activity against 5-lipoxygenase.,,8,,,Expert,H,BAO_0000357,,4294,B,
,1,168,,,,55,,,,CHEMBL618404,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,8,,,Autocuration,H,BAO_0000357,,4295,B,
,1,168,,,,55,,,,CHEMBL618405,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,8,,,Autocuration,H,BAO_0000357,,4296,B,
,1,168,,,,55,,,,CHEMBL618406,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,8,,,Autocuration,H,BAO_0000357,,4297,B,
,1,12338,,,,55,,,,CHEMBL618407,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,8,,,Expert,H,BAO_0000019,,4298,F,
,1,4501,,,,55,,,,CHEMBL618408,Tested for the inhibitory activity against 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4299,B,
,1,1132,,,,55,,,,CHEMBL618409,Compound was tested for its inhibitory activity against 5-lipoxygenase,,8,,,Autocuration,H,BAO_0000357,,4300,B,
,1,2117,,,,55,,,,CHEMBL618410,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,8,,,Autocuration,H,BAO_0000357,,4301,B,
,1,168,,,,55,,,,CHEMBL618411,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,8,,,Autocuration,H,BAO_0000357,,4302,B,
,1,168,,,,55,,,,CHEMBL618412,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,8,,,Autocuration,H,BAO_0000357,,4303,B,
,1,13575,,,,12166,,,RBL-1,CHEMBL618413,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,8,,702.0,Autocuration,H,BAO_0000219,,4304,B,
,1,11089,,,,12166,,,,CHEMBL618414,,,8,,,Autocuration,H,BAO_0000357,,4305,B,
,1,216,,,,10102,,,,CHEMBL618415,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,8,,,Autocuration,H,BAO_0000357,,4306,B,
,1,13165,,,,10102,,,,CHEMBL618416,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,8,,,Autocuration,H,BAO_0000019,,4307,B,
,1,3278,,,,10102,,,,CHEMBL876401,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,8,,,Autocuration,H,BAO_0000357,,4308,B,
,1,3278,,,,10102,,,,CHEMBL618417,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,8,,,Expert,H,BAO_0000357,,4309,B,
,1,11966,,,,10102,,,,CHEMBL618418,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,8,,,Autocuration,H,BAO_0000357,,4310,B,
,1,175,,,,10102,,,,CHEMBL618419,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,8,,,Autocuration,H,BAO_0000357,,4311,B,
,1,175,,,,10102,,,,CHEMBL618420,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,8,,,Autocuration,H,BAO_0000357,,4312,B,
,1,13449,,,,10102,,,,CHEMBL618421,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,8,,,Autocuration,H,BAO_0000357,,4313,B,
,1,12014,,,,11238,,,,CHEMBL618422,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,8,,,Autocuration,H,BAO_0000019,,4314,B,
,1,12014,,,,11238,,,,CHEMBL618423,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,8,,,Autocuration,H,BAO_0000019,,4315,B,
,1,12014,,,,11238,,,,CHEMBL618424,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,8,,,Autocuration,H,BAO_0000019,,4316,B,
,1,99,,,,100284,,,,CHEMBL618425,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,2,,,Intermediate,S,BAO_0000220,,4317,B,
,1,4349,,,,22226,,,,CHEMBL618426,The dark toxicity against 543 human galactophore carcinoma cells,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4318,F,
,1,4071,,,,80623,,,Panel (56 tumour cell lines),CHEMBL618427,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Homo sapiens,1,9606.0,390.0,Expert,N,BAO_0000219,,4319,F,
,1,17589,,,,80008,,,5637,CHEMBL618428,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Homo sapiens,1,9606.0,345.0,Expert,N,BAO_0000219,,4320,F,
,1,15002,,,,80008,,,5637,CHEMBL618429,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Homo sapiens,1,9606.0,345.0,Intermediate,N,BAO_0000219,,4321,F,
,1,13958,,,,80008,,,5637,CHEMBL618430,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Homo sapiens,1,9606.0,345.0,Intermediate,N,BAO_0000219,,4322,F,
,1,17589,,,,80008,,,5637,CHEMBL618431,Growth inhibition against human 5637 cell lines,Homo sapiens,1,9606.0,345.0,Expert,N,BAO_0000219,,4323,F,
,1,16748,,,,80008,,,5637,CHEMBL883799,Antitumor activity against human bladder carcinoma 5637 cells.,Homo sapiens,1,9606.0,345.0,Expert,N,BAO_0000219,,4324,F,
,1,16747,,,,80008,,,5637,CHEMBL618432,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens,1,9606.0,345.0,Intermediate,N,BAO_0000219,,4325,F,
,1,16747,,,,80008,,,5637,CHEMBL618433,Antitumor activity against human bladder carcinoma 5637 cells,Homo sapiens,1,9606.0,345.0,Intermediate,N,BAO_0000219,,4326,F,
,1,15285,,,,10443,,,,CHEMBL618434,In vitro inhibition of bovine trypsin(Trp).,Bos taurus,9,9913.0,,Expert,D,BAO_0000357,,4327,B,
,1,3726,,,,240,,,CV-1,CHEMBL618435,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Cercopithecidae,8,9527.0,407.0,Expert,H,BAO_0000219,,4328,B,
,1,5033,,,,10577,,,,CHEMBL876402,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,8,,,Autocuration,H,BAO_0000357,,4329,B,
,1,11756,,,,104698,,,,CHEMBL618436,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,6,,,Autocuration,H,BAO_0000019,,4330,F,
,1,11953,,In vivo,,22226,,,,CHEMBL618437,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,0,,,Autocuration,U,BAO_0000218,,4331,F,
,1,5033,,,,20033,,,,CHEMBL618438,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Cavia porcellus,9,10141.0,,Intermediate,D,BAO_0000357,,4332,B,
,1,11347,,,,17045,,Microsomes,,CHEMBL883800,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus,8,10116.0,,Expert,H,BAO_0000251,,4333,A,
,1,11347,,,,17045,,Microsomes,,CHEMBL618439,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Rattus norvegicus,8,10116.0,,Expert,H,BAO_0000251,,4334,A,
,1,1229,,,,22226,,,,CHEMBL618440,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,4335,F,
,1,1229,,,,22226,,,,CHEMBL618441,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,4336,F,
,1,17588,,,,11938,,,,CHEMBL618442,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Trypanosoma brucei,8,5691.0,,Expert,H,BAO_0000019,,4337,B,
,1,17588,,,,11938,,,,CHEMBL618443,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Trypanosoma brucei,8,5691.0,,Autocuration,H,BAO_0000019,,4338,B,
,1,17588,,,,11938,,,,CHEMBL619158,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Ovis aries,8,9940.0,,Expert,H,BAO_0000019,,4339,B,
,1,17588,,,,11938,,,,CHEMBL620974,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Ovis aries,8,9940.0,,Autocuration,H,BAO_0000019,,4340,B,
,1,16485,,,,11938,,,,CHEMBL620975,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,8,,,Autocuration,H,BAO_0000357,,4341,B,
,1,4337,,,,22226,,,,CHEMBL620976,Average inhibitory concentration against 60 human cell lines was reported,Homo sapiens,0,9606.0,,Intermediate,U,BAO_0000019,,4342,F,
,1,4112,,,,22226,,,,CHEMBL620977,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Homo sapiens,0,9606.0,,Expert,U,BAO_0000019,,4343,F,
,1,16160,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620978,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Homo sapiens,1,9606.0,542.0,Intermediate,N,BAO_0000219,,4344,F,
,1,16160,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620979,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Homo sapiens,1,9606.0,542.0,Intermediate,N,BAO_0000219,,4345,F,
,1,17376,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620980,In vitro mean growth inhibitory activity against 60-cell panel,,1,,542.0,Expert,N,BAO_0000219,,4346,F,
,1,17376,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620981,In vitro mean growth lethal concentration against 60-cell panel,,1,,542.0,Expert,N,BAO_0000219,,4347,F,
,1,17376,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620982,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,1,,542.0,Expert,N,BAO_0000219,,4348,F,
,1,17376,,,,80315,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620983,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,1,,542.0,Expert,N,BAO_0000219,,4349,F,
,1,3241,,,,104775,,,,CHEMBL620984,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4,,,Autocuration,H,BAO_0000019,,4350,F,
,1,3241,,,,104775,,,,CHEMBL620985,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4,,,Autocuration,H,BAO_0000019,,4351,F,
,1,3725,,,,275,,,,CHEMBL620986,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,8,,,Expert,H,BAO_0000357,,4352,B,
,1,10805,,,,50425,,,,CHEMBL620987,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Plasmodium falciparum,1,5833.0,,Expert,N,BAO_0000218,,4353,F,
,1,10805,,,,50425,,,,CHEMBL620988,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Plasmodium falciparum,1,5833.0,,Expert,N,BAO_0000218,,4354,F,
,1,10805,,,,50425,,,,CHEMBL620989,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,1,5833.0,,Expert,N,BAO_0000218,,4355,F,
,1,10805,,,,50425,,,,CHEMBL620990,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,1,5833.0,,Expert,N,BAO_0000218,,4356,F,
,1,10805,,,,50425,,,,CHEMBL620991,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Plasmodium falciparum,1,5833.0,,Intermediate,N,BAO_0000218,,4357,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL620992,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4358,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL620993,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4359,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL620994,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4360,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL620995,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4361,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL620996,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4362,F,
,1,10144,,,,80628,,,6C3HED,CHEMBL875581,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4363,F,
,1,10685,,In vivo,,22224,,,,CHEMBL620997,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4364,F,
,1,10685,,In vivo,,22224,,,,CHEMBL620998,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4365,F,
,1,10685,,In vivo,,22224,,,,CHEMBL620999,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4366,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621000,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4367,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621001,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4368,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621002,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4369,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621003,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4370,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621004,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4371,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621005,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4372,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621006,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4373,F,
,1,10685,,In vivo,,22224,,,,CHEMBL621007,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4374,F,
,1,10144,,,,22224,,,,CHEMBL621008,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4375,F,
,1,10144,,,,22224,,,,CHEMBL621009,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4376,F,
,1,10144,,,,22224,,,,CHEMBL857705,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4377,F,
,1,10144,,,,22224,,,,CHEMBL619828,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4378,F,
,1,10685,,,,22224,,,,CHEMBL619829,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4379,F,
,1,10685,,,,22224,,,,CHEMBL619830,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4380,F,
,1,10685,,,,22224,,,,CHEMBL619831,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4381,F,
,1,10685,,,,22224,,,,CHEMBL619832,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4382,F,
,1,10685,,,,22224,,,,CHEMBL619833,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4383,A,
,1,10685,,,,22224,,,,CHEMBL619834,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4384,A,
,1,10685,,,,22224,,,,CHEMBL619835,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4385,A,
,1,10685,,,,22224,,,,CHEMBL619836,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000218,,4386,A,
,1,8831,,,,80628,,,6C3HED,CHEMBL619837,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4387,F,
,1,11704,,In vivo,,22224,,,,CHEMBL619838,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,0,,,Autocuration,U,BAO_0000218,,4388,F,
,1,11704,,,,50594,,,,CHEMBL619839,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4389,A,
,1,10685,,In vivo,,80628,,,6C3HED,CHEMBL619840,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4390,F,
,1,10685,,In vivo,,80628,,,6C3HED,CHEMBL619841,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4391,F,
,1,11368,,,,80628,,,6C3HED,CHEMBL857704,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Mus musculus,1,10090.0,850.0,Expert,N,BAO_0000218,,4392,F,
,1,11368,,,,80628,,,6C3HED,CHEMBL619842,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Mus musculus,1,10090.0,850.0,Intermediate,N,BAO_0000218,,4393,F,
,1,11368,,,,80628,,,6C3HED,CHEMBL619843,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Mus musculus,1,10090.0,850.0,Expert,N,BAO_0000218,,4394,F,
,1,17763,,,,22226,,,,CHEMBL619844,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Staphylococcus aureus,0,1280.0,,Autocuration,U,BAO_0000019,,4395,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL857855,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4396,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619845,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4397,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619846,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4398,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619847,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4399,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL619848,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4400,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620893,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4401,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620894,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4402,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620895,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4403,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620896,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4404,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620897,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4405,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620898,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4406,B,
Liver,1,7411,,,,22226,,Microsomes,,CHEMBL620899,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000251,2107.0,4407,B,
Plasma,1,347,,In vivo,,22224,,,,CHEMBL620900,The apparent total plasma clearance in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4408,A,
,1,3341,,In vivo,,22224,,,,CHEMBL620901,Compound was evaluated for Hepatic clearance in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4409,A,
,1,17853,,In vivo,,22224,,,,CHEMBL620902,Lower clearance in monkey (i.v.) at 0.5 mpk,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4410,A,
,1,4514,,In vivo,,22224,,,,CHEMBL620903,Plasma clearance in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4411,A,
,1,6062,,In vivo,,22224,,,,CHEMBL620904,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4412,A,
,1,6821,,In vivo,,22224,,,,CHEMBL620905,Plasma clearance of compound was determined in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4413,A,
,1,6057,,In vivo,,22224,,,,CHEMBL620906,Plasma clearance was calculated in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4414,A,
,1,5145,,In vivo,,22224,,,,CHEMBL875420,Plasma clearance in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4415,A,
,1,6641,,In vivo,,22224,,,,CHEMBL620907,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4416,A,
,1,5472,,In vivo,,22224,,,,CHEMBL620908,Plasma clearance was evaluated in rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4417,A,
,1,4257,,In vivo,,22224,,,,CHEMBL620909,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4418,A,
,1,5546,,In vivo,,22224,,,,CHEMBL620910,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4419,A,
,1,5334,,In vivo,,22224,,,,CHEMBL620911,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4420,A,
,1,5334,,In vivo,,22224,,,,CHEMBL620912,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4421,A,
,1,17509,,In vivo,,22224,,,,CHEMBL620913,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4422,A,
,1,6535,,In vivo,,22224,,,,CHEMBL620914,Cmax in monkey after administration of 1 mg/kg iv,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4423,A,
,1,5668,,In vivo,,22224,,,,CHEMBL620915,Cmax was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4424,A,
,1,5922,,In vivo,,22224,,,,CHEMBL620916,Cmax in cynomolgus monkey by iv administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4425,A,
,1,5922,,In vivo,,22224,,,,CHEMBL620917,Cmax in cynomolgus monkey by po administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4426,A,
,1,6078,,In vivo,,22224,,,,CHEMBL620918,Cmax value evaluated in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4427,A,
,1,2661,,In vivo,,22224,,,,CHEMBL620919,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4428,A,
Plasma,1,3249,,In vivo,,22224,,,,CHEMBL620920,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4429,A,
Plasma,1,3249,,In vivo,,22224,,,,CHEMBL620921,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4430,A,
Plasma,1,5553,,In vivo,,22224,,,,CHEMBL620922,Maximal plasma concentration in squirrel monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4431,A,
,1,1916,,In vivo,,22224,,,,CHEMBL620923,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4432,A,
Plasma,1,6227,,In vivo,,22224,,,,CHEMBL620924,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4433,A,
,1,4809,,In vivo,,22224,,,,CHEMBL620925,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4434,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620926,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4435,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620927,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4436,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620928,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4437,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620929,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4438,A,
Plasma,1,6221,,In vivo,,22224,,,,CHEMBL620930,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4439,A,
,1,167,,,,22224,,,,CHEMBL620931,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4440,A,
,1,167,,,,22224,,,,CHEMBL620932,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4441,A,
,1,4257,,In vivo,,22224,,,,CHEMBL620933,Absolute bioavailability was evaluated in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4442,A,
,1,6221,,In vivo,,22224,,,,CHEMBL620934,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4443,A,
,1,17667,,In vivo,,22224,,,,CHEMBL620935,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4444,A,
,1,17267,,In vivo,,22224,,,,CHEMBL620936,Bioavailability of compound was determined in rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4445,A,
,1,4256,,In vivo,,22224,,,,CHEMBL620937,Bioavailability determined after oral administration in marmoset,marmosets,0,38020.0,,Autocuration,U,BAO_0000218,,4446,A,
,1,4256,,In vivo,,22224,,,,CHEMBL620938,Oral bioavailability in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4447,A,
,1,17853,,In vivo,,22224,,,,CHEMBL620939,Bioavailability in monkey (p.o.) at 2.0 mpk,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4448,A,
,1,16365,,In vivo,,22224,,,,CHEMBL620940,Bioavailability was evaluated after oral administration in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4449,A,
,1,1916,,In vivo,,22224,,,,CHEMBL620941,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4450,A,
,1,5334,,In vivo,,22224,,,,CHEMBL620942,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4451,A,
,1,5334,,In vivo,,22224,,,,CHEMBL620943,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4452,A,
,1,17592,,In vivo,,22224,,,,CHEMBL620944,Bioavailability of the compound was determined in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4453,A,
,1,1399,,In vivo,,22224,,,,CHEMBL620945,Bioavailability in squirrel monkey (dose 5 mg/kg),Saimiri sciureus,0,9521.0,,Autocuration,U,BAO_0000218,,4454,A,
,1,4809,,In vivo,,22224,,,,CHEMBL620946,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4455,A,
,1,3341,,In vivo,,22224,,,,CHEMBL620947,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4456,A,
,1,64,,In vivo,,22224,,,,CHEMBL620948,Compound was tested for bioavailability in squirrel monkey,Saimiri sciureus,0,9521.0,,Autocuration,U,BAO_0000218,,4457,A,
,1,5005,,In vivo,,22224,,,,CHEMBL620949,Oral bioavailability in Rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4458,A,
,1,5005,,In vivo,,22224,,,,CHEMBL620950,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4459,A,
,1,5237,,In vivo,,22224,,,,CHEMBL620951,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4460,A,
,1,5237,,In vivo,,22224,,,,CHEMBL620952,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4461,A,
,1,5302,,In vivo,,22224,,,,CHEMBL875421,Oral bioavailability in monkey (dose 5 mg/kg),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4462,A,
,1,17667,,In vivo,,22224,,,,CHEMBL620953,Oral bioavailability of compound at 5 mg/kg in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4463,A,
,1,6161,,In vivo,,50588,,,,CHEMBL873491,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4464,A,
,1,6161,,In vivo,,50588,,,,CHEMBL620954,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4465,A,
Plasma,1,3854,,,,50588,,,,CHEMBL620955,Plasma half life determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4466,A,
Plasma,1,993,,,,50588,,,,CHEMBL618097,Plasma half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4467,A,
Plasma,1,4514,,,,50588,,,,CHEMBL618268,Plasma half-life in Beagle dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4468,A,
Plasma,1,5334,,In vivo,,50588,,,,CHEMBL618269,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4469,A,
Plasma,1,5334,,In vivo,,50588,,,,CHEMBL618270,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4470,A,
,1,1466,,In vivo,,50588,,,,CHEMBL618271,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4471,A,
,1,1466,,In vivo,,50588,,,,CHEMBL873493,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4472,A,
,1,5313,,,,50588,,,,CHEMBL621031,Tested for the half life period in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4473,A,
,1,5313,,In vivo,,50588,,,,CHEMBL621032,Tested for the half life period in dog at dosage of 10 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4474,A,
,1,3880,,,,50588,,,,CHEMBL621033,The compound was tested for half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4475,A,
Plasma,1,3639,,,,50588,,,,CHEMBL621034,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4476,A,
,1,3880,,,,50588,,,,CHEMBL621035,The half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4477,A,
Plasma,1,3918,,,,50588,,,,CHEMBL621036,The plasma half-life in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4478,A,
Plasma,1,16452,,,,50588,,,,CHEMBL621037,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,4479,A,
,1,17796,,,,50588,,,,CHEMBL619812,Half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4480,A,
,1,5983,,In vivo,,50588,,,,CHEMBL619813,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4481,A,
,1,1466,,In vivo,,50588,,,,CHEMBL873335,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4482,A,
,1,16456,,In vivo,,50588,,,,CHEMBL619814,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,4483,A,
,1,6113,,In vivo,,50506,,,,CHEMBL619815,Cmax in ferrets after 30 mg/kg oral dose,Mustela putorius furo,1,9669.0,,Expert,N,BAO_0000218,,4484,A,
,1,6113,,In vivo,,50506,,,,CHEMBL619816,Emesis in ferrets at 30 mg/kg oral dose,Mustela putorius furo,1,9669.0,,Expert,N,BAO_0000218,,4485,F,
,1,17796,,In vivo,,22224,,,,CHEMBL619817,Bioavailability in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4486,A,
,1,17796,,In vivo,,100710,,,,CHEMBL619818,Volume of distribution in cynomolgus,Macaca fascicularis,1,9541.0,,Intermediate,N,BAO_0000218,,4487,A,
Plasma,1,5308,,,,22224,,,,CHEMBL619819,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,1969.0,4488,A,
,1,4877,,,,22224,,,,CHEMBL619820,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4489,A,
,1,4876,,,,22224,,,,CHEMBL875419,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4490,A,
Plasma,1,4878,,In vivo,,22224,,,,CHEMBL619821,AUC in guinea pig after 3mg/kg oral dose,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,1969.0,4491,A,
,1,5308,,In vivo,,22224,,,,CHEMBL619822,Bioavailability in guinea pig was tested,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4492,A,
,1,4877,,In vivo,,22224,,,,CHEMBL619823,Tested for oral bioavailability in guinea pig at 5 mg/kg,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4493,A,
,1,4876,,In vivo,,22224,,,,CHEMBL619824,Tested for the oral bioavailability of the compound,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4494,A,
,1,4876,,In vivo,,22224,,,,CHEMBL619825,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4495,A,
,1,5308,,In vivo,,22224,,,,CHEMBL619826,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4496,A,
Lung,1,4877,,In vivo,,22224,,,,CHEMBL619827,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,2048.0,4497,A,
,1,4878,,In vivo,,22224,,,,CHEMBL618167,Cmax in guinea pig after 3mg/kg oral dose,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4498,A,
Blood,1,5689,,,,22224,,,,CHEMBL618168,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,178.0,4499,A,
Brain,1,5689,,,,22224,,,,CHEMBL618169,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,955.0,4500,A,
,1,5689,,,,22224,,,,CHEMBL618170,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,4501,A,
Intestine,1,5689,,,,22224,,,,CHEMBL618171,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,160.0,4502,A,
Kidney,1,5689,,,,22224,,,,CHEMBL618172,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,2113.0,4503,A,
Liver,1,5689,,,,22224,,,,CHEMBL618173,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,2107.0,4504,A,
,1,5689,,,,22224,,,,CHEMBL618174,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,4505,A,
Spleen,1,5689,,,,22224,,,,CHEMBL875408,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,2106.0,4506,A,
,1,14465,,In vivo,,22224,,,,CHEMBL839827,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4507,A,
,1,5689,,,,22224,,,,CHEMBL618175,Partition coefficient was measured as -log (counts per min ),Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,4508,A,
,1,611,,In vivo,,22224,,,,CHEMBL618176,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4509,A,
,1,611,,In vivo,,22224,,,,CHEMBL618177,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4510,A,
,1,14465,,In vivo,,22224,,,,CHEMBL618178,Elimination T1/2 in Guinea pig (PO dose),Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4511,A,
,1,4876,,In vivo,,22224,,,,CHEMBL618179,"Tested for the half life period of the compound, intravenously",Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4512,A,
,1,5689,,,,22224,,,,CHEMBL873489,Half-life was measured,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,4513,A,
,1,7515,,,,22224,,,,CHEMBL618180,The time required for onset of inotropy after addition of a single dose of delta F75,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000019,,4514,A,
,1,17667,,In vivo,,22224,,,,CHEMBL618181,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4515,A,
,1,17667,,In vivo,,22224,,,,CHEMBL618182,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Cavia porcellus,0,10141.0,,Autocuration,U,BAO_0000218,,4516,A,
,1,4727,,In vivo,,22224,,,,CHEMBL618183,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4517,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618184,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4518,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618185,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4519,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618186,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4520,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618187,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4521,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618188,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4522,A,
,1,10107,,In vivo,,50594,,,,CHEMBL875409,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4523,A,
,1,10107,,In vivo,,50594,,,,CHEMBL618189,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4524,A,
Blood,1,3655,,In vivo,,50594,,,,CHEMBL618190,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4525,A,
Blood,1,3655,,In vivo,,50594,,,,CHEMBL618191,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4526,A,
Blood,1,3655,,In vivo,,50594,,,,CHEMBL618192,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4527,A,
Bone,1,3655,,In vivo,,50594,,,,CHEMBL618193,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,4528,A,
Bone,1,3655,,In vivo,,50594,,,,CHEMBL618194,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,4529,A,
Bone,1,3655,,In vivo,,50594,,,,CHEMBL618195,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,4530,A,
Brain,1,3655,,In vivo,,50594,,,,CHEMBL618196,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4531,A,
Brain,1,3655,,In vivo,,50594,,,,CHEMBL618197,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4532,A,
Brain,1,3655,,In vivo,,50594,,,,CHEMBL618198,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4533,A,
Heart,1,3655,,In vivo,,50594,,,,CHEMBL618199,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,4534,A,
Heart,1,3655,,In vivo,,50594,,,,CHEMBL618200,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,4535,A,
Heart,1,3655,,In vivo,,50594,,,,CHEMBL618201,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,4536,A,
Intestine,1,3655,,In vivo,,50594,,,,CHEMBL618202,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,4537,A,
Intestine,1,3655,,In vivo,,50594,,,,CHEMBL618203,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,4538,A,
Intestine,1,3655,,In vivo,,50594,,,,CHEMBL618204,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,4539,A,
Kidney,1,3655,,In vivo,,50594,,,,CHEMBL618205,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4540,A,
Kidney,1,3655,,In vivo,,50594,,,,CHEMBL618206,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4541,A,
Kidney,1,3655,,In vivo,,50594,,,,CHEMBL618207,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4542,A,
Liver,1,3655,,In vivo,,50594,,,,CHEMBL618208,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4543,A,
Liver,1,3655,,In vivo,,50594,,,,CHEMBL618932,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4544,A,
Liver,1,3655,,In vivo,,50594,,,,CHEMBL618933,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4545,A,
Lung,1,3655,,In vivo,,50594,,,,CHEMBL618934,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,4546,A,
Lung,1,3655,,In vivo,,50594,,,,CHEMBL618935,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,4547,A,
Lung,1,3655,,In vivo,,50594,,,,CHEMBL618936,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,4548,A,
Muscle tissue,1,3655,,In vivo,,50594,,,,CHEMBL618937,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,4549,A,
Muscle tissue,1,3655,,In vivo,,50594,,,,CHEMBL618938,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,4550,A,
Muscle tissue,1,3655,,In vivo,,50594,,,,CHEMBL619104,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,4551,A,
Spleen,1,3655,,In vivo,,50594,,,,CHEMBL619105,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,4552,A,
Spleen,1,3655,,In vivo,,50594,,,,CHEMBL619106,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,4553,A,
Spleen,1,3655,,In vivo,,50594,,,,CHEMBL619107,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,4554,A,
Stomach,1,3655,,In vivo,,50594,,,,CHEMBL875410,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,4555,A,
Stomach,1,3655,,In vivo,,50594,,,,CHEMBL619108,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,4556,A,
Stomach,1,3655,,In vivo,,50594,,,,CHEMBL619109,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,4557,A,
,1,16597,,In vivo,,50594,,,,CHEMBL619110,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4558,A,
,1,16597,,In vivo,,50594,,,,CHEMBL619111,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4559,F,
,1,16597,,In vivo,,50594,,,,CHEMBL619112,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4560,A,
,1,16597,,In vivo,,50594,,,,CHEMBL619113,MRT value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4561,A,
,1,17764,,In vivo,,50594,,,,CHEMBL619114,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4562,A,
,1,17764,,In vivo,,50594,,,,CHEMBL619115,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4563,F,
,1,3830,,,,81034,,,A2780,CHEMBL619116,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4564,F,
,1,3829,,,,81034,,,A2780,CHEMBL619117,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4565,F,
,1,2040,,,,81034,,,A2780,CHEMBL619118,Compound was evaluated for cytotoxicity against A2780 cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4566,F,
,1,15684,,,,81034,,,A2780,CHEMBL619119,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4567,F,
,1,15684,,,,81034,,,A2780,CHEMBL619120,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4568,F,
,1,15684,,,,81034,,,A2780,CHEMBL619121,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4569,F,
,1,15684,,,,81034,,,A2780,CHEMBL619122,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4570,F,
,1,15684,,,,81034,,,A2780,CHEMBL619123,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4571,F,
,1,15684,,,,81034,,,A2780,CHEMBL619124,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4572,F,
,1,2859,,,,81034,,,A2780,CHEMBL619125,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4573,F,
,1,5618,,,,81034,,,A2780,CHEMBL875411,In vitro inhibitory activity against human tumor cell line A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4574,F,
,1,15684,,,,81034,,,A2780,CHEMBL619126,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4575,F,
,1,15684,,,,81034,,,A2780,CHEMBL619127,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4576,F,
,1,15684,,,,81034,,,A2780,CHEMBL619128,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4577,F,
,1,15684,,,,81034,,,A2780,CHEMBL619129,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4578,F,
,1,2113,,,,81034,,,A2780,CHEMBL619130,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4579,F,
,1,2113,,,,81034,,,A2780,CHEMBL619131,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4580,F,
,1,16745,,,,81034,,,A2780,CHEMBL619132,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4581,F,
,1,16597,,,,81034,,,A2780,CHEMBL619133,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000218,,4582,F,
,1,15684,,,,81034,,,A2780,CHEMBL619134,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4583,F,
,1,15684,,,,81034,,,A2780,CHEMBL619135,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4584,F,
,1,2040,,,,81034,,,A2780,CHEMBL619136,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4585,F,
,1,2040,,,,81034,,,A2780,CHEMBL619137,Relative resistance factor in A2780 cisplatin-resistant line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4586,F,
,1,16165,,,,81034,,,A2780,CHEMBL883713,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4587,F,
,1,16165,,,,81034,,,A2780,CHEMBL875412,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4588,F,
,1,16597,,,,81034,,,A2780,CHEMBL619138,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000218,,4589,F,
,1,16597,,,,81034,,,A2780,CHEMBL619262,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000218,,4590,F,
,1,3992,,,,81034,,,A2780,CHEMBL619139,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4591,F,
,1,10553,,,,81034,,,A2780,CHEMBL619140,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4592,F,
,1,15608,,,,81034,,,A2780,CHEMBL619141,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4593,F,
,1,15608,,,,81034,,,A2780,CHEMBL619142,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4594,F,
,1,15608,,,,81034,,,A2780,CHEMBL619143,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4595,F,
,1,15608,,,,81034,,,A2780,CHEMBL619144,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4596,F,
,1,15608,,,,81034,,,A2780,CHEMBL619145,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4597,F,
,1,15608,,,,81034,,,A2780,CHEMBL619146,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4598,F,
,1,15569,,,,81034,,,A2780,CHEMBL619147,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4599,F,
,1,17420,,,,81034,,,A2780,CHEMBL619148,Antiproliferative effect of compound on A2780/DX cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4600,F,
,1,17420,,,,81034,,,A2780,CHEMBL619149,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4601,F,
,1,15099,,,,81034,,,A2780,CHEMBL619150,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4602,F,
,1,15099,,,,81034,,,A2780,CHEMBL619151,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4603,F,
,1,17672,,,,81034,,,A2780,CHEMBL883794,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4604,F,
,1,17672,,,,81034,,,A2780,CHEMBL619152,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4605,F,
,1,17270,,,,81034,,,A2780,CHEMBL619153,In vitro cytotoxicity against A2780ADR cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4606,F,
,1,17270,,,,81034,,,A2780,CHEMBL619154,In vitro cytotoxicity against A2780CIS cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4607,F,
,1,5574,,,,81034,,,A2780,CHEMBL619155,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4608,F,
,1,2113,,,,81034,,,A2780,CHEMBL619156,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4609,F,
,1,16913,,,,81034,,,A2780,CHEMBL619157,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4610,F,
,1,16913,,,,81034,,,A2780,CHEMBL619797,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4611,F,
,1,17839,,In vivo,,22224,,,,CHEMBL619798,Oral bioavailability of compound in rhesus macaques,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4612,A,
,1,6821,,In vivo,,22224,,,,CHEMBL619799,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4613,A,
,1,6078,,In vivo,,22224,,,,CHEMBL619800,Oral bioavailability evaluated in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4614,A,
,1,6535,,In vivo,,22224,,,,CHEMBL619801,Oral bioavailability in monkey (dose 1 mg/kg p.o.),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4615,A,
,1,4449,,In vivo,,22224,,,,CHEMBL619802,Oral bioavailability in Rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4616,A,
,1,6057,,In vivo,,22224,,,,CHEMBL619803,Oral bioavailability was calculated in rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4617,A,
,1,5922,,In vivo,,22224,,,,CHEMBL619965,Oral bioavailability in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4618,A,
,1,5940,,In vivo,,22224,,,,CHEMBL619966,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4619,A,
,1,6265,,In vivo,,22224,,,,CHEMBL619967,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4620,A,
,1,6265,,In vivo,,22224,,,,CHEMBL620073,Oral bioavailability in monkey (dose 1 mg/kg),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4621,A,
,1,6265,,In vivo,,22224,,,,CHEMBL620074,Oral bioavailability in monkey (dose 5 mg/kg),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4622,A,
,1,5940,,In vivo,,22224,,,,CHEMBL620075,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4623,A,
,1,5940,,In vivo,,22224,,,,CHEMBL620076,Oral bioavailability in monkey,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4624,A,
,1,4514,,In vivo,,22224,,,,CHEMBL620077,Oral bioavailability in rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4625,A,
,1,5546,,In vivo,,22224,,,,CHEMBL620078,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4626,A,
,1,5553,,In vivo,,22224,,,,CHEMBL620079,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Saimiri sciureus,0,9521.0,,Autocuration,U,BAO_0000218,,4627,A,
,1,6641,,In vivo,,22224,,,,CHEMBL620080,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4628,A,
,1,5472,,In vivo,,22224,,,,CHEMBL620081,Oral bioavailability in Rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4629,A,
,1,5668,,In vivo,,22224,,,,CHEMBL620082,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4630,A,
,1,5711,,In vivo,,22224,,,,CHEMBL620083,Oral bioavailability in monkey at 10 mg/kg of the compound,monkey,0,9443.0,,Autocuration,U,BAO_0000218,,4631,A,
,1,5145,,In vivo,,22224,,,,CHEMBL620084,Bioavailability in Rhesus monkey,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4632,A,
,1,3443,,,,22224,,,,CHEMBL620085,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4633,A,
,1,3443,,,,22224,,,,CHEMBL874595,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4634,A,
,1,3249,,In vivo,,22224,,,,CHEMBL873352,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4635,A,
,1,3249,,In vivo,,22224,,,,CHEMBL620086,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4636,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620087,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4637,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620088,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4638,A,
,1,5355,,In vivo,,22224,,,,CHEMBL620089,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4639,A,
,1,4809,,In vivo,,22224,,,,CHEMBL620090,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4640,A,
,1,4809,,In vivo,,22224,,,,CHEMBL620091,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4641,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620092,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000251,,4642,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620093,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000251,,4643,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620094,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000251,,4644,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620095,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000251,,4645,A,
,1,3443,,In vivo,,22224,,,,CHEMBL620096,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4646,A,
,1,3443,,In vivo,,22224,,,,CHEMBL620097,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4647,A,
,1,11271,,,,22224,,,,CHEMBL620098,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4648,A,
,1,3443,,,,22224,,,,CHEMBL620099,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4649,A,
,1,3443,,,,22224,,,,CHEMBL620100,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4650,A,
,1,6821,,,,22224,,,,CHEMBL620101,Elimination Half-life of compound was determined in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4651,A,
,1,17267,,,,22224,,,,CHEMBL620102,Half life of compound was determined in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4652,A,
Plasma,1,5819,,,,22224,,,,CHEMBL620103,Half life in monkey plasma,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000366,1969.0,4653,A,
Plasma,1,5819,,,,22224,,,,CHEMBL620104,Half life in monkey plasma; Not detected,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000366,1969.0,4654,A,
,1,1916,,In vivo,,22224,,,,CHEMBL874596,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4655,A,
,1,17509,,In vivo,,22224,,,,CHEMBL873490,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4656,A,
,1,1399,,,,22224,,,,CHEMBL620105,Terminal half life of the compound.,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4657,A,
,1,1916,,In vivo,,22224,,,,CHEMBL620780,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4658,A,
,1,4809,,In vivo,,22224,,,,CHEMBL620781,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4659,A,
,1,5546,,,,22224,,,,CHEMBL620956,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4660,A,
Urine,1,3443,,,,22224,,,,CHEMBL620957,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1088.0,4661,A,
Urine,1,3443,,,,22224,,,,CHEMBL620958,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1088.0,4662,A,
,1,4257,,In vivo,,22224,,,,CHEMBL620959,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4663,A,
,1,6221,,In vivo,,22224,,,,CHEMBL620960,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4664,A,
,1,5472,,In vivo,,22224,,,,CHEMBL620961,Volume of distribution was evaluated in rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4665,A,
,1,4727,,In vivo,,22224,,,,CHEMBL620962,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4666,A,
,1,4727,,In vivo,,22224,,,,CHEMBL620963,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4667,A,
,1,4727,,In vivo,,22224,,,,CHEMBL620964,Bioavailability in hamster was determined,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4668,A,
,1,4727,,In vivo,,22224,,,,CHEMBL620965,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4669,A,
,1,4727,,In vivo,,22224,,,,CHEMBL620966,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,4670,A,
Blood,1,4727,,,,22224,,,,CHEMBL620967,Half life of compound was determined in hamster blood,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000221,178.0,4671,A,
,1,1452,,,,22224,,,,CHEMBL620968,Michaelis-Menten constant of the compound.,Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,4672,A,
,1,1452,,,,22224,,,,CHEMBL874597,Vmax value was measured at 0 uM concentration of silyl ether.,Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,4673,A,
,1,1452,,,,22224,,,,CHEMBL620969,Vmax value was measured at 10 uM concentration of silyl ether.,Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,4674,A,
,1,1452,,,,22224,,,,CHEMBL620970,Vmax value was measured at 5 uM concentration of silyl ether.,Sus scrofa,0,9823.0,,Autocuration,U,BAO_0000019,,4675,A,
,1,11706,,,,235,,,,CHEMBL620971,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Homo sapiens,9,9606.0,,Expert,D,BAO_0000357,,4676,B,
,1,1916,,,,22224,,,,CHEMBL620972,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4677,A,
,1,17791,,,,22224,,,,CHEMBL620973,Compound was evaluated for area under the curve expressed as (h*ug/ml),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4678,A,
,1,7766,,,,22224,,,,CHEMBL618243,Active metabolite of ifosfamide determined in humans; A-Active,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4679,A,
,1,6567,,,,22224,,,,CHEMBL618244,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4680,A,
,1,6567,,,,22224,,,,CHEMBL618245,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4681,A,
,1,6567,,,,22224,,,,CHEMBL618246,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4682,A,
,1,6567,,,,22224,,,,CHEMBL618247,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4683,A,
,1,17791,,,,22224,,,,CHEMBL618248,Compound was evaluated for oral bioavailability in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4684,A,
Urine,1,7766,,,,22224,,,,CHEMBL618249,Metabolite of ifosfamide determined in urine; NF-Not found,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4685,A,
,1,6852,,,,22224,,,,CHEMBL618250,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4686,A,
,1,6852,,,,22224,,,,CHEMBL874598,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4687,A,
,1,6852,,,,22224,,,,CHEMBL618251,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4688,A,
,1,6852,,,,22224,,,,CHEMBL618252,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4689,A,
,1,6852,,,,22224,,,,CHEMBL618253,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4690,A,
,1,6852,,,,22224,,,,CHEMBL618254,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4691,A,
,1,6852,,,,22224,,,,CHEMBL618255,Percent of compound in healthy individuals (Group D),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4692,A,
Liver,1,4397,,,,22224,,Microsomes,,CHEMBL618983,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4693,A,
,1,17409,,,,22224,,,,CHEMBL618984,Binding towards human plasma protein at 10 uM,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4694,A,
,1,17409,,,,22224,,,,CHEMBL618985,Binding towards human plasma protein at 100 uM,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4695,A,
,1,17176,,,,22224,,,,CHEMBL618986,Human plasma protein binding activity was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4696,A,
,1,15444,,,,22224,,,,CHEMBL618987,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4697,A,
,1,17267,,,,22224,,,,CHEMBL618988,Percent binding of compound towards human plasma protein was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4698,A,
Liver,1,5944,,In vitro,,22224,,Microsomes,,CHEMBL618989,Plasma clearance in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4699,A,
Liver,1,5668,,In vitro,,22224,,Microsomes,,CHEMBL618990,In vitro intrinsic clearance in human liver microsome,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4700,A,
Liver,1,5669,,In vitro,,22224,,Microsomes,,CHEMBL618991,In vitro intrinsic clearance in human liver microsome,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4701,A,
,1,5041,,In vitro,,22224,,Microsomes,,CHEMBL876725,In vitro microsome metabolism clearance in human was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4702,A,
,1,5041,,In vitro,,22224,,Microsomes,,CHEMBL618992,In vitro microsome metabolism clearance in human was determined; High,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4703,A,
,1,5041,,In vitro,,22224,,Microsomes,,CHEMBL618993,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4704,A,
Liver,1,5676,,In vitro,,22224,,Microsomes,,CHEMBL618994,Pharmacokinetic property (clearance) in human liver microsome,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4705,A,
Liver,1,5944,,In vitro,,22224,,Microsomes,,CHEMBL618995,Plasma clearance in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4706,A,
Liver,1,17538,,In vitro,,22224,,Microsomes,,CHEMBL618996,In vitro clearance in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4707,A,
Liver,1,6331,,In vitro,,22224,,Microsomes,,CHEMBL618997,Intrinsic clearance in human liver microsomes was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4708,A,
Liver,1,5948,,In vitro,,22224,,Microsomes,,CHEMBL618998,Intrinsic clearance in human liver microsomes was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4709,A,
,1,5965,,In vivo,,22224,,,,CHEMBL618999,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4710,A,
,1,1916,,In vivo,,22224,,,,CHEMBL620223,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4711,A,
,1,5965,,,,22224,,,,CHEMBL620224,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4712,A,
,1,1299,,,,22224,,,,CHEMBL620225,Stability in human plasma 2 hr after incubation expressed as percent concentration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4713,A,
,1,1299,,,,22224,,,,CHEMBL620226,Stability in human plasma 4 hr after incubation expressed as percent concentration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4714,A,
Urine,1,7766,,,,22224,,,,CHEMBL620227,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4715,A,
Urine,1,7766,,,,22224,,,,CHEMBL876726,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4716,A,
Urine,1,7766,,,,22224,,,,CHEMBL620228,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4717,A,
Urine,1,7766,,,,22224,,,,CHEMBL620229,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4718,A,
,1,17764,,In vivo,,50594,,,,CHEMBL620230,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4719,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620231,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4720,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620232,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4721,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620233,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4722,F,
,1,14294,,,,50594,,,,CHEMBL620234,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4723,A,
,1,14294,,,,50594,,,,CHEMBL620235,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4724,A,
,1,14294,,,,50594,,,,CHEMBL620236,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4725,A,
Liver,1,6251,,,,50594,,,,CHEMBL620237,In vitro metabolic potential in mouse liver microsomes,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4726,A,
,1,17582,,,,50594,,,,CHEMBL620238,Ability of compound to bind to plasma protein was evaluated in HSA cells,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4727,A,
Adrenal gland,1,17811,,,,50594,,,,CHEMBL620239,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2369.0,4728,A,
Brain,1,17811,,,,50594,,,,CHEMBL620240,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4729,A,
Brain,1,17811,,,,50594,,,,CHEMBL620241,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4730,A,
,1,17811,,,,50594,,,,CHEMBL876727,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4731,A,
Kidney,1,17811,,,,50594,,,,CHEMBL620242,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4732,A,
,1,17811,,,,50594,,,,CHEMBL620243,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4733,A,
,1,5288,,,,50594,,,,CHEMBL620244,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4734,A,
Serum,1,2717,,,,50594,,,,CHEMBL620245,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1977.0,4735,A,
Serum,1,2717,,,,50594,,,,CHEMBL620246,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1977.0,4736,A,
Serum,1,2717,,,,50594,,,,CHEMBL620247,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1977.0,4737,A,
Plasma,1,17753,,In vivo,,50594,,,,CHEMBL620248,Half life of compound was determined in plasma of mice at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,4738,A,
Plasma,1,17753,,In vivo,,50594,,,,CHEMBL873497,Half life of compound was determined in plasma of mice at 40 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,4739,A,
Plasma,1,17753,,In vivo,,50594,,,,CHEMBL620249,Half life of compound was determined in plasma of mice at 5 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,4740,A,
,1,17764,,In vivo,,50594,,,,CHEMBL620250,Half life after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4741,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620251,Half life after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4742,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620252,Half life after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4743,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620253,Half life after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4744,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620254,Half life after intravenous administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4745,F,
,1,17764,,In vivo,,50594,,,,CHEMBL620255,Half life after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4746,A,
,1,16597,,In vivo,,50594,,,,CHEMBL620256,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4747,A,
,1,2675,,In vivo,,50594,,,,CHEMBL876728,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4748,A,
,1,2675,,In vivo,,50594,,,,CHEMBL620257,Maximum time required to reach Cp max was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4749,A,
,1,16597,,In vivo,,50594,,,,CHEMBL620258,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4750,A,
,1,4890,,In vivo,,50594,,,,CHEMBL620259,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4751,A,
,1,429,,In vivo,,50594,,,,CHEMBL620260,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4752,A,
Blood,1,17837,,In vivo,,50594,,,,CHEMBL620261,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4753,A,
,1,16597,,In vivo,,50594,,,,CHEMBL620262,Half life at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4754,A,
,1,16597,,In vivo,,50594,,,,CHEMBL620263,Half life at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4755,A,
,1,6619,,,,50594,,,,CHEMBL620264,Half life in ob/ob mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4756,A,
,1,4066,,In vivo,,50594,,,,CHEMBL620265,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4757,A,
,1,4239,,,,50594,,,,CHEMBL620266,Half-life was measured in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4758,A,
,1,5969,,In vivo,,50594,,,,CHEMBL620267,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4759,A,
,1,8999,,,,50594,,,,CHEMBL619364,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4760,A,
,1,8999,,,,50594,,,,CHEMBL619365,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4761,A,
Brain,1,17641,,,,50594,,,,CHEMBL619366,T2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4762,A,
Kidney,1,17641,,,,50594,,,,CHEMBL619367,T2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4763,A,
Liver,1,17641,,,,50594,,,,CHEMBL619368,T2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4764,A,
Lung,1,17641,,,,50594,,,,CHEMBL619369,T2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,4765,A,
Spleen,1,17641,,,,50594,,,,CHEMBL876729,T2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,4766,A,
,1,16597,,In vivo,,50594,,,,CHEMBL619370,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4767,A,
,1,4890,,In vivo,,50594,,,,CHEMBL619371,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4768,A,
,1,429,,In vivo,,50594,,,,CHEMBL619372,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4769,A,
,1,429,,In vivo,,50594,,,,CHEMBL620012,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4770,A,
,1,5969,,In vivo,,50594,,,,CHEMBL620013,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4771,A,
,1,16913,,,,81034,,,A2780,CHEMBL620014,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4772,F,
,1,16913,,,,81034,,,A2780,CHEMBL620015,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4773,F,
,1,16913,,,,81034,,,A2780,CHEMBL621010,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4774,F,
,1,16913,,,,81034,,,A2780,CHEMBL621011,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4775,F,
,1,16913,,,,81034,,,A2780,CHEMBL621012,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4776,F,
,1,16913,,,,81034,,,A2780,CHEMBL621013,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4777,F,
,1,17270,,,,81034,,,A2780,CHEMBL621014,In vitro cytotoxicity against A2780TAX cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4778,F,
,1,5618,,,,80017,,,A2780cisR,CHEMBL618154,In vitro inhibitory activity against human tumor cell line A2780cis,Homo sapiens,1,9606.0,481.0,Intermediate,N,BAO_0000219,,4779,F,
,1,17777,,,,81034,,,A2780,CHEMBL618155,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,4780,F,
,1,16112,,,,80017,,,A2780cisR,CHEMBL618156,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Homo sapiens,1,9606.0,481.0,Intermediate,N,BAO_0000219,,4781,F,
,1,15748,,,,80017,,,A2780cisR,CHEMBL618157,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Homo sapiens,1,9606.0,481.0,Intermediate,N,BAO_0000219,,4782,F,
,1,6633,,,,81034,,,A2780,CHEMBL618328,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4783,F,
,1,16930,,,,81034,,,A2780,CHEMBL618329,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4784,F,
,1,17496,,,,81034,,,A2780,CHEMBL618330,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4785,F,
,1,12989,,,,81034,,,A2780,CHEMBL618331,In vitro antitumor activity against A2780cisR cell line.,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,4786,F,
,1,4840,,,,81034,,,A2780,CHEMBL618332,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,4787,F,
,1,12989,,,,81034,,,A2780,CHEMBL618333,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,4788,F,
,1,16745,,,,80017,,,A2780cisR,CHEMBL618334,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Homo sapiens,1,9606.0,481.0,Intermediate,N,BAO_0000219,,4789,F,
,1,16597,,,,81034,,,A2780,CHEMBL618335,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,4790,F,
,1,16547,,,,11736,,,,CHEMBL618336,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,4791,B,
,1,16547,,,,11736,,,,CHEMBL618337,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,8,,,Expert,H,BAO_0000019,,4792,F,
,1,16547,,,,11736,,,,CHEMBL618338,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000019,,4793,F,
,1,15856,,,,278,,,HEK293,CHEMBL618339,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,4794,F,
,1,15856,,,,278,,,HEK293,CHEMBL618340,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Homo sapiens,9,9606.0,722.0,Expert,D,BAO_0000219,,4795,F,
,1,16547,,,,11831,,,,CHEMBL618341,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Mus musculus,9,10090.0,,Expert,D,BAO_0000019,,4796,B,
,1,16547,,,,11831,,,,CHEMBL618342,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,8,,,Expert,H,BAO_0000019,,4797,F,
,1,16547,,,,11831,,,,CHEMBL618343,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Mus musculus,9,10090.0,,Expert,D,BAO_0000019,,4798,F,
,1,17402,,,,280,,,,CHEMBL621038,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,8,,,Expert,H,BAO_0000357,,4799,B,
,1,11746,,,,22226,,,T-cells,CHEMBL621039,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Homo sapiens,0,9606.0,574.0,Autocuration,U,BAO_0000219,,4800,F,
,1,11746,,,,22226,,,T-cells,CHEMBL621040,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Homo sapiens,0,9606.0,574.0,Autocuration,U,BAO_0000219,,4801,F,
,1,5455,,,,80018,,,A-375,CHEMBL621041,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4802,F,
,1,2068,,,,80018,,,A-375,CHEMBL621042,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4803,F,
,1,2683,,,,80018,,,A-375,CHEMBL621043,In vitro antitumor activity against A375cell line extracted form melanoma,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4804,F,
,1,15313,,,,80018,,,A-375,CHEMBL621044,Inhibition of cell growth in (A375) melan cell line,Homo sapiens,1,9606.0,455.0,Expert,N,BAO_0000219,,4805,F,
,1,13739,,,,80018,,,A-375,CHEMBL621045,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4806,F,
,1,13739,,,,80018,,,A-375,CHEMBL621046,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4807,F,
,1,14750,,,,80018,,,A-375,CHEMBL621047,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,4808,F,
,1,14777,,,,80019,,,A-427,CHEMBL621048,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4809,F,
,1,14777,,,,80019,,,A-427,CHEMBL883798,Antiproliferative activity measured against A427 human lung carcinoma,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4810,F,
,1,17672,,,,80019,,,A-427,CHEMBL621049,Cytotoxicity against lung carcinoma A427 tumor cell lines,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4811,F,
,1,14368,,,,80019,,,A-427,CHEMBL621050,Inhibition of large cell lung carcinoma (A427),Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4812,F,
,1,14368,,,,80019,,,A-427,CHEMBL621051,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4813,F,
,1,13866,,,,80019,,,A-427,CHEMBL621052,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4814,F,
,1,2545,,,,80019,,,A-427,CHEMBL621053,Inhibitory concentration in human lung carcinoma A427 cell line,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4815,F,
,1,2545,,,,80019,,,A-427,CHEMBL621054,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4816,F,
,1,6062,,In vivo,,22224,,,,CHEMBL621055,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4817,A,
,1,4578,,In vivo,,22224,,,,CHEMBL876398,Tested for volume of distribution upon iv administration to african green monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4818,A,
,1,17592,,In vivo,,22224,,,,CHEMBL621056,Volume of distribution in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4819,A,
,1,5005,,In vivo,,22224,,,,CHEMBL621057,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4820,A,
,1,5005,,In vivo,,22224,,,,CHEMBL621058,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,,4821,A,
,1,5922,,In vivo,,22224,,,,CHEMBL621059,Pharmacokinetic property(Vdss) in cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4822,A,
,1,5355,,In vivo,,22224,,,,CHEMBL621060,The distribution volume after intravenous administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4823,A,
,1,5355,,In vivo,,22224,,,,CHEMBL621061,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4824,A,
,1,5355,,In vivo,,22224,,,,CHEMBL621062,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4825,A,
,1,6057,,In vivo,,22224,,,,CHEMBL621063,Volume displacement was calculated in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4826,A,
,1,5145,,In vivo,,22224,,,,CHEMBL621064,Volume of distribution in steady state was determined in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4827,A,
,1,6821,,In vivo,,22224,,,,CHEMBL621065,Volume of distribution of compound was determined in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4828,A,
,1,5334,,In vivo,,22224,,,,CHEMBL621066,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4829,A,
,1,5334,,In vivo,,22224,,,,CHEMBL621067,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4830,A,
,1,6641,,In vivo,,22224,,,,CHEMBL621068,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4831,A,
,1,2661,,In vivo,,22224,,,,CHEMBL876399,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4832,A,
,1,6535,,In vivo,,22224,,,,CHEMBL621069,Volume distribution in monkey after administration of 1 mg/kg iv,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4833,A,
,1,4809,,In vivo,,22224,,,,CHEMBL621070,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4834,A,
,1,6062,,In vivo,,22224,,,,CHEMBL621071,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4835,A,
,1,3443,,In vivo,,22224,,,,CHEMBL621072,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4836,A,
,1,4578,,In vivo,,22224,,,,CHEMBL618209,Oral systemic bioavailability upon iv administration to african green monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4837,A,
,1,4809,,In vivo,,22224,,,,CHEMBL618210,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4838,A,
,1,11271,,,,22224,,,,CHEMBL618211,Baboon plasma free fraction. ,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4839,A,
,1,6057,,,,22224,,,,CHEMBL618212,Area under the curve was calculated in rhesus monkey after iv administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4840,A,
,1,6057,,,,22224,,,,CHEMBL618213,Area under the curve was calculated in rhesus monkey after peroral administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4841,A,
,1,17853,,,,22224,,,,CHEMBL618214,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4842,A,
,1,5302,,In vivo,,22224,,,,CHEMBL873492,Half life period in monkey after 5 mg/kg dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4843,A,
,1,4257,,In vivo,,22224,,,,CHEMBL618272,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4844,A,
,1,4257,,In vivo,,22224,,,,CHEMBL618273,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4845,A,
Plasma,1,13501,,In vivo,,22224,,,,CHEMBL618274,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4846,A,
,1,5394,,In vivo,,22224,,,,CHEMBL618275,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4847,A,
,1,2661,,In vivo,,22224,,,,CHEMBL618276,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4848,A,
,1,3341,,,,22224,,,,CHEMBL618277,Compound was evaluated for terminal half life in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4849,A,
,1,3045,,In vivo,,22224,,,,CHEMBL618278,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4850,A,
Plasma,1,5005,,In vivo,,22224,,,,CHEMBL618279,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,1969.0,4851,A,
,1,4847,,,,22224,,,,CHEMBL618280,Half life of compound was determined in squirrel monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4852,A,
,1,4256,,In vivo,,22224,,,,CHEMBL618281,Half life after iv administration in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,4853,A,
Plasma,1,6535,,In vivo,,22224,,,,CHEMBL618282,Half life in monkey plasma after administration of 1 mg/kg iv,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,4854,A,
,1,6057,,,,22224,,,,CHEMBL618283,Half life was calculated in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4855,A,
,1,17592,,,,22224,,,,CHEMBL618284,Half life in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4856,A,
,1,6641,,In vivo,,22224,,,,CHEMBL618285,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4857,A,
,1,5472,,,,22224,,,,CHEMBL618286,Half life was evaluated in rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4858,A,
,1,6221,,In vivo,,22224,,,,CHEMBL618287,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4859,A,
,1,5668,,In vivo,,22224,,,,CHEMBL618288,Half life period was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4860,A,
,1,4809,,In vivo,,22224,,,,CHEMBL876393,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4861,A,
,1,5546,,In vivo,,22224,,,,CHEMBL618289,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4862,A,
,1,5553,,In vivo,,22224,,,,CHEMBL618290,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4863,A,
,1,6078,,,,22224,,,,CHEMBL618291,Half-life was calculated in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4864,A,
,1,5147,,,,22224,,,,CHEMBL618292,Half-life in Squirrel monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4865,A,
,1,5145,,,,22224,,,,CHEMBL618293,Half-life in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,4866,A,
,1,6062,,In vivo,,22224,,,,CHEMBL618294,Half-life was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4867,A,
,1,5355,,In vivo,,22224,,,,CHEMBL618295,Half-life period after intravenous administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4868,A,
,1,5355,,In vivo,,22224,,,,CHEMBL618296,Half-life period after oral administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4869,A,
,1,5355,,In vivo,,22224,,,,CHEMBL618297,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,4870,A,
Urine,1,7766,,,,22224,,,,CHEMBL618298,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4871,A,
Urine,1,7766,,,,22224,,,,CHEMBL618299,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4872,A,
Urine,1,7766,,,,22224,,,,CHEMBL618300,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4873,A,
Urine,1,7766,,,,22224,,,,CHEMBL618301,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4874,A,
Urine,1,7766,,,,22224,,,,CHEMBL618302,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4875,A,
Urine,1,7766,,,,22224,,,,CHEMBL876394,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4876,A,
Urine,1,7766,,,,22224,,,,CHEMBL618303,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4877,A,
Urine,1,7766,,,,22224,,,,CHEMBL618304,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4878,A,
,1,1916,,In vivo,,22224,,,,CHEMBL618305,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4879,A,
,1,16643,,In vivo,,22224,,,,CHEMBL618306,Oral bioavailability in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,4880,A,
,1,17248,,,,22224,,,,CHEMBL618307,Compound was tested for human plasma protein binding,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4881,A,
,1,17248,,,,22224,,,,CHEMBL618308,Compound was tested for human plasma protein binding; Not determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4882,A,
,1,6241,,,,22224,,,,CHEMBL618309,Protein binding activity of compound in human plasma; % Free,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4883,A,
,1,17716,,,,22224,,,,CHEMBL618310,Unbound fraction (plasma),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4884,A,
Plasma,1,17605,,,,22224,,,,CHEMBL873353,Half life for the hydrolysis of compound in human blood serum,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,4885,A,
Plasma,1,17625,,,,22224,,,,CHEMBL618311,Half life period in human plasma using phosphate buffer (0.08 M),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,4886,A,
Plasma,1,17625,,,,22224,,,,CHEMBL618312,Half life period in human plasma using phosphate buffer (0.1 M),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,4887,A,
Plasma,1,17747,,,,22224,,,,CHEMBL618313,Half-life in human plasma was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,4888,A,
,1,15613,,,,22224,,,,CHEMBL618314,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4889,A,
,1,354,,,,22224,,,,CHEMBL618315,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4890,A,
,1,3741,,,,22224,,,,CHEMBL618316,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4891,A,
,1,3741,,,,22224,,,,CHEMBL618317,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4892,A,
,1,3741,,,,22224,,,,CHEMBL620138,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4893,A,
,1,17599,,,,22224,,,,CHEMBL858280,Partition coefficient (logP),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4894,A,
,1,5486,,,,22224,,,,CHEMBL620139,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4895,A,
,1,5600,,,,22224,,Microsomes,,CHEMBL620140,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4896,A,
,1,14294,,,,22224,,,,CHEMBL620141,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4897,A,
,1,14294,,,,22224,,,,CHEMBL620142,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4898,A,
,1,14294,,,,22224,,,,CHEMBL620143,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4899,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620144,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4900,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620145,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4901,A,
,1,14294,,,,22224,,Microsomes,,CHEMBL620146,Metabolism of compound in human microsomes; Trace,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4902,A,
Liver,1,6260,,,,22224,,Microsomes,,CHEMBL620147,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4903,A,
,1,6187,,,,22224,,Microsomes,,CHEMBL620148,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,4904,A,
Liver,1,6251,,,,22224,,Microsomes,,CHEMBL620149,In vitro metabolic potential in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,4905,A,
,1,3246,,,,22224,,,,CHEMBL876412,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4906,A,
,1,17313,,,,22224,,,,CHEMBL619352,Tested for human plasma protein binding of the compound; Not tested,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4907,A,
,1,6227,,,,22224,,,,CHEMBL619353,Compound was tested for percent protein binding (PB) in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4908,A,
Plasma,1,5530,,,,22224,,,,CHEMBL619354,Protein binding in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1969.0,4909,A,
,1,6108,,,,22224,,,,CHEMBL619355,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4910,A,
,1,6108,,,,22224,,,,CHEMBL619356,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4911,A,
,1,2774,,,,22224,,,,CHEMBL619357,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4912,A,
,1,16643,,,,22224,,,,CHEMBL619358,In vitro rate of absorption observed as Caco-2 permeability in humans,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4913,A,
,1,17582,,,,22224,,,Caco-2,CHEMBL619359,Cellular permeability of compound was determined in Caco-2 cells; High,Homo sapiens,0,9606.0,495.0,Autocuration,U,BAO_0000219,,4914,A,
,1,6838,,,,22224,,,Caco-2,CHEMBL619360,Permeability in Caco-2 cells of compound,Homo sapiens,0,9606.0,495.0,Autocuration,U,BAO_0000219,,4915,A,
,1,6108,,,,22224,,,,CHEMBL619361,Permeability coefficient (A to B) in Caco-2 cell,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4916,A,
,1,6108,,,,22224,,,,CHEMBL619362,Permeability coefficient (B to A) in Caco-2 cell,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4917,A,
,1,6108,,,,22224,,,,CHEMBL619363,Permeability coefficient (Papp) (Caco-2 cell monolayer),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4918,A,
,1,2146,,,,22224,,,,CHEMBL618942,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4919,A,
,1,4514,,,,22224,,,,CHEMBL618943,Compound was tested for protein binding in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4920,A,
,1,6108,,,,22224,,,,CHEMBL618944,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,4921,A,
Urine,1,7766,,,,22224,,,,CHEMBL618945,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,4922,A,
,1,5969,,In vivo,,50594,,,,CHEMBL618946,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4923,A,
,1,3277,,In vivo,,50594,,,,CHEMBL876413,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4924,A,
,1,3802,,In vivo,,50594,,,,CHEMBL618947,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4925,A,
Plasma,1,2862,,In vivo,,50594,,,,CHEMBL618948,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,4926,A,
Plasma,1,6348,,In vivo,,50594,,,,CHEMBL618949,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,4927,A,
,1,17764,,In vivo,,50594,,,,CHEMBL618950,Tmax after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4928,F,
,1,5781,,In vivo,,50594,,,,CHEMBL618951,Tmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4929,A,
,1,17764,,In vivo,,50594,,,,CHEMBL618952,Tmax after peroral administration in mice at 2.4 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4930,A,
,1,4066,,In vivo,,50594,,,,CHEMBL618953,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4931,A,
Brain,1,17641,,In vivo,,50594,,,,CHEMBL618954,Tmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,4932,A,
Kidney,1,17641,,In vivo,,50594,,,,CHEMBL618955,Tmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4933,A,
Liver,1,17641,,In vivo,,50594,,,,CHEMBL618956,Tmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,4934,A,
Lung,1,17641,,In vivo,,50594,,,,CHEMBL618957,Tmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,4935,A,
,1,17764,,In vivo,,50594,,,,CHEMBL618958,Tmax in mice at 18 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4936,F,
,1,17764,,In vivo,,50594,,,,CHEMBL618959,Tmax in mice at 23 uM/kg i.v. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4937,F,
,1,17764,,In vivo,,50594,,,,CHEMBL618960,Tmax in mice at 25 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4938,F,
,1,17764,,In vivo,,50594,,,,CHEMBL876723,Tmax in mice at 26 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4939,F,
Spleen,1,17641,,In vivo,,50594,,,,CHEMBL618961,Tmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,4940,A,
,1,16597,,In vivo,,50594,,,,CHEMBL618962,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4941,A,
,1,16597,,In vivo,,50594,,,,CHEMBL618963,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4942,A,
,1,5951,,,,50594,,,,CHEMBL618964,Tmax value in IRC mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4943,A,
,1,5506,,In vivo,,50594,,,,CHEMBL618965,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4944,A,
,1,5506,,In vivo,,50594,,,,CHEMBL618966,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4945,A,
Urine,1,429,,,,50594,,,,CHEMBL618967,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,4946,A,
Urine,1,429,,,,50594,,,,CHEMBL618968,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,4947,A,
Urine,1,4066,,,,50594,,,,CHEMBL618969,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,4948,A,
,1,17734,,,,50594,,,,CHEMBL618970,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4949,A,
,1,17734,,,,50594,,,,CHEMBL618971,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4950,A,
,1,6062,,In vivo,,50594,,,,CHEMBL618972,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4951,A,
,1,5969,,In vivo,,50594,,,,CHEMBL618973,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4952,A,
,1,5969,,In vivo,,50594,,,,CHEMBL618974,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4953,A,
,1,5969,,In vivo,,50594,,,,CHEMBL618975,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4954,A,
,1,5980,,In vivo,,50594,,,,CHEMBL618976,Vd in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4955,A,
,1,17592,,In vivo,,50594,,,,CHEMBL618977,Volume of distribution in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4956,A,
,1,6348,,In vivo,,50594,,,,CHEMBL876724,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4957,A,
,1,17753,,In vivo,,50594,,,,CHEMBL618978,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4958,A,
,1,17753,,In vivo,,50594,,,,CHEMBL618979,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4959,A,
,1,17753,,In vivo,,50594,,,,CHEMBL618980,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4960,A,
,1,4239,,In vivo,,50594,,,,CHEMBL618981,Pharmacokinetic property (vdss) was measured in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4961,A,
,1,2862,,In vivo,,50594,,,,CHEMBL618982,Value distribution upon iv administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4962,A,
,1,17734,,In vivo,,50594,,,,CHEMBL620150,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4963,A,
,1,2675,,In vivo,,50594,,,,CHEMBL620151,Volume of distribution was evaluated in mice after intravenous administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4964,A,
,1,2675,,In vivo,,50594,,,,CHEMBL620152,Volume of distribution was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4965,A,
,1,17837,,In vivo,,50594,,,,CHEMBL620153,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4966,A,
,1,5727,,In vivo,,50594,,,,CHEMBL876395,Steady state volume of distribution was determined in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4967,A,
,1,17852,,In vivo,,50594,,,,CHEMBL620154,Volume distribution (steady state) of compound was determined in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4968,A,
,1,17764,,In vivo,,50594,,,,CHEMBL620155,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4969,A,
,1,16597,,In vivo,,50594,,,,CHEMBL620156,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4970,A,
,1,6062,,In vivo,,50594,,,,CHEMBL620157,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,4971,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL620158,Biodistribution of compound (oxidized form) in in kidney tissue,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,4972,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL620159,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4973,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL620160,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4974,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL620161,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,4975,A,
,1,10708,,,,80019,,,A-427,CHEMBL620162,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,4976,F,
,1,16597,,,,80852,,,A-431,CHEMBL620163,Inhibition of A431 human squamous cell carcinoma cell proliferation,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4977,F,
,1,16062,,,,80852,,,A-431,CHEMBL620833,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4978,F,
,1,16062,,,,80852,,,A-431,CHEMBL876396,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4979,F,
,1,16958,,,,80852,,,A-431,CHEMBL620834,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4980,F,
,1,6700,,,,80852,,,A-431,CHEMBL620835,Inhibition of A431 human carcinoma cell proliferation,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4981,F,
,1,17226,,,,80852,,,A-431,CHEMBL620836,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4982,F,
,1,6828,,,,80852,,,A-431,CHEMBL620837,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4983,F,
,1,12314,,,,80852,,,A-431,CHEMBL621017,In vitro cytotoxicity against epidermoid carcinoma cell line,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4984,F,
,1,13412,,,,9,,,A-431,CHEMBL621018,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000218,,4985,F,
,1,13299,,,,80852,,,A-431,CHEMBL621019,Antiproliferative activity of compound was measured on human tumor cell line A431.,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4986,F,
,1,17420,,,,80852,,,A-431,CHEMBL621020,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4987,F,
,1,13678,,,,80852,,,A-431,CHEMBL621021,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4988,F,
,1,14171,,,,9,,,A-431,CHEMBL621022,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,8,,500.0,Expert,H,BAO_0000219,,4989,F,
,1,6333,,,,80852,,,A-431,CHEMBL621023,Tested for antiproliferative activity against human A431 cells,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4990,F,
,1,2356,,,,9,,,A-431,CHEMBL621024,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,4991,F,
,1,15578,,,,80852,,,A-431,CHEMBL621025,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4992,F,
,1,5126,,,,80852,,,A-431,CHEMBL621026,Inhibition of A431 cell proliferation,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4993,F,
,1,6844,,,,80852,,,A-431,CHEMBL621027,Cytotoxic effect on A431 human epidermoid carcinoma cells,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4994,F,
,1,6844,,,,80852,,,A-431,CHEMBL876397,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,4995,F,
,1,4925,,,,80852,,,A-431,CHEMBL883797,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4996,F,
,1,4925,,,,80852,,,A-431,CHEMBL621028,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4997,F,
,1,13978,,,,80852,,,A-431,CHEMBL621029,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4998,F,
,1,16786,,,,80852,,,A-431,CHEMBL621030,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,4999,F,
,1,13412,,,,9,,,A-431,CHEMBL621147,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,8,,500.0,Expert,H,BAO_0000219,,5000,F,
,1,17824,,,,80852,,,A-431,CHEMBL621148,In vivo antiproliferative activity against A431 cell line,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000218,,5001,F,
,1,12751,,,,9,,,A-431,CHEMBL621149,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5002,F,
,1,12380,,,,80852,,,A-431,CHEMBL621150,Inhibition of A431 human epidermoid carcinoma cell proliferation,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,5003,F,
,1,4959,,,,9,,,A-431,CHEMBL621151,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5004,F,
,1,6333,,,,80852,,,A-431,CHEMBL621152,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5005,F,
,1,6333,,,,80852,,,A-431,CHEMBL621153,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5006,F,
,1,6333,,,,80852,,,A-431,CHEMBL884000,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5007,F,
,1,5296,,,,9,,,,CHEMBL621154,Inhibition of EGFR overexpressing A431 cell proliferation,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,5008,F,
,1,12624,,,,80852,,,A-431,CHEMBL621155,Inhibition of A431 cell proliferation,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,5009,F,
,1,14926,,,,9,,,A-431,CHEMBL621156,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5010,F,
,1,14926,,,,9,,,A-431,CHEMBL621157,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5011,F,
,1,14926,,,,9,,,A-431,CHEMBL621158,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,8,,500.0,Expert,H,BAO_0000219,,5012,F,
,1,15144,,,,80852,,,A-431,CHEMBL621159,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5013,F,
,1,15144,,,,80852,,,A-431,CHEMBL621160,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5014,F,
,1,5245,,,,80852,,,A-431,CHEMBL621161,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5015,F,
,1,5245,,,,80852,,,A-431,CHEMBL621162,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5016,F,
,1,5245,,,,80852,,,A-431,CHEMBL621163,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5017,F,
,1,5245,,,,80852,,,A-431,CHEMBL621164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5018,F,
,1,5245,,,,80852,,,A-431,CHEMBL621165,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5019,F,
,1,5922,,,,22224,,,,CHEMBL619159,Half-life period in cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5020,A,
Plasma,1,1116,,In vitro,,22224,,,,CHEMBL619160,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000366,1969.0,5021,A,
,1,17853,,In vivo,,22224,,,,CHEMBL619161,Longer half-life in monkey (i.v.) at 0.5 mpk,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5022,A,
Plasma,1,993,,,,22224,,,,CHEMBL619162,Plasma half life in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000366,1969.0,5023,A,
Plasma,1,4514,,,,22224,,,,CHEMBL619163,Plasma half-life in rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000366,1969.0,5024,A,
Plasma,1,5334,,In vivo,,22224,,,,CHEMBL619164,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,5025,A,
Plasma,1,5334,,In vivo,,22224,,,,CHEMBL619320,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,5026,A,
,1,4578,,In vivo,,22224,,,,CHEMBL619321,Tested for half life upon iv administration to african green monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5027,A,
,1,2661,,In vivo,,22224,,,,CHEMBL873336,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5028,A,
,1,5355,,In vivo,,22224,,,,CHEMBL619322,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5029,A,
,1,5355,,In vivo,,22224,,,,CHEMBL619323,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5030,A,
,1,5355,,In vivo,,22224,,,,CHEMBL619324,The time for peak concentration value after oral administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5031,A,
,1,11271,,,,22224,,,,CHEMBL619325,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5032,A,
,1,11271,,,,22224,,,,CHEMBL876411,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5033,A,
,1,11271,,,,22224,,,,CHEMBL619326,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5034,A,
,1,11271,,,,22224,,,,CHEMBL619327,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5035,A,
,1,11271,,,,22224,,,,CHEMBL619328,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5036,A,
,1,11271,,,,22224,,,,CHEMBL619329,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5037,A,
,1,11271,,,,22224,,,,CHEMBL619330,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5038,A,
,1,11271,,,,22224,,,,CHEMBL619331,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5039,A,
,1,11271,,,,22224,,,,CHEMBL619332,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5040,A,
,1,11271,,,,22224,,,,CHEMBL619333,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5041,A,
,1,11271,,,,22224,,,,CHEMBL619334,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5042,A,
,1,11271,,,,22224,,,,CHEMBL619335,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5043,A,
,1,11271,,,,22224,,,,CHEMBL619336,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5044,A,
,1,11271,,,,22224,,,,CHEMBL619337,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5045,A,
,1,11271,,,,22224,,,,CHEMBL619338,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5046,A,
,1,11271,,,,22224,,,,CHEMBL619339,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5047,A,
,1,5809,,In vivo,,50597,,,,CHEMBL619340,Bioavailability in rat (cannulated) (dose 2 mg/kg),Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5048,A,
Plasma,1,17720,,In vivo,,50597,,,,CHEMBL873496,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,5049,A,
Plasma,1,3546,,,,50597,,,,CHEMBL619341,AUC value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,5050,A,
Plasma,1,3546,,,,50597,,,,CHEMBL619342,AUC value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,5051,A,
,1,3546,,In vivo,,50597,,,,CHEMBL619343,Cmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5052,A,
,1,3546,,In vivo,,50597,,,,CHEMBL619344,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5053,A,
,1,3546,,In vivo,,50597,,,,CHEMBL619345,Tmax value in rat after oral administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5054,A,
,1,3546,,,,50597,,,,CHEMBL619346,Vc value in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5055,A,
,1,3546,,In vivo,,50597,,,,CHEMBL619347,Half life period in rat after IV administration at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,5056,A,
,1,10625,,,,22224,,,,CHEMBL619348,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5057,A,
,1,10625,,,,22224,,,,CHEMBL619349,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5058,A,
,1,10625,,,,22224,,,,CHEMBL619350,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5059,A,
,1,10625,,,,22224,,,,CHEMBL619351,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5060,A,
,1,10625,,,,22224,,,,CHEMBL875953,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5061,A,
,1,10625,,,,22224,,,,CHEMBL621716,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5062,A,
,1,10625,,,,22224,,,,CHEMBL621717,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5063,A,
,1,10625,,,,22224,,,,CHEMBL621718,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Papio hamadryas,0,9557.0,,Autocuration,U,BAO_0000019,,5064,A,
,1,3510,,,,22224,,,,CHEMBL621719,Area under curve after 1 mpk peroral administration to beagles,beagle,0,9615.0,,Autocuration,U,BAO_0000019,,5065,A,
,1,3510,,,,22224,,,,CHEMBL621720,Area under curve after 2 mpk peroral administration to beagles,beagle,0,9615.0,,Autocuration,U,BAO_0000019,,5066,A,
,1,3510,,In vivo,,22224,,,,CHEMBL621721,Cmax value after 1 mpk peroral administration to beagles,beagle,0,9615.0,,Autocuration,U,BAO_0000218,,5067,A,
Urine,1,7766,,,,22224,,,,CHEMBL621722,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5068,A,
Urine,1,7766,,,,22224,,,,CHEMBL621723,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5069,A,
Urine,1,7766,,,,22224,,,,CHEMBL621724,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5070,A,
Urine,1,7766,,,,22224,,,,CHEMBL623443,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5071,A,
Urine,1,7766,,,,22224,,,,CHEMBL623444,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5072,A,
Urine,1,7766,,,,22224,,,,CHEMBL623445,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5073,A,
Urine,1,7766,,,,22224,,,,CHEMBL623446,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1088.0,5074,A,
Liver,1,16643,,,,22224,,Microsomes,,CHEMBL623447,Metabolic stability observed at 30 min after administration in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5075,A,
,1,6852,,,,22224,,,,CHEMBL623448,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5076,A,
,1,6852,,,,22224,,,,CHEMBL623449,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5077,A,
,1,6852,,,,22224,,,,CHEMBL623450,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5078,A,
Liver,1,6567,,,,22224,,Microsomes,,CHEMBL623451,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5079,A,
,1,6570,,,,22224,,,,CHEMBL623452,Metabolic stability (% remaining at 30 mins) in human S9.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5080,A,
,1,6570,,,,22224,,,,CHEMBL623453,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5081,A,
Liver,1,5237,,,,22224,,Microsomes,,CHEMBL623454,Percent parent compound remaining after 20 min incubation with human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5082,A,
Liver,1,5237,,,,22224,,Microsomes,,CHEMBL623455,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5083,A,
Liver,1,5237,,,,22224,,Microsomes,,CHEMBL624371,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5084,A,
,1,5202,,,,22224,,,,CHEMBL624372,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,5085,A,
,1,5481,,,,22224,,,,CHEMBL624373,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5086,A,
,1,5481,,,,22224,,,,CHEMBL624374,Percent remaining in human plasma after incubation for 60 min at 37 C.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5087,A,
,1,3956,,,,22224,,,,CHEMBL624556,The percent remaining in human plasma after 30 min was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5088,A,
Plasma,1,5074,,,,22224,,,,CHEMBL624557,Conversion rate of the prodrug in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5089,A,
Plasma,1,5074,,,,22224,,,,CHEMBL624558,Conversion rate of the prodrug in human plasma; ND means no data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5090,A,
Blood,1,4727,,,,22224,,,,CHEMBL624559,Half life of compound was determined in human blood,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5091,A,
,1,5965,,,,22224,,,,CHEMBL624560,Half life of compound was determined in man with once daily dosing,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5092,A,
,1,5732,,In vitro,,22224,,Microsomes,,CHEMBL624561,Half life in human microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,5093,A,
Plasma,1,5819,,,,22224,,,,CHEMBL624562,Half life in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5094,A,
Plasma,1,5819,,,,22224,,,,CHEMBL624563,Half life in human plasma; Not detected,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5095,A,
,1,1916,,In vivo,,22224,,,,CHEMBL624564,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,5096,A,
Liver,1,6597,,In vitro,,22224,,Microsomes,,CHEMBL624565,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5097,A,
Plasma,1,5229,,,,22224,,,,CHEMBL875152,Half-life in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5098,A,
Plasma,1,5229,,,,22224,,,,CHEMBL624566,Half-life of the parent prodrug in plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5099,A,
Plasma,1,2192,,In vitro,,22224,,,,CHEMBL873805,In vitro half life in human plasma was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5100,A,
Liver,1,3032,,In vitro,,22224,,Microsomes,,CHEMBL624567,The compound was tested In Vitro for half life in human liver microsomes.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5101,A,
,1,1916,,In vivo,,22224,,,,CHEMBL624568,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,5102,A,
,1,17716,,In vivo,,22224,,,,CHEMBL624569,Observed volume of distribution,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,5103,A,
,1,15778,,In vivo,,22224,,,,CHEMBL624570,Oral bioavailability in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000218,,5104,A,
,1,17313,,,,22224,,,,CHEMBL624571,Tested for human plasma protein binding of the compound,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5105,A,
,1,4231,,,,22224,,,,CHEMBL624572,"First order rate constant, k was determined in human plasma",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5106,A,
,1,4755,,,,22224,,,,CHEMBL624573,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5107,A,
,1,4755,,,,22224,,,,CHEMBL875153,Observed rate constant in 80% human plasma at 37 degree Centigrade,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5108,A,
Liver,1,16907,,,,22224,,Microsomes,,CHEMBL624574,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5109,A,
,1,10839,,,,22224,,,,CHEMBL624575,The compound was tested for the plasma binding in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5110,A,
,1,10839,,,,22224,,,,CHEMBL624576,Plasma protein binding (human),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5111,A,
Liver,1,3199,,In vitro,,22224,,Microsomes,,CHEMBL624577,Compound was evaluated for half-life in human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5112,A,
Blood,1,1345,,In vitro,,22224,,,,CHEMBL624578,Half life measured in vitro for its stability in human blood,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5113,A,
Serum,1,4297,,,,22224,,,,CHEMBL622796,Half life in human serum,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1977.0,5114,A,
Serum,1,4297,,,,22224,,,,CHEMBL622797,Half life in human serum; ND=not determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1977.0,5115,A,
,1,4297,,,,22224,,,,CHEMBL622798,Half life were determined in CEM-SS cell extract in decomposition step 1,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5116,A,
,1,4297,,,,22224,,,,CHEMBL622799,Half life were determined in CEM-SS cell extract in decomposition step 2,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5117,A,
Plasma,1,4231,,,,22224,,,,CHEMBL622800,Half life of the in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5118,A,
,1,5633,,In vitro,,22224,,S9,,CHEMBL622801,Half life period in human hepatic S9 fraction was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000220,,5119,A,
Liver,1,5633,,In vitro,,22224,,Microsomes,,CHEMBL622802,Half life period in human liver microsome was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5120,A,
,1,17791,,,,22224,,,,CHEMBL622803,Half life period was determined; 6-7,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5121,A,
,1,17791,,,,22224,,,,CHEMBL875154,Half life period was evaluated in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5122,A,
Plasma,1,3160,,,,22224,,,,CHEMBL622804,Half life time in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5123,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622805,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5124,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL622611,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5125,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL622612,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5126,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL875160,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5127,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL622613,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5128,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL622614,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5129,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL622615,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5130,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL622616,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5131,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL622617,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5132,A,
Spleen,1,16438,,In vivo,,50594,,,,CHEMBL622618,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5133,A,
Spleen,1,16438,,In vivo,,50594,,,,CHEMBL622619,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5134,A,
Spleen,1,16438,,In vivo,,50594,,,,CHEMBL622620,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5135,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622621,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5136,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622622,Biodistribution of compound (oxidized form) in blood tissue,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5137,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622623,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5138,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622624,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5139,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622625,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5140,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622626,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5141,A,
Blood,1,16438,,In vivo,,50594,,,,CHEMBL622627,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5142,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622628,Biodistribution of compound (oxidized form) in brain tissue of mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5143,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622629,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5144,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622630,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5145,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622631,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5146,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622632,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5147,A,
Brain,1,16438,,In vivo,,50594,,,,CHEMBL622633,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,5148,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL622634,Biodistribution of compound (oxidized form) in heart tissue of mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5149,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL622635,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5150,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL875161,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5151,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL622636,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5152,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL623335,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5153,A,
Heart,1,16438,,In vivo,,50594,,,,CHEMBL623336,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5154,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL623337,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5155,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL623338,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5156,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL623339,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5157,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL623524,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5158,A,
Kidney,1,16438,,In vivo,,50594,,,,CHEMBL623525,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5159,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL623526,Biodistribution of compound (oxidized form) in liver tissue,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5160,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL623527,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5161,A,
Liver,1,16438,,In vivo,,50594,,,,CHEMBL623528,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5162,A,
,1,5245,,,,80852,,,A-431,CHEMBL624615,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5163,F,
,1,5245,,,,80852,,,A-431,CHEMBL621672,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5164,F,
,1,16289,,,,80852,,,A-431,CHEMBL621673,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,1,,500.0,Expert,N,BAO_0000218,,5165,F,
,1,16289,,,,80852,,,A-431,CHEMBL621674,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,1,,500.0,Expert,N,BAO_0000218,,5166,F,
,1,16093,,,,9,,,A-431,CHEMBL884002,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5167,F,
,1,16825,,,,80852,,,A-431,CHEMBL621850,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5168,F,
,1,4848,,,,80852,,,A-431,CHEMBL621851,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5169,F,
,1,14827,,,,9,,,A-431,CHEMBL621852,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5170,F,
,1,14827,,,,9,,,A-431,CHEMBL621853,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5171,F,
,1,16289,,,,80852,,,A-431,CHEMBL621854,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,1,,500.0,Expert,N,BAO_0000218,,5172,F,
,1,16289,,,,80852,,,A-431,CHEMBL621855,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,1,,500.0,Expert,N,BAO_0000218,,5173,F,
,1,16289,,,,80852,,,A-431,CHEMBL623724,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,1,,500.0,Expert,N,BAO_0000218,,5174,F,
,1,16289,,,,80852,,,A-431,CHEMBL623725,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,1,,500.0,Expert,N,BAO_0000218,,5175,F,
,1,16289,,,,80852,,,A-431,CHEMBL623726,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,1,,500.0,Expert,N,BAO_0000218,,5176,F,
,1,16289,,,,9,,,A-431,CHEMBL623727,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5177,F,
,1,16289,,,,9,,,A-431,CHEMBL623728,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,8,,500.0,Expert,H,BAO_0000219,,5178,F,
,1,16289,,,,80852,,,A-431,CHEMBL623729,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,1,,500.0,Expert,N,BAO_0000218,,5179,F,
,1,16289,,,,80852,,,A-431,CHEMBL623730,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,1,,500.0,Expert,N,BAO_0000218,,5180,F,
,1,16289,,,,80852,,,A-431,CHEMBL623731,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,1,,500.0,Expert,N,BAO_0000218,,5181,F,
,1,14555,,,,80852,,,A-431,CHEMBL623732,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,1,10090.0,500.0,Expert,N,BAO_0000218,,5182,F,
,1,14555,,,,80852,,,A-431,CHEMBL623733,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,1,10090.0,500.0,Expert,N,BAO_0000218,,5183,F,
,1,14555,,,,80852,,,A-431,CHEMBL623734,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,1,10090.0,500.0,Expert,N,BAO_0000218,,5184,F,
,1,14555,,,,80852,,,A-431,CHEMBL623735,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Mus musculus,1,10090.0,500.0,Expert,N,BAO_0000218,,5185,F,
,1,1937,,,,80852,,,A-431,CHEMBL623736,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,5186,F,
,1,13739,,,,80852,,,A-431,CHEMBL623737,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5187,F,
,1,3558,,,,80852,,,A-431,CHEMBL623738,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5188,F,
,1,3558,,,,80852,,,A-431,CHEMBL875168,Dose giving a 50% decrease in the living cell number (A437 cells),Homo sapiens,1,9606.0,500.0,Intermediate,N,BAO_0000219,,5189,F,
,1,17686,,,,80682,,,A549,CHEMBL623739,In vitro inhibitory concentration against proliferation of A459 cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5190,F,
,1,5305,,,,80682,,,A549,CHEMBL623740,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5191,F,
,1,3614,,,,80682,,,A549,CHEMBL624424,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5192,F,
,1,17229,,,,80021,,,A498,CHEMBL624425,In vitro antitumor activity against renal A498 tumor cell lines,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5193,F,
,1,15935,,,,80021,,,A498,CHEMBL624426,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5194,F,
,1,15935,,,,80021,,,A498,CHEMBL624427,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5195,F,
,1,15560,,,,80021,,,A498,CHEMBL624428,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5196,F,
,1,13891,,,,80021,,,A498,CHEMBL624429,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5197,F,
,1,13891,,,,80021,,,A498,CHEMBL624620,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5198,F,
,1,13788,,,,80021,,,A498,CHEMBL624621,Cytotoxicity on kidney carcinoma (A-498) cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5199,F,
,1,15403,,,,80021,,,A498,CHEMBL624622,Compound was evaluated against Human cell line renal A498,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5200,F,
,1,1009,,,,80021,,,A498,CHEMBL624623,Compound was tested for inhibition of A498 human renal cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5201,F,
,1,1043,,,,80021,,,A498,CHEMBL874365,Growth inhibitory activity against A498 human cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5202,F,
,1,5858,,,,80021,,,A498,CHEMBL624624,In vitro antitumor activity against human renal A498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5203,F,
,1,5958,,,,80021,,,A498,CHEMBL624625,In vitro cytotoxic activity against renal (A498) cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5204,F,
,1,5506,,,,80021,,,A498,CHEMBL624626,In vitro cytotoxic activity against human renal cancer (A498) cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5205,F,
,1,12781,,,,80021,,,A498,CHEMBL624627,Tested for cytostatic activity against renal A498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5206,F,
,1,14399,,,,80021,,,A498,CHEMBL883157,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5207,F,
,1,5958,,,,80021,,,A498,CHEMBL624628,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Homo sapiens,1,9606.0,624.0,Expert,N,BAO_0000219,,5208,F,
,1,3510,,In vivo,,22224,,,,CHEMBL624629,Cmax value after 2 mpk peroral administration to beagles,beagle,0,9615.0,,Autocuration,U,BAO_0000218,,5209,A,
,1,3510,,In vivo,,22224,,,,CHEMBL623551,Bioavailability,Canis lupus familiaris,0,9615.0,,Autocuration,U,BAO_0000218,,5210,A,beagle
,1,3510,,In vivo,,22224,,,,CHEMBL623552,Bioavailability after 1 mpk peroral administration to beagles,Canis lupus familiaris,0,9615.0,,Autocuration,U,BAO_0000218,,5211,A,beagle
,1,3510,,In vivo,,22224,,,,CHEMBL623553,Bioavailability after 2 mpk peroral administration to beagles,Canis lupus familiaris,0,9615.0,,Autocuration,U,BAO_0000218,,5212,A,beagle
,1,3085,,,,22224,,,,CHEMBL623554,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5213,A,
,1,3085,,,,22224,,,,CHEMBL623555,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5214,A,
,1,3085,,,,22224,,,,CHEMBL623556,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5215,A,
,1,9372,,,,22224,,,,CHEMBL623557,Solubility against bovine alpha-chymotrypsin,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5216,A,
,1,3085,,,,22224,,,,CHEMBL623558,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5217,A,
,1,3085,,,,22224,,,,CHEMBL623559,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5218,A,
Spleen,1,1469,,,,22224,,,,CHEMBL623560,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000221,2106.0,5219,A,
,1,4297,,,,22224,,,,CHEMBL623561,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5220,A,
,1,4297,,,,22224,,,,CHEMBL623562,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5221,A,
,1,17585,,,,22224,,,,CHEMBL623563,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5222,A,
Spleen,1,1336,,,,22224,,,,CHEMBL623564,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000221,2106.0,5223,A,
,1,3085,,,,22224,,,,CHEMBL873806,Half life in presence of 2 mg/mL BSA at pH 8.8,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5224,A,
,1,2857,,,,22224,,,,CHEMBL623565,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5225,A,
,1,2857,,,,22224,,,,CHEMBL623566,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5226,A,
,1,2857,,,,22224,,,,CHEMBL623567,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5227,A,
,1,1540,,,,22224,,,,CHEMBL623568,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Bos taurus,0,9913.0,,Autocuration,U,BAO_0000019,,5228,A,
Plasma,1,6316,,,,50588,,,,CHEMBL623569,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5229,A,
Plasma,1,17594,,,,50588,,,,CHEMBL623570,AUC after administration at 100 mg/kg/day in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5230,A,
Plasma,1,4953,,,,50588,,,,CHEMBL624254,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5231,A,
Plasma,1,16907,,,,50588,,,,CHEMBL624255,AUC value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5232,A,
Plasma,1,16907,,,,50588,,,,CHEMBL624256,AUC value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5233,A,
Plasma,1,2959,,,,50588,,,,CHEMBL624257,AUC value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5234,A,
Plasma,1,17594,,,,50588,,,,CHEMBL624258,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5235,A,
,1,5356,,,,50588,,,,CHEMBL875277,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5236,A,
,1,16807,,,,50588,,,,CHEMBL622667,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5237,A,
,1,4527,,,,50588,,,,CHEMBL622668,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5238,A,
,1,4527,,,,50588,,,,CHEMBL622669,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5239,A,
,1,15660,,,,50588,,,,CHEMBL622670,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5240,A,
,1,15660,,,,50588,,,,CHEMBL622671,Area under curve determined in dogs after oral administration of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5241,A,
,1,5802,,,,50588,,,,CHEMBL622672,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5242,A,
,1,3598,,,,50588,,,,CHEMBL622673,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,,5243,A,
,1,3598,,,,50588,,,,CHEMBL622674,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,,5244,A,
,1,5944,,,,50588,,,,CHEMBL622675,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5245,A,
,1,5944,,,,50588,,,,CHEMBL622676,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5246,A,
,1,5944,,,,50588,,,,CHEMBL622677,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5247,A,
,1,5944,,,,50588,,,,CHEMBL622678,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5248,A,
,1,4186,,,,50588,,,,CHEMBL622679,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5249,A,
,1,5007,,,,50588,,,,CHEMBL622680,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5250,A,
,1,5668,,,,50588,,,,CHEMBL622681,Area under curve was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5251,A,
,1,5668,,,,50588,,,,CHEMBL875278,Area under curve was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5252,A,
,1,5006,,,,50588,,,,CHEMBL622682,Area under curve was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5253,A,
,1,5006,,,,50588,,,,CHEMBL622683,Area under curve in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5254,A,
,1,3771,,,,50588,,,,CHEMBL622684,Area under curve in dogs at 10 mg/kg dose fo oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5255,A,
,1,3771,,,,50588,,,,CHEMBL622685,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5256,A,
,1,3771,,,,50588,,,,CHEMBL622686,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5257,A,
,1,1916,,,,50588,,,,CHEMBL618344,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5258,A,
,1,5302,,,,50588,,,,CHEMBL875582,Area under curve value in dog at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5259,A,
,1,5600,,,,50588,,,,CHEMBL618345,Area under curve was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5260,A,
,1,5600,,,,50588,,,,CHEMBL618346,Area under curve was determined after 0.3 mg/kg po administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5261,A,
,1,17764,,,,50588,,,,CHEMBL618347,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5262,A,
,1,4368,,,,50588,,,,CHEMBL618348,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5263,A,
,1,5318,,,,22224,,,,CHEMBL618349,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5264,A,
,1,5318,,,,22224,,,,CHEMBL618350,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5265,A,
,1,5318,,,,22224,,,,CHEMBL618351,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5266,A,
,1,5318,,,,22224,,,,CHEMBL618352,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5267,A,
Blood,1,14518,,,,22224,,,,CHEMBL873494,Time taken to reduce 50% of the concentration of compound in blood plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5268,A,
Plasma,1,2209,,,,22224,,,,CHEMBL618353,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5269,A,
Plasma,1,6787,,,,22224,,,,CHEMBL618354,Half life in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5270,A,
Plasma,1,4898,,,,22224,,,,CHEMBL875583,Half life in human plasma was reported,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5271,A,
Serum,1,6072,,,,22224,,,,CHEMBL618355,Half life in human serum,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,1977.0,5272,A,
Plasma,1,16907,,,,22224,,,,CHEMBL618356,Half life upon exposure to human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5273,A,
,1,5656,,In vitro,,22224,,Microsomes,,CHEMBL618357,t1/2 in human microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,,5274,A,
Plasma,1,4755,,,,22224,,,,CHEMBL618358,Half life period in 80% human plasma at 37 degree Centigrade,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5275,A,
Zone of skin,1,17503,,,,22224,,,,CHEMBL618359,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,14.0,5276,A,
Plasma,1,12357,,In vitro,,22224,,,,CHEMBL618360,Half-life measured in in vitro Cathepsin B assay in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5277,A,
,1,3076,,,,22224,,,,CHEMBL618361,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5278,A,
Liver,1,6410,,In vitro,,22224,,Microsomes,,CHEMBL618362,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5279,A,
Plasma,1,3741,,,,22224,,,,CHEMBL618363,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5280,A,
Plasma,1,3741,,,,22224,,,,CHEMBL618364,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5281,A,
Plasma,1,3741,,,,22224,,,,CHEMBL875584,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5282,A,
,1,1540,,,,22224,,,,CHEMBL618365,Half-life in the CEM cell extracts,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5283,A,
Plasma,1,2905,,,,22224,,,,CHEMBL873495,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5284,A,
Plasma,1,2905,,,,22224,,,,CHEMBL618366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5285,A,
,1,5523,,,,22224,,,,CHEMBL618367,Half-life was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5286,A,
Blood,1,1499,,,,22224,,,,CHEMBL618368,Half-life (human blood stability),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5287,A,
Blood,1,1499,,,,22224,,,,CHEMBL618369,Half-life (human blood stability); no data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5288,A,
Plasma,1,17065,,,,22224,,,,CHEMBL618370,Half-life in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5289,A,
,1,6861,,,,22224,,,,CHEMBL618371,CYP3A4 metabolism half-life (t1/2),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5290,A,
Blood,1,1499,,,,22224,,,,CHEMBL618372,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000221,178.0,5291,A,
Plasma,1,530,,In vitro,,22224,,,,CHEMBL618373,In vitro half life in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5292,A,
Plasma,1,1116,,In vitro,,22224,,,,CHEMBL618374,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5293,A,
Plasma,1,6695,,In vitro,,22224,,,,CHEMBL618375,In vitro hydrolysis in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5294,A,
Plasma,1,6695,,In vitro,,22224,,,,CHEMBL618376,In vitro hydrolysis in human plasma; no data,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5295,A,
Liver,1,10,,In vitro,,22224,,Microsomes,,CHEMBL618377,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5296,A,
Plasma,1,993,,,,22224,,,,CHEMBL618378,Plasma half life in human,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5297,A,
Plasma,1,15429,,,,22224,,,,CHEMBL618379,Stability after incubation with human plasma (at 37 degree C),Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5298,A,
Plasma,1,1675,,,,22224,,,,CHEMBL618380,T1/2 was evaluated in human plasma,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5299,A,
Plasma,1,2209,,,,22224,,,,CHEMBL618381,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5300,A,
Plasma,1,2209,,,,22224,,,,CHEMBL618382,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5301,A,
,1,5318,,,,22224,,,,CHEMBL618383,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5302,A,
,1,2412,,In vitro,,22224,,,,CHEMBL618384,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5303,A,
,1,2412,,In vitro,,22224,,,,CHEMBL618385,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5304,A,
Plasma,1,2906,,,,22224,,,,CHEMBL619099,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5305,A,
Plasma,1,2906,,,,22224,,,,CHEMBL619100,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000366,1969.0,5306,A,
,1,5495,,,,22224,,,,CHEMBL619101,Time taken for 50% to be consumed by serum PON1 was determined,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5307,A,
,1,5495,,,,22224,,,,CHEMBL619102,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000019,,5308,A,
Liver,1,4397,,,,22224,,Microsomes,,CHEMBL619103,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000251,2107.0,5309,A,
,1,2413,,,,22224,,,,CHEMBL619268,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5310,A,
,1,2413,,,,22224,,,,CHEMBL619269,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5311,A,
,1,2413,,,,22224,,,,CHEMBL619270,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5312,A,
,1,2413,,,,22224,,,,CHEMBL619271,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5313,A,
,1,2413,,,,22224,,,,CHEMBL875585,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5314,A,
,1,2413,,,,22224,,,,CHEMBL619272,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5315,A,
,1,6058,,,,80640,,,786-0,CHEMBL619273,Compound tested for growth inhibition of renal cancer cell line 786-0,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5316,F,
,1,17708,,,,80640,,,786-0,CHEMBL619274,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5317,F,
,1,14017,,,,80640,,,786-0,CHEMBL619275,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Homo sapiens,1,9606.0,391.0,Expert,N,BAO_0000219,,5318,F,
,1,16818,,,,80640,,,786-0,CHEMBL619276,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5319,F,
,1,16818,,,,80640,,,786-0,CHEMBL619277,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5320,F,
,1,16818,,,,80640,,,786-0,CHEMBL619278,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5321,F,
,1,11970,,,,80640,,,786-0,CHEMBL619279,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5322,F,
,1,12400,,,,80640,,,786-0,CHEMBL858458,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5323,F,
,1,12888,,,,80640,,,786-0,CHEMBL619280,Cytotoxic effect on renal cancer line 786-0,Homo sapiens,1,9606.0,391.0,Expert,N,BAO_0000219,,5324,F,
,1,15300,,,,80640,,,786-0,CHEMBL619281,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5325,F,
,1,14769,,,,80640,,,786-0,CHEMBL619282,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5326,F,
,1,15895,,,,80640,,,786-0,CHEMBL619283,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5327,F,
,1,17376,,,,80640,,,786-0,CHEMBL619284,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5328,F,
,1,14882,,,,80640,,,786-0,CHEMBL619285,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5329,F,
,1,14882,,,,80640,,,786-0,CHEMBL619286,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5330,F,
,1,15176,,,,80640,,,786-0,CHEMBL619287,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5331,F,
,1,12696,,,,80640,,,786-0,CHEMBL857455,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5332,F,
,1,2496,,,,80640,,,786-0,CHEMBL883801,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5333,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619288,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5334,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619289,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5335,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619290,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5336,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619291,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5337,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619292,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5338,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619293,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5339,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619294,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5340,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619295,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5341,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619296,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5342,F,
,1,11831,,,,80641,,,791T cell line,CHEMBL619297,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Homo sapiens,1,9606.0,972.0,Intermediate,N,BAO_0000219,,5343,F,
,1,12782,,,,80640,,,786-0,CHEMBL619298,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Homo sapiens,1,9606.0,391.0,Intermediate,N,BAO_0000219,,5344,F,
,1,1229,,,,22226,,,,CHEMBL619299,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,5345,F,
,1,15313,,,,80433,,,RPMI-8226,CHEMBL619300,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Homo sapiens,1,9606.0,741.0,Expert,N,BAO_0000219,,5346,F,
,1,15313,,,,80433,,,RPMI-8226,CHEMBL619301,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Homo sapiens,1,9606.0,741.0,Expert,N,BAO_0000219,,5347,F,
,1,11544,,,,80433,,,RPMI-8226,CHEMBL619302,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5348,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619303,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5349,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619304,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5350,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL857706,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5351,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619305,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5352,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619306,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5353,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619307,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5354,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619308,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5355,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619309,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5356,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL619310,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5357,F,
,1,14769,,,,80021,,,A498,CHEMBL619311,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5358,F,
,1,15354,,,,80021,,,A498,CHEMBL619312,Compound was tested for the growth inhibition of A498 renal tumor cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5359,F,
,1,17445,,,,80021,,,A498,CHEMBL619313,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5360,F,
,1,4337,,,,80021,,,A498,CHEMBL619314,In vitro inhibitory concentration against renal cancer cell line A498,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5361,F,
,1,15277,,,,80021,,,A498,CHEMBL619959,Cytotoxicity against A 498 tumor cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5362,F,
,1,4812,,,,80021,,,A498,CHEMBL619960,In vitro antitumor activity against A498 human cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5363,F,
,1,4812,,,,80021,,,A498,CHEMBL619961,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5364,F,
,1,4995,,,,80021,,,A498,CHEMBL619962,Inhibitory dose required against A498 human tumor cell lines,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5365,F,
,1,5847,,,,80021,,,A498,CHEMBL875586,Anticancer activity against one renal cancer (A498 cell line),Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5366,F,
,1,6557,,,,80021,,,A498,CHEMBL619963,In vitro cytotoxicity against melanoma A498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5367,F,
,1,2597,,,,80021,,,A498,CHEMBL619964,Compound was tested for growth inhibitory activity against A498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5368,F,
,1,6058,,,,80021,,,A498,CHEMBL620108,Compound tested for growth inhibition of renal cancer cell line A498,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5369,F,
,1,17708,,,,80021,,,A498,CHEMBL620109,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5370,F,
,1,15176,,,,80021,,,A498,CHEMBL620110,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5371,F,
,1,15300,,,,80021,,,A498,CHEMBL620111,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5372,F,
,1,11970,,,,80021,,,A498,CHEMBL620112,Tested for cytotoxicity against A498 cell lines in renal cancer,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5373,F,
,1,12400,,,,80021,,,A498,CHEMBL620113,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5374,F,
,1,12888,,,,80021,,,A498,CHEMBL620114,Cytotoxic effect on renal cancer lines A498,Homo sapiens,1,9606.0,624.0,Expert,N,BAO_0000219,,5375,F,
,1,3030,,,,80021,,,A498,CHEMBL620115,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5376,F,
,1,14769,,,,80021,,,A498,CHEMBL620116,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5377,F,
,1,17376,,,,80021,,,A498,CHEMBL620117,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5378,F,
,1,16558,,,,80021,,,A498,CHEMBL620118,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5379,F,
,1,5194,,,,80021,,,A498,CHEMBL620119,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5380,F,
,1,10708,,,,80021,,,A498,CHEMBL620120,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5381,F,
,1,16880,,,,80682,,,A549,CHEMBL620121,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5382,F,
,1,10196,,,,80682,,,A549,CHEMBL620122,Antitumor activity against A549 human lung carcinoma cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5383,F,
,1,10196,,,,80682,,,A549,CHEMBL620123,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5384,F,
,1,10196,,,,80682,,,A549,CHEMBL620124,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5385,F,
,1,12083,,,,80682,,,A549,CHEMBL620125,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5386,F,
,1,16464,,,,80682,,,A549,CHEMBL620126,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5387,F,
,1,16464,,,,80682,,,A549,CHEMBL883027,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5388,F,
,1,16470,,,,80682,,,A549,CHEMBL620127,In vitro cytotoxic activity against human lung A549 cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5389,F,
,1,16470,,,,80682,,,A549,CHEMBL620128,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5390,F,
,1,16470,,,,80682,,,A549,CHEMBL620129,In vitro cytotoxic activity against human lung A549 cell line),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5391,F,
,1,16470,,,,80682,,,A549,CHEMBL620130,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5392,F,
,1,16582,,,,80682,,,A549,CHEMBL620131,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5393,F,
,1,15935,,,,80682,,,A549,CHEMBL620132,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5394,F,
,1,15935,,,,80682,,,A549,CHEMBL620133,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5395,F,
,1,16597,,,,80682,,,A549,CHEMBL620134,Inhibition of A549 human lung carcinoma cell proliferation,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5396,F,
,1,17376,,,,80682,,,A549,CHEMBL620135,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5397,F,
,1,16496,,,,80682,,,A549,CHEMBL620136,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5398,F,
,1,16152,,,,80682,,,A549,CHEMBL620137,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5399,F,
,1,16152,,,,80682,,,A549,CHEMBL620268,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5400,F,
,1,16464,,,,80682,,,A549,CHEMBL620269,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5401,F,
,1,2288,,,,80682,,,A549,CHEMBL620270,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5402,F,
,1,17350,,,,80682,,,A549,CHEMBL620271,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5403,F,
,1,4090,,,,80682,,,A549,CHEMBL620272,Inhibition of A549 cancer cell proliferation,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5404,F,
,1,4090,,,,80682,,,A549,CHEMBL620273,Inhibition of A549 cancer cell proliferation (Not tested),Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5405,F,
,1,17350,,,,80682,,,A549,CHEMBL620274,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5406,F,
,1,4197,,,,80682,,,A549,CHEMBL620275,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5407,F,
,1,17072,,,,80682,,,A549,CHEMBL620276,Antiproliferative potency determined as inhibitory concentration against A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5408,F,
,1,17072,,,,80682,,,A549,CHEMBL620277,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5409,F,
,1,5194,,,,80682,,,A549,CHEMBL620278,Cytotoxicity against Renal cell lines A549 was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5410,F,
,1,4257,,,,50588,,,,CHEMBL620279,Area under curve was determined in dog after a 3 mg/kg of oral dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5411,A,
,1,6123,,,,50588,,,,CHEMBL620280,Area under curve was determined in dog after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5412,A,
,1,1337,,,,50588,,,,CHEMBL620281,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5413,A,
,1,1337,,,,50588,,,,CHEMBL620282,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5414,A,
,1,8833,,,,50588,,,,CHEMBL621134,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5415,A,
,1,8833,,,,50588,,,,CHEMBL621135,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5416,A,
,1,8833,,,,50588,,,,CHEMBL621136,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5417,A,
,1,8833,,,,50588,,,,CHEMBL621137,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5418,A,
Plasma,1,17657,,,,50588,,,,CHEMBL621138,Area under plasma concentration time curve in dog upon oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5419,A,
Plasma,1,17650,,,,50588,,,,CHEMBL875587,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5420,A,
,1,1977,,,,50588,,,,CHEMBL621139,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5421,A,
,1,1977,,,,50588,,,,CHEMBL621140,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5422,A,
,1,3132,,,,50588,,,,CHEMBL621141,Area under the curve for the compound was obtained when tested in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5423,A,
,1,5473,,,,50588,,,,CHEMBL621142,Area under the curve at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5424,A,
,1,5474,,,,50588,,,,CHEMBL621143,Area under the curve at a dose of 1 mg/kg (oral),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5425,A,
,1,5474,,,,50588,,,,CHEMBL621144,Area under the curve at i.v. dose of 0.2 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5426,A,
,1,6062,,,,50588,,,,CHEMBL621145,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5427,A,
,1,4709,,,,50588,,,,CHEMBL621146,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5428,A,
,1,2652,,,,50588,,,,CHEMBL622567,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5429,A,
,1,2652,,,,50588,,,,CHEMBL622568,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5430,A,
,1,2877,,,,50588,,,,CHEMBL622569,Compound was evaluated for area under the curve in dog blood.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5431,A,
,1,5444,,,,50588,,,,CHEMBL622570,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5432,A,
Plasma,1,5130,,,,50588,,,,CHEMBL622571,AUC in dog after oral dose (1 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5433,A,
,1,6265,,,,50588,,,,CHEMBL622572,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5434,A,
,1,4657,,,,50588,,,,CHEMBL622573,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5435,A,
,1,16367,,,,50588,,,,CHEMBL622574,Pharmacokinetic parameter AUC after intravenous administration to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5436,A,
,1,16367,,,,50588,,,,CHEMBL622575,Pharmacokinetic parameter AUC after oral administration to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5437,A,
,1,9579,,,,50588,,,,CHEMBL622576,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5438,A,
,1,9579,,,,50588,,,,CHEMBL622577,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5439,A,
,1,5983,,,,50588,,,,CHEMBL622578,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5440,A,
,1,6241,,,,50588,,,,CHEMBL622579,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5441,A,
,1,5313,,,,50588,,,,CHEMBL622580,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5442,A,
,1,5313,,,,50588,,,,CHEMBL622581,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5443,A,
,1,6642,,,,50588,,,,CHEMBL622582,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5444,A,
,1,6642,,,,50588,,,,CHEMBL622583,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5445,A,
,1,6641,,,,50588,,,,CHEMBL622584,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5446,A,
,1,6642,,,,50588,,,,CHEMBL622585,Oral AUCN in dog (dosed at 0.5 mpk iv ),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5447,A,
,1,17791,,,,50588,,,,CHEMBL622586,Compound was evaluated for oral bioavailability in dog; 90-100,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5448,A,
,1,17655,,,,50588,,,,CHEMBL623281,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5449,A,
,1,17655,,,,50588,,,,CHEMBL623282,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5450,A,
,1,6596,,,,50588,,,,CHEMBL623283,PAPP (membrane permeability) in dog kidney cell monolayer assay,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5451,A,
,1,3880,,,,50588,,,,CHEMBL623284,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5452,A,
,1,16367,,,,50588,,,,CHEMBL623285,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5453,A,
Plasma,1,17409,,,,50588,,,,CHEMBL623463,Plasma protein binding towards dog plasma at 10 uM,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5454,A,
Plasma,1,17409,,,,50588,,,,CHEMBL875952,Plasma protein binding towards dog plasma at 100 uM,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5455,A,
,1,2959,,In vivo,,50588,,,,CHEMBL621705,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5456,A,
,1,13501,,In vivo,,50588,,,,CHEMBL621706,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5457,A,
,1,4527,,In vivo,,50588,,,,CHEMBL621707,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5458,A,
,1,15145,,In vivo,,50588,,,,CHEMBL621708,Bioavailability in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5459,A,
,1,4219,,In vivo,,50588,,,,CHEMBL621709,Bioavailability,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5460,A,
,1,17538,,In vivo,,50588,,,,CHEMBL621710,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5461,A,
,1,17538,,In vivo,,50588,,,,CHEMBL621711,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5462,A,
,1,1466,,In vivo,,50588,,,,CHEMBL621712,Bioavailability in dog (dose 10.0 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5463,A,
,1,17650,,In vivo,,50588,,,,CHEMBL621713,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5464,A,
,1,3132,,In vivo,,50588,,,,CHEMBL621714,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5465,A,
,1,2413,,,,22224,,,,CHEMBL621715,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5466,A,
Liver,1,2413,,,,22224,,,,CHEMBL623717,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2107.0,5467,A,
Liver,1,2413,,,,22224,,,,CHEMBL623718,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2107.0,5468,A,
Liver,1,2413,,,,22224,,,,CHEMBL623719,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2107.0,5469,A,
,1,2413,,,,22224,,,,CHEMBL623720,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5470,A,
,1,2413,,,,22224,,,,CHEMBL623721,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5471,A,
Muscle tissue,1,2413,,,,22224,,,,CHEMBL623722,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2385.0,5472,A,
Muscle tissue,1,2413,,,,22224,,,,CHEMBL623723,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2385.0,5473,A,
Muscle tissue,1,2413,,,,22224,,,,CHEMBL618543,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2385.0,5474,A,
Spleen,1,2413,,,,22224,,,,CHEMBL618544,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2106.0,5475,A,
Spleen,1,2413,,,,22224,,,,CHEMBL875155,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,2106.0,5476,A,
,1,2413,,,,22224,,,,CHEMBL618545,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5477,A,
,1,2413,,,,22224,,,,CHEMBL618546,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5478,A,
,1,2413,,,,22224,,,,CHEMBL623529,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5479,A,
,1,2413,,,,22224,,,,CHEMBL623530,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5480,A,
,1,2413,,,,22224,,,,CHEMBL621764,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Mus sp.,0,10095.0,,Autocuration,U,BAO_0000218,,5481,A,
,1,17827,,,,22224,,,,CHEMBL621765,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5482,A,
Cerebellum,1,17827,,,,22224,,,,CHEMBL621766,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,2037.0,5483,A,
Frontal cortex,1,17827,,,,22224,,,,CHEMBL621767,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,1870.0,5484,A,
,1,17827,,,,22224,,,,CHEMBL621768,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5485,A,
Striatum,1,17827,,,,22224,,,,CHEMBL621769,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,2435.0,5486,A,
,1,17827,,,,22224,,,,CHEMBL621770,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5487,A,
Cerebellum,1,17827,,,,22224,,,,CHEMBL621771,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,2037.0,5488,A,
Frontal cortex,1,17827,,,,22224,,,,CHEMBL621772,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,1870.0,5489,A,
,1,17827,,,,22224,,,,CHEMBL621773,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5490,A,
Striatum,1,17827,,,,22224,,,,CHEMBL621774,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,2435.0,5491,A,
,1,17791,,,,22224,,,,CHEMBL621775,Compound was evaluated for oral bioavailability in rats,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5492,A,
Plasma,1,17667,,In vivo,,22224,,,,CHEMBL621776,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,5493,A,
,1,17791,,,,22224,,,,CHEMBL621777,Half life period was evaluated in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,5494,A,
,1,110,,In vivo,,22224,,,,CHEMBL875162,Half-life in rhesus monkeys by intravenous administration of dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,5495,A,
Plasma,1,5781,,,,50594,,,,CHEMBL621778,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,5496,A,
Plasma,1,17734,,,,50594,,,,CHEMBL621779,AUC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,5497,A,
Plasma,1,17718,,,,50594,,,,CHEMBL622479,AUC value was determined after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,5498,A,
,1,4573,,,,50594,,,,CHEMBL622480,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5499,A,
,1,3277,,,,50594,,,,CHEMBL622481,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5500,A,
,1,2862,,,,50594,,,,CHEMBL622482,Area under curve by ioral administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5501,A,
,1,2862,,,,50594,,,,CHEMBL622483,Area under curve by iv administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5502,A,
,1,5951,,,,50594,,,,CHEMBL622484,Area under curve at 0-8 hr in IRC mice after peroral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5503,A,
,1,17729,,,,50594,,,,CHEMBL622641,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5504,A,
,1,17728,,,,50594,,,,CHEMBL622642,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5505,A,
,1,17728,,,,50594,,,,CHEMBL622643,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5506,A,
,1,17729,,,,50594,,,,CHEMBL622644,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5507,A,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL622645,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5508,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL622646,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5509,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL621238,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5510,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL621239,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5511,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL621240,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5512,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL621241,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5513,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL621242,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5514,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620350,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5515,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620351,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5516,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620352,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5517,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620353,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5518,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620354,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5519,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620355,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5520,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620356,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5521,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620357,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5522,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620358,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5523,F,
,1,9424,,,,80433,,,RPMI-8226,CHEMBL620359,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Homo sapiens,1,9606.0,741.0,Expert,N,BAO_0000219,,5524,F,
,1,11544,,,,80433,,,RPMI-8226,CHEMBL620360,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5525,F,
,1,17378,,,,80433,,,RPMI-8226,CHEMBL620361,Cytotoxicity of compound against 8226/DOX1V cells,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5526,F,
,1,17378,,,,80433,,,RPMI-8226,CHEMBL620362,Cytotoxicity of compound against 8226/S cells,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5527,F,
,1,17079,,,,80433,,,RPMI-8226,CHEMBL620363,Inhibitory concentration against 8226 myeloma cancer cell line,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5528,F,
,1,17079,,,,80433,,,RPMI-8226,CHEMBL620364,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Homo sapiens,1,9606.0,741.0,Intermediate,N,BAO_0000219,,5529,F,
,1,13466,,,,80647,,,833K,CHEMBL620365,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Homo sapiens,1,9606.0,854.0,Intermediate,N,BAO_0000219,,5530,F,
,1,13466,,,,80647,,,833K,CHEMBL620366,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Homo sapiens,1,9606.0,854.0,Intermediate,N,BAO_0000219,,5531,F,
,1,2392,,,,80647,,,833K,CHEMBL620367,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Homo sapiens,1,9606.0,854.0,Expert,N,BAO_0000219,,5532,F,
,1,2392,,,,80647,,,833K,CHEMBL620368,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Homo sapiens,1,9606.0,854.0,Intermediate,N,BAO_0000219,,5533,F,
,1,6608,,,,22226,,,,CHEMBL620369,Inhibitory activity against caspase-1,,0,,,Autocuration,U,BAO_0000019,,5534,B,
,1,10199,,,,45,,,,CHEMBL620370,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Enterococcus faecalis,8,1351.0,,Autocuration,H,BAO_0000357,,5535,B,
,1,17749,,,,80648,,,8701-BC,CHEMBL620371,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Homo sapiens,1,9606.0,705.0,Intermediate,N,BAO_0000219,,5536,F,
,1,17749,,,,80648,,,8701-BC,CHEMBL620372,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Homo sapiens,1,9606.0,705.0,Intermediate,N,BAO_0000219,,5537,F,
,1,1229,,,,22226,,,,CHEMBL876492,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,5538,F,
,1,1229,,,,22226,,,,CHEMBL620373,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,5539,F,
,1,1229,,,,22226,,,,CHEMBL620374,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,0,,,Intermediate,U,BAO_0000019,,5540,F,
,1,6390,,,,22226,,,,CHEMBL620375,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,0,,,Autocuration,U,BAO_0000019,,5541,B,
,1,16219,,,,22226,,,,CHEMBL857902,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes,0,1314.0,,Autocuration,U,BAO_0000019,,5542,F,
,1,16219,,,,22226,,,,CHEMBL620376,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Streptococcus pyogenes,0,1314.0,,Autocuration,U,BAO_0000019,,5543,F,
,1,17043,,,,11922,,,,CHEMBL620377,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,8,,,Autocuration,H,BAO_0000357,,5544,B,
,1,6929,,,,81115,,,KB ,CHEMBL620378,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens,1,9606.0,324.0,Intermediate,N,BAO_0000219,,5545,F,
,1,6929,,,,81115,,,KB ,CHEMBL620379,Tested for in vitro cytotoxic potency of compound in 9KB assay,Homo sapiens,1,9606.0,324.0,Intermediate,N,BAO_0000219,,5546,A,
,1,7083,,,,22226,,,,CHEMBL620380,In vitro cytotoxicity of compound was tested against 9KB cells.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000219,,5547,F,
,1,12446,,,,80653,,,9L,CHEMBL884006,Cytotoxic concentration against 9L cells was determined on day 3,Rattus norvegicus,1,10116.0,392.0,Intermediate,N,BAO_0000219,,5548,F,
,1,15345,,,,80653,,,9L,CHEMBL620381,Tested in vitro for anticancer activity against 9L cells,Rattus norvegicus,1,10116.0,392.0,Expert,N,BAO_0000219,,5549,F,
,1,15345,,,,80653,,,9L,CHEMBL620382,Tested in vitro for anticancer activity against 9L cells; Not determined,Rattus norvegicus,1,10116.0,392.0,Expert,N,BAO_0000219,,5550,F,
,1,6301,,,,80682,,,A549,CHEMBL620383,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5551,F,
,1,4833,,,,80682,,,A549,CHEMBL876493,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5552,F,
,1,4833,,,,80682,,,A549,CHEMBL620384,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5553,F,
,1,4833,,,,80682,,,A549,CHEMBL620385,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5554,F,
,1,13330,,,,80682,,,A549,CHEMBL620386,Cytotoxicity against human lung carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5555,F,
,1,17517,,,,25,,,A549,CHEMBL620387,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Homo sapiens,9,9606.0,646.0,Expert,D,BAO_0000219,,5556,F,
,1,17517,,,,25,,,A549,CHEMBL621404,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Homo sapiens,9,9606.0,646.0,Expert,D,BAO_0000219,,5557,F,
,1,14425,,,,80682,,,A549,CHEMBL621405,"In vitro growth inhibition of A549, lung carcinoma",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5558,F,
,1,14425,,,,80682,,,A549,CHEMBL621406,"In vitro growth inhibition of A549, lung carcinoma.",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5559,F,
,1,5228,,,,80682,,,A549,CHEMBL621407,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5560,F,
,1,5351,,,,80682,,,A549,CHEMBL621408,Cytotoxic activity against human lung cancer A549 cell line was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5561,F,
,1,12198,,,,80682,,,A549,CHEMBL885345,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5562,F,
,1,13891,,,,80682,,,A549,CHEMBL621409,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5563,F,
,1,5677,,,,80682,,,A549,CHEMBL876034,Cytotoxicity in A549 (human carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5564,F,
,1,13788,,,,80682,,,A549,CHEMBL621410,Cytotoxicity on lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5565,F,
,1,13384,,,,80682,,,A549,CHEMBL621411,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5566,F,
,1,6726,,,,80682,,,A549,CHEMBL621412,Effective dose of compound against replication of A549 cell line was evaluated,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5567,F,
,1,3455,,,,80682,,,A549,CHEMBL621413,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5568,F,
,1,5726,,,,80682,,,A549,CHEMBL621414,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5569,F,
,1,5726,,,,80682,,,A549,CHEMBL621415,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5570,F,
,1,3936,,,,80682,,,A549,CHEMBL621416,The compound was evaluated for antiproliferative activity against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5571,F,
,1,14991,,,,80682,,,A549,CHEMBL621417,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5572,F,
,1,5243,,,,80682,,,A549,CHEMBL621418,Concentration required for growth inhibition of human lung carcinoma cell line A549,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5573,F,
,1,12858,,,,80682,,,A549,CHEMBL621419,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5574,F,
,1,6776,,,,80682,,,A549,CHEMBL621420,Growth inhibition against A549 cell line was evaluated,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5575,F,
,1,16558,,,,80682,,,A549,CHEMBL875823,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5576,F,
,1,4583,,,,80682,,,A549,CHEMBL621421,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5577,F,
,1,13514,,,,80682,,,A549,CHEMBL621422,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5578,F,
,1,15166,,,,80682,,,A549,CHEMBL884014,Chemosensitivity against DT-diaphorase rich A549 cell lines,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5579,F,
,1,13873,,,,80682,,,A549,CHEMBL621423,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5580,F,
,1,6447,,,,80682,,,A549,CHEMBL621424,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5581,F,
,1,2068,,,,80682,,,A549,CHEMBL621425,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5582,F,
,1,1863,,,,80682,,,A549,CHEMBL621426,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5583,F,
,1,13873,,,,80682,,,A549,CHEMBL621427,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5584,F,
,1,13873,,,,80682,,,A549,CHEMBL621428,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5585,F,
,1,13873,,,,80682,,,A549,CHEMBL621429,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5586,F,
,1,579,,,,80682,,,A549,CHEMBL621430,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5587,F,
,1,579,,,,80682,,,A549,CHEMBL621431,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5588,F,
,1,4584,,,,80682,,,A549,CHEMBL621432,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5589,F,
,1,5421,,,,80682,,,A549,CHEMBL621433,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5590,F,
,1,5421,,,,80682,,,A549,CHEMBL875824,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5591,F,
,1,5421,,,,80682,,,A549,CHEMBL621434,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5592,F,
,1,5421,,,,80682,,,A549,CHEMBL621435,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5593,F,
,1,14188,,,,80682,,,A549,CHEMBL621436,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5594,F,
,1,14188,,,,80682,,,A549,CHEMBL621437,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5595,F,
,1,15354,,,,80682,,,A549,CHEMBL621438,Compound was tested for the growth inhibition of A549 lung tumor cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5596,F,
,1,14253,,,,80682,,,A549,CHEMBL621439,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5597,F,
,1,13873,,,,80682,,,A549,CHEMBL621440,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5598,F,
,1,3043,,In vivo,,50588,,,,CHEMBL621441,Oral bioavailability in dog (conscious),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5599,A,
,1,3045,,In vivo,,50588,,,,CHEMBL621442,Compound was evaluated for the oral bioavailability after oral administration in dog.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5600,A,
,1,3022,,In vivo,,50588,,,,CHEMBL621443,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5601,A,
,1,4453,,In vivo,,50588,,,,CHEMBL621444,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5602,A,
,1,1696,,In vivo,,50588,,,,CHEMBL625133,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5603,A,
,1,5045,,In vivo,,50588,,,,CHEMBL625134,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5604,A,
,1,5356,,In vivo,,50588,,,,CHEMBL625135,Oral bioavailability in dog (fasted),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5605,A,
,1,17764,,In vivo,,50588,,,,CHEMBL625136,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5606,A,
,1,6448,,In vivo,,50588,,,,CHEMBL625137,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5607,A,
,1,1475,,In vivo,,50588,,,,CHEMBL625138,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5608,A,
,1,3788,,In vivo,,50588,,,,CHEMBL625139,Percent bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5609,A,
,1,3639,,In vivo,,50588,,,,CHEMBL872264,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5610,A,
,1,13397,,In vivo,,50588,,,,CHEMBL625140,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5611,A,
,1,2137,,In vivo,,50588,,,,CHEMBL624436,The compound was evaluated for bioavailability in dogs; 34-44,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5612,A,
,1,2959,,In vivo,,50588,,,,CHEMBL624437,Bioavailability in dog (dose 4 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5613,A,
,1,6448,,In vivo,,50588,,,,CHEMBL872261,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5614,A,
,1,6084,,,,50588,,,,CHEMBL624438,8 hour trough Blood level in dog was measured after administration of compound,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5615,A,
Plasma,1,3639,,In vivo,,50588,,,,CHEMBL624439,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5616,A,
,1,6316,,,,50588,,,,CHEMBL624440,C24 after oral administration at 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5617,A,
,1,5238,,,,50588,,,,CHEMBL624441,Clearance after oral and iv dosing in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5618,A,
Plasma,1,17796,,,,50588,,,,CHEMBL624442,Clearance of the drug was measured in the plasma of dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5619,A,
,1,2652,,,,50588,,,,CHEMBL624443,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5620,A,
,1,5654,,In vivo,,50588,,,,CHEMBL624444,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5621,A,
,1,6621,,In vivo,,50588,,,,CHEMBL624445,Clearance of compound was determined in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5622,A,
,1,6505,,In vivo,,50588,,,,CHEMBL624446,Clearance on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5623,A,
,1,5802,,In vivo,,50588,,,,CHEMBL624447,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5624,A,
,1,17267,,In vivo,,50588,,,,CHEMBL624448,Plasma clearance in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5625,A,
,1,4521,,In vivo,,50588,,,,CHEMBL624449,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5626,A,
,1,6535,,In vivo,,50588,,,,CHEMBL624450,Plasma clearance in dog after administration of 0.25 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5627,A,
,1,6535,,In vivo,,50588,,,,CHEMBL875942,Plasma clearance in dog after administration of 1 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5628,A,
,1,6535,,In vivo,,50588,,,,CHEMBL624451,Plasma clearance in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5629,A,
,1,5542,,In vivo,,50588,,,,CHEMBL624452,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5630,A,
,1,5199,,In vivo,,50588,,,,CHEMBL624453,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5631,A,
,1,16907,,In vivo,,50588,,,,CHEMBL624454,Plasma clearance after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5632,A,
,1,16907,,In vivo,,50588,,,,CHEMBL624455,Plasma clearance after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5633,A,
,1,16367,,In vivo,,50588,,,,CHEMBL624456,Plasma administration to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5634,A,
,1,5505,,In vivo,,50588,,,,CHEMBL624457,Plasma clearance was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5635,A,
,1,6215,,In vivo,,50588,,,,CHEMBL624458,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5636,A,
,1,1466,,In vivo,,50588,,,,CHEMBL624459,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5637,A,
Liver,1,5007,,In vitro,,102164,,Microsomes,,CHEMBL624460,Intrinsic clearance in human liver microsomes,Homo sapiens,2,9606.0,,Intermediate,S,BAO_0000251,2107.0,5638,A,
Liver,1,5007,,In vitro,,102164,,Microsomes,,CHEMBL624461,Intrinsic clearance in human liver microsomes,Homo sapiens,2,9606.0,,Intermediate,S,BAO_0000251,2107.0,5639,A,
,1,16452,,In vivo,,50588,,,,CHEMBL875943,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5640,A,
,1,16452,,In vivo,,50588,,,,CHEMBL624462,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5641,A,
,1,16452,,In vivo,,50588,,,,CHEMBL624463,Clearance in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5642,A,
,1,6221,,In vivo,,50588,,,,CHEMBL624464,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5643,A,
,1,5007,,In vivo,,50588,,,,CHEMBL624465,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5644,A,
,1,5668,,In vivo,,50588,,,,CHEMBL624466,Plasma clearance after peroral administration at 10 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5645,A,
,1,5668,,In vivo,,50588,,,,CHEMBL624467,Plasma clearance after peroral administration at 5 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5646,A,
,1,5668,,In vivo,,50588,,,,CHEMBL624468,Plasma clearance after peroral administration at 5 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5647,A,
,1,15660,,In vivo,,50588,,,,CHEMBL624469,Plasma clearance was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5648,A,
,1,15660,,In vivo,,50588,,,,CHEMBL624470,Plasma clearance was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5649,A,
,1,5983,,In vivo,,50588,,,,CHEMBL624471,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5650,A,
,1,5600,,In vivo,,50588,,,,CHEMBL624472,Total clearance was determined after 0.1 mg/kg iv administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5651,A,
,1,17764,,In vivo,,50588,,,,CHEMBL622775,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5652,A,
,1,6039,,In vivo,,50588,,,,CHEMBL622776,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5653,A,
,1,6039,,In vivo,,50588,,,,CHEMBL622777,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5654,A,
,1,6039,,In vivo,,50588,,,,CHEMBL622778,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5655,A,
,1,4368,,In vivo,,50588,,,,CHEMBL622779,Clearance by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5656,A,
,1,4305,,In vivo,,50588,,,,CHEMBL622780,Clearance by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5657,A,
Plasma,1,1918,,In vivo,,50588,,,,CHEMBL622781,Clearance value was evaluated in dog plasma,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5658,A,
,1,6005,,In vivo,,50588,,,,CHEMBL622782,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5659,A,
Plasma,1,4839,,In vivo,,50588,,,,CHEMBL622783,Compound was tested for plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5660,A,
,1,4239,,In vivo,,50588,,,,CHEMBL622784,Pharmacokinetic property (Plasma clearance) was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5661,A,
,1,17729,,,,50594,,,,CHEMBL622785,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5662,A,
,1,17728,,,,50594,,,,CHEMBL622786,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5663,A,
,1,5302,,,,50594,,,,CHEMBL622787,Area under curve value in mouse at a dose of 10 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5664,A,
,1,5506,,,,50594,,,,CHEMBL875949,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5665,A,
,1,5506,,,,50594,,,,CHEMBL622788,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5666,A,
,1,17764,,,,50594,,,,CHEMBL622789,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5667,F,
,1,17764,,,,50594,,,,CHEMBL622790,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5668,F,
,1,17764,,,,50594,,,,CHEMBL622791,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5669,F,
,1,17764,,,,50594,,,,CHEMBL622792,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5670,F,
,1,17764,,,,50594,,,,CHEMBL622793,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5671,A,
,1,17753,,,,50594,,,,CHEMBL622794,Area under curve was determined for the compound at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5672,A,
,1,17753,,,,50594,,,,CHEMBL622795,Area under curve was determined for the compound at 40 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5673,A,
,1,17753,,,,50594,,,,CHEMBL621803,Area under curve was determined for the compound at 5 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5674,A,
,1,3132,,,,50594,,,,CHEMBL621804,Area under the curve for the compound is obtained at dose 25 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5675,A,
,1,3132,,,,50594,,,,CHEMBL621805,Area under the curve for the compound was obtained when tested in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5676,A,
,1,17837,,,,50594,,,,CHEMBL621806,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5677,A,
,1,17837,,,,50594,,,,CHEMBL621807,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5678,A,
,1,6062,,,,50594,,,,CHEMBL621808,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5679,A,
,1,4066,,,,50594,,,,CHEMBL621809,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5680,A,
,1,16597,,,,50594,,,,CHEMBL621810,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5681,A,
,1,14239,,,,50594,,,,CHEMBL875164,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5682,A,
,1,14239,,,,50594,,,,CHEMBL621811,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5683,A,
,1,4890,,,,50594,,,,CHEMBL621812,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5684,A,
,1,429,,,,50594,,,,CHEMBL621813,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5685,A,
,1,429,,,,50594,,,,CHEMBL621814,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5686,A,
,1,5969,,,,50594,,,,CHEMBL621815,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5687,A,
,1,5969,,,,50594,,,,CHEMBL621816,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5688,A,
,1,5969,,,,50594,,,,CHEMBL621817,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5689,A,
,1,6091,,,,50594,,,,CHEMBL621818,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5690,A,
,1,6091,,,,50594,,,,CHEMBL621819,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5691,A,
,1,6091,,,,50594,,,,CHEMBL621820,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5692,A,
,1,6091,,,,50594,,,,CHEMBL621821,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5693,A,
,1,6178,,,,50594,,,,CHEMBL621822,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5694,A,
,1,6178,,,,50594,,,,CHEMBL619474,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5695,A,
,1,6619,,,,50594,,,,CHEMBL619475,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5696,A,
,1,6619,,,,50594,,,,CHEMBL619476,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5697,A,
,1,3760,,,,50594,,,,CHEMBL619477,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5698,A,
,1,3760,,,,50594,,,,CHEMBL619478,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5699,A,
,1,3760,,,,50594,,,,CHEMBL619479,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5700,A,
,1,3760,,,,50594,,,,CHEMBL619480,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5701,A,
,1,3192,,,,50594,,,,CHEMBL619481,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5702,A,
,1,3192,,,,50594,,,,CHEMBL619482,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5703,A,
,1,2675,,,,50594,,,,CHEMBL619483,Area under the curve was evaluated in mice after intravenous administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5704,A,
,1,2675,,,,50594,,,,CHEMBL619484,Area under the curve was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5705,A,
Plasma,1,16597,,,,50594,,,,CHEMBL619485,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,5706,A,
Plasma,1,16597,,,,50594,,,,CHEMBL619486,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,5707,A,
,1,16597,,,,50594,,,,CHEMBL619487,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5708,A,
,1,17734,,,,50594,,,,CHEMBL619488,AUMC after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5709,A,
Blood,1,7767,,In vivo,,50594,,,,CHEMBL620106,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5710,A,
,1,15345,,,,80653,,,9L,CHEMBL620107,The compound was tested in vitro for anticancer activity against 9L cells,,1,,392.0,Intermediate,N,BAO_0000219,,5711,F,
,1,2181,,,,22226,,,,CHEMBL620283,Anti proliferation activity determined; Weak effect,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,5712,F,
,1,2181,,,,22226,,,,CHEMBL875176,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000219,,5713,F,
,1,2181,,,,22226,,,,CHEMBL620284,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000219,,5714,F,
,1,2181,,,,22226,,,,CHEMBL623515,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000219,,5715,F,
,1,10486,,,,22226,,,,CHEMBL623516,The cytotoxic activity was in vitro tested by 9PS assay method,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,5716,F,
,1,10486,,,,22226,,,,CHEMBL623517,The cytotoxic activity was in vitro tested by 9PS assay method.,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,5717,F,
,1,15508,,,,22224,,,,CHEMBL857878,Partition coefficient (logD6.5),,0,,,Autocuration,U,BAO_0000019,,5718,A,
,1,5242,,,,81034,,,A2780,CHEMBL623518,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,5719,F,
,1,16167,,,,80018,,,A-375,CHEMBL624195,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,5720,F,
,1,4782,,,,80852,,,A-431,CHEMBL624196,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,5721,F,
,1,16093,,,,9,,,A-431,CHEMBL624197,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Homo sapiens,9,9606.0,500.0,Expert,D,BAO_0000219,,5722,F,
,1,2596,,,,80021,,,A498,CHEMBL624198,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5723,F,
,1,2596,,,,80021,,,A498,CHEMBL621287,in vitro cytotoxicity against A 498 cancer cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5724,F,
,1,3239,,,,80021,,,A498,CHEMBL621288,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5725,F,
,1,1847,,,,80021,,,A498,CHEMBL876496,Cytotoxic activity against A 498 renal cancer cell lines.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5726,F,
,1,10553,,,,80021,,,A498,CHEMBL621289,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5727,F,
,1,16219,,,,22226,,,,CHEMBL621290,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus,0,1280.0,,Autocuration,U,BAO_0000019,,5728,F,
,1,16219,,,,22226,,,,CHEMBL621291,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Staphylococcus aureus,0,1280.0,,Autocuration,U,BAO_0000019,,5729,F,
,1,16219,,,,22226,,,,CHEMBL621292,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus,0,1280.0,,Autocuration,U,BAO_0000019,,5730,F,
,1,16219,,,,22226,,,,CHEMBL621293,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Staphylococcus aureus,0,1280.0,,Autocuration,U,BAO_0000019,,5731,F,
,1,4782,,,,80682,,,A549,CHEMBL621294,Inhibitory concentration required against A 549 lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5732,F,
,1,11805,,,,80682,,,A549,CHEMBL621295,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5733,F,
,1,11805,,,,80682,,,A549,CHEMBL884007,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5734,F,
,1,2007,,,,80682,,,A549,CHEMBL621296,In vitro cytotoxicity against lung cancer A 549 cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5735,F,
,1,4594,,,,80682,,,A549,CHEMBL621297,Compound was tested for its cytotoxicity against A 549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5736,F,
,1,6018,,,,80682,,,A549,CHEMBL839828,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5737,F,
,1,6018,,,,80682,,,A549,CHEMBL620397,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5738,F,
,1,3599,,,,80682,,,A549,CHEMBL620398,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5739,F,
,1,2551,,,,80682,,,A549,CHEMBL620399,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5740,F,
,1,16132,,,,80682,,,A549,CHEMBL620400,In vitro inhibition of A549 (human lung cancer) cell growth.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5741,F,
,1,16132,,,,80682,,,A549,CHEMBL620401,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5742,F,
,1,2551,,,,80682,,,A549,CHEMBL620402,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5743,F,
,1,2551,,,,80682,,,A549,CHEMBL620403,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5744,F,
,1,11913,,,,22226,,,,CHEMBL620404,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,0,,,Autocuration,U,BAO_0000218,,5745,F,
,1,12621,,In vivo,,104694,,,,CHEMBL620405,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,4,,,Autocuration,H,BAO_0000218,,5746,F,
,1,12621,,In vivo,,104694,,,,CHEMBL620406,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,4,,,Autocuration,H,BAO_0000218,,5747,F,
,1,12621,,In vivo,,104694,,,,CHEMBL620407,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,4,,,Autocuration,H,BAO_0000218,,5748,F,
,1,12621,,In vivo,,104694,,,,CHEMBL620408,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,4,,,Autocuration,H,BAO_0000218,,5749,F,
,1,12621,,In vivo,,104694,,,,CHEMBL620409,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,4,,,Autocuration,H,BAO_0000218,,5750,F,
,1,3600,,,,80021,,,A498,CHEMBL620410,Inhibition of A-498 human Renal cell proliferation,Homo sapiens,1,9606.0,624.0,Expert,N,BAO_0000219,,5751,F,
,1,1796,,,,22226,,,,CHEMBL620411,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,5752,F,
,1,1796,,,,22226,,,,CHEMBL620412,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,5753,F,
,1,1796,,,,22226,,,,CHEMBL876596,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000019,,5754,F,
,1,16464,,,,80012,,,A 172,CHEMBL620413,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Homo sapiens,1,9606.0,622.0,Expert,N,BAO_0000219,,5755,F,
,1,16464,,,,80012,,,A 172,CHEMBL620414,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,5756,F,
,1,16464,,,,80012,,,A 172,CHEMBL620415,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,5757,F,
,1,13617,,,,80682,,,A549,CHEMBL620416,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5758,F,
,1,4584,,,,80682,,,A549,CHEMBL620417,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5759,F,
,1,13799,,,,80682,,,A549,CHEMBL620418,Cytotoxic activity evaluated against A549 tumor cells,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5760,F,
,1,16726,,,,80682,,,A549,CHEMBL620419,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5761,F,
,1,16109,,,,80682,,,A549,CHEMBL620420,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5762,F,
,1,16109,,,,80682,,,A549,CHEMBL620421,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5763,F,
,1,15474,,,,80682,,,A549,CHEMBL620422,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5764,F,
,1,6851,,,,80682,,,A549,CHEMBL620423,Cytotoxicity of compound against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5765,F,
,1,17534,,,,80682,,,A549,CHEMBL620424,Cytotoxicity against human lung cell carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5766,F,
,1,2621,,,,80682,,,A549,CHEMBL620425,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5767,F,
,1,830,,,,80682,,,A549,CHEMBL620426,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5768,F,
,1,14255,,,,80682,,,A549,CHEMBL620427,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5769,F,
,1,14255,,,,80682,,,A549,CHEMBL620428,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5770,F,
,1,1590,,,,80682,,,A549,CHEMBL620429,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5771,F,
,1,6146,,,,80682,,,A549,CHEMBL620430,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5772,F,
,1,17427,,,,80682,,,A549,CHEMBL839887,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5773,F,
,1,5280,,,,80682,,,A549,CHEMBL620431,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5774,F,
,1,16786,,,,80682,,,A549,CHEMBL884010,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5775,F,
,1,5895,,,,80682,,,A549,CHEMBL620538,In vitro cytotoxicity against A549 (human lung cancer),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5776,F,
,1,14297,,,,80682,,,A549,CHEMBL620539,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5777,F,
,1,17824,,,,80682,,,A549,CHEMBL623373,In vivo antiproliferative activity against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5778,F,
,1,14368,,,,80682,,,A549,CHEMBL623374,Inhibition of non-small-cell lung adenocarcinoma (A549),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5779,F,
,1,14368,,,,80682,,,A549,CHEMBL623375,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5780,F,
,1,14254,,,,80682,,,A549,CHEMBL623376,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5781,F,
,1,15897,,,,80682,,,A549,CHEMBL623377,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5782,F,
,1,13866,,,,80682,,,A549,CHEMBL623378,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5783,F,
,1,13370,,,,80682,,,A549,CHEMBL623379,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5784,F,
,1,4862,,,,80682,,,A549,CHEMBL623380,Inhibitory activity against A549 lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5785,F,
,1,4862,,,,80682,,,A549,CHEMBL623381,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5786,F,
,1,4862,,,,80682,,,A549,CHEMBL623382,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5787,F,
,1,15970,,,,80682,,,A549,CHEMBL623383,Inhibitory concentration against A549 (lung cancer) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5788,F,
,1,17713,,,,80682,,,A549,CHEMBL623384,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5789,F,
,1,4833,,,,80682,,,A549,CHEMBL623385,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5790,F,
,1,13736,,,,80682,,,A549,CHEMBL623386,Activity against A549 cancer cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5791,F,
,1,4312,,,,80682,,,A549,CHEMBL884105,The compound was evaluated for cytotoxicity against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5792,F,
,1,5421,,,,80682,,,A549,CHEMBL623387,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5793,F,
,1,5421,,,,80682,,,A549,CHEMBL621568,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5794,F,
,1,14717,,,,80682,,,A549,CHEMBL621569,Growth inhibitory activity was measured for human A549 tumor cell line.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5795,F,
,1,4634,,,,80682,,,A549,CHEMBL621570,Inhibitory activity against A549 lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5796,F,
,1,1149,,,,80682,,,A549,CHEMBL621571,Inhibitory activity against A549 cell line; inactive,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5797,F,
,1,5421,,,,80682,,,A549,CHEMBL621572,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5798,F,
,1,5421,,,,80682,,,A549,CHEMBL621573,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5799,F,
,1,5421,,,,80682,,,A549,CHEMBL621574,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5800,F,
,1,3320,,,,80682,,,A549,CHEMBL621575,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5801,F,
,1,3320,,,,80682,,,A549,CHEMBL621576,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5802,F,
,1,3320,,,,80682,,,A549,CHEMBL621577,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5803,F,
,1,3320,,,,80682,,,A549,CHEMBL621578,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5804,F,
,1,3320,,,,80682,,,A549,CHEMBL621579,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5805,F,
,1,5726,,,,80682,,,A549,CHEMBL621580,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5806,F,
,1,17800,,In vivo,,50588,,,,CHEMBL621581,Plasma clearance (in vivo) in mongrel dogs was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5807,A,
,1,5985,,In vivo,,50588,,,,CHEMBL621582,Plasma clearance was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5808,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621583,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5809,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621584,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5810,A,
Plasma,1,4839,,In vivo,,50588,,,,CHEMBL621585,Tested for plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5811,A,
,1,3639,,In vivo,,50588,,,,CHEMBL621586,The compound was tested for clearance in dog plasma.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5812,A,
,1,4838,,In vivo,,50588,,,,CHEMBL875835,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5813,A,
,1,4137,,In vivo,,50588,,,,CHEMBL621587,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5814,A,
Plasma,1,5017,,In vivo,,50588,,,,CHEMBL621588,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5815,A,
Liver,1,17538,,In vitro,,50588,,Microsomes,,CHEMBL621589,In vitro clearance in dog liver microsomes,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2107.0,5816,A,
,1,6161,,In vivo,,50588,,,,CHEMBL621590,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5817,A,
,1,6161,,In vivo,,50588,,,,CHEMBL621591,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5818,A,
,1,1696,,In vivo,,50588,,,,CHEMBL621592,Plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5819,A,
,1,6762,,In vivo,,50588,,,,CHEMBL621593,Clearance rate in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5820,A,
Plasma,1,5932,,In vivo,,50588,,,,CHEMBL621594,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5821,A,
,1,6305,,In vivo,,50588,,,,CHEMBL621595,Clearance in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5822,A,
,1,4942,,In vivo,,50588,,,,CHEMBL621596,Plasma clearance in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5823,A,
,1,4219,,In vivo,,50588,,,,CHEMBL621597,Plasma clearance was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5824,A,
,1,17853,,In vivo,,50588,,,,CHEMBL621598,Lower clearance in dog (i.v.) at 0.5 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5825,A,
,1,4514,,In vivo,,50588,,,,CHEMBL621599,Plasma clearance in Beagle dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5826,A,
,1,6448,,In vivo,,50588,,,,CHEMBL875836,Plasma clearance (Clp) in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5827,A,
,1,6227,,In vivo,,50588,,,,CHEMBL621600,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5828,A,
,1,6227,,In vivo,,50588,,,,CHEMBL621601,Plasma clearance (pharmacokinetic parameter) in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5829,A,
,1,6062,,In vivo,,50588,,,,CHEMBL618474,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5830,A,
,1,6821,,In vivo,,50588,,,,CHEMBL618475,Plasma clearance of compound was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5831,A,
,1,4709,,In vivo,,50588,,,,CHEMBL624524,Plasma clearance after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5832,A,
,1,4521,,In vivo,,50588,,,,CHEMBL624525,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5833,A,
,1,5374,,In vivo,,50588,,,,CHEMBL624526,Plasma clearance in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5834,A,
,1,6057,,In vivo,,50588,,,,CHEMBL624527,Plasma clearance was calculated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5835,A,
,1,4727,,In vivo,,50588,,,,CHEMBL624528,Plasma clearance at the dose of 2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5836,A,
,1,5145,,In vivo,,50588,,,,CHEMBL624529,Plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5837,A,
,1,17657,,In vivo,,50588,,,,CHEMBL624530,Plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5838,A,
,1,17657,,In vivo,,50588,,,,CHEMBL624531,Plasma clearance in dog; Unable to calculate,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5839,A,
,1,5145,,In vivo,,50588,,,,CHEMBL624532,Plasma clearance in rhesus monkey,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5840,A,
,1,6642,,In vivo,,50588,,,,CHEMBL624533,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5841,A,
,1,6641,,In vivo,,50588,,,,CHEMBL624534,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5842,A,
,1,6642,,In vivo,,50588,,,,CHEMBL624535,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5843,A,
,1,5472,,In vivo,,50588,,,,CHEMBL624536,Plasma clearance was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5844,A,
,1,5472,,In vivo,,50588,,,,CHEMBL624537,Plasma clearance was evaluated in dog; Not tested,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5845,A,
,1,5472,,In vivo,,50588,,,,CHEMBL624538,Plasma clearance was evaluated in rhesus,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5846,A,
,1,5472,,In vivo,,50588,,,,CHEMBL624539,Plasma clearance was evaluated in rhesus; Not tested,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5847,A,
,1,4257,,In vivo,,50588,,,,CHEMBL624540,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5848,A,
,1,6679,,In vivo,,50588,,,,CHEMBL624541,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5849,A,
,1,5546,,In vivo,,50588,,,,CHEMBL624542,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5850,A,
,1,6348,,In vivo,,50588,,,,CHEMBL624543,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5851,A,
,1,5474,,In vivo,,50588,,,,CHEMBL624544,Clearance value at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5852,A,
Plasma,1,6316,,In vivo,,50588,,,,CHEMBL624545,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5853,A,
,1,17594,,In vivo,,50588,,,,CHEMBL624546,Cmax after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5854,A,
,1,17594,,In vivo,,50588,,,,CHEMBL875957,Cmax after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5855,A,
,1,5802,,In vivo,,50588,,,,CHEMBL624547,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5856,A,
,1,6535,,In vivo,,50588,,,,CHEMBL624548,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5857,A,
,1,6535,,In vivo,,50588,,,,CHEMBL624549,Cmax in dog after administration of 1 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5858,A,
Plasma,1,1466,,In vivo,,50588,,,,CHEMBL624550,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,5859,A,
,1,6505,,In vivo,,50588,,,,CHEMBL621613,Cmax on p.o. administration of 10 mg/kg was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5860,A,
,1,5668,,In vivo,,50588,,,,CHEMBL621614,Cmax was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5861,A,
,1,5668,,In vivo,,50588,,,,CHEMBL623431,Cmax was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5862,A,
,1,5668,,In vivo,,50588,,,,CHEMBL623432,Cmax was determine after peroral administration at 5 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5863,A,
,1,5600,,In vivo,,50588,,,,CHEMBL623433,Cmax after 0.3 mg/kg po administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5864,A,
,1,17764,,In vivo,,50588,,,,CHEMBL623434,Cmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5865,A,
,1,6123,,In vivo,,50588,,,,CHEMBL623435,Cmax in dog after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5866,A,
,1,6123,,In vivo,,50588,,,,CHEMBL623436,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5867,A,
,1,6757,,In vivo,,50588,,,,CHEMBL875958,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5868,A,
,1,16907,,In vivo,,50588,,,,CHEMBL623437,Cmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5869,A,
Blood,1,7767,,In vivo,,50594,,,,CHEMBL623438,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5870,A,
Blood,1,7767,,In vivo,,50594,,,,CHEMBL623439,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,5871,A,
Bone,1,7767,,In vivo,,50594,,,,CHEMBL623440,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,5872,A,
Bone,1,7767,,In vivo,,50594,,,,CHEMBL623441,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,5873,A,
Bone,1,7767,,In vivo,,50594,,,,CHEMBL623442,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,5874,A,
,1,7767,,In vivo,,50594,,,,CHEMBL623469,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5875,A,
,1,7767,,In vivo,,50594,,,,CHEMBL623470,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5876,A,
,1,7767,,In vivo,,50594,,,,CHEMBL623471,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5877,A,
Heart,1,7767,,In vivo,,50594,,,,CHEMBL623472,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5878,A,
Heart,1,7767,,In vivo,,50594,,,,CHEMBL623473,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5879,A,
Heart,1,7767,,In vivo,,50594,,,,CHEMBL623474,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,5880,A,
Kidney,1,7767,,In vivo,,50594,,,,CHEMBL623475,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5881,A,
Kidney,1,7767,,In vivo,,50594,,,,CHEMBL623476,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5882,A,
Kidney,1,7767,,In vivo,,50594,,,,CHEMBL623477,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,5883,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL621896,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5884,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL621897,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5885,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL621898,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5886,A,
Liver,1,7767,,In vivo,,50594,,,,CHEMBL621899,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5887,A,
Liver,1,7767,,In vivo,,50594,,,,CHEMBL621900,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5888,A,
Liver,1,7767,,In vivo,,50594,,,,CHEMBL621901,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,5889,A,
Lung,1,7767,,In vivo,,50594,,,,CHEMBL621902,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,5890,A,
Lung,1,7767,,In vivo,,50594,,,,CHEMBL621903,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,5891,A,
Lung,1,7767,,In vivo,,50594,,,,CHEMBL622587,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,5892,A,
Muscle tissue,1,7767,,In vivo,,50594,,,,CHEMBL620285,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,5893,A,
Muscle tissue,1,7767,,In vivo,,50594,,,,CHEMBL875285,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,5894,A,
Muscle tissue,1,7767,,In vivo,,50594,,,,CHEMBL620286,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,5895,A,
,1,7767,,In vivo,,50594,,,,CHEMBL620287,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5896,A,
,1,7767,,In vivo,,50594,,,,CHEMBL620288,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5897,A,
,1,7767,,In vivo,,50594,,,,CHEMBL620289,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,5898,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL620290,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5899,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL620291,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5900,A,
Intestine,1,7767,,In vivo,,50594,,,,CHEMBL620292,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,160.0,5901,A,
Spleen,1,7767,,In vivo,,50594,,,,CHEMBL620293,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5902,A,
Spleen,1,7767,,In vivo,,50594,,,,CHEMBL620294,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5903,A,
Spleen,1,7767,,In vivo,,50594,,,,CHEMBL618614,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,5904,A,
Stomach,1,7767,,In vivo,,50594,,,,CHEMBL618615,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,5905,A,
Stomach,1,7767,,In vivo,,50594,,,,CHEMBL618616,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,5906,A,
,1,2036,,,,80012,,,A 172,CHEMBL618617,Cytotoxicity against A-172 human tumor cell lines,Homo sapiens,1,9606.0,622.0,Expert,N,BAO_0000219,,5907,F,
,1,2357,,,,80012,,,A 172,CHEMBL618618,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,5908,F,
,1,1457,,,,80014,,,A204,CHEMBL618619,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Homo sapiens,1,9606.0,623.0,Intermediate,N,BAO_0000219,,5909,F,
,1,4379,,,,81034,,,A2780,CHEMBL618620,Tested for antiproliferative activity against A-2780 tumoral cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,5910,F,
,1,1093,,,,80018,,,A-375,CHEMBL618621,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,5911,F,
,1,12152,,,,80018,,,A-375,CHEMBL618622,Tested in vitro against A-375 cell line human melanoma,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,5912,F,
,1,16464,,,,80019,,,A-427,CHEMBL618623,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Homo sapiens,1,9606.0,797.0,Expert,N,BAO_0000219,,5913,F,
,1,16464,,,,80019,,,A-427,CHEMBL618624,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5914,F,
,1,16582,,,,80019,,,A-427,CHEMBL618625,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Homo sapiens,1,9606.0,797.0,Expert,N,BAO_0000219,,5915,F,
,1,16464,,,,80019,,,A-427,CHEMBL618626,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5916,F,
,1,10413,,,,80019,,,A-427,CHEMBL618627,Antitumor activity on A-427 lung carcinoma cell lines,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5917,F,
,1,6418,,,,80019,,,A-427,CHEMBL618628,Cytotoxic activity against human A-427 lung tumor cell line,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5918,F,
,1,17134,,,,80019,,,A-427,CHEMBL618629,In vitro antitumor effects against human A-427 cell lines.,Homo sapiens,1,9606.0,797.0,Expert,N,BAO_0000219,,5919,F,
,1,16132,,,,80019,,,A-427,CHEMBL618630,In vitro inhibition of A-427 (human lung cancer) cell growth.,Homo sapiens,1,9606.0,797.0,Expert,N,BAO_0000219,,5920,F,
,1,16132,,,,80019,,,A-427,CHEMBL618631,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5921,F,
,1,16780,,,,80019,,,A-427,CHEMBL618632,Cytotoxic activity of compound against A-427 lung human tumor cell line,Homo sapiens,1,9606.0,797.0,Intermediate,N,BAO_0000219,,5922,F,
,1,4085,,,,80852,,,A-431,CHEMBL618633,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Homo sapiens,1,9606.0,500.0,Expert,N,BAO_0000219,,5923,F,
,1,1276,,,,80021,,,A498,CHEMBL619315,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5924,F,
,1,3498,,,,80021,,,A498,CHEMBL619316,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Homo sapiens,1,9606.0,624.0,Expert,N,BAO_0000219,,5925,F,
,1,1169,,,,80021,,,A498,CHEMBL619317,Cytotoxicity against human kidney carcinoma A-498cell lines,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5926,F,
,1,4450,,,,80021,,,A498,CHEMBL619318,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5927,F,
,1,3311,,,,80021,,,A498,CHEMBL619319,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5928,F,
,1,4461,,,,80021,,,A498,CHEMBL619739,Antitumor cytotoxic activity against A-498 cell line was determined,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5929,F,
,1,3311,,,,80021,,,A498,CHEMBL619740,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5930,F,
,1,3311,,,,80021,,,A498,CHEMBL883158,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5931,F,
,1,1457,,,,80021,,,A498,CHEMBL884012,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5932,F,
,1,3664,,,,80021,,,A498,CHEMBL619741,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5933,F,
,1,15895,,,,80021,,,A498,CHEMBL619742,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Homo sapiens,1,9606.0,624.0,Intermediate,N,BAO_0000219,,5934,F,
,1,11843,,,,80682,,,A549,CHEMBL876610,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5935,F,
,1,11843,,,,80682,,,A549,CHEMBL619743,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5936,F,
,1,17705,,,,80682,,,A549,CHEMBL619744,In vitro antiproliferative activity against human A-549 NSCL cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5937,F,
,1,17705,,,,80682,,,A549,CHEMBL619745,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5938,F,
,1,4369,,,,80682,,,A549,CHEMBL619746,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5939,F,
,1,4369,,,,80682,,,A549,CHEMBL619747,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5940,F,
,1,4369,,,,80682,,,A549,CHEMBL619748,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5941,F,
,1,4369,,,,80682,,,A549,CHEMBL619749,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5942,F,
,1,4369,,,,80682,,,A549,CHEMBL619750,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5943,F,
,1,4369,,,,80682,,,A549,CHEMBL624014,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5944,F,
,1,4369,,,,80682,,,A549,CHEMBL624015,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5945,F,
,1,4787,,,,80682,,,A549,CHEMBL885344,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5946,F,
,1,4787,,,,80682,,,A549,CHEMBL623224,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5947,F,
,1,6513,,,,80682,,,A549,CHEMBL623225,Cytotoxic activity against A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5948,F,
,1,6690,,,,80682,,,A549,CHEMBL622698,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5949,F,
,1,6690,,,,80682,,,A549,CHEMBL622699,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5950,F,
,1,12263,,,,80682,,,A549,CHEMBL622700,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5951,F,
,1,1054,,,,80682,,,A549,CHEMBL622701,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5952,F,
,1,1359,,,,80682,,,A549,CHEMBL622702,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5953,F,
,1,3547,,,,80682,,,A549,CHEMBL622703,Cytotoxic activity against human lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5954,F,
,1,5771,,,,80682,,,A549,CHEMBL622704,Cytotoxic activity towards A-549 cells,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5955,F,
,1,14425,,,,80682,,,A549,CHEMBL622705,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5956,F,
,1,14425,,,,80682,,,A549,CHEMBL622706,"In vitro percent inhibition of A549, lung carcinoma",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5957,F,
,1,14425,,,,80682,,,A549,CHEMBL622707,"In vitro percent inhibition of A549, lung carcinoma.",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5958,F,
,1,14425,,,,80682,,,A549,CHEMBL622708,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5959,F,
,1,5280,,,,80682,,,A549,CHEMBL622709,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5960,F,
,1,15176,,,,80682,,,A549,CHEMBL622710,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5961,F,
,1,15300,,,,80682,,,A549,CHEMBL622711,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5962,F,
,1,17824,,,,80682,,,A549,CHEMBL622712,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5963,F,
,1,17824,,,,80682,,,A549,CHEMBL622713,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5964,F,
,1,17824,,,,80682,,,A549,CHEMBL622714,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5965,F,
,1,17824,,,,80682,,,A549,CHEMBL622715,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5966,F,
,1,17824,,,,80682,,,A549,CHEMBL622716,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5967,F,
,1,17824,,,,80682,,,A549,CHEMBL622717,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5968,F,
,1,17528,,,,80682,,,A549,CHEMBL622718,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,5969,F,
,1,6870,,,,80682,,,A549,CHEMBL622719,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5970,F,
,1,6870,,,,80682,,,A549,CHEMBL622720,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5971,F,
,1,6870,,,,80682,,,A549,CHEMBL622721,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5972,F,
,1,6870,,,,80682,,,A549,CHEMBL622722,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5973,F,
,1,16726,,,,80682,,,A549,CHEMBL876030,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5974,F,
,1,6170,,,,80682,,,A549,CHEMBL620206,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5975,F,
,1,6583,,,,80682,,,A549,CHEMBL620207,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5976,F,
,1,6583,,,,80682,,,A549,CHEMBL620208,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5977,F,
,1,6583,,,,80682,,,A549,CHEMBL620209,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5978,F,
,1,6583,,,,80682,,,A549,CHEMBL620210,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5979,F,
,1,6583,,,,80682,,,A549,CHEMBL621639,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5980,F,
,1,17321,,,,80682,,,A549,CHEMBL621640,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5981,F,
,1,17528,,,,80682,,,A549,CHEMBL621641,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5982,F,
,1,12888,,,,80682,,,A549,CHEMBL621642,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,5983,F,
,1,4312,,,,80682,,,A549,CHEMBL621643,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5984,F,
,1,4312,,,,80682,,,A549,CHEMBL621644,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5985,F,
,1,4312,,,,80682,,,A549,CHEMBL621645,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,5986,F,
,1,17737,,,,80682,,,A549,CHEMBL621646,In vitro antiproliferative activity against A549 cell line,Mus musculus,1,10090.0,646.0,Intermediate,N,BAO_0000219,,5987,F,
,1,6630,,,,80682,,,A549,CHEMBL621647,Synergism with indomethacin in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5988,F,
,1,6630,,,,80682,,,A549,CHEMBL621648,Synergism with tolmetin in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5989,F,
,1,6630,,,,80682,,,A549,CHEMBL621649,Synergism with sulindac in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5990,F,
,1,6630,,,,80682,,,A549,CHEMBL621650,Antagonism of indomethacin in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5991,F,
,1,6630,,,,80682,,,A549,CHEMBL621651,Antagonism of sulindac in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5992,F,
,1,6630,,,,80682,,,A549,CHEMBL621652,Antagonism of tolmetin in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5993,F,
,1,6630,,,,80682,,,A549,CHEMBL621653,Synergism with indomethacin in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5994,F,
,1,6630,,,,80682,,,A549,CHEMBL621654,Synergism with sulindac in A549 cells,,1,,646.0,Intermediate,N,BAO_0000219,,5995,F,
,1,6630,,,,80682,,,A549,CHEMBL621655,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,1,,646.0,Intermediate,N,BAO_0000219,,5996,F,
,1,16907,,In vivo,,50588,,,,CHEMBL621656,Cmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5997,A,
,1,5944,,In vivo,,50588,,,,CHEMBL621657,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5998,A,
,1,5944,,In vivo,,50588,,,,CHEMBL621658,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,5999,A,
,1,5944,,In vivo,,50588,,,,CHEMBL621659,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6000,A,
,1,5944,,In vivo,,50588,,,,CHEMBL621660,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6001,A,
,1,2959,,In vivo,,50588,,,,CHEMBL621661,Cmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6002,A,
,1,6241,,In vivo,,50588,,,,CHEMBL621662,Cmax value in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6003,A,
,1,6241,,In vivo,,50588,,,,CHEMBL621663,Cmax value in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6004,A,
,1,2652,,In vivo,,50588,,,,CHEMBL621664,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6005,A,
Plasma,1,1806,,In vivo,,50588,,,,CHEMBL621665,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6006,A,
Plasma,1,1806,,In vivo,,50588,,,,CHEMBL621666,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6007,A,
,1,1021,,In vivo,,50588,,,,CHEMBL621667,Concentration maxima after oral dosing in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6008,A,
,1,1021,,In vivo,,50588,,,,CHEMBL876738,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6009,A,
,1,1021,,In vivo,,50588,,,,CHEMBL621668,Concentration maxima after oral dosing in dogs; not available,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6010,A,
,1,5444,,In vivo,,50588,,,,CHEMBL621669,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6011,A,
,1,5444,,In vivo,,50588,,,,CHEMBL621670,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6012,A,
,1,5444,,In vivo,,50588,,,,CHEMBL621671,In vivo maximal concentration was calculated at 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6013,A,
,1,5444,,In vivo,,50588,,,,CHEMBL622360,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6014,A,
,1,5444,,In vivo,,50588,,,,CHEMBL622361,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6015,A,
Plasma,1,5130,,In vivo,,50588,,,,CHEMBL622362,Cmax in dog plasma after oral dose (1 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6016,A,
Plasma,1,3249,,In vivo,,50588,,,,CHEMBL622363,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6017,A,
Plasma,1,5473,,In vivo,,50588,,,,CHEMBL622364,Maximal plasma concentration at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6018,A,
Plasma,1,5474,,In vivo,,50588,,,,CHEMBL622365,Maximal plasma concentration at a dose of 1 mg/kg (oral),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6019,A,
Plasma,1,4657,,In vivo,,50588,,,,CHEMBL622533,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6020,A,
,1,3031,,In vivo,,50588,,,,CHEMBL622534,Maximum concentration of compound in dog was evaluated.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6021,A,
,1,4527,,In vivo,,50588,,,,CHEMBL622535,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6022,A,
,1,4186,,In vivo,,50588,,,,CHEMBL876739,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6023,A,
,1,5007,,In vivo,,50588,,,,CHEMBL622536,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6024,A,
Plasma,1,3132,,In vivo,,50588,,,,CHEMBL622537,Maximum concentration obtained in dog plasma was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6025,A,
,1,5006,,In vivo,,50588,,,,CHEMBL622538,Maximum concentration was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6026,A,
,1,4727,,In vivo,,50588,,,,CHEMBL627867,Maximum concentration at the dose of 2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6027,A,
,1,1916,,In vivo,,50588,,,,CHEMBL627868,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6028,A,
Plasma,1,1918,,In vivo,,50588,,,,CHEMBL627869,Maximum concentration was evaluated in dog plasma,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6029,A,
,1,3045,,In vivo,,50588,,,,CHEMBL627870,Maximum concentration was evaluated after 75 min after administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6030,A,
Plasma,1,9579,,In vivo,,50588,,,,CHEMBL627871,Maximum plasma concentration determined in dog after oral administration of 17b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6031,A,
Plasma,1,9579,,In vivo,,50588,,,,CHEMBL627872,Maximum plasma concentration determined in dog after oral administration of 2b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6032,A,
Plasma,1,933,,In vivo,,50588,,,,CHEMBL627873,Maximum plasma concentration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6033,A,
Plasma,1,17839,,In vivo,,50588,,,,CHEMBL627874,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6034,A,
Plasma,1,17839,,In vivo,,50588,,,,CHEMBL627875,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6035,A,
Plasma,1,17839,,In vivo,,50588,,,,CHEMBL627876,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6036,A,
Plasma,1,17839,,In vivo,,50588,,,,CHEMBL627877,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6037,A,
Plasma,1,6348,,In vivo,,50588,,,,CHEMBL627878,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6038,A,
Plasma,1,16367,,In vivo,,50588,,,,CHEMBL627879,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6039,A,
Plasma,1,1337,,In vivo,,50588,,,,CHEMBL875355,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6040,A,
Plasma,1,1337,,In vivo,,50588,,,,CHEMBL627880,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6041,A,
Plasma,1,5199,,In vivo,,50588,,,,CHEMBL627881,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6042,A,
Plasma,1,17650,,In vivo,,50588,,,,CHEMBL627882,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6043,A,
Plasma,1,6679,,In vivo,,50588,,,,CHEMBL627883,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6044,A,
Plasma,1,5356,,In vivo,,50588,,,,CHEMBL628526,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6045,A,
Plasma,1,5356,,In vivo,,50588,,,,CHEMBL628527,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6046,A,
Plasma,1,6227,,In vivo,,50588,,,,CHEMBL628528,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6047,A,
Plasma,1,6227,,In vivo,,50588,,,,CHEMBL628529,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6048,A,
Plasma,1,6227,,In vivo,,50588,,,,CHEMBL628530,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6049,A,
Plasma,1,6227,,In vivo,,50588,,,,CHEMBL625243,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6050,A,
Plasma,1,3598,,In vivo,,50588,,,,CHEMBL625244,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,1969.0,6051,A,
,1,4368,,In vivo,,50588,,,,CHEMBL625245,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6052,A,
,1,6265,,In vivo,,50588,,,,CHEMBL625246,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6053,A,
Stomach,1,7767,,In vivo,,50594,,,,CHEMBL625247,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,6054,A,
Urine,1,7767,,In vivo,,50594,,,,CHEMBL625248,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,6055,A,
Urine,1,7767,,In vivo,,50594,,,,CHEMBL625249,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,6056,A,
Urine,1,7767,,In vivo,,50594,,,,CHEMBL625250,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1088.0,6057,A,
,1,17811,,,,50594,,,,CHEMBL625251,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6058,A,
,1,17811,,,,50594,,,,CHEMBL875356,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6059,A,
,1,17827,,,,50594,,,,CHEMBL625252,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6060,A,
Blood,1,17827,,,,50594,,,,CHEMBL625253,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,6061,A,
,1,17827,,,,50594,,,,CHEMBL625254,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6062,A,
,1,17827,,,,50594,,,,CHEMBL625255,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6063,A,
,1,17827,,,,50594,,,,CHEMBL625256,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6064,A,
Blood,1,17827,,,,50594,,,,CHEMBL625257,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,6065,A,
Blood,1,17827,,,,50594,,,,CHEMBL625258,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,6066,A,
,1,17827,,,,50594,,,,CHEMBL625259,Compound was evaluated for washout rate in mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6067,A,
,1,17827,,,,50594,,,,CHEMBL625260,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6068,A,
,1,17827,,,,50594,,,,CHEMBL625261,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6069,A,
,1,17827,,,,50594,,,,CHEMBL625262,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6070,A,
,1,17827,,,,50594,,,,CHEMBL622639,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6071,A,
,1,17257,,,,50594,,,,CHEMBL622640,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6072,A,
,1,17257,,,,50594,,,,CHEMBL622812,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6073,A,
,1,17257,,,,50594,,,,CHEMBL622813,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6074,A,
,1,17257,,,,50594,,,,CHEMBL622814,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6075,A,
,1,17827,,,,50594,,,,CHEMBL622815,Time at maximum activity in mice (Radiolabeled compound),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6076,A,
,1,3760,,,,50594,,,,CHEMBL625342,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6077,A,
,1,3760,,,,50594,,,,CHEMBL625343,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6078,A,
,1,17409,,,,50594,,,,CHEMBL877591,Binding towards mouse plasma protein at 10 uM,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6079,A,
,1,17409,,,,50594,,,,CHEMBL625344,Binding towards mouse plasma protein at 100 uM,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6080,A,
,1,2675,,In vivo,,50594,,,,CHEMBL625345,Bioavailability was evaluated in mice after intravenous administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6081,A,
,1,2675,,In vivo,,50594,,,,CHEMBL625346,Bioavailability was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6082,A,
,1,3132,,In vivo,,50594,,,,CHEMBL625347,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6083,A,
,1,3132,,In vivo,,50594,,,,CHEMBL625348,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6084,A,
,1,16597,,In vivo,,50594,,,,CHEMBL625349,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6085,A,
,1,2862,,In vivo,,50594,,,,CHEMBL625350,Oral bioavailability in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6086,A,
,1,17764,,In vivo,,50594,,,,CHEMBL882952,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6087,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL625351,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6088,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL625352,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6089,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL877592,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6090,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL625353,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6091,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL625354,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6092,A,
Brain,1,846,,In vivo,,50594,,,,CHEMBL626019,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6093,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL626020,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6094,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL626021,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6095,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL626022,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6096,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL626192,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6097,A,
,1,1276,,,,80682,,,A549,CHEMBL626193,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6098,F,
,1,3498,,,,80682,,,A549,CHEMBL626194,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6099,F,
,1,1169,,,,80682,,,A549,CHEMBL626195,Cytotoxicity against human lung carcinoma A-549 cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6100,F,
,1,4450,,,,80682,,,A549,CHEMBL626196,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6101,F,
,1,358,,,,80682,,,A549,CHEMBL626197,In vitro cytotoxicity against human lung carcinoma cell line A-549,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6102,F,
,1,358,,,,80682,,,A549,CHEMBL626198,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6103,F,
,1,358,,,,80682,,,A549,CHEMBL626199,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6104,F,
,1,358,,,,80682,,,A549,CHEMBL626200,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6105,F,
,1,358,,,,80682,,,A549,CHEMBL626201,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6106,F,
,1,358,,,,80682,,,A549,CHEMBL626202,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6107,F,
,1,358,,,,80682,,,A549,CHEMBL626203,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6108,F,
,1,15167,,,,80682,,,A549,CHEMBL626204,In vitro cytotoxicity against A-549 human lung cancer cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6109,F,
,1,4139,,,,80682,,,A549,CHEMBL624701,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6110,F,
,1,833,,,,80682,,,A549,CHEMBL624702,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6111,F,
,1,15718,,,,80682,,,A549,CHEMBL624703,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6112,F,
,1,12373,,,,80682,,,A549,CHEMBL624704,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6113,F,
,1,637,,,,80682,,,A549,CHEMBL624705,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6114,F,
,1,14867,,,,80682,,,A549,CHEMBL624706,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6115,F,
,1,4461,,,,80682,,,A549,CHEMBL624707,Antitumor cytotoxic activity against A-549 cell line was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6116,F,
,1,5406,,,,80682,,,A549,CHEMBL624708,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6117,F,
,1,4457,,,,80682,,,A549,CHEMBL624709,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6118,F,
,1,1386,,,,80682,,,A549,CHEMBL884107,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6119,F,
,1,3265,,,,80682,,,A549,CHEMBL624710,Antitumoral activity was assayed against A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6120,F,
,1,2359,,,,80682,,,A549,CHEMBL624711,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6121,F,
,1,4457,,,,80682,,,A549,CHEMBL624712,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6122,F,
,1,12454,,,,80682,,,A549,CHEMBL624713,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6123,F,
,1,1481,,,,80682,,,A549,CHEMBL624714,Compound was tested for inhibition of cell growth of A-549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6124,F,
,1,1750,,,,80682,,,A549,CHEMBL624715,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6125,F,
,1,5065,,,,80682,,,A549,CHEMBL624716,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6126,F,
,1,808,,,,80682,,,A549,CHEMBL619505,In vitro cytotoxicity against A549-human lung carcinoma cells.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6127,F,
,1,16364,,,,80682,,,A549,CHEMBL619506,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6128,F,
,1,1847,,,,80682,,,A549,CHEMBL619507,Cytotoxic activity against A-549 cell lines.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6129,F,
,1,1747,,,,80682,,,A549,CHEMBL619508,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6130,F,
,1,1003,,,,80682,,,A549,CHEMBL619509,Cytotoxicity against human A549 non small cell lung cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6131,F,
,1,15313,,,,80682,,,A549,CHEMBL619510,Inhibition of cell growth in (A-549) lung cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6132,F,
,1,3122,,,,80682,,,A549,CHEMBL619511,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6133,F,
,1,16049,,,,80682,,,A549,CHEMBL619512,In vitro antitumor activity against A-549 tumor cells.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6134,F,
,1,17134,,,,80682,,,A549,CHEMBL619513,In vitro antitumor effects against human A-549 cell lines.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6135,F,
,1,6406,,,,80682,,,A549,CHEMBL619514,In vitro cytotoxic activity of compound against A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6136,F,
,1,627,,,,80682,,,A549,CHEMBL619515,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6137,F,
,1,12307,,,,80682,,,A549,CHEMBL619516,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6138,F,
,1,17861,,,,80682,,,A549,CHEMBL884005,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6139,F,
,1,6682,,,,80682,,,A549,CHEMBL619517,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6140,F,
,1,6663,,,,80682,,,A549,CHEMBL619518,Inhibitory concentration of compound against A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6141,F,
,1,2454,,,,80682,,,A549,CHEMBL619519,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6142,F,
,1,14709,,,,80682,,,A549,CHEMBL876489,cytotoxic activity against leukemia (A-549) cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6143,F,
,1,15718,,,,80682,,,A549,CHEMBL619520,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6144,F,
,1,15718,,,,80682,,,A549,CHEMBL619521,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6145,F,
,1,17130,,,,80682,,,A549,CHEMBL619522,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6146,F,
,1,17130,,,,80682,,,A549,CHEMBL619523,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6147,F,
,1,17130,,,,80682,,,A549,CHEMBL619524,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6148,F,
,1,17130,,,,80682,,,A549,CHEMBL619525,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6149,F,
,1,6630,,,,80682,,,A549,CHEMBL619526,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,1,,646.0,Intermediate,N,BAO_0000219,,6150,F,
,1,16726,,,,80682,,,A549,CHEMBL619527,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6151,F,
,1,17846,,,,80682,,,A549,CHEMBL619528,Cytotoxicity against A549 cells; No cytotoxicity,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6152,F,
,1,3415,,,,80682,,,A549,CHEMBL619529,Cytotoxicity against human lung carcinoma (A549) cell lines,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6153,F,
,1,3415,,,,80682,,,A549,CHEMBL619530,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6154,F,
,1,5609,,,,80682,,,A549,CHEMBL876490,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6155,F,
,1,17206,,,,80682,,,A549,CHEMBL619531,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6156,F,
,1,17206,,,,80682,,,A549,CHEMBL619532,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6157,F,
,1,17206,,,,80682,,,A549,CHEMBL619533,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6158,F,
,1,17206,,,,80682,,,A549,CHEMBL619534,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6159,F,
,1,17206,,,,80682,,,A549,CHEMBL620164,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6160,F,
,1,17206,,,,80682,,,A549,CHEMBL620165,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6161,F,
,1,16295,,,,80682,,,A549,CHEMBL620166,Inhibition of A549 human lung tumor cell proliferation,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6162,F,
,1,16825,,,,80682,,,A549,CHEMBL620167,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6163,F,
,1,3439,,,,80682,,,A549,CHEMBL620168,In vitro cytotoxicity against human tumor cell line A549,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6164,F,
,1,10870,,,,80682,,,A549,CHEMBL620338,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6165,F,
,1,4845,,,,80682,,,A549,CHEMBL620339,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6166,F,
,1,5822,,,,80682,,,A549,CHEMBL620340,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6167,F,
,1,5822,,,,80682,,,A549,CHEMBL620341,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6168,F,
,1,5822,,,,80682,,,A549,CHEMBL876491,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6169,F,
,1,16381,,,,80682,,,A549,CHEMBL620342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6170,F,
,1,16381,,,,80682,,,A549,CHEMBL620343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6171,F,
,1,16381,,,,80682,,,A549,CHEMBL620344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6172,F,
,1,5609,,,,80682,,,A549,CHEMBL620345,In vitro anticancer activity against human lung (A549) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6173,F,
,1,4644,,,,80682,,,A549,CHEMBL620346,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6174,F,
,1,4644,,,,80682,,,A549,CHEMBL620347,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6175,F,
,1,4644,,,,80682,,,A549,CHEMBL620348,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6176,F,
,1,4644,,,,80682,,,A549,CHEMBL620349,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6177,F,
,1,5822,,,,80682,,,A549,CHEMBL618667,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6178,F,
,1,3415,,,,80682,,,A549,CHEMBL618668,Percentage inhibition of human lung carcinoma (A549) cell lines,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6179,F,
,1,16726,,,,80682,,,A549,CHEMBL876031,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6180,F,
,1,17206,,,,80682,,,A549,CHEMBL618759,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6181,F,
,1,17206,,,,80682,,,A549,CHEMBL618760,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6182,F,
,1,17206,,,,80682,,,A549,CHEMBL619000,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6183,F,
,1,17206,,,,80682,,,A549,CHEMBL619001,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6184,F,
,1,17206,,,,80682,,,A549,CHEMBL619002,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6185,F,
,1,17206,,,,80682,,,A549,CHEMBL619003,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6186,F,
,1,17206,,,,80682,,,A549,CHEMBL619597,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6187,F,
,1,17206,,,,80682,,,A549,CHEMBL619598,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6188,F,
,1,17206,,,,80682,,,A549,CHEMBL619599,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6189,F,
,1,17206,,,,80682,,,A549,CHEMBL619600,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6190,F,
,1,16726,,,,80682,,,A549,CHEMBL619601,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6191,F,
,1,17206,,,,80682,,,A549,CHEMBL619602,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6192,F,
,1,17206,,,,80682,,,A549,CHEMBL619603,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6193,F,
,1,17206,,,,80682,,,A549,CHEMBL619604,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6194,F,
,1,17206,,,,80682,,,A549,CHEMBL619605,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6195,F,
,1,6084,,In vivo,,50588,,,,CHEMBL619606,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6196,A,
,1,6084,,In vivo,,50588,,,,CHEMBL876032,Pharmacokinetic activity (Cmax) in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6197,A,
,1,4809,,In vivo,,50588,,,,CHEMBL619607,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6198,A,
,1,5983,,In vivo,,50588,,,,CHEMBL619608,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6199,A,
,1,6251,,In vivo,,50588,,,,CHEMBL619609,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6200,A,
Plasma,1,5932,,In vivo,,50588,,,,CHEMBL619610,Cmax in dog plasma after 30mg/kg oral dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6201,A,
Blood,1,4273,,In vivo,,50588,,,,CHEMBL619611,Tested for the peak blood level in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,6202,A,
,1,5313,,In vivo,,50588,,,,CHEMBL619612,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6203,A,
,1,5313,,In vivo,,50588,,,,CHEMBL619613,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6204,A,
Blood,1,6221,,In vivo,,50588,,,,CHEMBL619614,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,6205,A,
,1,4709,,,,50588,,,,CHEMBL619615,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6206,A,
,1,167,,,,50588,,,,CHEMBL619616,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6207,A,
Plasma,1,6241,,,,50588,,,,CHEMBL619617,Final plasma concentration in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6208,A,
,1,344,,,,50588,,,,CHEMBL619618,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6209,A,
,1,344,,,,50588,,,,CHEMBL876033,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6210,A,
,1,344,,,,50588,,,,CHEMBL619619,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6211,A,
,1,2189,,,,50588,,,,CHEMBL619620,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6212,A,
Urine,1,2189,,,,50588,,,,CHEMBL619621,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1088.0,6213,A,
Urine,1,2189,,,,50588,,,,CHEMBL619622,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1088.0,6214,A,
Urine,1,2189,,,,50588,,,,CHEMBL618874,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1088.0,6215,A,
,1,4257,,In vivo,,50588,,,,CHEMBL618875,Absolute bioavailability was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6216,A,
,1,6221,,In vivo,,50588,,,,CHEMBL618876,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6217,A,
,1,6215,,In vivo,,50588,,,,CHEMBL618877,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6218,A,
,1,17267,,In vivo,,50588,,,,CHEMBL618878,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6219,A,
,1,6621,,In vivo,,50588,,,,CHEMBL618879,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6220,A,
,1,3854,,In vivo,,50588,,,,CHEMBL618880,Bioavailability after intravenous administration in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6221,A,
,1,3854,,In vivo,,50588,,,,CHEMBL618881,Bioavailability after peroral administration in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6222,A,
,1,5007,,In vivo,,50588,,,,CHEMBL618882,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6223,A,
,1,4333,,In vivo,,50588,,,,CHEMBL624226,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6224,A,
Plasma,1,4333,,In vivo,,50588,,,,CHEMBL624227,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6225,A,
,1,5006,,In vivo,,50588,,,,CHEMBL624228,Bioavailability,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6226,A,
,1,5199,,In vivo,,50588,,,,CHEMBL624229,Bioavailability,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6227,A,
,1,4368,,In vivo,,50588,,,,CHEMBL624230,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6228,A,
,1,3771,,In vivo,,50588,,,,CHEMBL624231,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6229,A,
,1,4953,,In vivo,,50588,,,,CHEMBL624232,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6230,A,
,1,5064,,In vivo,,50588,,,,CHEMBL625127,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6231,A,
,1,17657,,In vivo,,50588,,,,CHEMBL625128,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6232,A,
,1,17796,,In vivo,,50588,,,,CHEMBL621675,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6233,A,
,1,17853,,In vivo,,50588,,,,CHEMBL621676,Bioavailability in dog (p.o.) at 2.0 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6234,A,
,1,4521,,In vivo,,50588,,,,CHEMBL621677,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6235,A,
,1,4521,,In vivo,,50588,,,,CHEMBL621678,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6236,A,
,1,5006,,In vivo,,50588,,,,CHEMBL621679,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6237,A,
,1,16365,,In vivo,,50588,,,,CHEMBL621680,Bioavailability was evaluated after oral administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6238,A,
,1,1916,,In vivo,,50588,,,,CHEMBL621681,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6239,A,
,1,1918,,In vivo,,50588,,,,CHEMBL876740,Bioavailability was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6240,A,
,1,4239,,In vivo,,50588,,,,CHEMBL621682,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6241,A,
,1,6505,,In vivo,,50588,,,,CHEMBL621683,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6242,A,
,1,5334,,In vivo,,50588,,,,CHEMBL621684,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6243,A,
,1,5334,,In vivo,,50588,,,,CHEMBL621685,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6244,A,
,1,4809,,In vivo,,50588,,,,CHEMBL621686,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6245,A,
,1,6348,,In vivo,,50588,,,,CHEMBL621687,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6246,A,
,1,6005,,In vivo,,50588,,,,CHEMBL621688,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6247,A,
,1,17804,,In vivo,,50588,,,,CHEMBL621689,Bioavailability of compound in dog was determined after peroral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6248,A,
,1,3184,,In vivo,,50588,,,,CHEMBL621690,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6249,A,
,1,1806,,In vivo,,50588,,,,CHEMBL621691,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6250,A,
,1,1806,,In vivo,,50588,,,,CHEMBL875941,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6251,A,
,1,1806,,In vivo,,50588,,,,CHEMBL621692,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6252,A,
,1,4839,,In vivo,,50588,,,,CHEMBL621693,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6253,A,
,1,5017,,In vivo,,50588,,,,CHEMBL621694,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6254,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL621695,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6255,A,
Heart,1,846,,In vivo,,50594,,,,CHEMBL621696,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,6256,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL621697,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6257,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL621698,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6258,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL623420,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6259,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL623421,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6260,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL623422,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6261,A,
Kidney,1,846,,In vivo,,50594,,,,CHEMBL623423,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6262,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL623424,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6263,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL623425,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6264,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL623426,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6265,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL623427,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6266,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL623428,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6267,A,
Liver,1,846,,In vivo,,50594,,,,CHEMBL875947,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6268,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL623429,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6269,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL623430,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6270,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL622588,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6271,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL622589,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6272,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL622751,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6273,A,
Lung,1,846,,In vivo,,50594,,,,CHEMBL622752,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6274,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL622753,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6275,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL622647,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6276,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL875163,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6277,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL622648,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6278,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL622649,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6279,A,
Brain,1,6599,,,,50594,,,CCRF S-180,CHEMBL622650,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,955.0,6280,A,
Brain,1,6599,,,,50594,,,CCRF S-180,CHEMBL622651,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,955.0,6281,A,
Brain,1,6599,,,,50594,,,CCRF S-180,CHEMBL622652,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,955.0,6282,A,
Brain,1,6599,,,,50594,,,CCRF S-180,CHEMBL622653,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,955.0,6283,A,
Brain,1,6599,,,,50594,,,CCRF S-180,CHEMBL622654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,955.0,6284,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL622655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6285,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL622656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6286,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL622657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6287,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL622658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6288,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL622659,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6289,A,
Kidney,1,6599,,,,50594,,,CCRF S-180,CHEMBL624630,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2113.0,6290,A,
Kidney,1,6599,,,,50594,,,CCRF S-180,CHEMBL624631,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2113.0,6291,A,
Kidney,1,6599,,,,50594,,,CCRF S-180,CHEMBL624632,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2113.0,6292,A,
,1,17130,,,,80682,,,A549,CHEMBL624633,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6293,F,
,1,17130,,,,80682,,,A549,CHEMBL624634,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6294,F,
,1,17130,,,,80682,,,A549,CHEMBL624635,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6295,F,
,1,17130,,,,80682,,,A549,CHEMBL624636,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6296,F,
,1,3263,,,,80682,,,A549,CHEMBL857055,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6297,F,
,1,6663,,,,80682,,,A549,CHEMBL624637,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6298,F,
,1,6663,,,,80682,,,A549,CHEMBL624638,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6299,F,
,1,6663,,,,80682,,,A549,CHEMBL874366,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6300,F,
,1,6663,,,,80682,,,A549,CHEMBL624639,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6301,F,
,1,6663,,,,80682,,,A549,CHEMBL624640,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6302,F,
,1,6663,,,,80682,,,A549,CHEMBL624641,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6303,F,
,1,6663,,,,80682,,,A549,CHEMBL624642,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6304,F,
,1,6663,,,,80682,,,A549,CHEMBL624643,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6305,F,
,1,6663,,,,80682,,,A549,CHEMBL624644,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6306,F,
,1,6663,,,,80682,,,A549,CHEMBL624645,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6307,F,
,1,3983,,,,80682,,,A549,CHEMBL619445,The compound was evaluated for its cytotoxic potency against A-549 cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6308,F,
,1,11141,,,,80682,,,A549,CHEMBL839886,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6309,F,
,1,5076,,,,80682,,,A549,CHEMBL619446,Cytotoxic activity of compound against A-549 tumor cell line.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6310,F,
,1,3311,,,,80682,,,A549,CHEMBL619447,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6311,F,
,1,3311,,,,80682,,,A549,CHEMBL619448,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6312,F,
,1,3311,,,,80682,,,A549,CHEMBL619449,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6313,F,
,1,5076,,,,80682,,,A549,CHEMBL619450,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6314,F,
,1,4150,,,,80682,,,A549,CHEMBL619451,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6315,F,
,1,2150,,,,80682,,,A549,CHEMBL619452,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6316,F,
,1,4644,,,,80682,,,A549,CHEMBL619453,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6317,F,
,1,263,,,,80682,,,A549,CHEMBL874367,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6318,F,
,1,11333,,,,80682,,,A549,CHEMBL619454,Cytotoxic concentration against A-549 tumor cells.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6319,F,
,1,11333,,,,80682,,,A549,CHEMBL619455,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6320,F,
,1,15895,,,,80682,,,A549,CHEMBL619456,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6321,F,
,1,16677,,,,50191,,,,CHEMBL619457,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Acinetobacter baumannii,1,470.0,,Expert,N,BAO_0000218,,6322,F,
,1,10624,,,,50192,,,,CHEMBL619458,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus,1,471.0,,Intermediate,N,BAO_0000218,,6323,F,
,1,16717,,,,50274,,,,CHEMBL619459,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus,1,5059.0,,Expert,N,BAO_0000218,,6324,F,
,1,16717,,,,50274,,,,CHEMBL619460,In vitro antifungal activity against Aspergillus flavus CM74,Aspergillus flavus,1,5059.0,,Expert,N,BAO_0000218,,6325,F,
,1,5513,,,,50416,,,,CHEMBL619461,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Aspergillus fumigatus,1,746128.0,,Intermediate,N,BAO_0000218,,6326,F,
,1,15962,,,,50416,,,,CHEMBL619462,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Aspergillus fumigatus,1,746128.0,,Intermediate,N,BAO_0000218,,6327,F,
,1,15962,,,,50416,,,,CHEMBL620388,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,1,746128.0,,Intermediate,N,BAO_0000218,,6328,F,
,1,15962,,,,50416,,,,CHEMBL620389,Antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,1,746128.0,,Intermediate,N,BAO_0000218,,6329,F,
,1,15962,,,,50416,,,,CHEMBL620390,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Aspergillus fumigatus,1,746128.0,,Intermediate,N,BAO_0000218,,6330,F,
,1,16717,,,,50416,,,,CHEMBL620391,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus,1,746128.0,,Expert,N,BAO_0000218,,6331,F,
,1,16717,,,,50416,,,,CHEMBL621073,In vitro antifungal activity against Aspergillus fumigatus 48238E,Aspergillus fumigatus,1,746128.0,,Expert,N,BAO_0000218,,6332,F,
,1,8117,,,,50296,,,,CHEMBL621074,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6333,F,
,1,8117,,,,50366,,,,CHEMBL621075,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6334,F,
,1,15472,,,,50535,,,,CHEMBL619554,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6335,F,
,1,15472,,,,50535,,,,CHEMBL619555,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6336,F,
,1,16443,,,,50169,,,,CHEMBL619556,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Aggregatibacter actinomycetemcomitans,1,714.0,,Intermediate,N,BAO_0000218,,6337,F,
,1,16443,,,,50169,,,,CHEMBL619557,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Aggregatibacter actinomycetemcomitans,1,714.0,,Intermediate,N,BAO_0000218,,6338,F,
,1,16443,,,,50169,,,,CHEMBL619558,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Aggregatibacter actinomycetemcomitans,1,714.0,,Intermediate,N,BAO_0000218,,6339,F,
,1,17206,,,,80682,,,A549,CHEMBL619559,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6340,F,
,1,17206,,,,80682,,,A549,CHEMBL619560,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6341,F,
,1,16381,,,,80682,,,A549,CHEMBL619561,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6342,F,
,1,16381,,,,80682,,,A549,CHEMBL619562,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6343,F,
,1,16381,,,,80682,,,A549,CHEMBL619563,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6344,F,
,1,16381,,,,80682,,,A549,CHEMBL857457,GI values against A549 cells (lung cancer),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6345,F,
,1,17206,,,,80682,,,A549,CHEMBL619564,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6346,F,
,1,16325,,,,80682,,,A549,CHEMBL619565,Inhibitory activity against A549 human adenocarcinoma,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6347,F,
,1,10708,,,,80682,,,A549,CHEMBL619566,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,6348,F,
,1,10708,,,,80682,,,A549,CHEMBL619567,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,6349,F,
,1,17376,,,,80682,,,A549,CHEMBL619568,Inhibitory activity against A549 lung adenocarcinoma cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6350,F,
,1,17376,,,,80682,,,A549,CHEMBL619569,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6351,F,
,1,17488,,,,80682,,,A549,CHEMBL619570,Cytotoxicity against human A549 lung cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6352,F,
,1,17404,,,,80682,,,A549,CHEMBL619571,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000218,,6353,F,
,1,10958,,,,80682,,,A549,CHEMBL619572,Growth inhibition of A549 (human lung carcinoma) cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6354,F,
,1,17099,,,,80682,,,A549,CHEMBL619573,Effective dose required for inhibitory activity against A549 human tumor cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6355,F,
,1,17099,,,,80682,,,A549,CHEMBL619574,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6356,F,
,1,4096,,,,80682,,,A549,CHEMBL619575,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6357,F,
,1,4096,,,,80682,,,A549,CHEMBL619576,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6358,F,
,1,4096,,,,80682,,,A549,CHEMBL619577,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6359,F,
,1,2525,,,,80682,,,A549,CHEMBL619578,In vitro inhibitory activity against A549 tumor cell culture,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6360,F,
,1,2525,,,,80682,,,A549,CHEMBL884009,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6361,F,
,1,5302,,,,80682,,,A549,CHEMBL619579,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6362,F,
,1,16325,,,,80682,,,A549,CHEMBL619580,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6363,F,
,1,16939,,,,80682,,,A549,CHEMBL619581,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6364,F,
,1,17229,,,,80682,,,A549,CHEMBL619582,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6365,F,
,1,17380,,,,80682,,,A549,CHEMBL619583,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6366,F,
,1,17380,,,,80682,,,A549,CHEMBL876502,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6367,F,
,1,1903,,,,80682,,,A549,CHEMBL619584,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6368,F,
,1,3838,,,,80682,,,A549,CHEMBL619585,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6369,F,
,1,14696,,,,80682,,,A549,CHEMBL619586,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6370,F,
,1,3838,,,,80682,,,A549,CHEMBL619587,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6371,F,
,1,1522,,,,80682,,,A549,CHEMBL619588,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6372,F,
,1,12400,,,,80682,,,A549,CHEMBL619589,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6373,F,
,1,14696,,,,80682,,,A549,CHEMBL619590,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6374,F,
,1,14769,,,,80682,,,A549,CHEMBL619591,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6375,F,
,1,14696,,,,80682,,,A549,CHEMBL619592,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6376,F,
,1,1888,,,,80682,,,A549,CHEMBL619593,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6377,F,
,1,12016,,,,80682,,,A549,CHEMBL620217,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6378,F,
,1,6058,,,,80682,,,A549,CHEMBL620218,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6379,F,
,1,17708,,,,80682,,,A549,CHEMBL620219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6380,F,
,1,12301,,,,80682,,,A549,CHEMBL620220,Antitumor activity against A549/ATCC cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6381,F,
,1,11970,,,,80682,,,A549,CHEMBL625141,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6382,F,
,1,11818,,,,80682,,,A549,CHEMBL625142,In vitro cytotoxicity against A549/ATCC cell line.,Homo sapiens,1,9606.0,646.0,Expert,N,BAO_0000219,,6383,F,
,1,12400,,,,80682,,,A549,CHEMBL625143,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6384,F,
,1,3381,,,,80682,,,A549,CHEMBL625144,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6385,F,
,1,17376,,,,80682,,,A549,CHEMBL622474,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6386,F,
,1,10708,,,,80682,,,A549,CHEMBL884104,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,646.0,Intermediate,N,BAO_0000219,,6387,F,
,1,2964,,,,22226,,,,CHEMBL622475,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000219,,6388,F,
,1,5005,,In vivo,,22224,,,,CHEMBL622476,Compound was tested for oral bioavailability in dogs,Canis lupus familiaris,0,9615.0,,Intermediate,U,BAO_0000218,,6389,A,
,1,6229,,In vivo,,50588,,,,CHEMBL875831,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6390,A,
,1,6229,,In vivo,,50588,,,,CHEMBL622477,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6391,A,
,1,5374,,In vivo,,50588,,,,CHEMBL622478,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6392,A,
,1,5374,,In vivo,,50588,,,,CHEMBL623172,Compound was tested for the oral bioavailability in dog; No availability,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6393,A,
,1,6265,,In vivo,,50588,,,,CHEMBL623173,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6394,A,
,1,5654,,In vivo,,50588,,,,CHEMBL623174,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6395,A,
,1,5654,,In vivo,,50588,,,,CHEMBL623175,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6396,A,
,1,16456,,In vivo,,50588,,,,CHEMBL623340,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6397,A,
,1,5302,,In vivo,,50588,,,,CHEMBL623341,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6398,A,
,1,3624,,In vivo,,50588,,,,CHEMBL623342,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6399,A,
,1,16452,,In vivo,,50588,,,,CHEMBL623343,Oral bioavailability of active FTIs in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6400,A,
,1,5802,,In vivo,,50588,,,,CHEMBL623344,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6401,A,
,1,3598,,In vivo,,50588,,,,CHEMBL623345,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,,6402,A,
,1,17839,,In vivo,,50588,,,,CHEMBL875832,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6403,A,
,1,6762,,In vivo,,50588,,,,CHEMBL623346,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6404,A,
,1,6821,,In vivo,,50588,,,,CHEMBL623347,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6405,A,
,1,6821,,In vivo,,50588,,,,CHEMBL623348,Oral bioavailability of compound was determined in dog; Not tested,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6406,A,
,1,5210,,In vivo,,50588,,,,CHEMBL623349,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6407,A,
,1,6227,,In vivo,,50588,,,,CHEMBL623350,Oral bioavailability (10 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6408,A,
,1,761,,In vivo,,50588,,,,CHEMBL623351,Oral bioavailability,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6409,A,
,1,761,,In vivo,,50588,,,,CHEMBL623352,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6410,A,
,1,761,,In vivo,,50588,,,,CHEMBL623353,Oral bioavailability administered in solution in rats,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6411,A,
,1,16907,,In vivo,,50588,,,,CHEMBL875833,Oral bioavailability after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6412,A,
,1,5474,,In vivo,,50588,,,,CHEMBL623354,Oral bioavailability at a dose of 1 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6413,A,
,1,6535,,In vivo,,50588,,,,CHEMBL623355,Oral bioavailability in dog (dose 1 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6414,A,
,1,6535,,In vivo,,50588,,,,CHEMBL623356,Oral bioavailability in Dog; ND = not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6415,A,
,1,3352,,In vivo,,50588,,,,CHEMBL623357,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6416,A,
,1,6168,,In vivo,,50588,,,,CHEMBL623358,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6417,A,
,1,5988,,In vivo,,50588,,,,CHEMBL623359,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6418,A,
,1,4942,,In vivo,,50588,,,,CHEMBL623360,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6419,A,
,1,4942,,In vivo,,50588,,,,CHEMBL623361,Oral bioavailability in dogs; No data,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6420,A,
,1,14541,,In vivo,,50588,,,,CHEMBL623362,Oral bioavailability measured in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6421,A,
,1,4449,,In vivo,,50588,,,,CHEMBL623363,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6422,A,
,1,6057,,In vivo,,50588,,,,CHEMBL623364,Oral bioavailability was calculated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6423,A,
,1,5600,,In vivo,,50588,,,,CHEMBL875834,Oral bioavailability after 0.3 mg/kg po administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6424,A,
,1,5542,,In vivo,,50588,,,,CHEMBL623365,Oral bioavailability in dog (i.v. dosing),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6425,A,
,1,5542,,In vivo,,50588,,,,CHEMBL623366,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6426,A,
,1,5546,,In vivo,,50588,,,,CHEMBL623367,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6427,A,
,1,4514,,In vivo,,50588,,,,CHEMBL623368,Oral bioavailability in Beagle dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6428,A,
,1,3624,,In vivo,,50588,,,,CHEMBL623369,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6429,A,
,1,3854,,In vivo,,50588,,,,CHEMBL623370,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6430,A,
,1,5836,,In vivo,,50588,,,,CHEMBL623371,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6431,A,
,1,5940,,In vivo,,50588,,,,CHEMBL623372,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6432,A,
,1,6168,,In vivo,,50588,,,,CHEMBL621351,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6433,A,
,1,6227,,In vivo,,50588,,,,CHEMBL621352,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6434,A,
,1,6251,,In vivo,,50588,,,,CHEMBL621353,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6435,A,
,1,6448,,In vivo,,50588,,,,CHEMBL621354,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6436,A,
,1,6647,,In vivo,,50588,,,,CHEMBL621355,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6437,A,
,1,5940,,In vivo,,50588,,,,CHEMBL621356,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6438,A,
,1,933,,In vivo,,50588,,,,CHEMBL621357,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6439,A,
,1,5210,,In vivo,,50588,,,,CHEMBL621358,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6440,A,
,1,6642,,In vivo,,50588,,,,CHEMBL621359,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6441,A,
,1,6641,,In vivo,,50588,,,,CHEMBL621360,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6442,A,
,1,6642,,In vivo,,50588,,,,CHEMBL621361,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6443,A,
,1,5472,,In vivo,,50588,,,,CHEMBL621362,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6444,A,
,1,5985,,In vivo,,50588,,,,CHEMBL621363,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6445,A,
,1,15660,,In vivo,,50588,,,,CHEMBL621364,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6446,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621166,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6447,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621167,Oral bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6448,A,
,1,6305,,In vivo,,50588,,,,CHEMBL621168,Oral bioavailability (F) in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6449,A,
,1,5210,,In vivo,,50588,,,,CHEMBL621169,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6450,A,
,1,5238,,In vivo,,50588,,,,CHEMBL875950,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6451,A,
,1,5668,,In vivo,,50588,,,,CHEMBL621170,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6452,A,
,1,5668,,In vivo,,50588,,,,CHEMBL621171,Oral bioavailability after peroral administration at 5 mpk in Dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6453,A,
,1,5668,,In vivo,,50588,,,,CHEMBL621172,Oral bioavailability in dog (dose 5 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6454,A,
,1,6084,,In vivo,,50588,,,,CHEMBL621173,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6455,A,
Kidney,1,6599,,,,50594,,,CCRF S-180,CHEMBL621174,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2113.0,6456,A,
Kidney,1,6599,,,,50594,,,CCRF S-180,CHEMBL621175,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2113.0,6457,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621176,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6458,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621177,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6459,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621178,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6460,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621179,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6461,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6462,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL875951,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6463,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL621181,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6464,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL621182,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6465,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL621183,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6466,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL621184,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6467,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621185,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6468,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621186,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6469,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621187,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6470,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621188,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6471,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621189,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6472,A,
Spleen,1,6599,,,,50594,,,CCRF S-180,CHEMBL621190,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2106.0,6473,A,
Spleen,1,6599,,,,50594,,,CCRF S-180,CHEMBL618520,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2106.0,6474,A,
Spleen,1,6599,,,,50594,,,CCRF S-180,CHEMBL621739,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2106.0,6475,A,
Spleen,1,6599,,,,50594,,,CCRF S-180,CHEMBL621740,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2106.0,6476,A,
Spleen,1,6599,,,,50594,,,CCRF S-180,CHEMBL621741,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2106.0,6477,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621742,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6478,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621743,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6479,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621744,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6480,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621745,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6481,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621746,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6482,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621747,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6483,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621748,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6484,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621749,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6485,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621750,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6486,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL621751,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6487,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL621752,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6488,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL621753,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6489,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL875955,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6490,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL621754,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6491,A,
Heart,1,6599,,,,50594,,,CCRF S-180,CHEMBL621755,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,948.0,6492,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL621756,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6493,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL624199,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6494,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL624200,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6495,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL624375,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6496,A,
Liver,1,6599,,,,50594,,,CCRF S-180,CHEMBL624376,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2107.0,6497,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL624377,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6498,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL624378,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6499,A,
,1,12269,,,,50067,,,,CHEMBL857901,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap,1,107673.0,,Intermediate,N,BAO_0000218,,6500,F,
,1,12269,,,,50067,,,,CHEMBL875274,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus,1,107673.0,,Intermediate,N,BAO_0000218,,6501,F,
,1,12269,,,,50067,,,,CHEMBL624379,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Acinetobacter calcoaceticus subsp. anitratus,1,107673.0,,Intermediate,N,BAO_0000218,,6502,F,
,1,12269,,,,50067,,,,CHEMBL624380,Compound tested for the antimicrobial activity against Acinetobacter anitratus,aeinetobacter anitrotap,1,107673.0,,Intermediate,N,BAO_0000218,,6503,F,
,1,10624,,,,50192,,,,CHEMBL624381,Activity against Acinetobacter calcoaceticus (AC54),Acinetobacter calcoaceticus,1,471.0,,Intermediate,N,BAO_0000218,,6504,F,
,1,17216,,,,50714,,,,CHEMBL624382,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Anolis carolinensis,1,28377.0,,Intermediate,N,BAO_0000218,,6505,F,
,1,17216,,,,50714,,,,CHEMBL624383,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Anolis carolinensis,1,28377.0,,Intermediate,N,BAO_0000218,,6506,F,
,1,9560,,,,50296,,,,CHEMBL624384,Chlorohexidine coefficient for Actinomyces naeslundii 631,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6507,F,
,1,9560,,,,50296,,,,CHEMBL624385,Chlorohexidine coefficient for Actinomyces naeslundii B74,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6508,F,
,1,9560,,,,50296,,,,CHEMBL624386,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6509,F,
,1,9560,,,,50296,,,,CHEMBL624387,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6510,F,
,1,9560,,,,50296,,,,CHEMBL624388,Plaque bactericidal index against Actinomyces naeslundii 631,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6511,F,
,1,9560,,,,50296,,,,CHEMBL624389,Plaque bactericidal index against Actinomyces naeslundii N/9,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6512,F,
,1,9560,,,,50296,,,,CHEMBL624390,Plaque bactericidal index against Actinomyces naeslundii B74,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6513,F,
,1,9560,,,,50296,,,,CHEMBL875275,Plaque bactericidal index against Actinomyces naeslundii N/3,Actinomyces naeslundii,1,1655.0,,Intermediate,N,BAO_0000218,,6514,F,
,1,114,,,,50056,,,,CHEMBL624391,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Artemia salina,1,85549.0,,Intermediate,N,BAO_0000218,,6515,F,
,1,114,,,,50056,,,,CHEMBL623636,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Artemia salina,1,85549.0,,Intermediate,N,BAO_0000218,,6516,F,
,1,10841,,,,50532,,,,CHEMBL623637,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6517,F,
,1,10841,,,,50532,,,,CHEMBL623638,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6518,F,
,1,10841,,,,50532,,,,CHEMBL623639,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6519,F,
,1,10841,,,,50532,,,,CHEMBL623640,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6520,F,
,1,10841,,,,50532,,,,CHEMBL623641,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6521,F,
,1,10841,,,,50532,,,,CHEMBL623642,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6522,F,
,1,10841,,,,50532,,,,CHEMBL623643,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6523,F,
,1,10841,,,,50532,,,,CHEMBL623644,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6524,F,
,1,10841,,,,50532,,,,CHEMBL623645,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6525,F,
,1,10841,,,,50532,,,,CHEMBL623646,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6526,F,
,1,10841,,,,50532,,,,CHEMBL623647,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6527,F,
,1,10841,,,,50532,,,,CHEMBL623648,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Ascaris suum,1,6253.0,,Intermediate,N,BAO_0000218,,6528,F,
,1,8117,,,,50366,,,,CHEMBL623649,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6529,F,
,1,8117,,,,50366,,,,CHEMBL623650,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6530,F,
,1,9560,,,,50366,,,,CHEMBL623651,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6531,F,
,1,9560,,,,50366,,,,CHEMBL623652,Chlorohexidine coefficient for Actinomyces viscosus M-100,Actinomyces viscosus,1,1656.0,,Expert,N,BAO_0000218,,6532,F,
,1,9560,,,,50366,,,,CHEMBL623653,Chlorohexidine coefficient for Actinomyces viscosus M-626,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6533,F,
,1,9560,,,,50366,,,,CHEMBL623654,Chlorohexidine coefficient for Actinomyces viscosus T14V,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6534,F,
,1,9560,,,,50366,,,,CHEMBL623655,Plaque bactericidal index against Actinomyces viscosus 8A06,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6535,F,
,1,9560,,,,50366,,,,CHEMBL623656,Plaque bactericidal index against Actinomyces viscosus M-100,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6536,F,
,1,9560,,,,50366,,,,CHEMBL623657,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Actinomyces viscosus,1,1656.0,,Expert,N,BAO_0000218,,6537,F,
,1,9560,,,,50366,,,,CHEMBL623658,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6538,F,
,1,9560,,,,50366,,,,CHEMBL623659,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6539,F,
,1,9560,,,,50366,,,,CHEMBL623660,Plaque bactericidal index against Actinomyces viscosus 626,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6540,F,
,1,9560,,,,50366,,,,CHEMBL623661,Plaque bactericidal index against Actinomyces viscosus T14V,Actinomyces viscosus,1,1656.0,,Intermediate,N,BAO_0000218,,6541,F,
,1,10986,,,,50535,,,,CHEMBL875281,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6542,F,
,1,10986,,,,50535,,,,CHEMBL623662,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6543,F,
,1,10986,,,,50535,,,,CHEMBL623663,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6544,F,
,1,10986,,,,50535,,,,CHEMBL623664,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6545,F,
,1,10986,,,,50535,,,,CHEMBL623665,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6546,F,
,1,10708,,,,80023,,,A673,CHEMBL621856,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,165.0,Intermediate,N,BAO_0000219,,6547,F,
,1,10708,,,,80661,,,A704,CHEMBL620432,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,645.0,Intermediate,N,BAO_0000219,,6548,F,
,1,416,,,,22226,,,,CHEMBL620433,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000219,,6549,F,
,1,14354,,,,80024,,,A9,CHEMBL620434,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6550,F,
,1,14354,,,,80024,,,A9,CHEMBL620435,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6551,F,
,1,5116,,,,80024,,,A9,CHEMBL620436,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Homo sapiens,1,9606.0,625.0,Intermediate,N,BAO_0000219,,6552,F,
,1,5116,,,,80024,,,A9,CHEMBL876597,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Homo sapiens,1,9606.0,625.0,Intermediate,N,BAO_0000219,,6553,F,
,1,15694,,,,81037,,,Human ovarian carcinoma cell line,CHEMBL620437,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Homo sapiens,1,9606.0,874.0,Expert,N,BAO_0000219,,6554,F,
,1,13038,,,,80024,,,A9,CHEMBL620438,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Mus musculus,1,10090.0,625.0,Expert,N,BAO_0000219,,6555,F,
,1,13038,,,,80024,,,A9,CHEMBL620439,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Mus musculus,1,10090.0,625.0,Expert,N,BAO_0000219,,6556,F,
,1,10923,,,,80024,,,A9,CHEMBL619657,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Mus musculus,1,10090.0,625.0,Expert,N,BAO_0000219,,6557,F,
,1,10923,,,,80024,,,A9,CHEMBL619658,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6558,F,
,1,10923,,,,80024,,,A9,CHEMBL619659,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6559,F,
,1,10923,,,,10649,,,,CHEMBL619660,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,8,,,Expert,H,BAO_0000019,,6560,F,
,1,10923,,,,80024,,,A9,CHEMBL619661,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6561,F,
,1,10923,,,,80024,,,A9,CHEMBL619662,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Mus musculus,1,10090.0,625.0,Intermediate,N,BAO_0000219,,6562,F,
,1,8158,,,,80663,,,AA6,CHEMBL619663,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Cricetulus griseus,1,10029.0,975.0,Intermediate,N,BAO_0000219,,6563,F,
,1,15494,,,,22226,,,,CHEMBL619664,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000219,,6564,F,
,1,15494,,,,22226,,,,CHEMBL619665,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Homo sapiens,0,9606.0,,Autocuration,U,BAO_0000219,,6565,F,
,1,12348,,,,80662,,,AA5,CHEMBL883244,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Homo sapiens,1,9606.0,974.0,Intermediate,N,BAO_0000219,,6566,F,
,1,12348,,,,80662,,,AA5,CHEMBL884011,Cytotoxicity was measured against AA5/HIV-1(IIIB),Homo sapiens,1,9606.0,974.0,Intermediate,N,BAO_0000219,,6567,F,
,1,2726,,,,80662,,,AA5,CHEMBL619666,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Homo sapiens,1,9606.0,974.0,Intermediate,N,BAO_0000219,,6568,F,
,1,2726,,,,80566,,,U-937,CHEMBL619667,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Homo sapiens,1,9606.0,379.0,Intermediate,N,BAO_0000219,,6569,F,
,1,10747,,,,80578,,,UV4,CHEMBL619668,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Cricetulus griseus,1,10029.0,274.0,Intermediate,N,BAO_0000219,,6570,F,
,1,11005,,,,80089,,,CHO-AA8,CHEMBL619669,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6571,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL876608,Average intracellular compound concentration when the hypoxic SER=1.6,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6572,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619670,Average intracellular compound concentration when the hypoxic SER=1.6.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6573,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619671,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6574,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619672,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6575,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619673,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6576,F,
,1,13436,,,,80089,,,CHO-AA8,CHEMBL619674,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6577,F,
,1,13435,,,,80089,,,CHO-AA8,CHEMBL619675,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6578,F,
,1,13302,,,,80089,,,CHO-AA8,CHEMBL619676,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6579,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619677,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6580,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619678,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6581,A,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL619679,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6582,A,
,1,12878,,,,80089,,,CHO-AA8,CHEMBL619680,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6583,A,
,1,12878,,,,80089,,,CHO-AA8,CHEMBL621457,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6584,A,
,1,14367,,,,80089,,,CHO-AA8,CHEMBL876609,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6585,F,
,1,14367,,,,80089,,,CHO-AA8,CHEMBL621458,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6586,F,
,1,12398,,,,80089,,,CHO-AA8,CHEMBL621459,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,hampster,1,36483.0,185.0,Expert,N,BAO_0000219,,6587,F,
,1,12878,,,,80089,,,CHO-AA8,CHEMBL621460,Aerobic growth inhibition in Chinese hamster cell line AA8,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6588,F,
,1,13820,,,,80089,,,CHO-AA8,CHEMBL621461,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6589,F,
,1,13436,,,,80089,,,CHO-AA8,CHEMBL621462,Inhibition of growth under aerobic conditions in AA8 cells,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6590,F,
,1,6084,,In vivo,,50588,,,,CHEMBL621463,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6591,A,
,1,5711,,In vivo,,50588,,,,CHEMBL621464,Oral bioavailability in dog at 10 mg/kg of the compound,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6592,A,
,1,4353,,In vivo,,50588,,,,CHEMBL621465,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6593,A,
,1,4353,,In vivo,,50588,,,,CHEMBL621466,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6594,A,
,1,17800,,In vivo,,50588,,,,CHEMBL621467,Oral bioavailability in dog (mongrel),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6595,A,
,1,3994,,In vivo,,50588,,,,CHEMBL621468,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6596,A,
,1,3994,,In vivo,,50588,,,,CHEMBL876734,Oral bioavailability in dog (dose 10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6597,F,
,1,5145,,In vivo,,50588,,,,CHEMBL618476,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6598,A,
,1,16452,,In vivo,,50588,,,,CHEMBL618477,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6599,A,
,1,16452,,In vivo,,50588,,,,CHEMBL618478,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6600,A,
,1,5983,,In vivo,,50588,,,,CHEMBL618479,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6601,A,
,1,4273,,In vivo,,50588,,,,CHEMBL618480,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6602,A,
,1,12500,,In vivo,,50588,,,,CHEMBL618481,Bioavailability in dog (dose 3-10 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6603,A,
Plasma,1,12500,,In vivo,,50588,,,,CHEMBL618482,The compound was tested for bioavailability of compound in plasma of dog; Complete,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6604,A,
,1,3639,,In vivo,,50588,,,,CHEMBL618483,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6605,A,
,1,3880,,In vivo,,50588,,,,CHEMBL618484,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6606,A,
,1,4838,,In vivo,,50588,,,,CHEMBL618485,Bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6607,A,
,1,15600,,In vivo,,50588,,,,CHEMBL618486,oral bioavailability was measured in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6608,A,
,1,17248,,,,50588,,,,CHEMBL618487,Compound was tested for plasma protein binding in dog; Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6609,A,
,1,17248,,,,50588,,,,CHEMBL618488,Compound was tested for plasma protein binding of dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6610,A,
,1,17248,,,,50588,,,,CHEMBL876735,Compound was tested for plasma protein binding of dog; Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6611,A,
,1,17443,,,,50588,,,,CHEMBL618489,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6612,A,
,1,4186,,In vivo,,50588,,,,CHEMBL618490,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6613,A,
,1,3749,,,,50588,,,,CHEMBL618491,Half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6614,A,
,1,3249,,In vivo,,50588,,,,CHEMBL618492,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6615,A,
,1,3022,,,,50588,,,,CHEMBL873354,Half life was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6616,A,
,1,3749,,,,50588,,,,CHEMBL618493,Half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6617,A,
,1,2517,,In vivo,,50588,,,,CHEMBL618494,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6618,A,
Heart,1,2517,,In vivo,,50588,,,,CHEMBL618495,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,948.0,6619,A,
Kidney,1,2517,,In vivo,,50588,,,,CHEMBL618496,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2113.0,6620,A,
Liver,1,2517,,In vivo,,50588,,,,CHEMBL618497,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2107.0,6621,A,
Lung,1,2517,,In vivo,,50588,,,,CHEMBL618498,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2048.0,6622,A,
Spleen,1,2517,,In vivo,,50588,,,,CHEMBL618499,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2106.0,6623,A,
,1,3639,,,,50588,,,,CHEMBL876736,LogP in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6624,A,
,1,6227,,,,50588,,,,CHEMBL618500,Partition coefficient (logP),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6625,A,
,1,6227,,,,50588,,,,CHEMBL857831,Partition coefficient in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6626,A,
,1,17764,,In vivo,,50588,,,,CHEMBL618501,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6627,A,
,1,4809,,In vivo,,50588,,,,CHEMBL618502,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6628,A,
,1,5600,,,,50588,,,,CHEMBL618503,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6629,A,
,1,14294,,,,50588,,,,CHEMBL618504,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6630,A,
,1,14294,,,,50588,,,,CHEMBL618505,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6631,A,
,1,14294,,,,50588,,,,CHEMBL618506,Metabolism of compound in dog S9 microsomes; Trace,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6632,A,
Liver,1,6251,,,,50588,,,,CHEMBL618507,In vitro metabolic potential in dog liver microsomes,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2107.0,6633,A,
,1,3748,,In vivo,,50588,,,,CHEMBL876737,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6634,A,
,1,2713,,In vivo,,50588,,,,CHEMBL618508,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6635,A,
,1,6512,,In vivo,,50588,,,,CHEMBL618509,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6636,A,
,1,6679,,In vivo,,50588,,,,CHEMBL618510,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6637,A,
,1,3749,,In vivo,,50588,,,,CHEMBL618511,The compound was tested for bioavailability in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6638,A,
,1,3749,,In vivo,,50588,,,,CHEMBL618512,The compound was tested for oral bioavailability in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6639,A,
,1,6742,,In vivo,,50588,,,,CHEMBL618513,Oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6640,A,
,1,6227,,,,50588,,,,CHEMBL618514,Compound was tested for percent protein binding (PB) in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6641,A,
,1,6874,,,,50588,,,,CHEMBL620052,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6642,A,
Plasma,1,2877,,In vivo,,50588,,,,CHEMBL620053,Compound was evaluated for plasma clearance.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6643,A,
Plasma,1,12500,,In vivo,,50588,,,,CHEMBL620054,The compound was tested for plasma clearance in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6644,A,
Plasma,1,12500,,In vivo,,50588,,,,CHEMBL620055,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6645,A,
,1,4709,,,,50588,,,,CHEMBL620056,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6646,A,
Liver,1,5542,,,,50588,,,,CHEMBL620057,In vitro relative rate of metabolism was determined in dog liver microsomes,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2107.0,6647,A,
,1,17594,,In vivo,,50588,,,,CHEMBL618939,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6648,A,
,1,2652,,In vivo,,50588,,,,CHEMBL618940,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6649,A,
,1,17764,,In vivo,,50588,,,,CHEMBL618941,Half life after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6650,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL624473,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6651,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL624474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6652,A,
Lung,1,6599,,,,50594,,,CCRF S-180,CHEMBL624475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,2048.0,6653,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL624476,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6654,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL623478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6655,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL623479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6656,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL623480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6657,A,
,1,6599,,,,50594,,,CCRF S-180,CHEMBL623481,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Mus musculus,1,10090.0,42.0,Intermediate,N,BAO_0000218,,6658,A,
Brain,1,17641,,,,50594,,,,CHEMBL623482,C2 in brain of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6659,A,
Kidney,1,17641,,,,50594,,,,CHEMBL623483,C2 in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6660,A,
Liver,1,17641,,,,50594,,,,CHEMBL623484,C2 in liver of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6661,A,
Lung,1,17641,,,,50594,,,,CHEMBL623485,C2 in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6662,A,
Spleen,1,17641,,,,50594,,,,CHEMBL623486,C2 in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,6663,A,
,1,17852,,In vivo,,50594,,,,CHEMBL623487,Plasma clearance in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6664,A,
,1,17764,,In vivo,,50594,,,,CHEMBL623488,Clearance of compound after intravenous administration in mice at 24 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6665,A,
,1,17837,,In vivo,,50594,,,,CHEMBL623489,Clearance from mouse blood following i.v. administration of 10 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6666,A,
,1,2675,,In vivo,,50594,,,,CHEMBL875157,Clearance was evaluated in mice after intravenous administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6667,A,
,1,2675,,In vivo,,50594,,,,CHEMBL623490,Clearance was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6668,A,
,1,4239,,In vivo,,50594,,,,CHEMBL623491,Pharmacokinetic property (Plasma clearance) was measured in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6669,A,
,1,17753,,In vivo,,50594,,,,CHEMBL623492,Plasma clearance of compound was determined at 40 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6670,A,
,1,17753,,In vivo,,50594,,,,CHEMBL623493,Plasma clearance of at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6671,A,
,1,17753,,In vivo,,50594,,,,CHEMBL623494,Plasma clearance at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6672,A,
,1,17753,,In vivo,,50594,,,,CHEMBL623495,Plasma clearance at 5 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6673,A,
,1,5727,,In vivo,,50594,,,,CHEMBL623496,Plasma clearance in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6674,A,
,1,2862,,In vivo,,50594,,,,CHEMBL623497,Plasma clearance value upon iv administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6675,A,
Plasma,1,5980,,In vivo,,50594,,,,CHEMBL623498,Total plasma clearance in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6676,A,
,1,17592,,In vivo,,50594,,,,CHEMBL623499,Clearance in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6677,A,
,1,17718,,In vivo,,50594,,,,CHEMBL623500,Clearance value was determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6678,A,
,1,16597,,In vivo,,50594,,,,CHEMBL623501,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6679,A,
,1,17384,,,,22229,,,,CHEMBL875158,Calculated partition coefficient (clogP),,0,,,Intermediate,U,BAO_0000100,,6680,P,
,1,6062,,In vivo,,50594,,,,CHEMBL623502,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6681,A,
,1,17734,,In vivo,,50594,,,,CHEMBL623503,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6682,A,
,1,6348,,In vivo,,50594,,,,CHEMBL623504,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6683,A,
,1,5969,,In vivo,,50594,,,,CHEMBL623505,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6684,A,
,1,5969,,In vivo,,50594,,,,CHEMBL623506,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6685,A,
,1,5969,,In vivo,,50594,,,,CHEMBL623507,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6686,A,
,1,16597,,In vivo,,50594,,,,CHEMBL623508,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6687,A,
,1,5781,,In vivo,,50594,,,,CHEMBL623509,Cmax after oral administration at 30 mg/kg in ICR mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6688,A,
,1,17764,,In vivo,,50594,,,,CHEMBL875159,Cmax after peroral administration in mice at 2.4 uM/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6689,A,
Brain,1,17641,,In vivo,,50594,,,,CHEMBL623510,Cmax in brain of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,955.0,6690,A,
Kidney,1,17641,,In vivo,,50594,,,,CHEMBL623511,Cmax in kidney of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,6691,A,
Liver,1,17641,,In vivo,,50594,,,,CHEMBL623512,Cmax in liver of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,6692,A,
Lung,1,17641,,In vivo,,50594,,,,CHEMBL623513,Cmax in lungs of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,6693,A,
,1,17764,,In vivo,,50594,,,,CHEMBL623514,Cmax in mice at 18 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6694,F,
,1,17764,,In vivo,,50594,,,,CHEMBL622609,Cmax in mice at 23 uM/kg i.v. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6695,F,
,1,17764,,In vivo,,50594,,,,CHEMBL622610,Cmax in mice at 24 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6696,F,
,1,17764,,In vivo,,50594,,,,CHEMBL621823,Cmax in mice at 25 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6697,F,
,1,17764,,In vivo,,50594,,,,CHEMBL621824,Cmax in mice at 26 uM/kg i.p. administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6698,F,
Spleen,1,17641,,In vivo,,50594,,,,CHEMBL621825,Cmax in spleen of mice at the oral dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,6699,A,
,1,16597,,In vivo,,50594,,,,CHEMBL621826,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6700,A,
,1,16597,,In vivo,,50594,,,,CHEMBL621827,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6701,A,
,1,5727,,In vivo,,50594,,,,CHEMBL621828,Cmax value was determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6702,A,
,1,5951,,In vivo,,50594,,,,CHEMBL621829,Cmax value in IRC mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6703,A,
,1,5506,,In vivo,,50594,,,,CHEMBL621830,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6704,A,
,1,5506,,In vivo,,50594,,,,CHEMBL621831,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6705,A,
Plasma,1,14239,,In vivo,,50594,,,,CHEMBL621832,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6706,A,
Plasma,1,4890,,In vivo,,50594,,,,CHEMBL624579,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6707,A,
,1,429,,In vivo,,50594,,,,CHEMBL624580,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6708,A,
,1,10986,,,,50535,,,,CHEMBL624581,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6709,F,
,1,10986,,,,50535,,,,CHEMBL624582,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6710,F,
,1,10986,,,,50535,,,,CHEMBL624583,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Acanthocheilonema viteae,1,6277.0,,Intermediate,N,BAO_0000218,,6711,F,
,1,13227,,,,80018,,,A-375,CHEMBL624584,Inhibitory activity against human tumor cell line A0375 melanoma.,Homo sapiens,1,9606.0,455.0,Intermediate,N,BAO_0000219,,6712,F,
,1,4481,,,,12512,,Brain membranes,,CHEMBL624585,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Rattus norvegicus,9,10116.0,,Expert,D,BAO_0000249,,6713,B,
,1,16931,,,,114,,,,CHEMBL875165,Forskolin-induced cAMP production at human A1 adenosine receptor,Homo sapiens,9,9606.0,,Expert,D,BAO_0000019,,6714,F,
,1,3850,,,,114,,,CHO,CHEMBL619490,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6715,F,
,1,3850,,,,114,,,CHO,CHEMBL619491,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,8,,449.0,Autocuration,H,BAO_0000219,,6716,F,
,1,3850,,,,114,,,CHO,CHEMBL619492,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,8,,449.0,Expert,H,BAO_0000219,,6717,F,
,1,3850,,,,114,,,CHO,CHEMBL619493,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,8,,449.0,Expert,H,BAO_0000219,,6718,F,
,1,3850,,,,114,,,CHO,CHEMBL619494,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,8,,449.0,Autocuration,H,BAO_0000219,,6719,F,
,1,3850,,,,114,,,CHO,CHEMBL619495,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,8,,449.0,Autocuration,H,BAO_0000219,,6720,F,
,1,3850,,,,114,,,CHO,CHEMBL619496,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6721,F,
,1,3850,,,,114,,,CHO,CHEMBL619497,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Homo sapiens,9,9606.0,449.0,Expert,D,BAO_0000219,,6722,F,
,1,3850,,,,114,,,CHO,CHEMBL619498,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,8,,449.0,Autocuration,H,BAO_0000219,,6723,F,
,1,3850,,,,114,,,CHO,CHEMBL619499,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6724,F,
,1,3850,,,,114,,,CHO,CHEMBL619500,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,8,,449.0,Expert,H,BAO_0000219,,6725,F,
,1,3850,,,,114,,,CHO,CHEMBL619501,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6726,F,
,1,3850,,,,114,,,CHO,CHEMBL619502,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,8,,449.0,Expert,H,BAO_0000219,,6727,F,
,1,3850,,,,114,,,CHO,CHEMBL619503,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,8,,449.0,Autocuration,H,BAO_0000219,,6728,F,
,1,3850,,,,114,,,CHO,CHEMBL619504,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,8,,449.0,Autocuration,H,BAO_0000219,,6729,F,
,1,3850,,,,114,,,CHO,CHEMBL621298,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6730,F,
,1,3850,,,,114,,,CHO,CHEMBL621299,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,8,,449.0,Expert,H,BAO_0000219,,6731,F,
,1,3850,,,,114,,,CHO,CHEMBL621300,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,8,,449.0,Autocuration,H,BAO_0000219,,6732,F,
,1,3850,,,,114,,,CHO,CHEMBL621301,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,8,,449.0,Autocuration,H,BAO_0000219,,6733,F,
,1,3850,,,,114,,,CHO,CHEMBL621302,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,8,,449.0,Expert,H,BAO_0000219,,6734,F,
,1,12680,,,,80013,,,A10,CHEMBL621303,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Oryctolagus cuniculus,1,9986.0,164.0,Intermediate,N,BAO_0000219,,6735,F,
,1,1313,,,,22226,,,A10,CHEMBL621304,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Rattus norvegicus,0,10116.0,164.0,Autocuration,U,BAO_0000219,,6736,F,
,1,1313,,,,22226,,,A10,CHEMBL621305,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Rattus norvegicus,0,10116.0,164.0,Autocuration,U,BAO_0000219,,6737,F,
,1,17567,,,,80013,,,A10,CHEMBL621306,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Rattus norvegicus,1,10116.0,164.0,Intermediate,N,BAO_0000219,,6738,F,
,1,17567,,,,80013,,,A10,CHEMBL618444,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Rattus norvegicus,1,10116.0,164.0,Intermediate,N,BAO_0000219,,6739,F,
,1,11819,,,,80013,,,A10,CHEMBL618445,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Rattus norvegicus,1,10116.0,164.0,Intermediate,N,BAO_0000219,,6740,F,
,1,13436,,,,80089,,,CHO-AA8,CHEMBL618446,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6741,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL618447,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6742,F,
,1,12651,,,,80089,,,CHO-AA8,CHEMBL618448,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6743,F,
,1,13300,,,,80089,,,CHO-AA8,CHEMBL618449,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6744,F,
,1,15296,,,,80089,,,CHO-AA8,CHEMBL618637,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6745,F,
,1,15328,,,,80089,,,CHO-AA8,CHEMBL618638,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6746,F,
,1,13302,,,,80089,,,CHO-AA8,CHEMBL618639,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6747,F,
,1,14367,,,,80089,,,CHO-AA8,CHEMBL618640,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6748,F,
,1,17002,,,,80089,,,CHO-AA8,CHEMBL618641,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6749,F,
,1,13436,,,,80089,,,CHO-AA8,CHEMBL618642,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6750,F,
,1,13435,,,,80089,,,CHO-AA8,CHEMBL618643,Inhibitory activity against aerobic growth of AA8 cells.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6751,F,
,1,10503,,,,80089,,,CHO-AA8,CHEMBL884013,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6752,A,
,1,10503,,,,80089,,,CHO-AA8,CHEMBL622723,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6753,F,
,1,10503,,,,80089,,,CHO-AA8,CHEMBL622724,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6754,F,
,1,15090,,,,80089,,,CHO-AA8,CHEMBL622725,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6755,F,
,1,10368,,,,80089,,,CHO-AA8,CHEMBL622726,Cytotoxicity against AA8 cell line,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6756,F,
,1,12651,,,,80089,,,CHO-AA8,CHEMBL622727,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6757,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL622728,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6758,A,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL622729,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6759,F,
,1,12687,,,,80089,,,CHO-AA8,CHEMBL622730,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6760,A,
,1,1890,,,,80089,,,CHO-AA8,CHEMBL622731,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6761,F,
,1,10747,,,,80089,,,CHO-AA8,CHEMBL622732,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6762,F,
,1,10747,,,,80089,,,CHO-AA8,CHEMBL622733,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Cricetulus griseus,1,10029.0,185.0,Intermediate,N,BAO_0000219,,6763,F,
,1,11616,,,,22224,,,,CHEMBL622734,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000218,,6764,F,
,1,11616,,,,80089,,,CHO-AA8,CHEMBL622735,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6765,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL618746,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6766,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL618747,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6767,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL620540,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6768,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL620541,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6769,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL620542,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6770,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL620543,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6771,F,
,1,3471,,,,22224,,,CHO-AA8,CHEMBL618832,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6772,F,
,1,11616,,,,80089,,,CHO-AA8,CHEMBL618833,Concentration required to reduce AA8 cell survival by 10%,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6773,F,
,1,2656,,,,22224,,,CHO-AA8,CHEMBL618834,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6774,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL618835,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6775,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL618836,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6776,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL618837,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6777,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL618838,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6778,F,
,1,16156,,,,22224,,,CHO-AA8,CHEMBL618839,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6779,F,
,1,2656,,,,22224,,,CHO-AA8,CHEMBL618840,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6780,F,
,1,11005,,,,22224,,,,CHEMBL618841,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,6781,F,
,1,11942,,,,22224,,,CHO-AA8,CHEMBL618842,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6782,F,
,1,2128,,,,22224,,,CHO-AA8,CHEMBL618843,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6783,F,
,1,16907,,In vivo,,50588,,,,CHEMBL618844,Half life period after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6784,A,
,1,16907,,In vivo,,50588,,,,CHEMBL618845,Half life period after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6785,A,
,1,9579,,In vivo,,50588,,,,CHEMBL618846,Half life was measured after oral 2b administration (tested in 6 dogs),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6786,A,
,1,9579,,In vivo,,50588,,,,CHEMBL618847,Half life was measured in dog after oral 17b administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6787,A,
,1,9579,,In vivo,,50588,,,,CHEMBL618848,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6788,A,
,1,9579,,In vivo,,50588,,,,CHEMBL618849,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6789,A,
,1,16907,,In vivo,,50588,,,,CHEMBL618850,Tmax value after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6790,A,
,1,16907,,In vivo,,50588,,,,CHEMBL618851,Tmax value after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6791,A,
,1,3184,,In vivo,,50588,,,,CHEMBL873815,Compound was evaluated for its half life when administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6792,A,
Plasma,1,5017,,In vivo,,50588,,,,CHEMBL618852,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6793,A,
,1,6821,,,,50588,,,,CHEMBL618853,Elimination Half-life of compound was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6794,A,
,1,17839,,In vivo,,50588,,,,CHEMBL618854,Half life of compound in dog following oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6795,A,
,1,17267,,,,50588,,,,CHEMBL618855,Half life of compound was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6796,A,
Blood,1,4727,,,,50588,,,,CHEMBL618856,Half life of compound was determined in dog blood,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,6797,A,
,1,5238,,In vivo,,50588,,,,CHEMBL875827,Half life after oral and iv dosing in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6798,A,
,1,4942,,,,50588,,,,CHEMBL618857,Half life in dogs in hours,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6799,A,
,1,6505,,In vivo,,50588,,,,CHEMBL618858,Half life on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6800,A,
,1,5130,,In vivo,,50588,,,,CHEMBL618859,t1/2 in dog after oral dose (1 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6801,A,
,1,1475,,,,50588,,,,CHEMBL618860,Half life was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6802,A,
,1,17804,,In vivo,,50588,,,,CHEMBL618861,Half life period of compound was determined after intravenous administration at 2 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6803,A,
,1,17804,,In vivo,,50588,,,,CHEMBL622539,Half life period of compound was determined after peroral administration at 2 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6804,A,
,1,6084,,In vivo,,50588,,,,CHEMBL622540,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6805,A,
,1,6084,,In vivo,,50588,,,,CHEMBL873803,Half life period (10 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6806,A,
,1,5542,,In vivo,,50588,,,,CHEMBL873804,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6807,A,
,1,5542,,In vivo,,50588,,,,CHEMBL624311,Half life period by po administration in dog at a dose of 0.3 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6808,A,
,1,6084,,,,50588,,,,CHEMBL624312,Half life period in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6809,A,
,1,6241,,In vivo,,50588,,,,CHEMBL624313,Half life period in dogs after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6810,A,
,1,1916,,In vivo,,50588,,,,CHEMBL624314,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6811,A,
,1,6621,,,,50588,,,,CHEMBL624315,Half-life of compound was determined in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6812,A,
Plasma,1,1696,,,,50588,,,,CHEMBL624316,Half-life in dog plasma,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6813,A,
,1,17800,,,,50588,,,,CHEMBL624317,Half-life in mongrel dogs was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6814,A,
,1,17657,,In vivo,,50588,,,,CHEMBL624318,Half-life in dog upon oral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6815,A,
,1,17657,,In vivo,,50588,,,,CHEMBL624319,Half-life in dog upon oral administration; Unable to calculate,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6816,A,
,1,4239,,,,50588,,,,CHEMBL624496,Half-life was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6817,A,
,1,5985,,,,50588,,,,CHEMBL624497,Half-life was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6818,A,
,1,9932,,,,50588,,,,CHEMBL624498,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6819,A,
,1,5199,,In vivo,,50588,,,,CHEMBL624499,Oral half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6820,A,
Plasma,1,5199,,In vivo,,50588,,,,CHEMBL624500,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6821,A,
Plasma,1,1475,,,,50588,,,,CHEMBL624501,Plasma half life was evaluated,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6822,A,
Plasma,1,1475,,,,50588,,,,CHEMBL623666,Plasma half life was evaluated in Dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6823,A,
Plasma,1,1475,,,,50588,,,,CHEMBL623667,Plasma half life was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6824,A,
,1,6316,,In vivo,,50588,,,,CHEMBL623668,T1/2 (Half-life) was after oral administration at 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6825,A,
,1,4883,,,,50588,,,,CHEMBL623669,Tested for the half life value in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6826,A,
,1,4727,,In vivo,,50588,,,,CHEMBL623670,Maximum time at the dose of 2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6827,A,
,1,1916,,In vivo,,50588,,,,CHEMBL623671,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6828,A,
Blood,1,1337,,In vivo,,50588,,,,CHEMBL875945,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,6829,A,
Blood,1,1337,,In vivo,,50588,,,,CHEMBL623672,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,6830,A,
,1,6265,,In vivo,,50588,,,,CHEMBL623673,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6831,A,
,1,4809,,In vivo,,50588,,,,CHEMBL623674,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6832,A,
,1,5983,,In vivo,,50588,,,,CHEMBL623675,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6833,A,
,1,5313,,,,50588,,,,CHEMBL872526,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6834,A,
,1,5313,,In vivo,,50588,,,,CHEMBL623676,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6835,A,
Plasma,1,17650,,In vivo,,50588,,,,CHEMBL623677,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6836,A,
Plasma,1,5199,,In vivo,,50588,,,,CHEMBL623678,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6837,A,
Plasma,1,933,,,,50588,,,,CHEMBL623679,Time taken for maximum plasma concentration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6838,A,
,1,16367,,In vivo,,50588,,,,CHEMBL623680,Time to reach Cmax after oral administration to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6839,A,
Plasma,1,6348,,In vivo,,50588,,,,CHEMBL623681,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,6840,A,
,1,6316,,In vivo,,50588,,,,CHEMBL623682,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6841,A,
,1,6215,,In vivo,,50588,,,,CHEMBL623683,Tmax after peroral administration (1 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6842,A,
,1,3598,,In vivo,,50588,,,,CHEMBL623684,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,,6843,A,
,1,4527,,In vivo,,50588,,,,CHEMBL622745,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6844,A,
,1,17764,,In vivo,,50588,,,,CHEMBL622746,Tmax after peroral administration in dogs at 2.4 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6845,A,
,1,5969,,In vivo,,50594,,,,CHEMBL622747,In vivo Cmax in mice at dose of 100 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6846,A,
,1,5969,,In vivo,,50594,,,,CHEMBL622748,In vivo Cmax in mice at dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6847,A,
,1,4573,,In vivo,,50594,,,,CHEMBL622749,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6848,A,
Plasma,1,3277,,In vivo,,50594,,,,CHEMBL622750,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6849,A,
Plasma,1,17734,,In vivo,,50594,,,,CHEMBL623411,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6850,A,
Plasma,1,3132,,In vivo,,50594,,,,CHEMBL875946,Maximum concentration obtained in mouse plasma was determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6851,A,
Plasma,1,3132,,In vivo,,50594,,,,CHEMBL623412,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6852,A,
Plasma,1,6348,,In vivo,,50594,,,,CHEMBL623413,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6853,A,
Plasma,1,17729,,In vivo,,50594,,,,CHEMBL623414,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6854,A,
Plasma,1,17729,,In vivo,,50594,,,,CHEMBL623415,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6855,A,
Plasma,1,17729,,In vivo,,50594,,,,CHEMBL623416,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6856,A,
Plasma,1,17728,,In vivo,,50594,,,,CHEMBL623417,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6857,A,
Plasma,1,17728,,In vivo,,50594,,,,CHEMBL623418,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6858,A,
Plasma,1,17728,,In vivo,,50594,,,,CHEMBL623419,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6859,A,
,1,4066,,In vivo,,50594,,,,CHEMBL622816,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6860,A,
,1,6178,,In vivo,,50594,,,,CHEMBL623313,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6861,A,
,1,6178,,In vivo,,50594,,,,CHEMBL623314,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6862,A,
,1,3760,,In vivo,,50594,,,,CHEMBL876788,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6863,A,
,1,3760,,In vivo,,50594,,,,CHEMBL623315,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6864,A,
,1,3760,,In vivo,,50594,,,,CHEMBL623316,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6865,A,
,1,3760,,In vivo,,50594,,,,CHEMBL623317,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6866,A,
,1,5961,,In vivo,,50594,,,,CHEMBL623319,Cmax in male mice after 2 mg/kg oral dose,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6868,A,
,1,6137,,In vivo,,50594,,,,CHEMBL623320,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6869,A,
,1,3802,,In vivo,,50594,,,,CHEMBL623321,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6870,A,
,1,3535,,,,50594,,,,CHEMBL623322,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6871,A,
,1,3535,,,,50594,,,,CHEMBL623323,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6872,A,
,1,3535,,,,50594,,,,CHEMBL623324,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6873,A,
,1,3535,,,,50594,,,,CHEMBL623325,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6874,A,
,1,3535,,,,50594,,,,CHEMBL623326,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6875,A,
,1,3535,,,,50594,,,,CHEMBL623327,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6876,A,
Plasma,1,2862,,,,50594,,,,CHEMBL623328,Maximum concentration in plasma upon oral administration in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6877,A,
Plasma,1,2675,,,,50594,,,,CHEMBL623329,Maximum plasma concentration was evaluated in mice after oral administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6878,A,
Plasma,1,2675,,In vivo,,50594,,,,CHEMBL623330,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,6879,A,
,1,5399,,,,50594,,,,CHEMBL876789,Dose at which the compound induced fecal excretion in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,6880,A,
,1,11819,,,,80013,,,A10,CHEMBL623333,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Rattus norvegicus,1,10116.0,164.0,Expert,N,BAO_0000219,,6893,F,
,1,11819,,,,80013,,,A10,CHEMBL623334,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Rattus norvegicus,1,10116.0,164.0,Expert,N,BAO_0000219,,6894,F,
,1,11819,,,,80013,,,A10,CHEMBL627536,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Rattus norvegicus,1,10116.0,164.0,Expert,N,BAO_0000219,,6895,F,
,1,11819,,,,80013,,,A10,CHEMBL627537,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Rattus norvegicus,1,10116.0,164.0,Expert,N,BAO_0000219,,6896,F,
,1,16361,,,,80013,,,A10,CHEMBL627538,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Rattus norvegicus,1,10116.0,164.0,Intermediate,N,BAO_0000219,,6897,F,
,1,2288,,,,80655,,,A121,CHEMBL884106,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6898,F,
,1,10404,,,,80655,,,A121,CHEMBL625294,Anticancer activity against human ovarian carcinoma A121 cells,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6899,F,
,1,14790,,,,80655,,,A121,CHEMBL625295,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6900,F,
,1,14790,,,,80655,,,A121,CHEMBL625296,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6901,F,
,1,14253,,,,80655,,,A121,CHEMBL625297,Growth inhibition of human ovarian carcinoma (A121) cell line,Homo sapiens,1,9606.0,393.0,Expert,N,BAO_0000219,,6902,F,
,1,13617,,,,80655,,,A121,CHEMBL625298,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Homo sapiens,1,9606.0,393.0,Expert,N,BAO_0000219,,6903,F,
,1,1003,,,,80655,,,A121,CHEMBL625960,Cytotoxicity against human A121 ovarian cells,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6904,F,
,1,830,,,,80655,,,A121,CHEMBL625961,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6905,F,
,1,12307,,,,80655,,,A121,CHEMBL625962,In vitro cytotoxicity against human ovarian carcinoma A21,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6906,F,
,1,14254,,,,80655,,,A121,CHEMBL624717,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6907,F,
,1,13370,,,,80655,,,A121,CHEMBL624718,Inhibitory activity of compound against human A121 ovarian cell line.,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6908,F,
,1,14790,,,,80655,,,A121,CHEMBL624719,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6909,F,
,1,3614,,,,80655,,,A121,CHEMBL624720,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Homo sapiens,1,9606.0,393.0,Intermediate,N,BAO_0000219,,6910,F,
,1,2664,,,,80012,,,A 172,CHEMBL624721,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,6911,F,
,1,2037,,,,80012,,,A 172,CHEMBL624722,In vitro cytotoxicity against A172 human tumor cell lines.,Homo sapiens,1,9606.0,622.0,Expert,N,BAO_0000219,,6912,F,
,1,14539,,,,80012,,,A 172,CHEMBL877597,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,6913,F,
,1,2836,,,,80012,,,A 172,CHEMBL624723,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,6914,F,
,1,10708,,,,80012,,,A 172,CHEMBL624724,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Homo sapiens,1,9606.0,622.0,Intermediate,N,BAO_0000219,,6915,F,
,1,8975,,,,104729,,,,CHEMBL624725,Association constant against A2 adenosine receptor,Canis lupus familiaris,4,9615.0,,Autocuration,H,BAO_0000224,,6916,B,
,1,7645,,,,80656,,,A2,CHEMBL624726,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,fish,1,,1085.0,Intermediate,N,BAO_0000219,,6917,F,
,1,11377,,,,104713,,,,CHEMBL857535,Ratio of Ki for adenosine A2 and A1 receptor binding,Rattus norvegicus,5,10116.0,,Autocuration,D,BAO_0000224,,6918,B,
,1,13528,,,,80014,,,A204,CHEMBL624727,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Homo sapiens,1,9606.0,623.0,Expert,N,BAO_0000219,,6919,F,
,1,10160,,,,80014,,,A204,CHEMBL624728,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Homo sapiens,1,9606.0,623.0,Expert,N,BAO_0000219,,6920,F,
,1,15144,,,,80015,,,A2058,CHEMBL624729,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Homo sapiens,1,9606.0,404.0,Intermediate,N,BAO_0000219,,6921,F,
,1,13160,,,,80657,,,A253 cell line,CHEMBL624730,Growth inhibition against Human squamous cell line(A 253),Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6922,F,
,1,12898,,,,80657,,,A253 cell line,CHEMBL624731,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6923,F,
,1,13069,,,,80657,,,A253 cell line,CHEMBL624732,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6924,F,
,1,15984,,,,80657,,,A253 cell line,CHEMBL883245,Growth inhibition of A253 cell lines.,Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6925,F,
,1,15564,,,,80657,,,A253 cell line,CHEMBL624733,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6926,F,
,1,15564,,,,80657,,,A253 cell line,CHEMBL624734,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6927,F,
,1,15564,,,,80657,,,A253 cell line,CHEMBL624735,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Homo sapiens,1,9606.0,973.0,Intermediate,N,BAO_0000219,,6928,F,
,1,4720,,,,81034,,,A2780,CHEMBL621780,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6929,F,
,1,16112,,,,81034,,,A2780,CHEMBL877598,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6930,F,
,1,16597,,,,81034,,,A2780,CHEMBL621781,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,6931,F,
,1,16378,,,,81034,,,A2780,CHEMBL621782,Cytotoxicity against human cancer cell lines A2780 (ovarian),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6932,F,
,1,16085,,,,81034,,,A2780,CHEMBL621783,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,6933,F,
,1,16317,,,,81034,,,A2780,CHEMBL621784,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6934,F,
,1,15748,,,,81034,,,A2780,CHEMBL621785,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6935,F,
,1,16597,,,,81034,,,A2780,CHEMBL621968,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,6936,F,
,1,16597,,,,81034,,,A2780,CHEMBL621969,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,6937,F,
,1,16597,,,,81034,,,A2780,CHEMBL621970,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,6938,F,
,1,15608,,,,81034,,,A2780,CHEMBL621971,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6939,F,
,1,15608,,,,81034,,,A2780,CHEMBL621972,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6940,F,
,1,15608,,,,81034,,,A2780,CHEMBL884108,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,6941,F,
,1,15296,,,,22224,,,,CHEMBL623826,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,6942,F,
,1,10251,,,,22224,,,CHO-AA8,CHEMBL623827,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6943,A,
,1,10251,,,,22224,,,CHO-AA8,CHEMBL623828,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6944,F,
,1,10251,,,,22224,,,CHO-AA8,CHEMBL623829,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6945,F,
,1,10251,,,,22224,,,CHO-AA8,CHEMBL623830,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6946,F,
,1,11858,,,,22224,,,,CHEMBL623831,Growth inhibition against CHO-derived cell line AA8,Cricetulus griseus,0,10029.0,,Autocuration,U,BAO_0000019,,6947,F,
,1,11858,,,,22224,,,CHO-AA8,CHEMBL623832,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6948,F,
,1,11616,,,,80089,,,CHO-AA8,CHEMBL623833,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,hampster,1,36483.0,185.0,Expert,N,BAO_0000219,,6949,F,
,1,11616,,,,80089,,,CHO-AA8,CHEMBL623834,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6950,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL623835,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6951,F,
,1,11396,,,,22224,,,CHO-AA8,CHEMBL623836,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6952,F,
,1,10518,,,,22224,,,CHO-AA8,CHEMBL623837,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Cricetulus griseus,0,10029.0,185.0,Autocuration,U,BAO_0000219,,6953,F,
,1,11616,,,,80089,,,CHO-AA8,CHEMBL623838,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Cricetulus griseus,1,10029.0,185.0,Expert,N,BAO_0000219,,6954,F,
,1,14837,,,,12675,,,,CHEMBL623839,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,8,,,Autocuration,H,BAO_0000019,,6955,F,
,1,14837,,,,12675,,,,CHEMBL623840,Number of binding sites (n) of isolated serum protein AAG,,8,,,Autocuration,H,BAO_0000019,,6956,F,
,1,16037,,,,22222,,,,CHEMBL623841,Association constant for binding to AATT duplex,,3,,,Intermediate,M,BAO_0000225,,6957,B,
,1,16597,,,,100090,,,ABAE,CHEMBL623842,Inhibition of ABAE human fibroblast cell proliferation,Homo sapiens,1,9606.0,416.0,Expert,N,BAO_0000219,,6958,F,
,1,8831,,,,80668,,,AC755,CHEMBL623843,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Mus musculus,1,10090.0,1064.0,Intermediate,N,BAO_0000218,,6959,F,
,1,13419,,,,102444,,,,CHEMBL618669,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Oryctolagus cuniculus,9,9986.0,,Expert,D,BAO_0000218,,6960,F,
,1,13419,,In vivo,,102444,,,,CHEMBL618670,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Oryctolagus cuniculus,9,9986.0,,Expert,D,BAO_0000218,,6961,F,
,1,15778,,,,69,,,,CHEMBL618671,Inhibitory activity against angiotensin-converting enzyme (ACE).,,8,,,Autocuration,H,BAO_0000357,,6962,B,
,1,15778,,,,69,,,,CHEMBL618672,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,8,,,Autocuration,H,BAO_0000357,,6963,B,
,1,12988,,,,80669,,,ACH-2 cell line,CHEMBL618673,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Homo sapiens,1,9606.0,978.0,Intermediate,N,BAO_0000219,,6964,F,
,1,12988,,,,80669,,,ACH-2 cell line,CHEMBL618674,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Homo sapiens,1,9606.0,978.0,Intermediate,N,BAO_0000219,,6965,F,
,1,12988,,,,22224,,,T cell line,CHEMBL618675,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Human immunodeficiency virus 1,0,11676.0,998.0,Autocuration,U,BAO_0000219,,6966,F,
,1,12988,,,,22224,,,T cell line,CHEMBL618676,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1,0,11676.0,998.0,Autocuration,U,BAO_0000219,,6967,F,
,1,12988,,,,22224,,,T cell line,CHEMBL618677,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Human immunodeficiency virus 1,0,11676.0,998.0,Autocuration,U,BAO_0000219,,6968,F,
,1,11843,,,,80025,,,ACHN,CHEMBL618678,Inhibition of growth of renal cancer ACHN cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6969,F,
,1,16939,,,,80025,,,ACHN,CHEMBL618679,Inhibition of growth of ACHN renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6970,F,
,1,4782,,,,80025,,,ACHN,CHEMBL618680,Inhibitory concentration required against ACHN renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6971,F,
,1,6310,,,,80025,,,ACHN,CHEMBL618681,Concentration required to inhibit growth of human renal (ACHN) cell line,Homo sapiens,1,9606.0,626.0,Expert,N,BAO_0000219,,6972,F,
,1,6310,,,,80025,,,ACHN,CHEMBL618682,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6973,F,
,1,12858,,,,80025,,,ACHN,CHEMBL618683,Cytotoxic activity against ACHN Renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6974,F,
,1,17380,,,,80025,,,ACHN,CHEMBL618684,Cytotoxicity evaluation against ACHN renal cancer cells,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6975,F,
,1,5858,,,,80025,,,ACHN,CHEMBL618685,In vitro antitumor activity against human renal ACHN cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6976,F,
,1,3838,,,,80025,,,ACHN,CHEMBL876499,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6977,F,
,1,3838,,,,80025,,,ACHN,CHEMBL618686,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6978,F,
,1,5406,,,,80025,,,ACHN,CHEMBL618687,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6979,F,
,1,4071,,,,80025,,,ACHN,CHEMBL618688,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6980,F,
,1,4071,,,,80025,,,ACHN,CHEMBL618689,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Homo sapiens,1,9606.0,626.0,Expert,N,BAO_0000219,,6981,F,
,1,4071,,,,80025,,,ACHN,CHEMBL618690,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6982,F,
,1,15002,,,,80025,,,ACHN,CHEMBL618691,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6983,F,
,1,14769,,,,80025,,,ACHN,CHEMBL619373,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6984,F,
,1,13958,,,,80025,,,ACHN,CHEMBL884008,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6985,F,
,1,1665,,,,80025,,,ACHN,CHEMBL619374,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6986,F,
,1,15354,,,,80025,,,ACHN,CHEMBL619375,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6987,F,
,1,15354,,,,80025,,,ACHN,CHEMBL619376,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6988,F,
,1,13978,,,,80025,,,ACHN,CHEMBL619377,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6989,F,
,1,6798,,,,80025,,,ACHN,CHEMBL619378,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,6990,F,
,1,2959,,In vivo,,50588,,,,CHEMBL872527,Tmax value after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6991,A,
,1,9932,,,,50588,,,,CHEMBL876500,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6992,A,
,1,5546,,,,50588,,,,CHEMBL619379,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6993,A,
,1,16907,,In vivo,,50588,,,,CHEMBL619538,Volume distribution after 15 mg/kg iv dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6994,A,
,1,16907,,In vivo,,50588,,,,CHEMBL619539,Volume distribution after 30 mg/kg po dose in Dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6995,A,
,1,4257,,In vivo,,50588,,,,CHEMBL619540,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6996,A,
,1,4305,,In vivo,,50588,,,,CHEMBL619541,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6997,A,
,1,5472,,In vivo,,50588,,,,CHEMBL619542,Volume of distribution was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6998,A,
,1,6062,,In vivo,,50588,,,,CHEMBL619543,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,6999,A,
,1,3598,,,,50588,,,,CHEMBL619544,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Expert,N,BAO_0000218,,7000,A,
,1,12500,,In vivo,,50588,,,,CHEMBL619545,The compound was tested for volume of distribution in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7001,A,
,1,12500,,In vivo,,50588,,,,CHEMBL619546,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7002,A,
,1,6227,,In vivo,,50588,,,,CHEMBL619547,Vd (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7003,A,
,1,6227,,In vivo,,50588,,,,CHEMBL619548,Vd in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7004,A,
,1,4219,,In vivo,,50588,,,,CHEMBL619549,Volume distribution was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7005,A,
,1,1696,,In vivo,,50588,,,,CHEMBL619550,Volume of distribution in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7006,A,
,1,5542,,In vivo,,50588,,,,CHEMBL876501,Volume of distribution by as 4 fold increase by iv administration in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7007,A,
,1,5199,,In vivo,,50588,,,,CHEMBL619551,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7008,A,
,1,6348,,In vivo,,50588,,,,CHEMBL619552,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7009,A,
,1,4727,,In vivo,,50588,,,,CHEMBL619553,Volume distribution at the dose of 2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7010,A,
,1,16367,,In vivo,,50588,,,,CHEMBL618722,Steady state volume of distribution was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7011,A,
,1,2652,,In vivo,,50588,,,,CHEMBL618723,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7012,A,
,1,16452,,In vivo,,50588,,,,CHEMBL618724,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7013,A,
,1,16452,,In vivo,,50588,,,,CHEMBL618725,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7014,A,
,1,16452,,In vivo,,50588,,,,CHEMBL618726,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7015,A,
,1,5334,,In vivo,,50588,,,,CHEMBL618727,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7016,A,
,1,4239,,In vivo,,50588,,,,CHEMBL624233,Pharmacokinetic property (vdss) was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7017,A,
,1,4709,,In vivo,,50588,,,,CHEMBL624234,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7018,A,
,1,5600,,In vivo,,50588,,,,CHEMBL624235,Vdss was determined after iv 0.1 mg/kg administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7019,A,
,1,6057,,In vivo,,50588,,,,CHEMBL624236,Volume displacement was calculated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7020,A,
,1,5654,,In vivo,,50588,,,,CHEMBL624237,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7021,A,
,1,5505,,In vivo,,50588,,,,CHEMBL624238,Volume distribution constant was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7022,A,
,1,4527,,In vivo,,50588,,,,CHEMBL624239,Volume distribution at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7023,A,
,1,4521,,In vivo,,50588,,,,CHEMBL875829,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7024,A,
,1,4521,,In vivo,,50588,,,,CHEMBL624240,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7025,A,
,1,15660,,In vivo,,50588,,,,CHEMBL624241,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7026,A,
,1,15660,,In vivo,,50588,,,,CHEMBL624242,Volume distribution (Vdss) was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7027,A,
,1,6679,,In vivo,,50588,,,,CHEMBL624243,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7028,A,
,1,5145,,In vivo,,50588,,,,CHEMBL624244,Volume of distribution in steady state was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7029,A,
,1,6821,,In vivo,,50588,,,,CHEMBL624245,Volume of distribution of compound was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7030,A,
,1,4137,,In vivo,,50588,,,,CHEMBL624246,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7031,A,
,1,5334,,In vivo,,50588,,,,CHEMBL624247,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7032,A,
,1,15660,,In vivo,,50588,,,,CHEMBL624248,Volume of distribution (Vdss) was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7033,A,
,1,6642,,In vivo,,50588,,,,CHEMBL624249,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7034,A,
,1,6641,,In vivo,,50588,,,,CHEMBL624250,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7035,A,
,1,6642,,In vivo,,50588,,,,CHEMBL624251,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7036,A,
,1,11659,,,,50588,,,,CHEMBL624252,Maximum rate of depolarization of the upstroke of the action potential,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7037,A,
,1,6448,,In vivo,,50588,,,,CHEMBL624253,Steady state volume distribution in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7038,A,
,1,5474,,In vivo,,50588,,,,CHEMBL624950,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7039,A,
,1,1466,,In vivo,,50588,,,,CHEMBL624951,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7040,A,
,1,6535,,In vivo,,50588,,,,CHEMBL875830,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7041,A,
,1,6535,,In vivo,,50588,,,,CHEMBL624952,Volume distribution in dog after administration of 1 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7042,A,
,1,17764,,In vivo,,50588,,,,CHEMBL624953,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7043,A,
,1,6215,,In vivo,,50588,,,,CHEMBL624954,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7044,A,
,1,6505,,In vivo,,50588,,,,CHEMBL624955,Vss on i.v. administration of 2 mg/kg was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7045,A,
,1,3639,,,,50588,,,,CHEMBL624956,Vss was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7046,A,
,1,3639,,,,50588,,,,CHEMBL625129,Vss in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7047,A,
,1,6062,,In vivo,,50588,,,,CHEMBL625130,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7048,A,
,1,4942,,In vivo,,50588,,,,CHEMBL625131,Volume distribution in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7049,A,
,1,17796,,In vivo,,50588,,,,CHEMBL625132,Volume of distribution in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7050,A,
,1,4883,,In vivo,,50588,,,,CHEMBL872263,Tested for the oral bioavailability in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7051,A,
,1,17837,,In vivo,,50594,,,,CHEMBL624336,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7060,A,
,1,17729,,In vivo,,50594,,,,CHEMBL624337,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7061,A,
,1,17729,,In vivo,,50594,,,,CHEMBL624338,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7062,A,
,1,4239,,In vivo,,50594,,,,CHEMBL624339,Bioavailability was measured in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7063,A,
,1,17592,,In vivo,,50594,,,,CHEMBL624340,Bioavailability in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7064,A,
,1,6348,,In vivo,,50594,,,,CHEMBL624341,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7065,A,
,1,2801,,In vivo,,50594,,,,CHEMBL624342,Bioavailability in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7066,A,
,1,2801,,In vivo,,50594,,,,CHEMBL624343,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7067,A,
,1,17718,,In vivo,,50594,,,,CHEMBL624344,Oral bioavailability in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7068,A,
,1,5727,,In vivo,,50594,,,,CHEMBL624345,Oral availability at 50 mg/kg po in male mice,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7069,A,
,1,5302,,In vivo,,50594,,,,CHEMBL624346,Oral bioavailability in mouse (dose 10 mg/kg),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7070,A,
,1,3598,,In vivo,,50594,,,,CHEMBL624347,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Mus musculus,1,10090.0,,Expert,N,BAO_0000218,,7071,A,
,1,5961,,In vivo,,50594,,,,CHEMBL624348,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7072,A,
,1,6091,,In vivo,,50594,,,,CHEMBL622754,Oral bioavailability in mouse,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7074,A,
,1,6091,,In vivo,,50594,,,,CHEMBL622755,Oral bioavailability in vivo in mice;ND=Not determined,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7075,A,
,1,5711,,In vivo,,50594,,,,CHEMBL622756,Oral bioavailability in mouse at 10 mg/kg of the compound,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7076,A,
,1,17728,,In vivo,,50594,,,,CHEMBL622757,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7077,A,
,1,17728,,In vivo,,50594,,,,CHEMBL622758,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7078,A,
,1,3802,,In vivo,,50594,,,,CHEMBL622759,Tested for bioavailability of the compound,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7079,A,
,1,3802,,In vivo,,50594,,,,CHEMBL622760,Tested for half life at the dose of 10 mg/kg when administered intravenously,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7080,A,
Plasma,1,14029,,,,50594,,,,CHEMBL622761,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,7081,A,
Plasma,1,14029,,,,50594,,,,CHEMBL622762,The plasma half life of compound was determined on heparin prepared by human plasma. ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,7082,A,
Plasma,1,14029,,,,50594,,,,CHEMBL622763,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,7083,A,
Plasma,1,14029,,,,50594,,,,CHEMBL622764,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,7084,A,
Plasma,1,14029,,,,50594,,,,CHEMBL622765,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,1969.0,7085,A,
,1,17753,,,,50594,,,,CHEMBL622766,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7086,F,
,1,17753,,,,50594,,,,CHEMBL622767,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7087,A,
,1,17753,,,,50594,,,,CHEMBL622768,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,,7088,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL875948,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7089,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622769,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7090,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622770,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7091,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622771,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7092,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622772,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7093,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622773,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7094,A,
Blood,1,10107,,In vivo,,50594,,,,CHEMBL622774,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,178.0,7095,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL621725,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7096,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL621726,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7097,A,
,1,15608,,,,81034,,,A2780,CHEMBL621727,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7098,F,
,1,3290,,,,81034,,,A2780,CHEMBL622413,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7099,F,
,1,2859,,,,81034,,,A2780,CHEMBL622414,Compound was evaluated for cytotoxicity against A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7100,F,
,1,15688,,,,81034,,,A2780,CHEMBL622415,Inhibition of A2780 cell clonogenic assay,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7101,F,
,1,5642,,,,81034,,,A2780,CHEMBL884001,Cytotoxic effect on ovarian cancer cell line (A2780),Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7102,F,
,1,6633,,,,81034,,,A2780,CHEMBL622416,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7103,F,
,1,3906,,,,81034,,,A2780,CHEMBL622417,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7104,F,
,1,6788,,,,81034,,,A2780,CHEMBL622590,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7105,F,
,1,17582,,,,81034,,,A2780,CHEMBL622591,Antiproliferative activity against human A2780 cells,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7106,F,
,1,17764,,,,81034,,,A2780,CHEMBL622592,Inhibition of human A2780 cell proliferation,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7107,F,
,1,17764,,,,81034,,,A2780,CHEMBL622593,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7108,F,
,1,17764,,,,81034,,,A2780,CHEMBL622594,Inhibition of human A2780 cell proliferation (No data),Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7109,F,
,1,2815,,,,81034,,,A2780,CHEMBL622595,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7110,F,
,1,16930,,,,81034,,,A2780,CHEMBL622596,Compound was evaluated against human Ovarian carcinoma cell line A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7111,F,
,1,17777,,,,81034,,,A2780,CHEMBL622597,Growth inhibition against A2780 wild-type ovarian cell lines,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7112,F,
,1,17777,,,,81034,,,A2780,CHEMBL622598,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7113,F,
,1,16936,,,,104766,,,,CHEMBL622599,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Homo sapiens,5,9606.0,,Autocuration,D,BAO_0000019,,7114,F,
,1,13759,,,,81034,,,A2780,CHEMBL622600,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7115,F,
,1,13759,,,,81034,,,A2780,CHEMBL622601,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7116,F,
,1,13759,,,,81034,,,A2780,CHEMBL622602,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7117,F,
,1,13759,,,,81034,,,A2780,CHEMBL622603,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7118,F,
,1,15292,,,,81034,,,A2780,CHEMBL622604,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7119,F,
,1,15292,,,,81034,,,A2780,CHEMBL622605,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7120,F,
,1,15069,,,,81034,,,A2780,CHEMBL622606,In vitro inhibition of human ovarian cell line A2780,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7121,F,
,1,15069,,,,81034,,,A2780,CHEMBL619463,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7122,F,
,1,14073,,,,81034,,,A2780,CHEMBL619464,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7123,F,
,1,14553,,,,81034,,,A2780,CHEMBL619465,Concentration required to inhibit A2780-cell growth by 50%,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7124,F,
,1,13040,,,,81034,,,A2780,CHEMBL619466,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7125,F,
,1,6891,,,,81034,,,A2780,CHEMBL619467,Cytotoxic effect on human ovarian (A2780) cancer cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7126,F,
,1,15569,,,,81034,,,A2780,CHEMBL619468,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7127,F,
,1,14190,,,,81034,,,A2780,CHEMBL619469,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7128,F,
,1,15014,,,,81034,,,A2780,CHEMBL619470,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7129,F,
,1,15014,,,,81034,,,A2780,CHEMBL619471,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7130,F,
,1,17496,,,,81034,,,A2780,CHEMBL619472,Cytotoxicity against human ovarian carcinoma A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7131,F,
,1,13617,,,,81034,,,A2780,CHEMBL619473,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7132,F,
,1,13617,,,,81034,,,A2780,CHEMBL874368,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7133,F,
,1,13617,,,,81034,,,A2780,CHEMBL884003,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7134,F,
,1,13617,,,,81034,,,A2780,CHEMBL622690,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7135,F,
,1,17672,,,,81034,,,A2780,CHEMBL622691,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7136,F,
,1,4544,,,,81034,,,A2780,CHEMBL622692,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7137,F,
,1,4544,,,,81034,,,A2780,CHEMBL623406,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7138,F,
,1,16317,,,,81034,,,A2780,CHEMBL884004,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7139,F,
,1,15099,,,,81034,,,A2780,CHEMBL623407,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7140,F,
,1,13978,,,,81034,,,A2780,CHEMBL623408,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7141,F,
,1,12989,,,,81034,,,A2780,CHEMBL623409,In vitro antitumor activity against A2780 cell line.,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7142,F,
,1,5574,,,,81034,,,A2780,CHEMBL623410,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7143,F,
,1,13528,,,,81034,,,A2780,CHEMBL623576,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7144,F,
,1,12782,,,,80025,,,ACHN,CHEMBL623577,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7145,F,
,1,14255,,,,80025,,,ACHN,CHEMBL623578,The IC50 value was measured on ACHN cell line in renal tumor type.,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7146,F,
,1,16364,,,,80025,,,ACHN,CHEMBL623579,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7147,F,
,1,17376,,,,80025,,,ACHN,CHEMBL623580,In vitro lethal concentration against most sensitive ACHN cell line,Homo sapiens,1,9606.0,626.0,Expert,N,BAO_0000219,,7148,F,
,1,12016,,,,80025,,,ACHN,CHEMBL623581,Tested for cytotoxic activity against renal cancer ACHN cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7149,F,
,1,6058,,,,80025,,,ACHN,CHEMBL857456,Compound tested for growth inhibition of renal cancer cell line ACHN,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7150,F,
,1,17708,,,,80025,,,ACHN,CHEMBL623582,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7151,F,
,1,15176,,,,80025,,,ACHN,CHEMBL623583,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7152,F,
,1,2806,,,,80025,,,ACHN,CHEMBL623584,In vitro anticancer activity against ACHN renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7153,F,
,1,15300,,,,80025,,,ACHN,CHEMBL623585,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7154,F,
,1,16364,,,,80025,,,ACHN,CHEMBL623586,Percent selectivity was evaluated in renal ACHN cell lines,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7155,F,
,1,13859,,,,80025,,,ACHN,CHEMBL623587,In vitro inhibitory activity against renal ACHN cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7156,F,
,1,11970,,,,80025,,,ACHN,CHEMBL875279,Tested for cytotoxicity against ACHN cell lines in renal cancer,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7157,F,
,1,2450,,,,80025,,,ACHN,CHEMBL623588,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7158,F,
,1,12696,,,,80025,,,ACHN,CHEMBL623589,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7159,F,
,1,12400,,,,80025,,,ACHN,CHEMBL623590,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7160,F,
,1,12888,,,,80025,,,ACHN,CHEMBL623591,Cytotoxic effect on renal cancer line ACHN,Homo sapiens,1,9606.0,626.0,Expert,N,BAO_0000219,,7161,F,
,1,3156,,,,80025,,,ACHN,CHEMBL623592,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7162,F,
,1,3381,,,,80025,,,ACHN,CHEMBL623593,In vitro inhibition of Renal Cancer ACHN cell lines,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7163,F,
,1,16747,,,,80025,,,ACHN,CHEMBL623594,Antitumor activity against human renal adenocarcinoma ACHN cells,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7164,F,
,1,16748,,,,80025,,,ACHN,CHEMBL621833,Antitumor activity against human renal adenocarcinoma ACHN cells.,Homo sapiens,1,9606.0,626.0,Expert,N,BAO_0000219,,7165,F,
,1,12062,,,,80025,,,ACHN,CHEMBL621834,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7166,F,
,1,14769,,,,80025,,,ACHN,CHEMBL621835,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7167,F,
,1,15895,,,,80025,,,ACHN,CHEMBL621836,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7168,F,
,1,17376,,,,80025,,,ACHN,CHEMBL621837,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7169,F,
,1,14882,,,,80025,,,ACHN,CHEMBL875280,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7170,F,
,1,14882,,,,80025,,,ACHN,CHEMBL621838,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7171,F,
,1,15661,,,,80025,,,ACHN,CHEMBL621839,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Homo sapiens,1,9606.0,626.0,Intermediate,N,BAO_0000219,,7172,F,
,1,9680,,,,22224,,,,CHEMBL621840,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,0,,,Autocuration,U,BAO_0000019,,7173,A,
,1,14579,,,,10647,,,,CHEMBL621841,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,8,,,Autocuration,H,BAO_0000019,,7174,F,
,1,17290,,,,50529,,,HEL,CHEMBL622979,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Cytomegalovirus,1,10358.0,468.0,Expert,N,BAO_0000218,,7175,F,
,1,17290,,,,50529,,,,CHEMBL876595,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Cytomegalovirus,1,10358.0,,Intermediate,N,BAO_0000218,,7176,F,
,1,15891,,,,12159,,,,CHEMBL620221,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,8,,,Autocuration,H,BAO_0000357,,7177,B,
,1,15890,,,,12159,,,,CHEMBL620222,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,8,,,Autocuration,H,BAO_0000357,,7178,B,
,1,3801,,,,80670,,,ADDP cell line,CHEMBL620506,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Bos taurus,1,9913.0,979.0,Intermediate,N,BAO_0000219,,7179,F,
,1,9222,,,,80671,,,ADJ/PC6,CHEMBL620507,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7180,F,
,1,9222,,,,80671,,,ADJ/PC6,CHEMBL620508,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7181,F,
,1,7257,,,,80671,,,ADJ/PC6,CHEMBL620509,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7182,F,
,1,7257,,,,80671,,,ADJ/PC6,CHEMBL620510,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7183,F,
,1,7257,,,,80671,,,ADJ/PC6,CHEMBL620511,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7184,A,
,1,8084,,,,80671,,,ADJ/PC6,CHEMBL620512,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Mus musculus,1,10090.0,980.0,Intermediate,N,BAO_0000219,,7185,F,
,1,14943,,,,22224,,,,CHEMBL620513,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,7186,F,
,1,14943,,,,22224,,,,CHEMBL620514,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,7187,F,
,1,14943,,,,22224,,,,CHEMBL620515,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Mus musculus,0,10090.0,,Autocuration,U,BAO_0000019,,7188,F,
,1,10524,,In vivo,,22224,,,,CHEMBL620516,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Bacillus subtilis,0,1423.0,,Autocuration,U,BAO_0000218,,7189,A,
Plasma,1,3546,,,,50588,,,,CHEMBL620517,AUC value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7190,A,
Plasma,1,3546,,,,50588,,,,CHEMBL620518,AUC value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7191,A,
,1,3546,,In vivo,,50588,,,,CHEMBL620519,Cmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7192,A,
,1,3546,,In vivo,,50588,,,,CHEMBL621386,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7193,A,
,1,3546,,In vivo,,50588,,,,CHEMBL621387,Tmax value in dog after oral administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7194,A,
,1,3184,,In vivo,,50588,,,,CHEMBL621388,Compound was evaluated for its clearance when administered intravenously in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7195,A,
,1,16456,,In vivo,,50588,,,,CHEMBL621389,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7196,A,
,1,4809,,In vivo,,50588,,,,CHEMBL621390,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7197,A,
,1,4219,,,,22229,,,,CHEMBL621391,Calculated partition coefficient (clogP),,0,,,Intermediate,U,BAO_0000100,,7198,P,
,1,3748,,,,50588,,,,CHEMBL621392,Half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7199,A,
,1,3132,,,,50588,,,,CHEMBL621393,Time taken for EC90 was determined when tested in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7200,A,
,1,4219,,,,50588,,,,CHEMBL621394,Half life (iv) was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7201,A,
Liver,1,16907,,,,50588,,,,CHEMBL621395,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,2107.0,7202,A,
,1,6057,,,,50588,,,,CHEMBL621396,Area under the curve was calculated in dog after iv administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7203,A,
,1,6057,,,,50588,,,,CHEMBL621397,Area under the curve was calculated in dog after peroral administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7204,A,
,1,17853,,,,50588,,,,CHEMBL621398,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7205,A,
,1,3639,,,,50588,,,,CHEMBL618818,pKa was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7206,A,
,1,14541,,,,50588,,,,CHEMBL618819,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7207,A,
,1,16456,,In vivo,,50588,,,,CHEMBL618820,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7208,A,
,1,16456,,In vivo,,50588,,,,CHEMBL873810,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7209,A,
,1,2652,,In vivo,,50588,,,,CHEMBL876606,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7210,A,
,1,3624,,,,50588,,,,CHEMBL618821,Compound was evaluated for the half-life (t 1/2) in hours,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7211,A,
Blood,1,1337,,In vivo,,50588,,,,CHEMBL618822,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,7212,A,
Blood,1,1337,,In vivo,,50588,,,,CHEMBL618823,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,7213,A,
,1,4709,,In vivo,,50588,,,,CHEMBL618824,Half life after intravenous administration of 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7214,A,
,1,15660,,,,50588,,,,CHEMBL618825,Half life was measured in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7215,A,
,1,5302,,In vivo,,50588,,,,CHEMBL618826,Half life period in dog after 5 mg/kg dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7216,A,
,1,17791,,,,50588,,,,CHEMBL618827,Half life period was evaluated in dog; 4-4.8,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7217,A,
,1,6348,,In vivo,,50588,,,,CHEMBL618828,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7218,A,
,1,4257,,In vivo,,50588,,,,CHEMBL618829,Half-life was determined in dog after a3 mg/kg of iv dose,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7219,A,
,1,3771,,,,50588,,,,CHEMBL618830,Half-life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7220,A,
,1,6305,,,,50588,,,,CHEMBL618831,Half life in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7221,A,
Plasma,1,13501,,In vivo,,50588,,,,CHEMBL619489,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7222,A,
,1,17594,,In vivo,,50588,,,,CHEMBL619649,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7223,A,
,1,3045,,In vivo,,50588,,,,CHEMBL876607,Compound was evaluated for the half life period after iv administration in Beagle dog.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7224,A,
,1,3043,,In vivo,,50588,,,,CHEMBL619650,Compound was evaluated for the half life period after oral administration in conscious dog.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7225,A,
,1,4839,,,,50588,,,,CHEMBL619651,Compound was tested for half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7226,A,
,1,4839,,,,50588,,,,CHEMBL619652,Compound was tested for its half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7227,A,
,1,5802,,In vivo,,50588,,,,CHEMBL619653,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7228,A,
,1,17839,,,,50588,,,,CHEMBL619654,Half life of compound in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7229,A,
,1,4219,,In vivo,,50588,,,,CHEMBL619655,Half life (iv) was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7230,A,
Blood,1,13966,,,,50588,,,,CHEMBL619656,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,178.0,7231,A,
Plasma,1,3994,,In vivo,,50588,,,,CHEMBL873812,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7232,A,
Plasma,1,3994,,In vivo,,50588,,,,CHEMBL621365,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7233,F,
,1,4453,,,,50588,,,,CHEMBL621366,Half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7234,A,
Plasma,1,6535,,,,50588,,,,CHEMBL621367,Half life in dog plasma,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7235,A,
Plasma,1,6535,,In vivo,,50588,,,,CHEMBL621368,Half life in dog plasma after administration of 0.25 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7236,A,
Plasma,1,6535,,In vivo,,50588,,,,CHEMBL621369,Half life in dog plasma after administration of 1 mg/kg iv,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7237,A,
Plasma,1,3132,,In vivo,,50588,,,,CHEMBL621370,Half life in dog plasma was determined at dose 10 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7238,A,
,1,5374,,,,50588,,,,CHEMBL621371,Half life in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7239,A,
,1,5007,,In vivo,,50588,,,,CHEMBL621372,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7240,A,
Plasma,1,16907,,,,50588,,,,CHEMBL621373,Half life upon exposure to human plasma,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7241,A,
,1,6057,,,,50588,,,,CHEMBL621374,Half life was calculated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7242,A,
,1,5006,,,,50588,,,,CHEMBL621375,Half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7243,A,
,1,5473,,,,50588,,,,CHEMBL621376,Half life was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7244,A,
,1,4368,,In vivo,,50588,,,,CHEMBL619624,Half life by intravenous administration of 1.2 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7245,A,
,1,6448,,,,50588,,,,CHEMBL875840,Half life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7246,A,
,1,4353,,,,50588,,,,CHEMBL619625,Half life in dog after intra venous administration of the compound,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7247,A,
,1,4353,,,,50588,,,,CHEMBL619626,Half life in dog after intra venous administration of the compound; ND means Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7248,A,
,1,4353,,In vivo,,50588,,,,CHEMBL619627,Half life in dog after po administration of the compound,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7249,A,
,1,4353,,In vivo,,50588,,,,CHEMBL873817,Half life in dog after po administration of the compound; ND means Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7250,A,
,1,6265,,In vivo,,50588,,,,CHEMBL619628,Half life in dog at the single oral dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7251,A,
,1,5006,,,,50588,,,,CHEMBL619629,Half life in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7252,A,
,1,5356,,In vivo,,50588,,,,CHEMBL619630,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7253,A,
,1,405,,,,50588,,,,CHEMBL619631,Half life in rat,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7254,A,
,1,6642,,In vivo,,50588,,,,CHEMBL619632,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7255,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL619633,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7256,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL875841,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7257,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL619634,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7258,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL619635,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7259,A,
Bone,1,10107,,In vivo,,50594,,,,CHEMBL619636,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000001.0,7260,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619637,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7261,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619638,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7262,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619639,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7263,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619640,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7264,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619641,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7265,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619642,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7266,A,
Gut,1,10107,,In vivo,,50594,,,,CHEMBL619643,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,10000004.0,7267,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL619644,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7268,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621112,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7269,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621113,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7270,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621114,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7271,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621115,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7272,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621116,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7273,A,
Heart,1,10107,,In vivo,,50594,,,,CHEMBL621117,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,948.0,7274,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621118,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7275,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621119,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7276,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621120,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7277,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621757,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7278,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621758,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7279,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621759,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7280,A,
Kidney,1,10107,,In vivo,,50594,,,,CHEMBL621760,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2113.0,7281,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL621761,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7282,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL621762,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7283,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL621763,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7284,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL624502,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7285,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL624503,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7286,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL624504,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7287,A,
Liver,1,10107,,In vivo,,50594,,,,CHEMBL624505,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2107.0,7288,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL624506,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7289,A,
,1,5895,,,,81034,,,A2780,CHEMBL624507,In vitro cytotoxicity against A2780 (human ovarian cancer),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7290,F,
,1,6338,,,,81034,,,A2780,CHEMBL624508,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7291,F,
,1,15163,,,,81034,,,A2780,CHEMBL624509,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7292,F,
,1,15163,,,,81034,,,A2780,CHEMBL624510,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7293,F,
,1,15000,,,,81034,,,A2780,CHEMBL875956,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7294,F,
,1,15000,,,,81034,,,A2780,CHEMBL839885,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7295,F,
,1,14729,,,,81034,,,A2780,CHEMBL624511,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7296,F,
,1,17270,,,,81034,,,A2780,CHEMBL624512,In vitro cytotoxicity against A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7297,F,
,1,5685,,,,81034,,,A2780,CHEMBL624513,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7298,F,
,1,3563,,,,81034,,,A2780,CHEMBL624514,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7299,F,
,1,17753,,,,81034,,,A2780,CHEMBL618547,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000218,,7300,F,
,1,16317,,,,81034,,,A2780,CHEMBL618548,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7301,F,
,1,16936,,,,81034,,,A2780,CHEMBL618549,Inhibition of tubulin polymerization in analogy of ca.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7302,F,
,1,3801,,,,81034,,,A2780,CHEMBL618550,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7303,F,
,1,6181,,,,81034,,,A2780,CHEMBL618551,Cytotoxic effect in ovarian cancer cell line (A2780),Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7304,F,
,1,5318,,,,81034,,,A2780,CHEMBL618552,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7305,F,
,1,4840,,,,81034,,,A2780,CHEMBL618553,Tested for the cytotoxicity in A2780 ovarian cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7306,F,
,1,15748,,,,81034,,,A2780,CHEMBL618554,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7307,F,
,1,15748,,,,81034,,,A2780,CHEMBL618555,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7308,F,
,1,15748,,,,80017,,,A2780cisR,CHEMBL618556,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,1,,481.0,Intermediate,N,BAO_0000219,,7309,F,
,1,15748,,,,80017,,,A2780cisR,CHEMBL618557,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,1,,481.0,Intermediate,N,BAO_0000219,,7310,F,
,1,15748,,,,80017,,,A2780cisR,CHEMBL618558,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,1,,481.0,Intermediate,N,BAO_0000219,,7311,F,
,1,15748,,,,80017,,,A2780cisR,CHEMBL618559,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,1,,481.0,Intermediate,N,BAO_0000219,,7312,F,
,1,17753,,,,81034,,,A2780,CHEMBL618560,In vivo log of cells killed after administration of compound in A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000218,,7313,F,
,1,17753,,In vivo,,81034,,,A2780,CHEMBL618561,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000218,,7314,F,
,1,16936,,,,81034,,,A2780,CHEMBL618562,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7315,F,
,1,16936,,,,81034,,,A2780,CHEMBL618563,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7316,F,
,1,16936,,,,81034,,,A2780,CHEMBL618564,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7317,F,
,1,16936,,,,81034,,,A2780,CHEMBL618565,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7318,F,
,1,17528,,,,81034,,,A2780,CHEMBL618566,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000218,,7319,F,
,1,6633,,,,81034,,,A2780,CHEMBL618567,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7320,F,
,1,15000,,,,81034,,,A2780,CHEMBL618568,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7321,F,
,1,17528,,,,81034,,,A2780,CHEMBL618569,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7322,F,
,1,16936,,,,81034,,,A2780,CHEMBL621857,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7323,F,
,1,16936,,,,81034,,,A2780,CHEMBL621858,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7324,F,
,1,16936,,,,81034,,,A2780,CHEMBL621859,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7325,F,
,1,16936,,,,81034,,,A2780,CHEMBL621860,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7326,F,
,1,16936,,,,81034,,,A2780,CHEMBL621861,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7327,F,
,1,16936,,,,81034,,,A2780,CHEMBL621862,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Homo sapiens,1,9606.0,478.0,Expert,N,BAO_0000219,,7328,F,
,1,16936,,,,81034,,,A2780,CHEMBL621863,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7329,F,
,1,16936,,,,81034,,,A2780,CHEMBL621864,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7330,F,
,1,16936,,,,81034,,,A2780,CHEMBL621865,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7331,F,
,1,17737,,,,81034,,,A2780,CHEMBL621866,In vitro antiproliferative activity against A2780 cell line,Mus musculus,1,10090.0,478.0,Intermediate,N,BAO_0000219,,7332,F,
,1,17764,,,,81034,,,A2780,CHEMBL621867,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Mus musculus,1,10090.0,478.0,Expert,N,BAO_0000219,,7333,F,
,1,3830,,,,81034,,,A2780,CHEMBL621868,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7334,F,
,1,3829,,,,81034,,,A2780,CHEMBL875282,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Homo sapiens,1,9606.0,478.0,Intermediate,N,BAO_0000219,,7335,F,
,1,3546,,,,50588,,,,CHEMBL621869,Vc value in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7336,A,
,1,3546,,In vivo,,50588,,,,CHEMBL621870,Half life period in dog after IV administration at a dose of 5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7337,A,
,1,5668,,,,22224,,,,CHEMBL621871,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7338,A,
Plasma,1,3443,,,,22224,,,,CHEMBL621243,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,7339,A,
Plasma,1,3443,,,,22224,,,,CHEMBL621244,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,1969.0,7340,A,
,1,4256,,In vivo,,22224,,,,CHEMBL621245,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,7341,A,
,1,4256,,In vivo,,22224,,,,CHEMBL621246,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,7342,A,
,1,4256,,In vivo,,22224,,,,CHEMBL621247,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis,0,9541.0,,Autocuration,U,BAO_0000218,,7343,A,
,1,4256,,In vivo,,22224,,,,CHEMBL618386,Oral Bioavailability in rat,Rattus norvegicus,0,10116.0,,Autocuration,U,BAO_0000218,,7344,A,
,1,1916,,,,22224,,,,CHEMBL618387,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7345,A,
,1,5302,,,,22224,,,,CHEMBL618388,Area under curve value in monkey at a dose of 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7346,A,
,1,4257,,,,22224,,,,CHEMBL618389,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7347,A,
,1,5355,,,,22224,,,,CHEMBL618574,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7348,A,
,1,5355,,,,22224,,,,CHEMBL618575,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7349,A,
,1,5355,,,,22224,,,,CHEMBL618576,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7350,A,
,1,6078,,,,22224,,,,CHEMBL618577,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7351,A,
,1,6078,,,,22224,,,,CHEMBL876487,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7352,A,
,1,6062,,,,22224,,,,CHEMBL618578,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7353,A,
,1,2661,,,,22224,,,,CHEMBL618579,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7354,A,
,1,2661,,,,22224,,,,CHEMBL618580,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7355,A,
,1,5394,,,,22224,,,,CHEMBL618581,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7356,A,
,1,4397,,,,22224,,,,CHEMBL618582,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7357,A,
,1,17509,,,,22224,,,,CHEMBL618583,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7358,A,
,1,17509,,,,22224,,,,CHEMBL618584,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7359,A,
,1,6641,,In vivo,,22224,,,,CHEMBL618585,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7360,A,
,1,5355,,,,22224,,,,CHEMBL618586,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7361,A,
,1,3443,,In vivo,,22224,,,,CHEMBL618587,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7362,A,
,1,3443,,In vivo,,22224,,,,CHEMBL618588,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7363,A,
,1,17409,,,,22224,,,,CHEMBL618589,Binding towards monkey plasma protein at 10 uM,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7364,A,
,1,17409,,,,22224,,,,CHEMBL618590,Binding towards monkey plasma protein at 100 uM,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7365,A,
,1,1052,,In vivo,,22224,,,,CHEMBL872262,Apparent bioavailability in squirrel monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7366,A,
,1,13501,,In vivo,,22224,,,,CHEMBL618591,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7367,A,
,1,17509,,In vivo,,22224,,,,CHEMBL618592,Bioavailability in monkey (dose 2 mg/kg),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,7368,A,
,1,5394,,In vivo,,22224,,,,CHEMBL876488,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7369,A,
,1,2661,,In vivo,,22224,,,,CHEMBL618593,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7370,A,
,1,11219,,In vivo,,22224,,,,CHEMBL618594,Bioavailability in monkey (i.d. dosing),monkey,0,9443.0,,Autocuration,U,BAO_0000218,,7371,A,
,1,3045,,In vivo,,22224,,,,CHEMBL618595,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7372,A,
,1,17796,,,,22224,,,,CHEMBL621469,Clearance of the drug was measured in cynomolgus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000019,,7373,A,
,1,1399,,In vivo,,22224,,,,CHEMBL621470,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7374,A,
,1,2661,,In vivo,,22224,,,,CHEMBL621471,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7375,A,
Plasma,1,5005,,In vivo,,22224,,,,CHEMBL621472,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,0,9544.0,,Autocuration,U,BAO_0000218,1969.0,7376,A,
,1,17267,,In vivo,,22224,,,,CHEMBL621473,Plasma clearance in rhesus monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7377,A,
,1,6535,,In vivo,,22224,,,,CHEMBL621474,Plasma clearance in monkey after administration of 1 mg/kg iv,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7378,A,
,1,5922,,In vivo,,22224,,,,CHEMBL621475,Plasma clearance in cynomolgus monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7379,A,
,1,6221,,In vivo,,22224,,,,CHEMBL621476,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7380,A,
,1,5668,,In vivo,,22224,,,,CHEMBL624290,Plasma clearance after peroral administration at 10 mpk in Rhesus,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7381,A,
,1,5355,,In vivo,,22224,,,,CHEMBL624291,The total clearance was determined after intravenous administration in cynomolgus monkeys,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7382,A,
,1,5355,,In vivo,,22224,,,,CHEMBL624292,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7383,A,
,1,5355,,In vivo,,22224,,,,CHEMBL624293,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7384,A,
,1,4578,,In vivo,,22224,,,,CHEMBL624294,Tested for Clearance upon iv administration to african green monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7385,A,
,1,17592,,In vivo,,22224,,,,CHEMBL624295,Clearance in monkey,Cercopithecidae,0,9527.0,,Autocuration,U,BAO_0000218,,7386,A,
,1,6641,,In vivo,,50588,,,,CHEMBL624296,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7387,A,
,1,6642,,In vivo,,50588,,,,CHEMBL624297,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7388,A,
,1,16367,,In vivo,,50588,,,,CHEMBL624298,Half life was evaluated after intravenous administration to dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7389,A,
,1,5472,,,,50588,,,,CHEMBL624299,Half life was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7390,A,
,1,5474,,,,50588,,,,CHEMBL624300,Half life was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7391,A,
,1,5654,,In vivo,,50588,,,,CHEMBL624301,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7392,A,
,1,6227,,In vivo,,50588,,,,CHEMBL624302,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7393,A,
,1,6227,,In vivo,,50588,,,,CHEMBL876026,Half life period after intravenous administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7394,A,
,1,6221,,In vivo,,50588,,,,CHEMBL624303,Half life period after oral administration (2.5 mg/kg) in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7395,A,
,1,4527,,,,50588,,,,CHEMBL624304,Half life period at a dose of 1 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7396,A,
,1,5668,,In vivo,,50588,,,,CHEMBL624305,Half life period was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7397,A,
,1,5668,,In vivo,,50588,,,,CHEMBL624306,Half life period was determine after peroral administration at 5 mpk in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7398,A,
,1,3854,,,,50588,,,,CHEMBL624307,Half life period was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7399,A,
,1,5505,,,,50588,,,,CHEMBL624308,Half life period was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7400,A,
,1,6251,,In vivo,,50588,,,,CHEMBL624309,Half life period by iv administration in dog at a dose of 6 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7401,A,
,1,1918,,,,50588,,,,CHEMBL624310,Half life period was evaluated in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7402,A,
,1,5546,,In vivo,,50588,,,,CHEMBL625003,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7403,A,
,1,4809,,In vivo,,50588,,,,CHEMBL625004,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7404,A,
,1,6215,,In vivo,,50588,,,,CHEMBL625005,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7405,A,
,1,4527,,In vivo,,50588,,,,CHEMBL873813,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7406,A,
,1,17594,,In vivo,,50588,,,,CHEMBL625006,Half-life after oral dose of compound at 3 mg/kg in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7407,A,
,1,17839,,In vivo,,50588,,,,CHEMBL625007,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7408,A,
,1,17839,,In vivo,,50588,,,,CHEMBL876027,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7409,A,
,1,17839,,In vivo,,50588,,,,CHEMBL625008,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7410,A,
,1,17839,,In vivo,,50588,,,,CHEMBL625009,Half-life of compound in dog following p.o. administration of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7411,A,
Plasma,1,5210,,,,50588,,,,CHEMBL625010,Half-life of compound in plasma of dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7412,A,
,1,5210,,,,50588,,,,CHEMBL625011,Half-life of compound was determined in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7413,A,
,1,2959,,In vivo,,50588,,,,CHEMBL621553,Half-life after administration of 4 mg/Kg oral dose in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7414,A,
,1,4137,,In vivo,,50588,,,,CHEMBL621554,Half-life after intravenous administration of 1 mg/kg/h in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7415,A,
,1,5064,,,,50588,,,,CHEMBL621555,Half-life in Dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7416,A,
,1,5147,,,,50588,,,,CHEMBL621556,Half-life in Dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7417,A,
,1,5145,,,,50588,,,,CHEMBL621557,Half-life in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7418,A,
,1,6123,,In vivo,,50588,,,,CHEMBL621558,Half-life in dog after oral administration at 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7419,A,
,1,6123,,In vivo,,50588,,,,CHEMBL621559,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7420,A,
,1,4333,,,,50588,,,,CHEMBL621560,Half-life in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7421,A,
,1,4333,,,,50588,,,,CHEMBL876028,Half-life in dogs; ND indicates not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7422,A,
Plasma,1,12500,,,,50588,,,,CHEMBL621561,Half-life in plasma of dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7423,A,
Plasma,1,12500,,,,50588,,,,CHEMBL621562,Half-life in plasma of dog at dose of 3-10 mgkg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7424,A,
,1,6005,,In vivo,,50588,,,,CHEMBL621563,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7425,A,
,1,6062,,In vivo,,50588,,,,CHEMBL621564,Half-life was measured in dog after an iv dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7426,A,
,1,17650,,In vivo,,50588,,,,CHEMBL621565,Half-life was measured in dogs after an oral dose of 10 uM/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7427,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621566,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7428,A,
,1,5530,,In vivo,,50588,,,,CHEMBL621567,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7429,A,
,1,5600,,In vivo,,50588,,,,CHEMBL622978,Half-life of the compound after 0.3 mg/kg po administration in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7430,A,
,1,6039,,In vivo,,50588,,,,CHEMBL873814,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7431,A,
,1,6039,,In vivo,,50588,,,,CHEMBL623219,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7432,A,
,1,6039,,In vivo,,50588,,,,CHEMBL624477,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7433,A,
,1,6227,,,,50588,,,,CHEMBL624478,t1/2 in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7434,A,
,1,14541,,,,50588,,,,CHEMBL624479,Half-life period measured in dogs,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7435,A,
,1,4521,,In vivo,,50588,,,,CHEMBL624480,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7436,A,
,1,4521,,In vivo,,50588,,,,CHEMBL623595,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7437,A,
,1,6679,,In vivo,,50588,,,,CHEMBL623596,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7438,A,
Plasma,1,1116,,In vitro,,50588,,,,CHEMBL623597,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,1969.0,7439,A,
,1,5444,,In vivo,,50588,,,,CHEMBL623598,In vivo half life period was calculated at 1 mg/kg in dog,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7440,A,
,1,5444,,In vivo,,50588,,,,CHEMBL623599,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7441,A,
,1,17853,,In vivo,,50588,,,,CHEMBL623600,Longer half-life in dog (i.v.) at 0.5 mpk,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7442,A,
,1,4353,,In vivo,,50588,,,,CHEMBL623601,Oral bioavailability in dog (dose 5 uM/kg),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7443,A,
,1,16452,,In vivo,,50588,,,,CHEMBL623602,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7444,A,
,1,16452,,In vivo,,50588,,,,CHEMBL623603,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7445,A,
,1,16452,,In vivo,,50588,,,,CHEMBL623604,Bioavailability in dog (dose 1 mg/kg i.v.),Canis lupus familiaris,1,9615.0,,Intermediate,N,BAO_0000218,,7446,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623605,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7447,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623606,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7448,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623607,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7449,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623608,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7450,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623609,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7451,A,
Lung,1,10107,,In vivo,,50594,,,,CHEMBL623610,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2048.0,7452,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623611,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7453,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623612,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7454,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623613,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7455,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623614,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7456,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623615,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7457,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623616,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7458,A,
Muscle tissue,1,10107,,In vivo,,50594,,,,CHEMBL623617,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2385.0,7459,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL875944,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7460,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623618,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7461,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623619,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7462,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623620,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7463,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623621,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7464,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623622,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7465,A,
Zone of skin,1,10107,,In vivo,,50594,,,,CHEMBL623623,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,14.0,7466,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL623624,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7467,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL618521,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7468,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL618522,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7469,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL618523,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7470,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL618524,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7471,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL618525,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7472,A,
Spleen,1,10107,,In vivo,,50594,,,,CHEMBL624586,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,2106.0,7473,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624587,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7474,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624588,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7475,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624589,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7476,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624590,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7477,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624591,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7478,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624592,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7479,A,
Stomach,1,10107,,In vivo,,50594,,,,CHEMBL624593,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Mus musculus,1,10090.0,,Intermediate,N,BAO_0000218,945.0,7480,A,
,1,4689,,In vivo,,50597,,,,CHEMBL624594,Oral bioavailability in rat,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7481,A,
,1,4950,,In vivo,,50597,,,,CHEMBL624595,Tested for the bioavailability in rat,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7482,A,
,1,5328,,In vivo,,50597,,,,CHEMBL624596,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7483,A,
,1,406,,In vivo,,50597,,,,CHEMBL624597,Bioavailability in rat,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7484,A,
,1,12500,,In vivo,,50597,,,,CHEMBL624598,Bioavailability in rat,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7485,A,
,1,12500,,In vivo,,50597,,,,CHEMBL624599,Bioavailability in rat (dose 3-10 mg/kg),Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7486,A,
,1,5247,,In vivo,,50597,,,,CHEMBL875166,Bioavailability in rat,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7487,A,
Plasma,1,4186,,In vivo,,50597,,,,CHEMBL624600,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,7488,A,
Plasma,1,4186,,In vivo,,50597,,,,CHEMBL624601,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,7489,A,
,1,6647,,In vivo,,50597,,,,CHEMBL624602,Half life after oral administration was determined in rats at 6 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7490,A,
,1,6484,,,,50597,,,,CHEMBL624603,Half life was determined,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7491,A,
,1,3249,,In vivo,,50597,,,,CHEMBL624604,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7492,A,
Plasma,1,6281,,In vivo,,50597,,,,CHEMBL624605,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,1969.0,7493,A,
,1,3307,,,,50597,,,,CHEMBL624606,Half life in rats,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7494,A,
Blood,1,12058,,In vivo,,50597,,,,CHEMBL624607,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7495,A,
,1,8833,,,,50597,,,,CHEMBL624608,Hill coefficient of the compound,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7496,A,
Blood,1,3193,,,,50597,,,,CHEMBL624609,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7497,A,
Blood,1,3193,,,,50597,,,,CHEMBL624610,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7498,A,
Blood,1,3193,,,,50597,,,,CHEMBL624611,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7499,A,
Blood,1,3193,,,,50597,,,,CHEMBL624612,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7500,A,
Blood,1,3193,,,,50597,,,,CHEMBL875167,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7501,A,
Blood,1,3193,,,,50597,,,,CHEMBL624613,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7502,A,
Blood,1,3193,,,,50597,,,,CHEMBL624614,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7503,A,
,1,5960,,,,50597,,,,CHEMBL624392,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,,7504,A,
Brain,1,13950,,In vivo,,50597,,,,CHEMBL624393,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,955.0,7505,A,
Brain,1,13950,,In vivo,,50597,,,,CHEMBL624394,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,955.0,7506,A,
Brain,1,13950,,In vivo,,50597,,,,CHEMBL624395,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,955.0,7507,A,
Brain,1,13950,,In vivo,,50597,,,,CHEMBL624396,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,955.0,7508,A,
Brain,1,13950,,In vivo,,50597,,,,CHEMBL624397,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,955.0,7509,A,
Thyroid gland,1,13950,,In vivo,,50597,,,,CHEMBL624398,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,2046.0,7510,A,
Thyroid gland,1,13950,,In vivo,,50597,,,,CHEMBL624399,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,2046.0,7511,A,
Thyroid gland,1,13950,,In vivo,,50597,,,,CHEMBL624400,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,2046.0,7512,A,
Thyroid gland,1,13950,,In vivo,,50597,,,,CHEMBL624401,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,2046.0,7513,A,
Thyroid gland,1,13950,,In vivo,,50597,,,,CHEMBL624402,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,2046.0,7514,A,
Blood,1,9866,,In vivo,,50597,,,,CHEMBL624403,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7515,A,
Blood,1,9866,,In vivo,,50597,,,,CHEMBL624404,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7516,A,
Blood,1,9866,,In vivo,,50597,,,,CHEMBL624405,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,178.0,7517,A,
Bone,1,9866,,In vivo,,50597,,,,CHEMBL624406,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,10000001.0,7518,A,
Bone,1,9866,,In vivo,,50597,,,,CHEMBL624407,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,10000001.0,7519,A,
Bone,1,9866,,In vivo,,50597,,,,CHEMBL624408,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,10000001.0,7520,A,
Heart,1,9866,,In vivo,,50597,,,,CHEMBL618644,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,948.0,7521,A,
Heart,1,9866,,In vivo,,50597,,,,CHEMBL618645,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,948.0,7522,A,
Heart,1,9866,,In vivo,,50597,,,,CHEMBL618646,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,1,10116.0,,Intermediate,N,BAO_0000218,948.0,7523,A,
